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ABSTRACT 
 
 
Introduction: Cerebral hypoperfusion and impaired cerebral venous drainage are reported to 
be risk factors for multiple sclerosis (MS). Furthermore, lifestyle and biochemistry have 
significant effects on the brain and vascular system.  This study investigates, with vascular 
ultrasound, the risk factors for extracranial vascular disease in patients with MS. 
 
Methods: Grey-scale imaging, Colour and Spectral Doppler analysis of the carotid arteries and 
internal jugular veins were performed on a cohort of 50 female participants (25 MS patients 
and 25 age-matched controls). The major neck vessels were sonographically interrogated to 
determine patency, carotid intima media thickness (cIMT), carotid artery cross-sectional 
diameters (CSD), internal jugular vein (IJV) cross-sectional area (CSA), stenosis, occlusions 
and abnormal blood flow patterns. Both cohorts underwent blood tests, genetic tests and a 
lifestyle assessment. The MS participants had a neurological assessment to determine MS 
disability status (Expanded Disability Status Scale, EDSS). 
 
Results: Statistically significant associations (p-value <0.05) were found between the 
extracranial vascular ultrasound variables and biochemical markers (s-iron, s-transferrin, %Tf 
saturation, ferritin, haemoglobin, vitamin B12, s-folate, homocysteine, CRP, 25-OH vitamin D, 
total cholesterol, HDL and triglycerides), lifestyle factors, genetic factors (HLA DRB1*1501 
allele) and MS disability in both cohorts. The carotid artery blood flow parameters were 
negatively associated with MS disability, whereas the cIMT was positively associated with MS 
disability. Physical activity was positively associated with carotid artery blood flow velocities 
and passive smoking was found to have a negative association in the MS cohort of participants. 
Passive smokers also demonstrated a larger IJV CSA in comparison to non-smokers in both 
cohorts. In addition, drinking 1-13 units of alcohol/week was positively associated with carotid 
blood flow velocities in MS participants. 
 
Conclusion: Several significant positive and negative associations between extracranial 
vascular ultrasound variables and genetic, lifestyle, biochemical and vascular factors as well 
as MS disability were demonstrated in this study. The new MS findings that unfolded in this 
study include significant associations between: 1) the carotid vessel diameters and 
biochemical and lifestyle parameters as well as the presence of the HLA DRB1*1501 allele; 2) 
IJV CSA in MS and biochemical and lifestyle parameters, specifically passive smoking; 3) MS 
disability and carotid artery blood flow velocities; and 4) carotid artery blood flow parameters 
and biochemical markers. Further studies are therefore needed to establish the clinical 
relevance of these new findings 
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CHAPTER ONE 
 
INTRODUCTION 
 
In this chapter, an overview of the study is described. The overview includes description of 
multiple sclerosis (MS), pathogenesis of MS and disability progression, background and 
rationale of the study, research methodology, hypothesis, research objectives, risks and 
outcome. 
Multiple sclerosis (MS) is described as a chronic inflammatory demyelinating disease affecting 
the central nervous system (CNS). The disease, which frequently starts in young adulthood, 
affects both the white and grey matter of the CNS. (Stadelmann et al., 2011;  Van Horssen et 
al., 2011)  According to the Multiple Sclerosis International Federation (2013), the number of 
persons with MS worldwide has increased from 2.1 million in 2008 to 2.3 million in 2013. The 
prevalence of MS is heterogeneous worldwide, however this demyelinating disease is 
commonly seen in countries of high-income (Leray et al., 2016). 
 
Symptoms associated with MS include physical and mental disturbances caused by the neural 
damage, resulting in distortion of nerves impulses travelling to and from the brain (National MS 
Society, 2016). 
 
1.1 PATHOGENESIS OF MS  
Inflammation associated with MS may be due to a phenomenon caused by cytodegeneration 
of neurons and/or oligodendrocytes without involvement of immune cells or a physiological 
process secondary to the immune system activation (Bogie et al., 2014; Haider, 2015 and 
Palumbo, 2017).  
 
Several factors contribute to the development, exacerbation and disability progression of MS, 
however the exact aetiology and pathogenesis of the disease remains unclear (Mike et al., 
2011). The several factors associated with the MS pathophysiological processes are 
environmental, immunological, genetic, lifestyle, biochemical and vascular in origin. According 
to Loy et al. (2017), fatigue is perceived to be the most common and disabling symptom in 
persons with MS. 
 
1.2 BACKGROUND AND RATIONALE OF THE STUDY 
Multiple Sclerosis (MS) is characterised by demyelination within the central nervous system 
(CNS), which may result in neurological disabilities over time, causing considerable hardship 
to patients and their families, in addition to being costly to treat. Standard medication for MS 
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does not improve disease outcome, although it may reduce the relapse rate and slow disease 
progression in about 50% of patients (Axtell et al., 2011). 
The aetiology of MS is still  not yet well understood, however immune dysregulation caused by 
a complex interplay of genetic and environmental factors appears to be associated with the 
disease process (Hadgkiss et al., 2014). Genetic studies have linked HLA II genes to disease 
risk in MS, however no genetic factors have been exclusively found that predict disease 
outcome (Ramagopalan et al., 2008). 
 
Recent studies have linked impaired cerebral venous outflow with MS and surgical correction 
thereof results in rapid improvement of MS symptoms (Zamboni, 2006). Currently, no 
information is available in the literature on the prevalence of carotid artery disease in MS and 
its association with disability progression. 
Ultrasound technology has become an important tool for healthcare professionals as it offers 
many advantages compared to other imaging modalities. It is cost effective, easily available, 
and does not use ionizing radiation. The use of diagnostic ultrasound as an imaging tool to 
interrogate the extracranial vascular ultrasound systems, allows for immediate identification of 
vascular pathology (if present) which can then be treated appropriately, thus preventing 
progression of vascular disease, reduce disease burden and extend the person’s life 
expectancy  
This case-control study will determine, by ultrasound and laboratory tests, the prevalence of 
extracranial cerebrospinal venous and carotid artery disease, abnormal biochemical 
parameters, genetic and lifestyle risk factors in the selected sample of MS patients within the 
region of the Western Cape. 
 
1.2 OVERVIEW OF METHODOLOGY 
 A case-control study was performed on a cohort of MS participants and age-matched controls.  
 
The research participants had the following examinations, tests and assessments in the 
Western Cape, South Africa: 
 Carotid artery and internal jugular vein ultrasound examinations which were performed 
at a private Radiology practice by the (principal investigator) PI who is an experienced 
vascular sonographer 
 Blood tests performed by a private pathology laboratory 
 Genetic tests conducted at a pathology research facility affiliated with the University of 
Stellenbosch 
 The neurological assessments were conducted by a clinician at a tertiary hospital to 
determine the disability status of the MS participants. 
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An ultrasound system with Grey-scale imaging and Doppler facilities were used to interrogate 
the carotid arteries (CAs) and the internal jugular veins (IJVs). 
The following carotid artery (CA) variables were captured: 
 blood flow velocities,  
 blood flow ratios,  
 common carotid artery (CCA) intima media thickness,  
 cross-sectional diameters of the CAs, 
 plaque formation, 
 and percentage vessel stenosis (if present) 
 
The following internal jugular vein (IJV) ultrasound variables were captured: 
 blood flow velocities 
 cross-sectional area (CSA) of the proximal IJV 
The blood tests included assessment of multiple biochemical markers which influences 
vascular function and disability progression in MS. Genotyping was performed using single 
nucleotide polymorphism (SNP) genotyping assays. The HLA DRB1*1501 was investigated by 
use of a haplotype tagging SNP. This human leukocyte antigen is strongly associated with MS 
in the majority of populations tested worldwide (Alcina et al., 2012). 
 
A neurological assessment included the testing of the cranial nerves, sensation, reflexes, 
coordination, balance and walking in the cohort of MS participants. 
 
1.3 HYPOTHESIS 
Multiple sclerosis is a complex disease influenced by numerous contributing factors. Therefore, 
it is hypothesised that genetic, vascular, biochemical and lifestyle factors are significantly 
associated with the development of extracranial vascular pathology in multiple sclerosis. 
 
1.4 RESEARCH OBJECTIVES 
The main objectives of the study were to: 
 Compare the Ultrasound findings of the extracranial vascular systems in the two 
cohorts (MS and free from MS) 
 Establish an association between the Human Leukocyte Antigen (HLA) DRB1*1501 
gene and the Grey-scale, Colour and Spectral Doppler analysis of the carotid arteries 
(CAs) and internal jugular veins (IJVs) in the two cohorts. 
 Establish an association between biochemical markers (homocysteine, Vitamin D, iron, 
Vitamin B12, C-reactive protein (CRP), blood lipids) and the grey-scale, colour and 
spectral Doppler analysis of the CAs and IJVs in the two participant groups. 
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 Establish an association between lifestyle factors and the grey-scale, colour and 
spectral Doppler analysis of the CAs and IJVs in the two cohorts. 
 Establish an association between disability and the grey-scale, colour and spectral 
Doppler analysis of the CAs and IJVs in the active MS cohort. 
1.5 RISKS  
There are no known risks associated with diagnostic ultrasound imaging, however the as low 
reasonably achievable (ALARA) principle should be adhered to when interrogating soft tissue 
and vascular structures within the human body. Fowlkes and Hollard (1998:52) postulates that 
there are no known biological effects when diagnostic ultrasound imaging machines are used 
appropriately. Diagnostic ultrasound is an operator-dependent imaging modality, thus should 
only be used by trained sonographers.  
 
CONCLUSION 
Multiple statistically significant associations and comparisons between the ultrasound 
variables, genetic, biochemical and lifestyle parameters were found. Some of which is novel 
and that which corroborates with previous MS studies of similar context. 
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CHAPTER TWO 
 
LITERATURE REVIEW 
 
INTRODUCTION 
MS is described as the most frequently seen inflammatory demyelinating disease affecting the 
central nervous system (CNS)  resulting from the interaction of genetic and  environmental 
factors which are currently still not well understood (Kidd, 2001; Didonna &.Oksenberg, 2015;  
Sand, 2015; Leray et al., 2016). According to the Multiple Sclerosis International Federation 
(2013), the number of persons with MS worldwide has increased from 2.1 million in 2008 to 
2.3 million in 2013. The prevalence of the disease varies from high levels in North America 
and Europe to low levels in Eastern Asia and sub-Saharan Africa (2/100 000 population) (Leray 
et al, 2016). Epidemiological studies also indicate a higher prevalence of MS in countries of 
affluence further from the equator where high caloric, high fat diets are common (Hadgkiss et 
al., 2014: 125). Multiple sclerosis is a relatively common disease in Europe, the United States, 
Canada, New Zealand, and parts of Australia. In high-risk populations, the lifetime risk for MS 
is about 1 in 200 for women and  fewer for men (Ascherio & Munger, 2007) with the mean age 
of onset at approximately 30 years (Giampaolo et al., 2013). The female-to-male ratio for MS 
ranges between 1.5 and 2.5 in most populations (Ascherio & Munger, 2007). 
In 1967, Geoffrey Dean reported results of a survey on MS in the White South African 
population. The incidence, prevalence and mortality of the disease were high amongst the 
White South Africans with it being higher in the English-speaking and lower in Afrikaans-
speaking populations. The disease has been reported to be less common amongst the 
Coloured and Asian South Africans, and rare amongst Black Africans (Dean, 1967). Further 
studies on MS in South Africa by Modi et al (2008) state that there are approximately 5 000 
persons suffering from MS in South Africa with Gauteng and the Western Cape having the 
most persons with MS. The study concludes that MS is widely diagnosed in the White South 
African population and affects females more than males (F:M=3:1).  
Multiple sclerosis is associated with many symptoms which include physical (muscle 
weakness, weak reflexes, muscle spasm), mental and at times psychiatric disturbances due 
to the neural damage which occurs and blocks the communication among different parts of the 
nervous system (National MS Society, 2016). 
 
2.1 DESCRIPTION: MS 
Multiple sclerosis is stated to be the most common chronic disabling neurological disease of 
young adults that attacks the central nervous system (brain, spinal cord and optic nerves) 
(Paz Soldan & Rodriguez, 2002 ; National MS Society, 2016). This  chronic autoimmune 
inflammatory and demyelinating disease of the central nervous system causes destruction of 
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the fatty substance (myelin) that surrounds and insulates the nerve fibres as well as the nerve 
fibres themselves (Taylor et al., 2014; National MS Society, 2016). 
A damaged myelin sheath or nerve fibre will cause nerve impulses travelling to and from the 
brain to be distorted or interrupted which in turn produces the variety of symptoms found in MS 
patients. The damaged myelin forms scar tissue, termed sclerosis, giving the disease its name 
(National MS Society, 2016). 
There are 3 common disease courses of MS: relapsing remitting, primary progressive, and 
secondary progressive (National MS Society, 2017a; MS Association of America, 2019).  
2.2 CLASSIFICATION 
2.2.1 Relapsing-remitting Multiple Sclerosis  
Relapsing remitting MS (RRMS) is the most common disease course which is characterised 
by acute attacks of new or increasing neurologic symptoms. Approximately 85 per cent of 
persons with MS are diagnosed with RRMS. In RRMS, the nerve fibres and myelin are affected 
by the inflammatory attacks. The patients will experience periods when symptoms flare up 
aggressively (relapse/an exacerbation) followed by periods of good recovery (remission) 
(National MS Society, 2017a; MS Association of America, 2019). Some of the symptoms 
experienced by patients include visual impairment, numbness, intestinal and urinary disorders 
as well as learning and memory impairment. Each stage may set off new symptoms or 
exacerbate the existing ones. (Millefiorini et al., 1997; Ghasemi et al., 2017).  
 
2.2.2 Primary-progressive Multiple Sclerosis  
Primary-progressive MS (PPMS) affects approximately 10-15% of MS patients who experience 
a slow progressive downhill course without any distinct clinical episodes and who tend to have 
fewer MRI lesions (Hafler, 1999; Ghasemi et al., 2017). In this disease course, the patient’s 
neurologic function and disability worsens from the onset of symptoms without periodic 
relapses or remissions (National MS Society, 2017a; MS Association of America, 2019). It has 
been suggested by Rovaris et al (2006) that the median time between onset of PPMS and 
progression to the secondary progressive stage is 19 years. One third of relapsing- remitting 
disease patients go on to have progressive disease (Hafler, 1999). 
 
2.2.3 Secondary-progressive Multiple Sclerosis  
Secondary-progressive MS (SPMS) disease course is characterised as a progression from the 
initial relapsing-remitting course. Most MS persons diagnosed with RRMS will eventually 
transition to SPMS where there is a progressive worsening of neurologic function and disability 
over time (National MS Society, 2017a; MS Association of America, 2019). There are no 
occasional relapses, plateaus or remissions (Lublin & Reingold, 1996). Many MS patients 
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experience increased weakness, intestinal and urinary system disorders, fatigue, stiffness, 
mental orders and psychological impairment (Ghasemi et al., 2017). 
 
2.3 DIAGNOSTIC CRITERIA 
The criteria for diagnosis of MS, as seen in Table 2.1, which is based on the integration of 
clinical, imaging and laboratory assessments is known as the McDonald criteria. The criteria 
were updated in 2010 and revised again in 2017 by the International Panel on the Diagnosis 
of Multiple Sclerosis. The panel met to examine the requirements for demonstrating 
dissemination of lesions in space (DIS) and time (DIT) and focus on the application of the 
McDonald criteria (National MS Society, 2010; Polman et al., 2011; Thompson et al., 2017; 
Thompson et al., 2018). 
 
Table 2.1: The 2017 McDonald Criteria for Diagnosis of MS in patients with an attack at onset 
Number of clinical 
attacks 
Number of lesions with 
objective clinical evidence 
Additional Data Needed for the 
diagnosis of  MS  
≥2 clinical attacks ≥ 2  None* 
≥2 clinical attacks 1 (as well as clear-cut historical 
evidence of a previous 
attack involving a lesion in a 
distinct anatomical location†) 
None* 
≥2 clinical attacks 1  Dissemination in space demonstrated 
by an additional clinical attack 
implicating a different CNS site or by 
MRI‡ 
1 clinical attack ≥ 2 Dissemination in time demonstrated 
by an additional clinical attack or by 
MRI§ OR demonstration of CSF-
specific oligoclonal bands¶ 
1 clinical attack 1 Dissemination in space demonstrated 
by an additional clinical attack 
implicating a different CNS site or by 
MRI‡ 
AND 
Dissemination in time demonstrated 
by an additional clinical attack or by 
MRI§ OR demonstration of CSF-
specific oligoclonal bands¶ 
*No additional tests are required to demonstrate dissemination in space and time. ‡The MRI criteria for 
dissemination in space are described in Table 2.2. ¶The presence of CSF-specific oligoclonal bands does not 
demonstrate dissemination in time per se but can substitute for the requirement for demonstration of this measure. 
(Adapted from McDonald et al., 2001; Polman et al., 2011; Giampaolo et al., 2013; Thompson et al., 2017) 
 
 
Table 2.2: 2017 McDonald criteria for demonstration of dissemination in space and time by MRI 
in a patient with a clinically isolated syndrome 
Dissemination in space can be demonstrated by one or more T2-hyperintense lesions* that are 
characteristic of multiple sclerosis in two or more of four areas of the CNS: periventricular, cortical or 
juxtacortical, and infratentorial brain regions, and the spinal cord 
Dissemination in time can be demonstrated by the simultaneous presence of gadolinium-enhancing 
and non-enhancing lesions* at any time or by a new T2-hyperintense or gadolinium-enhancing lesion 
on follow-up MRI, with reference to a baseline scan, irrespective of the timing of the baseline MRI 
*Unlike the 2010 McDonald criteria, no distinction between symptomatic and asymptomatic MRI lesions is required. 
(Adapted from Polman et al., 2011; Thompson et al., 2017) 
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2.3.1 TOOLS FOR MAKING A DIAGNOSIS 
2.3.1.1 Medical History and Neurological exam  
Early detection of MS is key as it provides an opportunity to seek treatment and plan for the 
future. Obtaining a history about the onset of the first symptoms, neurological disorders and 
other illnesses such as diabetes, thyroid diseases, food habits, geographic locations and 
history of medications taken as well as substance abuse is important (National MS Society, 
2010; Ghasemi et al., 2017). A full neurological exam is performed which includes testing the 
cranial nerves (vision, hearing, facial sensation, strength, swallowing), sensation, reflexes, 
coordination, balance and walking (National MS Society, 2017b). 
 
2.3.1.2 Magnetic resonance imaging (MRI) 
Magnetic resonance imaging (MRI) is the imaging modality of choice, with 95-99% specificity, 
and allows for an earlier and more definitive diagnosis of MS. Presence of white matter lesions 
(WML) in different parts of the central nervous system can be detected with a high sensitivity 
and specificity. MRI can also differentiate between old, new and active lesions (Barkhof et al., 
1997; Tintoré et al., 2003; Dähnert, 2007;  National MS Society, 2010). This imaging modality 
offers 3 main applications in MS namely: 1) in conjunction with the characteristic symptoms,  it 
can provide an earlier diagnosis than symptoms alone; 2) enhance the understanding of the 
pathophysiology of MS and the pathophysiological changes which are related to the clinical 
manifestation of the disease; 3) it can monitor the effects of therapies and identify the response 
to therapy in MS patients (Lövblad et al., 2010). In addition, contrast agents, such as 
Gadolinium, are used as part of the MRI imaging protocol to enhance the WML in the brain 
(Gulani et al., 2017). Bakshi and colleagues (2014) also postulate that the application of MRI 
techniques such as dynamic contrast-enhanced imaging and double-inversion recovery 
imaging has improved the visualisation and characterisation of damage to white and grey 
matter. These techniques reveal new insights into the morphology and evolution of MS lesions. 
 
2.3.1.3 Visual Evoked Potential (VEP) 
Visual Evoked Potential (VEP) tests are recordings of the nervous system’s electrical 
responses to the stimulation of specific sensory pathways. VEP tests are useful in identifying 
a clinically silent lesion which sometimes provide evidence of scarring along the nerve 
pathways that do not show up during the neurological examination (National MS Society, 2010; 
Giampaolo et al., 2013). 
 
2.3.1.4 Cerebrospinal Fluid (CSF) Analysis 
Analysis of CSF obtained from a spinal tap can detect levels of certain immune system proteins 
and presence of oligoclonal bands (OCBs). These bands are found in the spinal fluid of 
approximately 90-95% of persons with MS and indicate immune response within the CSF. The 
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presence of OCBs or an increased immunoglobulin (IgG) index indicates the presence of 
intrathecal immunoglobulin synthesis which is considered the most important abnormality in 
the CSF (National MS Society, 2010; Giampaolo et al., 2013). However OCBs cannot be used 
as positive proof of MS because they are present in other diseases as well, therefore results 
must be interpreted in the context of the clinical diagnosis (National MS Society, 2010; 
(Giampaolo et al., 2013). 
 
2.3.1.5 Blood tests 
Blood sample analysis for detection of abnormal biochemical parameters, specifically vitamin 
deficiencies, may be diagnostically helpful (National MS Society, 2010; Ghasemi et al., 2017). 
In addition, several abnormal levels of homocysteine, total cholesterol, fibrinogen, high-density 
lipoprotein, low-density lipoprotein and c-reactive protein have been associated with peripheral 
arterial and cardiovascular disease. If these abnormal levels are demonstrated in MS, then it 
can be deduced that vascular risk factors play a role in the development and progression of 
the disease. 
 
2.4 PATHOGENESIS OF MULTIPLE SCLEROSIS AND DISABILITY PROGRESSION 
There are several factors that contribute to the development, exacerbation and progression of 
MS, however the pathogenesis of MS still remains unclear. Scientists believe that a 
combination of several factors (immunological, environmental, infectious and genetic) may be 
involved (Kidd, 2001; Zamboni et al., 2009a:392; National MS Society, 2010; Ghasemi et al., 
2017). Additional factors such as smoking, stress, diet, lifestyle and vascular disease may also 
play a causative role in the development of MS (D’haeseleer et al., 2011; Hedström et al., 
2014a; Koriem, 2016).  
Disability progression is a major challenge in MS, and there is no consensus as to the causes 
of disability progression (Thompson et al., 2018). Other studies (Davis et al., 2014) point to 
lifestyle factors as the main promoters or ameliorators of disability, suggesting that the cells 
that synthesise and repair myelin, oligodendrocytes (OLs), are the main effectors of disease 
outcome. Myelination of axons in the CNS by OLs is described as an extremely complex 
interaction, specific to vertebrates. Myelination allows the solitary conduction between nodes 
of Ranvier and increases both speed and efficiency of nerve conduction (Dulamea, 2017). In 
addition, to myelination, there is evidence that OLs  also provide trophic support and  serve as 
a source of energy (Funfschilling et al., 2013). According to Bartzokis (2011), myelin 
contributes to congitive capacity and physical functions.  Therefore, it can be deduced that an 
association exists between myelin destruction and status of disability. 
Disability status in MS can be accurately determined by clinicians using a specially designed 
instrument called the Expanded Disability Status Scale (EDSS) (Kurtzke, 1983). It is 
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considered to be the gold standard and is used in all clinical trials. The EDSS ranges from 0 
to 10, with higher values denoting greater disability (Table 2.3). 
 
 
Table 2.3 Kurtzke Expanded Disability Status Scale (EDSS) 
Score Description 
0 Normal neurological examination 
1 No disability, minimal signs in FS* 
1.5 No disability, minimal signs in >1 FS 
2 Minimal disability in 1 FS 
2.5 Mild disability in 1 FS or minimal disability in 2 FSs 
3 Moderate disability in 1FS or mild disability in 3 or 4 FSs. Fully ambulatory 
3.5 Fully ambulatory but with moderate disability in 1 FS and more than minimal disability in several 
others 
4 Fully ambulatory without aid, self-sufficient, up and about ~12hrs/day despite relatively severe 
disability; able to walk without aid/rest for ~500m 
4.5 Fully ambulatory without aid, up and about much of the day, able to work a full day, may otherwise 
have some limitation of full activity or require minimal assistance, characterised by relatively severe 
disability, able  to walk without the aid of rest for ~300m. 
5 Ambulatory without aid or rest ~200m; disability severe enough to impair full daily activities (works 
a full day without special provision) 
5.5 Ambulatory without aid or rest for ~100m; disability severe enough to preclude full daily activities 
6 Intermittent or unilateral constant assistance (stick, crutch, brace) required to walk for ~100m with 
or without resting 
6.5 Constant bilateral assistance (stick, crutches, braces) required to walk for ~20m without resting 
7 Unable to walk beyond ~5m, even with aid, essentially restricted to wheelchair; wheels self in 
standard wheelchair and transfers alone; up and about in wheelchair for ~12hrs/day 
7.5 Unable to take more than a few steps, restricted to wheelchair; may need aid in transfer; wheels 
him-/herself, but cannot carry on in standard wheelchair for a full day, may require motorised 
wheelchair. 
8 Essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed much of 
the day; retains many self-care functions; generally has effective use of arms 
8.5 Essentially restricted to bed much of the day; has some effective use of arms, retains some self-
care functions 
9 Confined to bed; can still communicate and eat 
9.5 Totally helpless bed-bound patient; unable to communicate effectively or eat/swallow 
10 Death due to MS 
FS = functional system, FSs = functional systems, MS = multiple sclerosis 
*Each system (visual, pyramidal, etc.) has a separate FS scale; scores are compiled to assist designation of the 
overall score. 
(Adapted from Kurtzke, 1983; Giampaolo et al., 2013) 
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2.4.1 ENVIRONMENTAL FACTORS 
Environmental factors including vitamin deficiency, diet, physical activity and obesity as well 
as smoking are associated with the onset of MS (Ghasemi et al., 2017). 
 
2.4.1.1 Vitamin D deficiency 
Vitamin D is a lipid-soluble vitamin, which acts like a hormone. Compared to other vitamins 
which have an essential organic compound that cannot be synthesized by the body and needs 
to be ingested, vitamin D can be synthesized (Ross et al., 2011). The active form of vitamin D, 
1,25-dihydroxyvitamin D (1,25[OH]2VD), also known as calcitriol, has chemical similarities to 
hormones such as testosterone, oestrogen, and cortisol. The active form of vitamin D plays a 
crucial role in lymphocyte activation and proliferation, T-helper cell differentiation, tissue-
specific lymphocyte homing, the production of specific antibody isotopes, and regulation of the 
immune response (Mora et al., 2008). According to Sintzel et al (2018) the main sources of 
vitamin D are sunlight, diet, and supplementation. 
MS is more prevalent in populations in colder climates which is related to lack of vitamin D due 
to lack of sunlight (Koriem, 2016). Mokry and colleagues (2015) conducted a randomized study 
to evaluate whether genetically lowered vitamin D level influences the risk of MS. The findings 
of the study were consistent with evidence from observational studies which demonstrated that 
low vitamin D levels influence the risk of MS and also reflect findings from functional studies 
that have implicated vitamin D as an important regulator in the expression of major 
histocompatibility complex (MHC) class II genes. This evidence provides reason to further 
investigate whether vitamin D supplementation may reduce MS susceptibility in those most at 
risk. Berezowska and colleageus (2019)  postulate that other epidemiologic and experimental 
studies (Runia et al., 2012, Wacker & Holick, 2013, Duan et al., 2014, Harandi et al., 2014, 
Fitzgerald et al., 2015)  investigating the effectiveness of vitamin D supplementation in MS 
have shown that low serum vitamin D levels may exacerbate MS symptoms and therefore are 
associated with higher relapse rates, occurrence of new lesions, and greater degree of 
disability. Therefore it can be concluded that higher serum 25(OH)D is significantly associated 
with lower MS incidence (Leray et al., 2016). 
The risk of MS is 40% lower among women reporting regular intake of at least 400 IU/day of 
vitamin D supplements. High circulating levels of vitamin D have been associated with lower 
risk of MS, and  higher serum 25-hydroxy-vitamin D (25 (OH)D) levels (>40 ng/ml) correlated 
with fewer MRI lesions and relapses (Correale & Gaitán, 2015). Although the correction of 
vitamin D insufficiency plays an  important role in MS risk and disease activity (Thompson et 
al., 2018), the impact of vitamin D supplementation on MS disability remains inadequately 
investigated.(Sintzel et al., 2018). 
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2.4.1.2 Diet 
Several studies have found associations between diet and disease outcome in MS. Davis et 
al. (2014) showed significant associations between disability as measured by the EDSS, and 
a low intake of fruits and vegetables. Van Rensburg et al. (2006) state that some MS patients, 
who present with low blood iron parameters, benefit from iron supplementation.  Iron and a 
functional folate-vitamin B12-methylation pathway are needed for regeneration of myelin. In a 
pilot study these MS patients were taking a regimen of nutritional supplements designed to 
promote the regeneration of myelin. Patients participating in the study also had blood tests 
done to determine the level of haemoglobin, serum iron, transferrin, Tf saturation, Ferritin, CRP 
(C-reactive protein), cholesterol, homocysteine, serum folate, vitamin B12, 25-OH Vitamin D, 
Fibrinogen and D-dimer. The results of the study indicated that the patients on the regimen 
displayed significant neurological improvement. 
A study conducted by Hadgkiss et al (2014) to explore the association between dietary factors 
(including fat, fruit and vegetable intake, dairy and meat consumption), and health-related 
quality of life (HRQOL), the disability and relapse rate in a large international sample of people 
with multiple sclerosis (MS) demonstrated a strong and significant association of healthy 
dietary habits with better physical and mental HRQOL and a lower level of disability in people 
with MS.  
Modern diets, which are predominantly heat-processed, contain high levels of advanced 
glycation end products (AGEs) which are naturally present in uncooked animal-derived foods. 
Grilling, broiling, roasting, searing and frying of these foods result  in acceleration of new AGE 
formation (Chen et al., 2013). Maillard-Lefebvre et al (2009) postulate that these products 
result from a non-enzymatic reaction between sugars and free amino acids of proteins. 
Furthermore, AGEs and their specific receptor for AGEs (RAGEs), were reported to be 
involved in microvascular and macrovascular complications. AGEs accumulate in the vessel 
wall where the cell structure and function is perturbed (Goldin et al., 2006). This pathological 
effect promotes oxidative stress and inflammation by binding with the cell surface (Chen et al., 
2013). 
The increased formation and accumulation of AGEs is associated with diabetes, renal failure, 
aging, inflammation and Alzheimer’s disease (Maillard-Lefebvre et al., 2009). According to 
Goldin et al (2006), AGEs also contribute to the development of atherosclerosis which is a 
major vascular complication of diabetes. In a study, “Advanced glycation end products: from 
precursor to RAGE: round and round we go” by Ramasamy et al (2012), a positive correlation 
was discovered between coronary artery disease and RAGE. Burke and colleagues (2004) 
examined atherosclerotic plaques in diabetic and non-diabetic subjects and observed that the 
extent of RAGE expression was significantly higher in the diabetic versus the non-diabetic 
population.  
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Jelinek and colleagues (2013) conducted a study on the role of fish consumption and omega 
3 supplementation in an international cohort of people with MS. The findings indicated that 
those consuming fish most frequently and those taking the largest doses of omega 3s were 
more likely to have normal mobility or only some disability. On the contrary, those not taking 
omega 3s were more likely to require major mobility support, and those taking omega 3s were 
more likely to be in the normal/some disability group. The study thus proves that frequent 
consumption of fish and omega 3 fatty acid supplementation are strongly associated with 
improved quality of life, reduced disease activity and disability in this large international cohort 
of people with MS.  
Fragoso (2014) states that a diet rich in omega-3 unsaturated fatty acids, polyphenols and 
probiotics has been described to influence the development and character of regulatory T 
lymphocytes (Tregs). These cell types are emerging as key targets for the dietary prevention 
of chronic inflammatory diseases. In addition, a diet high in salt generates Th17 cells which  
appear to be highly pathogenic and related to proinflammatory cytokines (Issazadeh-Navikas 
et al., 2012; Kim & Lee, 2013). Cytokines are described by Dinarello (2000) as regulators of 
the host’s responses to infection, immune responses, inflammation, and trauma. 
Proinflammatory cytokines act to make the disease worse whereas others serve to reduce 
inflammation and promote healing (anti-inflammatory).  
Diet is not only strongly associated with reduced risk of relapse but also associated with 
depression risk, measures of fatigue, BMI and metabolic markers in MS (Taylor et al., 2014; 
Yadav et al., 2016). 
 
2.4.1.3 Obesity and Physical Activity 
Overweight or obese individuals have twice the risk of developing MS in adulthood. Exposure 
to a diet high in fat and cholesterol, high protein, high sugar and excess salt intake  promotes 
obesity, cardiovascular disease and autoimmune diseases (Fragoso, 2014). Higher BMI 
correlates with increased intake of saturated fats and low physical activity (Davis et al., 2014).  
Increased BMI is also a risk factor for mortality from cardiovascular disease (CVD) – including 
coronary heart disease (CHD), ischaemic and haemorrhage stroke.  According to Kavak 
(2015), women who had higher weight in adolescence and BMI in early adulthood were 
younger at MS onset. In addition to this, Hedström and colleagues (2014b) assessed the 
interaction between adolescent obesity and HLA risk genes in the aetiology of MS and 
observed a significant interaction between the HLA-DRB1*15 allele and obesity with regard to 
MS risk. It can thus be hypothesized that obesity-related inflammatory/immunological 
mechanisms are a contributory factor in explaining the association between adolescent obesity 
and increased risk of MS. 
Exercise in MS is a form of treatment that does not lead to adverse effects and is beneficial in 
relation to various aspects of the disease, including fatigue, depression and disability (Fragoso, 
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2014: 891). According to Hägg et al (2005), physical activity improves cardiac and vascular 
function by lowering the carotid artery intima media thickness (IMT) and arterial wall stiffness. 
Arterial stiffness and increased IMT are the two main predictors of CVD. Increased IMT of the 
common carotid artery also serves as a surrogate marker for early atherosclerosis. 
Marck et al (2016) conducted a study on the prevalence of comorbidities, overweight and 
obesity and associations with modifiable factors in an international sample of Persons with 
Multiple Sclerosis (PwMS) recruited online through social media, MS societies and websites. 
The study data indicated that overweight and obese PwMS reported lower mental and physical 
health HRQOL compared to those with normal weight.  BMI was significantly associated with 
levels of disability, with obese participants 1.4 times more likely to have moderate to severe 
disability. Obesity and comorbidities including back pain, depression and anxiety may lead 
directly to decreased quality of life, and may indirectly interfere with health and wellbeing 
through lack of physical activity and quality of sleep. Prevention or treatment of comorbidities 
and obesity in PwMS should be an imperative goal in MS management (Merlino et al., 2009, 
Motl et al., 2011, Culpepper & Wallin, 2015). 
 
2.4.1.4 Smoking 
Smoking increases MS disability and is considered  one of the most established environmental 
factors influencing MS risk (Davis et al., 2014; Hedström et al., 2014a). Cigarette smoking 
increases the risk of developing autoimmune diseases; and the risk of developing MS among 
smokers is two-fold that of non-smokers. Smoking MS patients have a more severe disease 
course and a faster disability progression rate (Fragoso, 2014). Smoking does not only 
increase MS risk, it also shortens the time to the secondary progressive course of MS (SPMS). 
The cessation of smoking will therefore slowly decrease the negative effects of MS, 
independent of the cumulative dose of smoking (van der Vuurst de Vries et al., 2018). Current 
evidence (Ghasemi et al., 2017)  suggests that the nitric oxide (NO) and carbon monoxide 
(CO) produced by smoking plays a causative role in the destruction of nerve fibres.  NO is a 
toxic soluble gas which, in pathological concentrations, can damage neurons and 
oligodendrocytes (Dawson et al., 1993, Merrill et al., 1993). Lipid peroxidation and 
mitochondrial damage that result from NO can lead to oligodendrocytes apoptosis (cell death), 
axonal degeneration, and demyelination (Mitrovic et al., 1995) . Ghasemi et al (2017) also state 
that a previous study by Somogyi et al (1981) has shown that CO exposure leads to blockage 
of tissue oxygenation, degradation of myelin basic protein (MBP), axonal injury and a 
subsequent inflammatory response including activated microglia and CD4+ lymphocyte 
invasion of the CNS, which results in demyelination (Thom et al., 2004). Smoking also 
increases the level of C-reactive protein, fibrinogen and inflammatory factors (IL-6) and may 
lead to dysregulation of B-cell and T-cell homeostasis (Abbasi, 2016). Smoking, which also 
plays an important role in the development of early atherosclerosis, is also found to cause 
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reduction in the cross-sectional diameter of the internal jugular veins  (Nelson et al., 2014; Qu 
& Qu, 2015). 
 
2.4.2 GENETIC FACTORS 
MS is not a monogenetic disease although there are numerous genetic changes which are 
responsible for MS symptoms. In the 1970s, the human leukocyte antigen (HLA) locus was the 
first genetic factor related to the disease. This locus, which plays a role in MS diagnosis, is 
located in the short arm of chromosome 6, in a region called major histocompatibility complex 
(MHC) (Muñoz-Culla et al., 2013, Yaldizli et al., 2016, Goodin, 2015). Within this region, the 
genes encode highly polymorphic cell-surface glycoproteins that are key components of the 
immune system (Muñoz-Culla et al., 2013).  The HLA locus contains many genes that have 
important functions in the immune system (Küçükali et al., 2015). Within this region HLA-DR2+, 
HLA-DQ6 , DQA 0102 and DQB1 0602 , HLA-DRB1, DR15 , DRB1*1501, and DRB1*1503  
are genes susceptible to the onset of MS (Ghasemi et al., 2017). Furthermore, according to 
Ghasemi et al (2017), there are studies which show that the risk of MS in family members of a 
patient depends on the amount of genetic information they share (Ebers et al., 1995, Sadovnick 
et al., 1996, Sadovnick et al., 1999). 
HLA genes are also related to other autoimmune disease such as Diabetes Type I. Specifically, 
the HLA-DRB*1501 haplotype is the genetic factor most strongly associated with the 
development of MS (Yaldizli et al., 2016). Okuda et al (2009) conducted a study on the 
“Genotype–Phenotype correlations in multiple sclerosis: genes influence disease severity 
inferred by 1HMR spectroscopy and MRI measures” and observed a clear association between 
DRB1 * 1501* status and four domains of disease severity. In a sample of 505 MS patients, 
DRB1*1501+ patients had significantly more women (74% versus 63%; P=0.009) and a 
younger mean age at disease onset (32.4 years versus 34.3 years; P=0.025).  Their findings 
suggest that DRB1*1501+ increases disease severity in MS. However, recent hereditary 
studies showed that at least twelve genes outside HLA in chromosome 6 are also related to 
MS (Koriem, 2016). It is therefore clear that HLA-DRB1*15:01 has the strongest association 
with MS risk (Didonna & Oksenberg, 2015). 
 
2.4.3 VASCULAR AND BIOCHEMICAL FACTORS 
There are indications that vascular factors may play a role in demyelination since myelin 
production and maintenance in the brain is dependent on the delivery of nutrients and removal 
of toxic waste products by the blood (Davis et al., 2014). According to D’haeseleer et al (2011) 
there are three forms of vascular abnormalities associated with MS: first, an increased risk for 
ischaemic disease; secondly, global cerebral hypoperfusion and thirdly, a chronic state of 
impaired venous drainage.  
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2.4.3.1 Vessel Wall  
The arterial and venous vessel wall is comprised of 3 layers; the intima (innermost luminal 
layer), media (middle) and adventitia (outermost layer). The intimal layer is lined by the 
endothelium which is a continuous layer of flat polygonal endothelial cells (ECs) that come into 
direct contact with blood flow (Sumpio & Chin, 2014:34). The endothelium, which participates 
in physiologic and pathologic processes, also reacts to physical forces, chemical signalling, 
and immunologic mediators (Sumpio & Chin, 2014:34). The endothelium provides a 
continuous lining throughout the arteries, capillaries, veins, heart valves, and endocardial 
surfaces. The ECs are covered by a glycoprotein coat (glycocalix) that is accountable for the 
antithrombogenic properties of the endothelial surface (Levy & Tedgui, 1999). The glycocalix 
also reduces friction from blood flow and serves as a barrier for fluid loss through the vessel 
wall. The thickness of the glycoprotein coat varies across the vascular tree (van den Berg et 
al, 2003). During inflammation, the glycocalix is sheared off, permitting the attachment of 
leukocytes and the transport of water from microvessels, resulting in the possible initiation of 
atherosclerotic lesion development (Sumpio & Chin, 2014). A positive association exists 
between lumen diameter and acute myocardial infarction (Kappus et al., 2014). Carotid artery 
lumen diameter is influenced by carotid intima media thickness (cIMT), where an increase in 
cIMT causes reduction of the lumen diameter. According to Kamenskiy et al. (2015), the carotid 
artery bulb diameter increases with increasing age. This could be related to degradation of 
intramural elastin in the vessel walls. 
 
Tettey et al (2014) postulate that vascular risk factors and vascular comorbidities such as 
obesity, dyslipidaemia, type-2 diabetes and cardiovascular disease have been associated with 
MS onset and disease progression. 
 
2.4.3.2 Homocysteine and vascular disease 
Increased homocysteine (Hcy) levels in MS patients are associated with vascular damage and 
iron deficiency as described by Van Rensburg et al (2006). The risk for the development of 
atherosclerotic vascular disease is increased with mild to moderate elevation of 
homocysteinemia (Guo et al, 2009). There are two types of hyperhomocysteinemia: firstly, the 
rare but severe form due to major genetic mutations of the enzymes implicated in 
homocysteine metabolism; secondly the more common form causes moderately elevated 
homocysteine levels related to a pathogenesis such as genetic and environmental factors 
(Hankey & Eikenboom, 1999). Increased levels of homocysteinemia are also associated with 
endothelial dysfunction in blood vessels (Woo et al, 2002). Hyperhomocysteinemia can cause 
injury to the endodermis of the blood vessels, activate the platelets and enhance the production 
of fibrinogen, which is associated with vascular damage (Reinhart, 2003). This results in the 
proliferation of smooth muscle cells, which can cause narrowing (stenosis) of the lumen of 
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blood vessels. Long term use of folic acid improves arterial endothelial function and has 
potential of preventing atherosclerosis in persons with hyperhomocysteinemia (Guo et al, 
2009). 
According to Ďurfinová et al (2018), an elevated homocysteine serum level is also an 
independent cardiovascular disease risk factor modifiable by nutrition. Hyperhomocysteinemia 
(> 15 μmol/l) may lead to an enhancement of the adverse effects of risk factors like  
hypertension, lipid and lipoprotein metabolism, as well as promotion of the inflammation 
development (Ganguly & Alam, 2015). 
 
2.4.3.3 High-density lipoprotein (HDL) and vascular disease 
High-density lipoprotein (HDL), a biomarker, is a heterogeneous complex of differing size, 
density, surface charge, and lipoprotein content. Serum levels of this biomarker is thought to 
be inversely related with atherosclerotic vascular disease risk (Chang et al., 2015) . Risk 
factors for coronary artery disease (CAD) are the same as for cerebrovascular disease. 
Measurement of the IMT of the carotid artery (CIMT) by B-mode ultrasound is regarded as the 
technique used to quantify atherosclerosis. Prediction of patients at risk of atherosclerosis 
allows preventative measures to be implemented to avoid progress of the disease (Stein, 
2004). Increased CIMT is widely accepted to be a surrogate marker for early atherosclerosis, 
and risk factors include increased hypertension, body mass index (BMI), LDL cholesterol, 
homocysteine and fibrinogen. IMT also increases with age (Grebe et al., 2010).  
 
2.4.3.4 Cholesterol, Low-density lipoprotein (LDL) and vascular disease 
Cholesterol plays an important role in neuronal physiology. Most of the cholesterol in the adult 
brain is in the myelin sheath formed by oligodendrocytes to insulate axons. The important 
source of cholesterol for peripheral tissues are low density lipoprotein particles (LDL) 
(Ďurfinová et al., 2018). Low density lipoprotein cholesterol (LDL-C) plays a causative role in 
the development of atherosclerotic cardiovascular disease (ASCVD) (Penson et al., 2018). 
The LDLs which are driven by arterial blood pressure are carried through the arterial wall by 
fluid flux. In the arterial intima, LDLs could become prone to oxidation or other modification. 
(Ďurfinová et al., 2018). As described by Penson et al (2018), the radical chain oxidation of 
LDL fatty acids causes modification of ApoB100 on LDL surface. Scavenger receptors on 
macrophages recognise the modified ApoB100 and the immune cells digest the ox-LDL 
(oxidised LDL) and transform into foam cells. The foam cells grow until they rupture, which 
attracts more immune cells which finally results in the inflammation of the arterial wall and 
vascular dysfunction. 
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2.4.3.5 Carotid intima-media thickness (CIMT) and cardiovascular disease (CVD) 
The arterial wall is comprised of 3 layers (intima, media and adventitia) where intima-media 
(IM) thickening (>0.8mm) of the carotid arteries serves as a surrogate marker for early 
atherosclerosis. Carotid artery atherosclerosis is known to be associated with symptoms of 
cerebral ischaemia. The carotid intima-media thickness (cIMT), measured by carotid 
ultrasound, is also used to predict the occurrence and identify persons at risk of cardiovascular 
disease (Lee & Park, 2014; Qu & Qu, 2015; Müller-Scholden et al., 2019). 
Atherosclerosis, which may begin in childhood as arterial damage in the intima, is described 
as an inflammatory disease of the vascular wall (usually arterial), where components of the 
immune system are involved in the steps of the atherosclerotic process (Ross,1999; Blake & 
Ridker, 2001; Glass & Witztum, 2001; Hallenbeck et al., 2005; Hansson, 2005; Calder,  2012;  
Owens, 2014; Akbari-Sedigh et al., 2019). The endothelium lines all blood vessels and in 
normal physiological conditions, contributes to vascular homoeostasis, by actively regulating 
vascular tone, controlling  permeability between the bloodstream and the underlying vascular 
wall, regulating medial smooth muscle cell growth, and controlling platelet function, coagulation 
and fibrinolysis (Baker et al., 2018). The mean and maximum CIMT are independently 
influenced by age, blood creatinine levels and non-high density lipoprotein (HDL) cholesterol 
levels (Bosevski, 2011).  Circulating low-density lipoprotein concentrations are associated with 
CIMT (Ross et al., 2012; Dessein et al., 2013), and high levels of oxidized LDL (OxLDL) are 
significantly associated with increased levels of CIMT (Lopes-Virella et al., 2011, Hunt et al., 
2013, Paim et al., 2013). Several studies have also shown that low serum 25-hydroxyvitamin 
D3 (25(OH)D) levels in childhood were associated with increased CIMT in adulthood 
(Robinson et al., 2014) Therefore, early application of 25(OH)D or coupling with oral lipid-
lowering drugs such as statins may be helpful for preventing subclinical atherosclerosis (Qu & 
Qu, 2015). 
Multiple sclerosis patients could have an increased CVR (cardiovascular risk), based on 
elevation of some aggressive and atherogenic molecules in serum such as  Ox-LDL and small  
HDL-cholesterol (HDL-c) (Palavra et al., 2013).  Lipoproteins are involved in the regulation of 
neural functions in the CNS through local mechanisms that are linked to systemic lipid 
metabolism (Gotthardt et al., 2000, Stockinger et al., 2000).  
Palavra and colleagues (2013) conducted a study aimed to characterize a population of 
multiple sclerosis (MS) patients in terms of traditional and new cardiovascular risk factors and 
assess their putative correlation with clinical disease activity (evaluated by the Expanded 
Disability Status Scale [EDSS]).  Their findings indicated that worsening MS disability was 
associated with higher levels of LDL, total cholesterol and triglycerides. MS patients appear to 
present a profile indicative of an increased CVR, when compared with healthy subjects of well- 
matched age and sex. The clinical activity of the disease (given by the EDSS score) correlated 
significantly and directly with some markers of CVR, specifically Ox-LDL. It is therefore 
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recommended that early pharmacotherapeutic intervention to prevent premature development 
of cardiovascular disease in these patients should be considered. 
 
2.4.3.6 Extracranial arterial and venous pathology 
Current literature does not demonstrate any studies or study data on the prevalence of carotid 
artery disease in persons with MS. However, there has been renewed interest in studying 
extracranial venous changes associated with the development and MS. This is a result of a 
controversial finding that abnormalities in the extracranial venous system  is associated with 
the disease (Beggs, 2013). This condition, known as chronic cerebrospinal venous 
insufficiency (CCSVI), is a venous pathology that is believed to play a causative role in the 
development of the disease (Zamboni et al. 2009a; Zamboni et al. 2009a; Simka et al. 2010;  
Monti et al., 2011;  Nicolaides et al., 2011; Zivadinov et al., 2011; Barreto et al., 2013; Comi et 
al., 2013; Farina et al., 2013; Krsmanovic et al. 2013; Leone et al., 2013, Zavoreo et al., 2013; 
Zivadinov et al., 2013; Ciciarello et al., 2014, Rasman, 2015). CCSVI is characterized by 
multiple intraluminal stenotic malformations of the internal jugular veins (IJVs) and the azygos 
vein, and has been shown to be associated with impaired blood flow from the brain to the heart 
in patients with MS (Zamboni et al., 2012). CCSVI also appears to be associated with changes 
in the intracranial vasculature, with a strong correlation shown between CCSVI severity and 
decreased cerebral blood flow (CBF) in both the white matter (WM) and grey matter (GM) of 
patients with MS (Beggs, 2013). 
Decreased arterial flow to the brain may cause a decreased cerebral venous outflow in MS 
patients (Sundstrőm et al, 2010). The internal jugular veins (IJVs) are considered to be the 
main outflow pathway for intracranial venous blood (Schreiber et al., 2003:1802). A cross-
sectional study on the prevalence of abnormal blood flow patterns and effects of biochemistry 
and lifestyle factors on the major neck vessels in patients with Multiple Sclerosis, demonstrated 
a significant difference in cross-sectional diameters of IJVs. Smoking MS patients displayed a 
smaller IJV diameter in comparison to non-smoking MS patients on Doppler Ultrasound 
(Nelson, et al., 2014). Haemodynamic of the IJVs  may reflect cerebral venous drainage 
conditions and appear to influence intracranial hemodynamics, perfusion of the brain as well 
as  the dynamics of CSF system (Mancini et al., 2014). 
 
Doppler Ultrasound is useful for identifying outflow disturbances and morphological 
abnormalities associated with the IJVs and vertebral veins (VVs). Krsmanović et al (2013) 
conducted a study  to assess the prevalance of CCSVI and small IJVs among MS patients and 
controls using Doppler ultrasound. Their findings illustrated a higher EDSS among small IJV-
positive patients in comparison to those presenting with normal veins. IJV stenosis, is defined 
either as a cross-sectional area (CSA) ≤ 0.3 cm2  or as a local CSA reduction of ≥50% (Zamboni 
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et al., 2009a;  Zamboni et al., 2009b; Doepp et al., 2010) and  is one of the most frequently 
observed CCSVI criteria in patients with MS (Krsmanović et al., 2013). 
On the contrary, Wattjes and colleagues (2011) conducted a study aimed to investigate 
the intracranial and extracranial venous anatomy and the venous flow profile in patients with 
MS and healthy controls using magnetic resonance venography (MRV). Their findings of 
anomalies of the cranial venous outflow anatomy were frequently observed in both MS patients 
and healthy controls. It is likely that these findings reveal anatomical variations of venous 
drainage rather than clinical relevant venous outflow obstructions. These findings were 
corroborated by a recent prospective 5-year follow-up study (Gandhi et al., 2019), assessing 
the relationship of variations in extracranial  venous anatomy, indicative of chronic 
cerebrospinal venous insufficiency (CCSVI) on Doppler sonography, according to the 
International Society for Neurovascular Disease (ISNVD) proposed consensus criteria, with 
clinical outcomes and disease progression in MS patients. The study data confirmed that the 
presence of variations in extracranial venous anatomy is not exclusive to the MS patients, as 
there was no significant difference in the prevalence of those in MS patients versus His (healthy 
individuals), at the follow-up. Thus, a causal association between CCSVI and MS cannot be 
implied. 
 
2.5 TREATMENT 
The treatment of MS is challenging and involves the use of immunomodulator drugs and 
symptom management to treat the specific symptoms such as fatigue, spasticity, and pain. 
The indication ultimately depends on the clinical course of the disease (Garg & Smith, 2015; 
Huang et al., 2017). 
Treatments for MS are divided into 3 categories namely:1) acute relapse management, 2) 
disease-modifying treatments (DMTs) and 3) symptomatic treatments. 
 
1)  Acute relapse management -   For a relapse of  moderate functional severity or worse, 
Doshi & Chataway (2017) report that a high-dose of 500–1 000 mg per day of 
methylprednisolone therapy for 3–5 days should be considered. Although corticosteroids are 
not disease modifying, they can be used to shorten the duration of the relapse. 
 
2) Disease-modifying treatments (DMTs) - There are over 10 approved MS DMTs which vary 
in degrees of efficacy for reducing relapse risk and preserving neurological function. However, 
their long-term benefits remain unclear.  The approved DMTs include 4 interferon beta 
preparations and glatiramer acetate (GA), Mitoxantrone, Natalizumab, 3 oral DMTs 
(fingolimod, teriflunomide, and dimethyl fumarate/BG-12), Alemtuzumab, Ocrelizumab, 
Laquinimod and Daclizumab. (Wingerchuk & Carter, 2014; Garg & Smith, 2015;  Huang et al., 
2017). 
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3) Symptomatic treatments - Patients with MS experience a large range of significant and 
disabling symptoms, including fatigue, cognitive impairment, bladder dysfunction, faecal 
incontinence, pain and spasticity  as illustrated in Table 2.4 (Garg & Smith, 2015, Doshi & 
Chataway, 2017). 
 
Table 2.4 Suggested symptomatic treatment in MS 
Symptom Drug Interventional  Multidisciplinary 
input 
Fatigue Amantadine  Occupational therapy 
and physiotherapy: 
fatigue management 
assessment and exercise 
programme 
Cognition/low mood Depression: e.g. 
citalopram duloxetine 
 Neuropsychology 
service, cognitive 
behavioural therapy, 
occupational therapy 
Spasticity Baclofen, abapentin, 
tizanidine,clonazepam, 
dantrolene 
Intrathecalclofen, 
botulinum toxin 
 
Physiotherapy 
Bladder Frequency/urgency: 
oxybutynin, solifenacin, 
tolterodine, mirabegron 
 
Nocturia: 
desmopressin/DDAVP 
spray 
Residual bladder volume 
>100 ml: intermittent self-
catheterisation or 
permanent catheter; 
intravesicular botulinum 
toxin, 
Uro-neurology 
Sexual dysfunction Sildenafil, tadalafil, 
alprostadil, yohimbine 
 Uro-neurology 
Constipation Fibre/fluid, bulking 
agents, osmotic stimulant 
laxatives, suppositories, 
transanal irrigation 
  
Faecal incontinence Codeine, loperamide 
 
 Biofeedback, neuro- 
gastroenterology 
Pain Amitriptyline, pregabalin, 
gabapentin, lamotrigine 
  
Ataxia/tremor Propranolol, clonazepam, 
levetiracetam, isoniazid 
(with pyridoxine), 
carbamazepine, 
ondansetron 
 
Botulinum toxin, 
thalamotomy 
Physiotherapy, 
occupational therapy, 
audiovestibular therapy 
 
Oscillopsia Gabapentin, memantine, 
levetiracetam, 
clonazepam, baclofen 
 Neuro-ophthalmology 
(Doshi & Chataway, 2017). 
 
According to Feinstein et al (2015)  physiotherapy has a small, but a significant beneficial effect 
on balance in MS patients with mild to moderate disability. However, the evidence for the 
effects in severely disabled persons are scarce. In addition, exercise may delay disease 
progression by reducing inflammation and encouraging neuronal repair (Feinstein et al., 2015). 
Huang  and colleagues (2017) state that vitamin D provides beneficial therapeutic effects in 
small studies and administration of simvastatin may be beneficial for MS. 
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CONCLUSION 
MS is a complex disease attributed to multiple genetic, biochemical, lifestyle, environmental 
and vascular factors which influences the onset and progression of the disease. Various 
studies have been performed to establish a significant association between the various factors 
and MS, however some of the findings are equivocal and inconclusive This means that there 
is still a demanding need for further research studies to be undertaken to identify the causes 
for the development and disability progression of the disease, which will inform treatment 
methods for improved quality of life in MS patients. 
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CHAPTER THREE 
 
RESEARCH DESIGN AND METHODOLOGY 
 
INTRODUCTION 
A case-control study was performed on a cohort of 50 participants which included 25 controls 
and 25 participants clinically diagnosed with multiple sclerosis (MS). The purpose of the study 
was to use ultrasound imaging, in conjunction with lifestyle factors, biochemical and genetic 
testing, to identify risk factors associated with extracranial vascular pathology in MS. All 
participants received a carotid artery (CA) and internal jugular vein (IJV) ultrasound that 
included colour and spectral Doppler analysis. 
This ultrasound study was a component of another ethically approved study titled: “The 
implementation of a comprehensive gene-based, pathology supported intervention program in 
patients with disorders that include a component of demyelination such as multiple sclerosis 
(MS)” NO7/09/203 (Division of Chemical Pathology, Tygerberg Hospital and University of 
Stellenbosch). MS patients were age-matched with MS free controls which were recruited by 
the principal investigator of the ultrasound study (PI). Ultrasound examinations of all the 
participants were performed by the PI at a Radiology practice, Cape Town, Western Cape, 
South Africa. 
3.1 HYPOTHESIS 
Genetic, vascular, biochemical and lifestyle factors are significantly associated with the 
development of extracranial vascular pathology in Multiple Sclerosis. 
3.2 RESEARCH OBJECTIVES 
The main objectives of the study were to: 
 Compare the Ultrasound findings of the extracranial vascular systems in the two 
cohorts (MS and free from MS) 
 Establish an association between the Human Leukocyte Antigen (HLA) DRB1*1501 
gene and the Grey-scale, Colour and Spectral Doppler analysis of the carotid arteries 
(CAs) and internal jugular veins (IJVs) in the two cohorts. 
 Establish an association between biochemical markers (homocysteine, Vitamin D, iron, 
Vitamin B12, C-reactive protein (CRP), blood lipids) and the grey-scale, colour and 
spectral Doppler analysis of the CAs and IJVs in the two participant groups. 
 Establish an association between lifestyle factors such as physical activity, body mass 
index (BMI) and diet; and the grey-scale, colour and spectral Doppler analysis of the 
CAs and IJVs in the two cohorts. 
 Establish an association between disability and the grey-scale, colour and spectral 
Doppler analysis of the CAs and IJVs in the active MS cohort. 
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3.3 SAMPLE 
3.3.1 Sample size 
A minimum of 25 participants with MS were required to demonstrate statistically significant 
results. The formula used for calculation of the sample size was:  
n = 4 (p)(1-p)/interval2 
n = 4(0.5)(1-0.5)/(0.2)2 
   = 4(0.5)(0.5)/0.04 
   =1/0.04 
   = 25 
 
n -sample size 
p- observed population (0.5=50%) 
confidence interval -0.2 (20%) 
A sample of 50 participants were recruited with one group of 25 as the active MS cohort and 
the other of 25 as the control group.  
 
3.3.2 Inclusion and Exclusion criteria 
Inclusion criteria were as follows: 
Active cohort, 
 participants clinically diagnosed with MS according to McDonald’s criteria (McDonald 
et al., 2001). 
 
Control group, 
 age-matched participants free of MS 
 
Both cohorts included: 
 only female patients from all race groups and ages (>18 years). According to Modi et 
al (2008), more females than males are diagnosed with MS in South Africa, therefore 
only females were included in the study. 
 persons who were normotensive (including persons on medical management for 
hypertension) 
 non-smokers exposed to passive smoking  
25 
 
 
Exclusion criteria were as follows: 
 Persons who have been diagnosed with other neurological diseases including 
neuromyelitis and acute disseminated encephalomyelitis (ADEM). 
 Persons previously diagnosed with carotid artery and extracranial venous disease. 
 Persons who have a previous medical history of diabetes mellitus and cardiovascular 
disease. 
 Male patients 
3.4 DATA COLLECTION 
The participants’ age, gender and ultrasound findings were captured from the ultrasound 
reporting templates onto the research datasheet. Biochemical data (full blood count, 
haematinics, inflammatory markers, cardiac markers/risk factors, lipids and vitamins) were 
retrieved from the participants’ blood results. Medical and lifestyle data were retrieved from the 
questionnaire that participants completed on entry to the study and the EDSS from the 
disability status score sheet. Genetic data was extracted from the password-protected website 
Gknowmix.com where only registered users have access. All retrieved data was captured onto 
the Microsoft Excel research database. 
3.5 DIAGNOSTIC ULTRASOUND 
The as low as reasonably achievable (ALARA) Doppler ultrasound thermal index of <100 
mW/cm2 was maintained at all times during the ultrasound examinations to prevent the possible 
adverse biological effects of Doppler ultrasound which may include heating and cavitation of 
tissues (Kremkau, 2006: 352). 
The GE (General Electric) Logiq S8 and  Logiq E9 ultrasound systems with Grey-scale imaging 
and Doppler facilities (colour and Spectral Doppler) and a 9-12 MHz multifrequency linear 
transducer with coupling gel were used to assess the carotid arteries and extracranial venous 
system. A high frequency linear transducer was used to optimally visualise the superficial 
vasculature, namely the common carotid arteries (CCAs), internal carotid arteries (ICAs), 
external carotid arteries (ECAs), vertebral arteries (VAs) and internal jugular veins (IJVs).  
Grey-scale imaging was used to: 
 interrogate the major neck vessels for tortuosity, anatomical variation, plaque formation 
in the carotid arteries,  
 measure the intima media thickness (IMT) of the CCA, 
 measure the cross-sectional diameter (CSD) of the proximal, mid and distal CCA, 
 measure the CSD of the proximal ICA, ECA and proximal VA  
 measure the cross-sectional area (CSA) of the proximal IJV at the level of the 
supraclavicular notch. 
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Colour Doppler was used to assess the vessels for patency, direction of blood flow, any colour-
filling defects and presence of an occlusion.  
Spectral Doppler analysis was used to detect carotid artery stenosis by measuring the peak 
systolic and end diastolic velocities within the carotid vessel. The pulse repetition frequency 
(PRF) for this study was adjusted to 150 cm/s for assessment of the carotid arteries, 100 cm/s 
for the VAs and 60 cm/s for the IJVs. These frequencies were adjusted to detect blood flow at 
the specified velocities in each vessel and prevent the artefact, aliasing which is a limitation 
associated with spectral Doppler analysis. The resistance of the distal vascular bed the vessels 
feed influences the blood flow velocity and blood flow profile exhibited within the vessel. The 
waveforms of the carotid vessels, VAs and IJVs were illustrated using spectral Doppler 
analysis.  
The captured ultrasound images were stored onto the ultrasound system’s hard drive and 
picture archive communications system (PACS). The ultrasound images were also copied onto 
a compact disc (CD) using the Epson PP-100 II CD writer. 
3.5.1 Carotid Ultrasound protocol 
The carotid and vertebral arteries were imaged using grey-scale imaging, colour and spectral 
Doppler analysis. The vessels were assessed for plaque formation, patency and stenosis. 
The carotid ultrasound findings for each participant were captured onto a datasheet (See 
Appendix A). 
Table 3.1 illustrates the recommended normal and abnormal values of ultrasound findings. 
 
Table 3.1 Carotid Ultrasound findings 
DOCUMENTED ULTRASOUND FINDING  NORMAL and ABNORMAL VALUES  
Intima media thickness (IMT) of CCA  IMT >0.8 mm is regarded as abnormal (Stone & 
Hass, 2014)  
ICA (internal carotid artery)  Peak systolic velocity (PSV) should be <125 
cm/s with a high end diastolic velocity (EDV)  
(Myers & Clough, 2004:104)  
CCA (common carotid artery)  The CCA is regarded as 50% stenotic if the PSV 
is increased more than twofold in comparison 
with the proximal velocity (Myers & Clough, 
2004:107)  
ECA (external carotid artery)  The PSV should not exceed 200 cm/s (Carroll, 
2005:959)  
Peak systolic velocity ratios of ICA/CCA  A ratio of <2 is associated with a 0-49% ICA 
stenosis. A ratio that exceeds 3.5 corresponds 
to >75% stenosis (Carroll, 2005:959 & NASCET, 
1991).  
End diastolic velocity of ICA  An end-diastolic velocity of <40cm/s is indicative 
of 0-49% ICA stenosis (NASCET, 1991)  
Plaque formation (location, size and morphology)  
Location and degree of stenosis if present  
Occlusion/s if present  
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The North American Symptomatic Carotid Endarterectomy Trials (NASCET) criteria was 
used to grade internal carotid artery stenosis, where a stenosis ≥ 70% is regarded as 
significant (NASCET, 1991) (see Appendix B).  
 
3.5.1.1 Grey-scale imaging of the carotid artery 
Using grey-scale imaging the CCA was assessed in the transverse (Figure 3.1) and 
longitudinal planes (Figure 3.2) from the supraclavicular notch up to its bifurcation and along 
the ICA and ECA to its distal extent. This assessment was performed to identify any anatomical 
variation, tortuosity and plaque formation. 
 
                               Figure 3.1.Ultrasound model in supine position with  
                               transducer in transverse plane. 
                                          
 
 
 
 
 
Figure 3.2 Ultrasound model in supine position with the transducer in the longitudinal 
plane assessing the CCA.  
 
An average IMT over a 2 cm segment of the mid CCA was measured in the longitudinal plane 
(Figure 3.3). An IMT of 0.8mm is regarded as upper limit of normal. The ultrasound system 
has a built-in software programme which calculates the average IMT of the sampled segment.  
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Figure 3.3 Grey-scale image of a normal left CCA in the longitudinal plane.  
Average IMT = 0.57mm (upper limit of normal = 0.8mm) 
        (Permission granted by patient #C15). 
 
 
 
The cross-sectional diameter (CSD) of the proximal, mid and distal CCA and proximal ICA and 
ECA were measured wall to wall and recorded (See Figure 3.4). 
 
 
Figure 3.4. Cross-sectional diameter (CSD) of the mid                                                                         
right CCA. CSD = 7 mm (Permission granted by 
                                  patient #CO7) 
                                      
 
 
3.5.1.2 Colour Doppler of the carotid artery 
Colour Doppler is useful in assessing patency of the vessel, direction of blood flow as well as 
detecting colour filling defects which are indicative of abnormal blood flow within the vessel. 
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The CCA, ICA, ECA and vertebral artery were scanned in the longitudinal plane and assessed 
using colour Doppler. The gain was adjusted so that only the lumen of the vessel displayed 
colour flow, thus preventing colour aliasing. The colour box was placed in a position parallel to 
the vessel being sampled. 
3.5.1.3 Spectral Doppler analysis of the carotid artery 
Once the vessels have been assessed with grey-sale and colour Doppler imaging, spectral 
Doppler was used to measure the peak systolic velocity (PSV) and end diastolic velocity (EDV) 
of the CCA, ICA, ECA and VA.  
A Doppler angle of 60° and a sample volume (SV) of 2 mm was used to produce an accurate 
velocity measurement. The angle cursor should be parallel to the wall of the segment of the 
vessel being sampled as illustrated in Figure 3.5. At least 3 waveforms of each vessel should 
be captured and recorded. 
 
                Figure 3.5. Colour and spectral Doppler analysis of  
                a normal left common carotid artery (CCA) at a Doppler 
                angle of 60 degrees (solid arrows). The peak systolic velocity 
                = 134.7 cm/s, end diastolic velocity = 33.9 cm/s. 
                               (Permission granted by patient #MS03) 
                 
 
 
A spectral waveform of the mid CCA (Figure 3.5) approximately 3 cm distal to the carotid bulb 
was recorded and the proximal and mid segments of the ICA (Figure 3.6) and ECA (Figure 
3.7). If the carotid bifurcation is at the level of the angle of mandible then only the proximal 
segments of the ICA and ECA can be optimally visualized and assessed. The PSV and EDV 
of the mid VA (Figure 3.8) was also recorded. 
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                                  Figure 3.6. Colour and spectral Doppler analysis of a  
        normal left internal carotid artery (ICA).  
                                  peak systolic velocity = 93.2cm/s, end diastolic 
                                  velocity= 30.7 cm/s. (Permission granted by patient 
                                #CO2) 
 
                                  
 
 
                                Figure 3.7. Spectral Doppler analysis of a normal left  
                                proximal external carotid artery (ECA). PSV=128.5 cm/s,  
       EDV=26.1 cm/s (Permission granted by patient #CO12) 
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    Figure 3.8. Colour and spectral Doppler analysis of a normal  
                              left mid vertebral artery. PSV=52.7 cm/s, EDV=21.2 cm/s.  
                   (Permission granted by patient #CO1) 
                              
3.5.2 Extracranial cerebrospinal venous ultrasound protocol 
Grey-scale imaging, colour Doppler and spectral Doppler were employed to assess the internal 
jugular vein in longitudinal and transverse planes. 
The IJV was assessed with the patient in the supine position as the IJV is the dominant outflow 
pathway with the patient in this position. As a result, the IJV can be easily visualised on 
ultrasound imaging. The IJV was assessed for patency and stenosis. The IJV findings of each 
participant were captured onto a template (See Appendix C): 
 Patency and blood flow velocities of the proximal, mid and distal right and left IJVs. 
 Cross-sectional area (CSA) of the proximal right and left IJV at the level of the 
supraclavicular notch. 
 
3.5.2.1 Grey-scale imaging of the internal jugular vein 
The IJV was assessed with the patient in the supine position and the head slightly extended. 
The entire IJV from the supraclavicular notch to the angle of mandible was interrogated in the 
longitudinal and transverse planes, keeping the probe pressure on the vessel to a minimum. 
The CSA of the proximal right and left IJV was measured at the level of supraclavicular notch 
as seen in Figure 3.9. 
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   Figure 3.9. Cross-sectional area of the proximal left  
   IJV. CSA=99 mm2. (Permission granted by patient #MS11) 
 
   
  
3.5.2.2 Colour Doppler of the internal jugular vein 
Colour Doppler was used to assess patency of a vessel, identify any colour filling defects and 
abnormal flow within the vessel. The proximal, mid and distal segments of the IJV were 
assessed with the colour box parallel to the vessel being sampled.  
3.5.2.3 Spectral Doppler analysis of the internal jugular vein 
Spectral Doppler interrogation included sampling of the proximal, mid and distal segments of 
the IJV using a Doppler angle of 60° and a sample volume size of 2 mm. The Doppler angle 
was parallel to the vessel wall and the centre of the vessel lumen was sampled as seen in 
Figure 3.10. 
 
      Figure 3.10. Colour and spectral Doppler analysis of the left mid IJV. The vein is patent  
      with normal directional flow away from the brain (blue). The sample volume (SV) is at  
      2 mm (solid arrows). The peak blood flow velocity is at 20.4 cm/s (Permission granted  
      by patient #MS20) 
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Each ultrasound examination (carotid and extracranial venous ultrasound) took approximately 
40 minutes. All ultrasound examinations were done by the PI who is an experienced vascular 
sonographer. All cases were reported by a radiologist and participants with abnormal findings 
were referred to their respective neurologist or general practitioner for further management. 
3.6 LIFESTYLE AND DISABILITY DATA 
Participants completed a medical and lifestyle questionnaire on entry to the study (See 
Appendix D). The questionnaire recorded the number of days per week of eating certain foods 
retrospectively over a period of 3 months. Intake of 5 or more fruits and vegetables was also 
recorded. Information on family history, own medical history, clinical symptoms and medication 
was documented. Physical activity was self-reported and categorised into high (exercise 4 or 
more times a week), moderate (exercise 2-3 times a week) or low (exercise occasionally or 
complete lack of exercise). 
 
The disability status of the MS participants was assessed by a clinician using the Expanded 
Disability Status Scale (EDSS) (Kurtzke, 1983). According to Madras (2014), this scale 
quantifies disability in MS patients according to their signs and symptoms observed during a 
neurological assessment. 
 
3.7 BIOCHEMICAL ANALYSIS 
Blood was drawn for biochemistry and genetic testing in the morning between 09h00 and 
10h30 to standardise for diurnal variation. 
The biochemical parameters were determined using the following methods: 
 Immunoturbidimetry 
 Chemilluminescense 
 Enzymatic method 
 Glycerol phosphate oxidase 
 Accelerator selective detergent method 
 Measuring liquid selective detergent 
3.8 GENETIC ANALYSIS 
Genotyping was performed by real-time polymerase chain reaction (PCR) assays on the 
Roche Lightcycler LC480-II using hydrolysis probe TaqMan® single nucleotide polymorphism 
(SNP) genotyping assays. The HLA DRB1*1501 was investigated by use of a haplotype 
tagging SNP, rs9271366 (Field et al., 2010). 
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3.9 DATA ANALYSIS 
3.9.1 Study data of the cohort of 50 participants (25 MS and 25 controls) 
Mixed model repeated measures ANOVA were used to compare left and right vessel 
measurements. One way ANOVA was used for comparison of measurements between groups 
(patients with MS and patients free of MS). The ANOVA F-test and the Mann-Whitney U test 
were used to test the same hypothesis. Spearman and Pearson’s’ correlations were used for 
testing relationships between biochemical, genetic, lifestyle variables and ultrasound 
measurements. 
 
3.9.2 Match-merged data 
The data of the current case-control study (Ultrasound investigation of risk factors for 
extracranial vascular pathology in patients with multiple sclerosis) were matched and merged 
with data of a previous cross-sectional observational ethically approved study titled: Ultrasound 
evaluation of the extracranial cerebrospinal venous system and carotid arteries in patients with 
multiple sclerosis (Nelson et al., 2014). Ethical approval for the previous study was granted by 
the Cape Peninsula University of Technology (CPUT), study Registration Number NHREC: 
REC-230408-014. The previous (study A) and current (study B) studies were conducted by the 
same principal investigator. 
The data of studies A and B were merged to demonstrate a stronger association between 
lifestyle, biochemistry, genetics, disability status and the ultrasound parameters in MS. The 
matching genetic, lifestyle, biochemical and ultrasound variables including disability status of 
the cohort of 23 MS participants for study A (excluding males) and 25 MS participants on study 
B, were merged and analysed. 
 
The same ultrasound technique for study B, as described in 3.5, was employed in study A. The 
ultrasound variables assessed in study A were the: 
 Intima media thickness (IMT) of the right and left common carotid artery (CCA) 
 peak systolic and end-diastolic velocities of the right and left CCA and internal carotid 
artery (ICA),  
 peak systolic velocities of the right and left vertebral artery (VA) and external carotid 
artery (ECA) 
 right and left peak systolic velocity ratios: ICA/CCA 
 right and left end-diastolic velocity ratios: ICA/CCA 
 patency and cross-sectional diameters (CSDs) of the right and left proximal, mid and 
distal internal jugular veins (IJVs) 
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Mixed model repeated measures ANOVA were used to compare left and right vessel 
measurements in the combined cohort of MS participants on study A and B. Spearman 
correlations were used in addition for testing relationships between biochemical, genetic, 
lifestyle variables and ultrasound measurements in the combined cohort of MS participants 
(studies A and B). 
 
3.10 ETHICAL DIMENSIONS 
The primary purpose of this study involving human participants was to determine the possible 
risks for the development of extracranial vascular disease in persons diagnosed with multiple 
sclerosis. If the possible risks can be demonstrated, then persons with MS can be advised of 
preventative measures that can be implemented for improved quality of life. 
Various factors are taken into consideration when undertaking health research. In this study, 
the following was considered: 
3.10.1 Permission to perform ultrasound examinations 
Permission, in writing, to scan the research participants at a private radiology practice has 
been granted (Appendix E). 
 
3.10.2 Research ethics committee 
The study was granted ethical approval by the Faculty of Health and Wellness Sciences 
Research Ethics Committee (FREC) of the Cape Peninsula University of Technology (CPUT) 
[Approval reference no: CPUT/HW-REC 2017/H4 (renewal)] (See Appendix F). The study was 
conducted according to the code of ethics of the World Medical Association (Declaration of 
Helsinki). 
 
3.10.3 Informed consent 
All participants were asked to voluntarily read and sign a written informed consent. Participants 
were informed that they have a right to withdraw from the study at any time. The informed 
consent was available in 2 languages (English and Afrikaans) (Appendix G).  Consent in 
isiXhosa, the third regional language, was not available as MS is a very rare disease amongst 
Black Africans. The incidence is reported to be highest amongst English-speaking white South 
Africans and lower in Afrikaans-speaking white South Africans (Dean, 1967). 
 
3.10.4 Risks, burdens and benefits 
No interventional procedures were performed on the participants; thus no significant risks or 
burdens were expected. The benefits included a free Ultrasound examination of the carotid 
arteries and internal jugular veins with a radiological report. If any pathology was identified, 
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then the participants were referred to the appropriate physician for further management and 
treatment.  
There are no known risks associated with ultrasound imaging. Fowlkes and Hollard (1998:52) 
postulates that there are no known biological effects when diagnostic ultrasound imagining 
machines are used appropriately by trained sonographers. 
3.10.5 Privacy, confidentiality and respect 
Every precaution was taken to protect the privacy of the participants and the confidentiality of 
the personal information. Respect was maintained at all times. Only the PI involved in the study 
had access to data and participant information. The principal investigator was responsible for 
inventory and organisation of the data collection forms. Participants were assigned a code 
which was used on all study paperwork. All data was kept in a locked room and the electronic 
database was locked with coded access. Data with the patient codes was made accessible to 
the supervisor and statistician. 
 
3.10.6 Publication of results 
Results of the study will be made publicly available by publication in peer-reviewed journals 
where persons in the medical and scientific community can evaluate the results. Publication of 
the results also allows other researchers to repeat the study to confirm the study findings. The 
applied research methods and design can also be used in clinical and academic teaching. The 
knowledge gained through this study will also be presented at conferences, congresses and 
seminars.  
 
 
 CONCLUSION 
This chapter presents a detailed description of the research design and methodology 
undertaken which ensures trustworthiness of the study. This detailed description also allows 
for easy transferability of the design and methods to other studies of similar context where the 
findings of this study can be replicated, improved or disproved.  
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CHAPTER FOUR 
RESULTS 
 
INTRODUCTION 
This chapter provides the significant and non-significant associations between the extracranial 
vascular ultrasound variables and the biochemical markers genetic, lifestyle and disability 
parameters in the MS group of participants and healthy controls.  
Significant and non-significant associations and differences between 2 variables are 
represented by the p-value (calculated probability) and the correlation coefficient, r. 
 A p value of >0.05 is considered non-significant, whilst significant correlations are associated 
with a p value <0.05. A p value is described as the product of hypothesis testing using multiple 
statistical tests. The r value ranges from +1.0 where there’s a positive relationship to -1.0, 
where there is a negative relationship (inverse association) (Marshall & Jonker, 2011). 
 
The results of this study are presented in a graphic and tabular format.  
 
4.1 ANTHROPOMETRIC AND DEMOGRAPHIC DATA 
From October 2017 through to December 2018, 50 extracranial vascular ultrasound 
examinations were completed. Of these, 25 were MS participants and 25 age-matched healthy 
controls. 
The demographic and anthropometric data of the MS participants and controls are summarised 
in Table 4.1. 
 
      Table 4.1: Characteristics of MS participants and controls 
Parameter MS participants (n=25) Controls (n=25) 
 
Gender 
 
female 
 
female 
 
Mean age (years ± SD) 
 
49.2 ± 11.53 
 
49.6 ± 11.74 
BMI (kg/m2  ± SD )  25.29 ± 6.48 (n=24) 27.73 ± 5.82 
Left Systolic BP (mmHg ± SD) 123.4 ± 9.13 120.56 ± 9.88 
Left Diastolic BP (mmHg ± SD) 79.36 ± 9.25 77.96 ± 10.63 
Right Systolic BP (mmHg ± SD) 125.72 ± 9.48 123.36 ± 11.43 
Right Diastolic BP (mmHg ± SD) 81.4 ± 6.94 78.92 ± 9.65 
 
Mean age at onset (years ± SD) 
 
36 ± 9.85 
_ 
 
 
Disease duration (years ± SD) 
 
13.2 ± 7.27 
_ 
 
EDSS (mean ± SD), (n=23) 
 
2.8 ± 2.02 
_ 
 
BMI, body mass index; BP, blood pressure; EDSS, Expanded Disability Status Scale; SD, standard deviation.  
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4.2 COMPARISON BETWEEN THE ULTRASOUND FINDINGS OF THE EXTRACRANIAL 
VASCULAR SYSTEMS IN THE TWO COHORTS (ACTIVE MS AND CONTROL GROUP) 
 
4.2.1 Comparison between the ultrasound findings of carotid arteries: CCA, ICA, ECA 
and VA 
No significant difference (p>0.05) was demonstrated between the right and left carotid artery 
ultrasound variables in the MS group and control group (Table 4.2 and 4.3). 
 
     Table 4.2: Comparison between the right carotid artery ultrasound variables in MS    
     participants and controls 
Ultrasound variable  
 
MS participants (n=25) 
 
Controls (n=25) p-value* 
Right CCA IMT (mm) 0.53 (0.49-0.57) 0.55 (0.51-0.59) 0.48 
Right CCA PSV (cm/s) 96.64 (88.80-104.47) 98.49 (90.11-106.87) 0.75 
Right CCA EDV (cm/s) 29.54 (27.04-32.05) 27.30 (24.62-29.98) 0.22 
Right ICA PSV (cm/s) 88.47 (81.41-95.62) 89.68 (82.25-97.25) 0.82 
Right ICA EDV (cm/s) 35.98 (32.08-39.89) 36.19 (32.05-40.42) 0.94 
Right ECA PSV (cm/s) 85.17 (76.96-93.39) 83.69 (74.91-92.47) 0.81 
Right  VA PSV (cm/s) 53.13 (47.52-58.74) 54.99 (48.99-60.98) 0.65 
Right VA EDV (cm/s) 18.01 (15.74-20.29) 18.69 (16.26-21.12) 0.69 
Right PSV ICA/CCA ratio   0.93 (0.85-1.01) 0.94 (0.85-1.03) 0.82 
Right EDV ICA/CCA ratio  1.22 (1.08-1.37) 1.34 (1.19-1.50) 0.25 
CSD PROX right CCA  (mm) 6.65 (6.39-6.91) 6.83 (6.55-7.11) 0.35 
CSD mid right CCA (mm) 6.46 (6.18-6.74) 6.56 (6.26-6.86) 0.62 
CSD distal right CCA (mm) 6.85 (6.54-7.15) 6.99 (6.66-7.31) 0.53 
CSD PROX right ICA (mm) 6.54 (6.13-6.91) 6.33 (5.91-6.75) 0.49 
CSD PROX right ECA (mm) 4.38 (4.10-4.66) 4.59 (4.29-4.89) 0.3 
CSD PROX right VA (mm) 3.40 (3.19-3.61) 3.48 (3.26-3.70) 0.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results are presented as mean (range), *F-test; CCA, common carotid artery; ECA, external carotid artery; EDV, end-
diastolic velocity; ICA, internal carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; PROX, 
proximal; VA, vertebral artery. 
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Table 4.3: Comparison between the left carotid artery ultrasound variables in the MS participants 
and controls 
Ultrasound variable  
 
MS participants (n=25) 
 
Controls (n=25) p-value* 
Left CCA IMT (mm) 0.57 (0.52-0.62) 0.58 (0.52-0.64) 0.81 
Left CCA PSV (cm/s) 100.22 (92.24-108.20) 102.75 (94.21-111.28) 0.67 
Left CCA EDV (cm/s) 29.91 (27.15-32.66) 27.88 (24.94-30.82) 0.32 
Left ICA PSV (cm/s) 92.05 (82.41-101.69) 91.89 (81.58-102.20) 0.98 
Left ICA EDV (cm/s) 39.22 (35.03-43.41) 35.36 (30.88-39.84) 0.21 
Left ECA PSV (cm/s) 82.44 (74.68-90.19) 82.35 (74.06-90.64) 0.99 
Left VA PSV (cm/s) 59.14 (52.90-65.37) 57.69 (51.02-64.35) 0.75 
Left VA EDV (cm/s) 21.94 (19.14-24.73) 20.25 (17.26-23.24) 0.41 
Left PSV ICA/CCA ratio 0.96 (0.85-1.08) 0.95 (0.83-1.08) 0.88 
Left EDV ICA/CCA ratio 1.33 (1.18-1.47) 1.30 (1.15-1.46) 0.81 
CSD PROX left CCA (mm) 6.46 (6.23-6.68) 6.61 (6.37-6.84) 0.35 
CSD mid left CCA (mm) 6.42 (6.25-6.60) 6.42 (6.23-6.60) 0.96 
CSD distal left CCA (mm) 6.75 (6.52-6.97) 6.81 (6.56-7.05) 0.72 
CSD PROX left ICA (mm) 6.30 (5.91-6.68) 6.79 (6.38-7.20) 0.09 
CSD PROX left ECA (mm) 4.17 (3.94-4.40) 4.44 (4.20-4.69) 0.11 
CSD PROX left VA (mm) 3.44 (3.20-3.69) 3.52 (3.26-3.78) 0.67 
 
 
 
 
 
 
4.2.2 Comparison between the ultrasound findings of the internal jugular veins 
No significant difference (p>0.05) was demonstrated between the right and left IJV (proximal 
and distal segments) ultrasound variables (Table 4.4) in the MS group and control group. 
However, a significant difference (F-test p-value 0.02) was demonstrated between the PV of 
the mid right IJV in the MS group (55.76, 48.24-63.28) and control group (41.94, 33.90-49.98) 
(Figure 4.1, Table 4.4). 
 
 
 
 
 
 
 
Results are presented as mean (range), *F-test; CCA, common carotid artery; EDV, end-diastolic velocity; ECA, external carotid 
artery; ICA, internal carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; PROX, proximal; VA, vertebral 
artery. 
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  Table 4.4: Comparison between the right and left IJV ultrasound variables in MS participants 
  and controls 
Ultrasound variable 
 
MS participants (n=25) 
 
Controls (n=25) p-value* 
PV PROX right IJV (cm/s) 49.34 (41.86-56.81) 40.04 (32.05-48.03) 0.09 
PV mid right IJV 55.76 (48324-63.28) 41.94 (33.90-49.98 0.02 
PV distal right IJV (cm/s) 56.22 (47.02-65.42) 49.58 (39.75-59.42) 0.33 
PV PROX left IJV (cm/s) 43.68 (33.61-53.75) 39.42 (28.65-50.19) 0.56 
PV mid left IJV (cm/s) 43.52 (37.12-49.92) 36.08 (29.24-42.93) 0.12 
PV distal left IJV (cm/s) 49.77 (41.34-58.19) 40.66 (31.66-49.67) 0.14 
CSA PROX right IJV (mm2) 142.49 (110.60-174.37) 151.62 (117.53-185.70) 0.7 
CSA PROX left IJV (mm2) 102.71 (67.92-137-51) 134.02 (96.83-171.22) 0.22 
 
 
    
 
 
 
 
F(1,46)=6.377, p=0.02
Vertical bars denote 0.95 confidence intervals
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Figure 4.1: Significant difference between the PV of the mid right IJV in the MS group and 
control group 
 
 
PV, peak velocity; RT, right; IJV, internal jugular vein; MS group: mean PSV MID RT IJV=55.76cm/s, CONTROL group: mean 
PV MID RT IJV=41.94cm/s 
Results are presented as mean (range), *F-test; PV, peak velocity; PROX, proximal; IJV, internal jugular vein; CSA-cross-
sectional area. 
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4.3 ASSOCIATION BETWEEN THE HUMAN LEUKOCYTE ANTIGEN (HLA) DRB1*1501 
ALLELE AND THE GREY-SCALE, COLOUR AND SPECTRAL DOPPLER ANALYSIS OF 
THE CAROTID ARTERIES (CAs) AND INTERNAL JUGULAR VEINS (IJVs) IN THE TWO 
COHORTS. 
 
4.3.1 Association between the Human Leukocyte Antigen (HLA) DRB1*1501 allele and 
the carotid arteries:  CCA, ICA, ECA and VA. 
 
In a correlation analysis, no significant association (p>0.05) was demonstrated between the 
right and left CCA, ICA and VA ultrasound variables and the HLA DRB1*1501 allele in the 
active MS and control groups (Table 4.5 and 4.6). However, a significant association (p-value 
0.03) between the HLA) DRB1*1501 allele and the CSD of the proximal right ECA was 
determined in the two cohorts (Figure 4.2, Table 4.5) as follows: 
 CSD PROX RT ECA (mean ± SD), 4.56  ± 0.79 mm (WT, MS group, n=9) 
 CSD PROX RT ECA (mean ± SD), 4.21 ± 0.64 mm (HET/HOM, MS group, n=16) 
 CSD PROX RT ECA (mean ± SD), 4.31  ± 0.61 mm (WT, control group, n=18) 
 CSD PROX RT ECA (mean ± SD), 4.87 ± 0.67 mm (HET/HOM, control group, n=7) 
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Table 4.5: Association between HLA DRB1*1501 allele and the right carotid artery ultrasound 
variables 
Ultrasound variable MS participants (n=25) Controls (n=25) p-value* 
 
HLA  DRB1*1501 allele HLA  DRB1*1501 allele 
 
WT 
 (n=9) 
HET/HOM 
(n=16) 
WT  
(n=18) 
HET/HOM 
(n=7) 
RT CCA IMT (mm) 0.52 ± 0.11 0.54 ± 0.11 0.52 ± 0.06 0.58 ± 0.11 0.53 
RT CCA PSV (cm/s) 99.17 ± 14.66 94.11 ± 15.33 97.07 ± 20.85 99.91 ± 23.87 0.49 
RT CCA EDV (cm/s) 
 
31.24 ± 5.21 27.84 ± 7.25 25.76 ± 4.14 28.84 ± 7.56 0.08 
RT ICA PSV (cm/s) 91.22 ± 23.74 85.72 ± 15.89 88.52 ± 14.62 90.84 ± 14.28 0.45 
RT ICA EDV (cm/s) 37.24 ± 10.91 34.73 ± 9.45 34.64 ± 8.00 37.74 ± 10.40 0.33 
RT ECA PSV (cm/s) 83.79 ± 21.82 86.56 ± 16.58 83.02 ± 17.98 84.37 ± 26.50 0.91 
RT  VA PSV (cm/s) 49.90 ± 15.01 56.37 ± 13.34 58.98 ± 12.88 51.00 ± 12.45 0.08 
RT VA EDV (cm/s) 17.98 ± 7.78 18.05 ± 5.67 18.65 ± 3.64 18.73 ± 5.19 1 
RT PSV ICA/CCA ratio  0.93 ± 0.22 0.93 ± 0.18 0.93 ± 0.20 0.95 ± 0.19 0.89 
RT EDV ICA/CCA ratio  1.19 ± 0.27 1.26 ± 0.35 1.37 ± 0.40 1.32 ± 0.17 0.6 
CSD PROX RT CCA (mm) 6.68 ± 0.48 6.63 ± 0.85 6.71 ± 0.38 6.96 ± 0.63 0.43 
CSD mid RT CCA (mm) 6.33 ± 0.48 6.59 ± 0.84 6.43 ± 0.37 6.69 ± 0.92 1 
CSD dist RT CCA (mm) 6.72 ± 0.55 6.97 ± 0.89 6.89 ± 0.60 7.09 ± 0.82 0.91 
CSD PROX RT ICA (mm) 6.61 ± 0.96 6.44 ± 0.86 6.26 ± 0.99 6.40 ± 0.88 0.58 
CSD PROX RT ECA (mm) 4.56 ± 0.79 4.21 ± 0.64 4.31 ± 0.61 4.87 ± 0.67 0.03 
CSD PROX RT VA (mm) 3.22 ± 0.39 3.49 ± 0.42  3.49 ± 0.40 3.47 ± 0.91 0.23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results are presented as mean ± SD (standard deviation); *F-test; RT, right; LT, left; CCA, common carotid artery; IMT, intima 
media thickness; PSV, peak systolic velocity; EDV, end-diastolic velocity; ICA, internal carotid artery; ECA, external carotid artery; 
VA, vertebral artery, CSD, cross-sectional diameter; PROX, proximal; dist, distal 
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Table 4.6: Association between HLA DRB1*1501 allele and the left carotid artery ultrasound 
variables 
  Ultrasound variable MS participants (n=25) Controls (n=25) p-value* 
 HLA  DRB1*1501 allele HLA  DRB1*1501 allele 
 
 
WT                     
(n=9) 
 
HET/HOM 
(n=16) 
 
WT                 
(n=18) 
 
HET/HOM 
(n=7) 
LT CCA IMT (mm) 0.57 ± 0.08 0.57 ± 0.12  0.59 ± 0.15  0.57± 0.13  0.84 
Left CCA PSV (cm/s) 100.61 ± 24.54  99.83 ± 20.77  101.25 ± 13.22   104.24 ± 20.03  0.75 
Left CCA EDV (cm/s) 29.71 ± 4.03  30.1 ± 9.08   27.26 ± 3.97  28.5 ± 7.59  0.83 
Left ICA PSV (cm/s) 94.78 ± 28.58  89.33 ± 29.52  91.84 ± 15.7  91.94 ± 9.37  0.69 
Left ICA EDV (cm/s) 41 ± 13.54  37.44 ± 10.47  34.88 ± 8  35.84 ± 8.16  0.46 
Left ECA PSV (cm/s) 83.13 ± 1.99  81.74 ± 16.6  82.56 ± 19.57  82.14 ± 19.16  0.93 
Left VA PSV (cm/s) 60.6 ± 12.07) 57.68 ± 13.31  55.54 ± 16.48  59.83 ± 17  0.43 
Left VA EDV (cm/s) 23.41 ± 7.86  20.46 ± 7.3  19.49 ± 5.52  21.01 ± 6.23  0.28 
Left PSV ICA/CCA ratio 0.97 ± 0.23 0.96 ± 0.25  1.01 ± 0.36  0.9 ± 0.16  0.53 
 
Left EDV ICA/CCA ratio 1.38 ± 0.38  1.28 ± 0.33  1.29 ± 0.36  1.31 ± 0.32  0.54 
CSD PROX left CCA (mm) 6.39 ± 0.3 6.53 ± 0.58 6.59 ± 0.53 6.63 ± 0.65 0.77 
CSD mid left CCA (mm) 6.23 ± 0.33  6.61 ± 0.47  6.36 ± 0.39  6.47 ± 0.49  0.3 
CSD distal left CCA (mm) 6.66 ± 0.55  6.84 ± 0.62  6.78 ± 0.45  6.83 ± 0.56  0.68 
CSD PROX left ICA (mm) 5.98 ± 1.01 6.62 ± 0.98  6.67 ± 0.87  6.91 ± 0.73  0.49 
CSD PROX left ECA  mm) 3.9 ± 0.67  4.44 ± 0.59  4.37 ± 0.38  4.51 ± 0.71  0.25 
CSD PROX left VA (mm) 3.41 ± 0.61  3.48 ± 0.46  3.43 ± 0.65  3.6 ± 0.61  0.78 
 
 
 
 
 
Results are presented as mean ± SD (standard deviation); CCA, common carotid artery; IMT, intima media thickness; PSV, 
peak systolic velocity; EDV, end-diastolic velocity; ICA, internal carotid artery; ECA, external carotid artery; VA, vertebral 
artery; CSD, cross-sectional diameter; PROX, proximal 
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F(1,46)=5.074, p=0.03
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Figure 4.2: Significant association between the HLA DRB1*1501 allele and the CSD of the 
proximal right ECA in the MS group and control group. 
 
 
 
 
 
4.3.2 Association between the Human Leukocyte Antigen (HLA) DRB1*1501 allele and 
the internal jugular veins. 
 
No significant association (p>0.05) between the right and left IJV ultrasound variables and 
the HLA DRB1*1501 allele in the active MS and control groups was demonstrated (Table 
4.7). 
 
 
 
 
 
 
 
 
 
CSD, cross-sectional diameter; PROX, proximal; RT, right; ECA, external carotid artery; WT, wild type; HET, heterogeneous; 
HOM, homogenous 
MS group: Mean CSD PROX RT ECA 4.56mm (WT), 4.21mm (HET/HOM) 
CONTROL group: Mean CSD PROX RT ECA 4.31 mm (WT), 4.87 mm (HET/HOM) 
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Table 4.7: Association between the HLA DRB1*1501 allele and the internal jugular vein 
ultrasound variables 
 
Ultrasound variable 
 
MS participants (n=25) 
 
Controls (n=25) 
 
p-value* 
 
HLA DRB1*1501 allele HLA DRB1*1501 allele 
 
 
WT 
(n=9) 
 
HET/HOM 
(n=16) 
 
WT 
(n=18) 
 
HET/HOM 
(n=7) 
 
PV prox right IJV (cm/s) 52.92 ± 21.45  45.76 ± 15.01  39.15 ± 20.36  40.93 ± 9.07  0.41 
PV mid right IJV (cm/s) 54.33 ± 15.20  57.18 ± 24.95  34.94 ± 12.38  48.94 ± 12.97  0.31  
PV distal right IJV (cm/s) 59.5 ± 17.88  52.93 ± 27.22  40.96 ± 10.96  58.2 ± 33.49  0.08 
PV prox left IJV (cm/s) 46.78 ± 28.74  40.58 ± 17.83  41.04 ± 29.50  37.8 ± 7.79  0.84 
PV mid left IJV (cm/s) 44.19 ± 16.80  42.85 ± 18.58  32.16 ± 12.40  40.01 ± 10.49  0.33 
PV distal left IJV (cm/s) 49.24 ± 14.31  50.29 ±25.84  42.06 ± 19.29  39.27 ± 9.80  0.76 
CSA PROX right IJV (mm2) 156.22 ± 47.11  128.75 ± 67.01  155.94 ± 78.26  147.29 ±113.05  0.69 
CSA PROX left IJV (mm2) 116.11 ± 81.54  89.31 ± 40.2  136.33 ± 114.81  131.71 ± 50.24  0.66 
 
 
 
4.4 ASSOCIATION BETWEEN BIOCHEMICAL MARKERS AND THE GREY-SCALE, 
COLOUR AND SPECTRAL DOPPLER ANALYSIS OF THE CAs AND IJVs IN 
PARTICIPANTS WITH MS (MS GROUP) AND PARTICIPANTS FREE FROM MS 
(CONTROL GROUP). 
 
4.4.1 Association between serum iron (s-iron) concentrations and the extracranial 
vascular ultrasound variables 
 
MS group: A statistically significant positive correlation was demonstrated between serum iron 
(s-iron) concentrations and the PSV of the right ICA (Pearson p-value 0.02, Spearman p-value 
0.03), the right ICA/CCA PSV ratio (Pearson p-value 0.04, Spearman p-value 0.01) and the 
left CCA IMT (Spearman 0.03). A significant negative correlation was found between s-iron 
concentrations and the CSD of the proximal left vertebral artery (Pearson p-value 0.02, 
Spearman p-value 0.02) in the MS group (Table 4.8). 
 
Control group: In the control group, a statistically significant negative correlation was 
demonstrated between s-iron concentrations and the PSV of the proximal right ECA 
(Spearman p-value 0.01) and the PV of the distal left IJV (Spearman p-value 0.04) (Table 4.9). 
 
 
 
Results are presented as mean ± SD (standard deviation); *F-test; PS, peak velocity, PROX, proximal; IJV, internal jugular 
vein; CSA, cross-sectional area 
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Table 4.8: Correlation between serum iron concentration and the extracranial vascular 
ultrasound variables in the MS group 
Biochemical 
marker 
 
Ultrasound variable 
Pearson Spearman # 
cases 
 
group r p r p 
s-iron  RT CCA IMT (mm) 0.15 0.46 0.31 0.13 25 MS 
s-iron  RT CCA PSV (cm/s) 0.04 0.85 -0.05 0.82 25 MS 
s-iron  RT CCA EDV (cm/s) 0 1 -0.11 0.6 25 MS 
s-iron  CSD PROX RT CCA (mm) -0.3 0.14 -0.35 0.09 25 MS 
s-iron  CSD MID RT CCA (mm) -0.12 0.57 -0.07 0.74 25 MS 
s-iron  CSD DIST RT CCA (mm) -0.08 0.72 -0.05 0.8 25 MS 
s-iron  RT ICA PSV (cm/s) 0.47 0.02 0.44 0.03 25 MS 
s-iron  RT ICA EDV (cm/s) 0.42 0.04 0.29 0.15 25 MS 
s-iron  CSD PROX RT ICA (mm) -0.08 0.7 -0.04 0.83 25 MS 
s-iron  PROX ECA RT PSV cm/s) 0.06 0.78 -0.04 0.83 25 MS 
s-iron  CSD PROX RT ECA (mm) -0.1 0.64 -0.04 0.86 25 MS 
s-iron  RT VA PSV (cm/s) 0.07 0.74 0.03 0.88 25 MS 
s-iron  RT VA EDV (cm/s) 0.15 0.47 0.11 0.59 25 MS 
s-iron  CSD PROX RT VA (mm) 0.05 0.79 0.09 0.66 25 MS 
s-iron  RT PSV ICA/CCA ratio 0.42 0.04 0.48 0.01 25 MS 
s-iron  RT EDV ICA/ECA ratio 0.48 0.01 0.35 0.08 25 MS 
s-iron  LT CCA IMT (mm) 0.23 0.26 0.44 0.03 25 MS 
s-iron  LT CCA PSV (cm/s) -0.02 0.91 -0.14 0.5 25 MS 
s-iron  LT CCA EDV (cm/s) -0.02 0.92 -0.08 0.69 25 MS 
s-iron  CSD PROX LT CCA (mm) -0.22 0.29 -0.16 0.45 25 MS 
s-iron  CSD MID LT CCA (mm) -0.12 0.57 -0.06 0.76 25 MS 
s-iron  CSD DIST LT CCA (mm) -0.15 0.47 -0.11 0.61 25 MS 
s-iron  LT ICA PSV (cm/s) 0.08 0.72 0.05 0.8 25 MS 
s-iron  LT ICA EDV (cm/s) 0.31 0.14 0.18 0.4 25 MS 
s-iron  CSD PROX LT ICA (mm) -0.15 0.48 -0.07 0.74 25 MS 
s-iron  PROX LT ECA PSV (cm/s) -0.04 0.83 -0.12 0.55 25 MS 
s-iron  CSD PROX LT ECA (mm) -0.09 0.68 -0.14 0.5 25 MS 
s-iron  LT VA PSV (cm/s) -0.3 0.15 -0.24 0.25 25 MS 
s-iron  LT VA EDV (cm/s) -0.22 0.3 -0.15 0.48 25 MS 
s-iron  CSD PROX LT VA (mm) -0.45 0.02 -0.45 0.02 25 MS 
s-iron  LT PSV ICA/CCA ratio 0.28 0.18 0.35 0.08 25 MS 
s-iron  LT EDV ICA/ECA ratio 0.31 0.13 0.33 0.11 25 MS 
s-iron  PV PROX RT IJV (cm/s) 0.19 0.36 0.13 0.54 25 MS 
s-iron  PV MID RT IJV (cm/s) -0.08 0.7 -0.06 0.76 25 MS 
s-iron  PV DIST RT IJV (cm/s) 0.03 0.88 0.17 0.41 25 MS 
s-iron  CSA PROX RT IJV (mm2) -0.29 0.15 -0.34 0.09 25 MS 
s-iron  PV PROX LT IJV (cm/s) 0.19 0.36 0.06 0.77 25 MS 
s-iron  PV MID LT IJV (cm/s) 0.17 0.42 0.17 0.43 25 MS 
s-iron  PV DIST LT IJV (cm/s) -0.03 0.88 0.04 0.84 25 MS 
s-iron  CSA PROX LT IJV (mm2) 0.01 0.95 -0.14 0.51 25 MS 
 
 
 
 
 
 
s-iron, serum iron concentration; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic 
velocity; EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, 
internal carotid artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein. 
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Table 4.9: Correlation between serum iron (s-iron) concentration and the extracranial vascular 
ultrasound variables in the control group 
Biochemical 
marker 
 
Ultrasound variable 
Pearson Spearman # 
cases 
 
group r p r p 
s-iron RT CCA IMT (mm) 0.14 0.52 0.12 0.57 25 CONTROL 
s-iron RT CCA PSV (cm/s) -0.12 0.57 -0.09 0.68 25 CONTROL 
s-iron RT CCA EDV (cm/s) -0.13 0.54 -0.15 0.49 25 CONTROL 
s-iron CSD PROX RT CCA (mm) 0.18 0.39 0.28 0.18 25 CONTROL 
s-iron CSD MID RT CCA (mm) 0.19 0.36 0.28 0.18 25 CONTROL 
s-iron CSD DIST RT CCA (mm) -0.03 0.88 0.01 0.96 25 CONTROL 
s-iron RT ICA PSV (cm/s) -0.04 0.84 0.06 0.78 25 CONTROL 
s-iron RT ICA EDV (cm/s) 0.25 0.23 0.23 0.26 25 CONTROL 
s-iron CSD PROX RT ICA (mm) 0.03 0.89 -0.02 0.93 25 CONTROL 
s-iron PROX ECA RT PSV (cm/s) -0.36 0.07 -0.49 0.01 25 CONTROL 
s-iron CSD PROX RT ECA (mm) 0.04 0.84 0.05 0.8 25 CONTROL 
s-iron RT VERT A PSV (cm/s) -0.26 0.21 -0.24 0.26 25 CONTROL 
s-iron RT VERT A EDV (cm/s) -0.25 0.22 -0.16 0.46 25 CONTROL 
s-iron CSD PROX RT VERT A (mm) 0.23 0.27 0.15 0.47 25 CONTROL 
s-iron RT PSV ICA/CCA ratio 0.07 0.73 0.11 0.61 25 CONTROL 
s-iron RT EDV ICA/ECA ratio 0.34 0.09 0.31 0.13 25 CONTROL 
s-iron LT CCA IMT (mm) -0.04 0.86 0.01 0.97 25 CONTROL 
s-iron LT CCA PSV (cm/s) -0.24 0.24 -0.25 0.23 25 CONTROL 
s-iron LT CCA EDV (cm/s) -0.15 0.48 -0.02 0.94 25 CONTROL 
s-iron CSD PROX LT CCA (mm) 0.01 0.95 -0.06 0.77 25 CONTROL 
s-iron CSD MID LT CCA (mm) 0.13 0.54 0.08 0.69 25 CONTROL 
s-iron CSD DIST LT CCA (mm) 0.11 0.61 0.03 0.88 25 CONTROL 
s-iron LT ICA PSV (cm/s) -0.05 0.82 0.08 0.72 25 CONTROL 
s-iron LT ICA EDV (cm/s) -0.05 0.82 -0.04 0.85 25 CONTROL 
s-iron CSD PROX LT ICA (mm) -0.11 0.62 -0.02 0.94 25 CONTROL 
s-iron PROX LT ECA PSV (cm/s) -0.11 0.6 -0.09 0.66 25 CONTROL 
s-iron CSD PROX LT ECA (mm) -0.02 0.94 -0.08 0.71 25 CONTROL 
s-iron LT VERT A PSV (cm/s) -0.2 0.34 -0.13 0.53 25 CONTROL 
s-iron LT VERT A EDV (cm/s) -0.2 0.33 -0.07 0.76 25 CONTROL 
s-iron CSD PROX LT VERT A (mm) 0.17 0.43 0.16 0.44 25 CONTROL 
s-iron LT PSV ICA/CCA ratio 0.27 0.19 0.39 0.06 25 CONTROL 
s-iron LT EDV ICA/ECA ratio 0.08 0.7 0.12 0.56 25 CONTROL 
s-iron PV PROX RT IJV (cm/s) -0.08 0.7 0.03 0.87 25 CONTROL 
s-iron PV MID RT IJV (cm/s) 0.22 0.3 0.32 0.12 25 CONTROL 
s-iron PV DIST RT IJV (cm/s) 0.21 0.3 0.28 0.17 25 CONTROL 
s-iron CSA PROX RT IJV (mm2) 0.05 0.82 0.09 0.66 25 CONTROL 
s-iron PV PROX LT IJV (cm/s) -0.24 0.25 -0.01 0.95 25 CONTROL 
s-iron PV MID LT IJV (cm/s) -0.28 0.18 -0.17 0.41 25 CONTROL 
s-iron PV DIST LT IJV (cm/s) -0.42 0.04 -0.34 0.09 25 CONTROL 
s-iron CSA PROX LT IJV (mm2) -0.14 0.51 0 1 25 CONTROL 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic 
velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, 
external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein. 
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4.4.2 Association between serum transferrin (s-transferrin) and the extracranial 
vascular ultrasound variables  
 
MS group: In the MS group, a statistically significant negative correlation was found between 
s-transferrin and the CSD of the proximal left ECA (Pearson p-value 0.04) and a positive 
correlation between the PV of the proximal left IJV (Pearson p-value <0.01). No significant 
association was demonstrated between the remaining variables in this group (Table 4.10). 
 
Control group: In the control group, as illustrated in Table 4.11, a statistically significant 
negative association was found between s-transferrin and the EDV of the right ICA (Pearson 
p-value 0.03), right EDV ICA/ECA ratio (Pearson p-value 0.02) and the PSV of the proximal 
left ECA (Spearman p-value 0.03). In addition, a statistically significant positive association 
was found between s-transferrin and the CSD of the proximal left ECA (Pearson p-value 0.04) 
and the PV of the proximal right and left IJV (Spearman p-value <0.01, Pearson p-value <0.01). 
No significant association was found between the remaining variables. 
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Table 4.10: Correlation between serum transferrin and the extracranial ultrasound variables in 
the MS group 
Biochemical 
marker 
 
Ultrasound variable 
Pearson Spearman # 
cases 
 
group r p r p 
S-transf  RT CCA IMT (mm) 0.15 0.47 0.25 0.24 25 MS 
S-transf  RT CCA PSV (cm/s) 0.27 0.19 0.36 0.08 25 MS 
S-transf  RT CCA EDV (cm/s) -0.03 0.89 0.07 0.75 25 MS 
S-transf  CSD PROX RT CCA (mm) 0.19 0.36 0.33 0.11 25 MS 
S-transf  CSD MID RT CCA (mm) -0.01 0.97 0.19 0.35 25 MS 
S-transf  CSD DIST RT CCA (mm) -0.11 0.61 0.11 0.61 25 MS 
S-transf  RT ICA PSV (cm/s) 0.36 0.08 0.08 0.71 25 MS 
S-transf  RT ICA EDV (cm/s) 0.17 0.42 -0.03 0.88 25 MS 
S-transf  CSD PROX RT ICA (mm) -0.32 0.12 -0.07 0.75 25 MS 
S-transf  PROX ECA RT PSV (cm/s) 0.08 0.72 -0.02 0.93 25 MS 
S-transf  CSD PROX RT ECA (mm) -0.19 0.36 0.01 0.98 25 MS 
S-transf  RT VA PSV (cm/s) 0.21 0.32 0.15 0.46 25 MS 
S-transf  RT VA EDV (cm/s) -0.18 0.4 -0.16 0.45 25 MS 
S-transf  CSD PROX RT VA (mm) -0.33 0.11 -0.28 0.17 25 MS 
S-transf  RT PSV ICA/CCA ratio 0.09 0.65 -0.24 0.26 25 MS 
S-transf  RT EDV ICA/ECA ratio 0.07 0.75 -0.16 0.43 25 MS 
S-transf  LT CCA IMT (mm) 0.16 0.45 0.25 0.22 25 MS 
S-transf  LT CCA PSV (cm/s) 0.36 0.07 0.14 0.52 25 MS 
S-transf  LT CCA EDV (cm/s) 0.05 0.82 -0.14 0.49 25 MS 
S-transf  CSD PROX LT CCA (mm) 0.11 0.61 0.39 0.05 25 MS 
S-transf  CSD MID LT CCA (mm) 0.02 0.94 0.05 0.8 25 MS 
S-transf  CSD DIST LT CCA (mm) 0.07 0.74 0.08 0.72 25 MS 
S-transf  LT ICA PSV (cm/s) 0.29 0.16 0.18 0.38 25 MS 
S-transf  LT ICA EDV (cm/s) 0.14 0.49 -0.22 0.3 25 MS 
S-transf  CSD PROX LT ICA (mm) -0.14 0.51 -0.16 0.45 25 MS 
S-transf  PROX LT ECA PSV (cm/s) -0.02 0.92 0.14 0.51 25 MS 
S-transf  CSD PROX LT ECA (mm) -0.41 0.04 -0.16 0.44 25 MS 
S-transf  LT VA PSV (cm/s) 0.19 0.37 0.22 0.3 25 MS 
S-transf  LT VA EDV (cm/s) 0.1 0.63 0.06 0.76 25 MS 
S-transf  CSD PROX LT VA (mm) 0.09 0.68 0.12 0.56 25 MS 
S-transf  LT PSV ICA/CCA ratio 0.02 0.92 -0.07 0.74 25 MS 
S-transf  LT EDV ICA/ECA ratio 0.16 0.46 -0.02 0.92 25 MS 
S-transf  PV PROX RT IJV (cm/s) -0.1 0.65 -0.09 0.67 25 MS 
S-transf  PV MID RT IJV (cm/s) 0.14 0.51 0.17 0.43 25 MS 
S-transf  PV DIST RT IJV (cm/s) -0.08 0.69 -0.02 0.92 25 MS 
S-transf  CSA PROX RT IJV (mm2) -0.37 0.07 -0.09 0.67 25 MS 
S-transf  PV PROX LT IJV (cm/s) 0.7 <0.01 0.02 0.92 25 MS 
S-transf  PV MID LT IJV (cm/s) 0.38 0.06 0.06 0.79 25 MS 
S-transf  PV DIST LT IJV (cm/s) 0.21 0.31 0.09 0.66 25 MS 
S-transf  CSA PROX LT IJV (mm2) -0.21 0.32 0.04 0.85 25 MS 
 
 
 
S-transf, serum trasnferrin; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic 
velocity; EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, 
internal carotid artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein. 
 
50 
 
 
Table 4.11: Correlation between serum transferrin and the extracranial ultrasound variables in 
the control group 
Biochemical 
marker 
 
Ultrasound variable 
Pearson Spearman # 
cases 
 
group r p r p 
S-transf RT CCA IMT (mm) -0.12 0.56 -0.16 0.45 25 CONTROL 
S-transf  RT CCA PSV (cm/s) -0.14 0.51 0.03 0.87 25 CONTROL 
S-transf  RT CCA EDV (cm/s) 0.08 0.72 0.15 0.47 25 CONTROL 
S-transf  CSD PROX RT CCA (mm) -0.16 0.45 -0.15 0.47 25 CONTROL 
S-transf  CSD MID RT CCA (mm) -0.1 0.62 -0.01 0.96 25 CONTROL 
S-transf  CSD DIST RT CCA (mm) 0.02 0.94 -0.02 0.94 25 CONTROL 
S-transf  RT ICA PSV (cm/s) -0.09 0.66 -0.25 0.23 25 CONTROL 
S-transf  RT ICA EDV (cm/s) -0.43 0.03 -0.22 0.29 25 CONTROL 
S-transf  CSD PROX RT ICA (mm) 0.14 0.51 0.16 0.45 25 CONTROL 
S-transf  PROX ECA RT PSV (cm/s) 0.02 0.93 -0.24 0.25 25 CONTROL 
S-transf  CSD PROX RT ECA (mm) 0.07 0.75 0.4 0.05 25 CONTROL 
S-transf  RT VA PSV (cm/s) -0.15 0.48 -0.08 0.69 25 CONTROL 
S-transf  RT VA EDV (cm/s) -0.22 0.29 -0.11 0.59 25 CONTROL 
S-transf  CSD PROX RT VA (mm) -0.17 0.41 -0.18 0.4 25 CONTROL 
S-transf  RT PSV ICA/CCA ratio 0.05 0.8 -0.19 0.36 25 CONTROL 
S-transf  RT EDV ICA/CCA ratio -0.46 0.02 -0.21 0.31 25 CONTROL 
S-transf  LT CCA IMT (mm) -0.18 0.4 -0.32 0.12 25 CONTROL 
S-transf  LT CCA PSV (cm/s) 0.11 0.62 -0.04 0.87 25 CONTROL 
S-transf  LT CCA EDV (cm/s) 0.24 0.25 -0.15 0.48 25 CONTROL 
S-transf  CSD PROX LT CCA (mm) 0.22 0.28 0.14 0.51 25 CONTROL 
S-transf  CSD MID LT CCA (mm) 0.15 0.48 0.01 0.97 25 CONTROL 
S-transf  CSD DIST LT CCA (mm) -0.01 0.96 -0.17 0.42 25 CONTROL 
S-transf  LT ICA PSV (cm/s) -0.02 0.92 -0.15 0.46 25 CONTROL 
S-transf  LT ICA EDV (cm/s) -0.17 0.41 -0.06 0.78 25 CONTROL 
S-transf  CSD PROX LT ICA (mm) 0.33 0.11 -0.05 0.82 25 CONTROL 
S-transf  PROX LT ECA PSV (cm/s) -0.13 0.54 -0.43 0.03 25 CONTROL 
S-transf  CSD PROX LT ECA (mm) 0.28 0.17 0.41 0.04 25 CONTROL 
S-transf  LT VA PSV (cm/s) -0.05 0.79 -0.02 0.91 25 CONTROL 
S-transf  LT VA EDV (cm/s) 0.05 0.82 0.01 0.97 25 CONTROL 
S-transf  CSD PROX LT VA (mm) -0.18 0.38 -0.09 0.67 25 CONTROL 
S-transf  LT PSV ICA/CCA ratio -0.12 0.57 -0.07 0.75 25 CONTROL 
S-transf  LT EDV ICA/ECA ratio -0.29 0.16 0.09 0.68 25 CONTROL 
S-transf  PV PROX RT IJV (cm/s) 0.25 0.23 0.54 <0.01 25 CONTROL 
S-transf  PV MID RT IJV (cm/s) -0.23 0.27 0.11 0.58 25 CONTROL 
S-transf  PV DIST RT IJV (cm/s) -0.15 0.47 0.16 0.44 25 CONTROL 
S-transf  CSA PROX RT IJV (mm2) 0.05 0.8 -0.03 0.89 25 CONTROL 
S-transf  PV PROX LT IJV (cm/s) 0.66 <0.01 0.36 0.08 25 CONTROL 
S-transf  PV MID LT IJV (cm/s) 0.22 0.29 0.3 0.15 25 CONTROL 
S-transf  PV DIST LT IJV (cm/s) 0.11 0.6 0.32 0.12 25 CONTROL 
S-transf  CSA PROX LT IJV (mm2) 0.03 0.89 0.17 0.42 25 CONTROL 
 
 
 
 
 
 
S-transf, serum transferrin; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic 
velocity; EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal 
carotid artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein. 
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4.4.3 Association between percentage (%) transferrin saturation and the extracranial 
vascular ultrasound variables 
 
MS group: A significant positive association was demonstrated between percentage 
transferrin saturation and the following extracranial vascular ultrasound variables in the MS 
group as tabulated in Table 4.12: 
 Right ICA PSV; Pearson p-value 0.03, Spearman p-value 0.03 
 Right PSV ICA/CCA ratio; Pearson p-value 0.01, Spearman p-value <0.01 
 Right EDV ICA/CCA ratio; Pearson p-value 0.03, Spearman p-value 0.04 
Similarly, a significant negative association was found between percentage transferrin 
saturation and the CSD of the proximal right CCA (Spearman p-value 0.04), CSD proximal left 
VA (Spearman p-value 0.04) and the CSA proximal right IJV (Spearman p-value 0.04). No 
significant association was found between the remaining extracranial vascular ultrasound 
variables and percentage transferrin saturation (Table 4.12). 
 
Control group: In the control group, a significant negative correlation was found between the 
PV of the distal left IJV (Pearson p-value 0.01). No significant association (p>0.05) was 
demonstrated between percentage transferrin saturation and the remaining 39 extracranial 
vascular ultrasound variables (Table 4.13). 
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Table 4.12: Correlation between percentage transferrin saturation and the extracranial vascular 
ultrasound variables in the MS group 
Biochemical 
marker 
 
Ultrasound variable 
Pearson Spearman # 
cases 
 
group r p r p 
% Tf sat RT CCA IMT (mm) 0.13 0.55 0.26 0.21 25 MS 
% Tf sat RT CCA PSV (cm/s) -0.11 0.6 -0.17 0.4 25 MS 
% Tf sat RT CCA EDV (cm/s) -0.06 0.76 -0.21 0.32 25 MS 
% Tf sat CSD PROX RT CCA (mm) -0.33 0.1 -0.42 0.04 25 MS 
% Tf sat CSD MID RT CCA (mm) -0.15 0.48 -0.05 0.83 25 MS 
% Tf sat CSD DIST RT CCA (mm) -0.12 0.57 -0.06 0.76 25 MS 
% Tf sat RT ICA PSV (cm/s) 0.43 0.03 0.43 0.03 25 MS 
% Tf sat RT ICA EDV (cm/s) 0.37 0.07 0.32 0.12 25 MS 
% Tf sat CSD PROX RT ICA (mm) -0.12 0.56 -0.12 0.57 25 MS 
% Tf sat PROX ECA RT PSV (cm/s) 0.11 0.59 0.06 0.76 25 MS 
% Tf sat CSD PROX RT ECA (mm) -0.16 0.45 -0.16 0.43 25 MS 
% Tf sat RT VA PSV (cm/s) 0.04 0.83 0.08 0.7 25 MS 
% Tf sat RT VA EDV (cm/s) 0.09 0.66 0.09 0.67 25 MS 
% Tf sat CSD PROX RT VA (mm) 0.06 0.76 0.05 0.8 25 MS 
% Tf sat RT PSV ICA/CCA ratio 0.49 0.01 0.54 <0.01 25 MS 
% Tf sat RT EDV ICA/CCA ratio 0.44 0.03 0.41 0.04 25 MS 
% Tf sat LT CCA IMT (mm) 0.22 0.3 0.34 0.1 25 MS 
% Tf sat LT CCA PSV (cm/s) 0.02 0.93 -0.04 0.85 25 MS 
% Tf sat LT CCA EDV (cm/s) 0.06 0.79 0.09 0.66 25 MS 
% Tf sat CSD PROX LT CCA (mm) -0.3 0.14 -0.23 0.26 25 MS 
% Tf sat CSD MID LT CCA (mm) -0.13 0.54 -0.06 0.78 25 MS 
% Tf sat CSD DIST LT CCA (mm) -0.23 0.26 -0.23 0.27 25 MS 
% Tf sat LT ICA PSV (cm/s) 0.1 0.65 0.11 0.62 25 MS 
% Tf sat LT ICA EDV (cm/s) 0.35 0.09 0.26 0.21 25 MS 
% Tf sat CSD PROX LT ICA (mm) -0.07 0.74 -0.07 0.74 25 MS 
% Tf sat PROX LT ECA PSV (cm/s) -0.1 0.64 -0.03 0.88 25 MS 
% Tf sat CSD PROX LT ECA (mm) 0.01 0.95 -0.14 0.5 25 MS 
% Tf sat LT VA PSV (cm/s) -0.31 0.13 -0.25 0.23 25 MS 
% Tf sat LT VA EDV (cm/s) -0.23 0.26 -0.12 0.58 25 MS 
% Tf sat CSD PROX LT VA (mm) -0.4 0.05 -0.42 0.04 25 MS 
% Tf sat LT PSV ICA/CCA ratio 0.25 0.22 0.32 0.12 25 MS 
% Tf sat LT EDV ICA/ECA ratio 0.3 0.14 0.23 0.27 25 MS 
% Tf sat PV PROX RT IJV (cm/s) 0.17 0.41 0.14 0.52 25 MS 
% Tf sat PV MID RT IJV (cm/s) -0.07 0.74 -0.01 0.96 25 MS 
% Tf sat PV DIST RT IJV (cm/s) 0.01 0.96 0.17 0.41 25 MS 
% Tf sat CSA PROX RT IJV (mm2) -0.31 0.13 -0.41 0.04 25 MS 
% Tf sat PV PROX LT IJV (cm/s) 0.19 0.36 0.12 0.58 25 MS 
% Tf sat PV MID LT IJV (cm/s) 0.22 0.28 0.22 0.29 25 MS 
% Tf sat PV DIST LT IJV (cm/s) 0 0.99 0.11 0.6 25 MS 
% Tf sat CSA PROX LT IJV (mm2) 0 1 -0.19 0.37 25 MS 
 
 
 
 
% Tf sat, percentage transferrin saturation; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, 
peak systolic velocity; EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, 
distal; ICA, internal carotid artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal 
jugular vein. 
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Table 4.13: Correlation between percentage transferrin saturation and the extracranial 
ultrasound variables in the control group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
% Tf sat RT CCA IMT (mm) 0.25 0.22 0.13 0.54 25 CONTROL 
% Tf sat 
RT CCA PSV (cm/s) -0.1 0.65 -0.03 0.89 25 CONTROL 
% Tf sat 
RT CCA EDV (cm/s) -0.1 0.63 -0.13 0.52 25 CONTROL 
% Tf sat 
CSD PROX RT CCA (mm) 0.06 0.77 0.19 0.37 25 CONTROL 
% Tf sat 
CSD MID RT CCA (mm) 0.11 0.59 0.14 0.52 25 CONTROL 
% Tf sat 
CSD DIST RT CCA (mm) -0.04 0.84 -0.06 0.79 25 CONTROL 
% Tf sat 
RT ICA PSV (cm/s) 0.05 0.82 0.15 0.46 25 CONTROL 
% Tf sat 
RT ICA EDV (cm/s) 0.26 0.21 0.22 0.29 25 CONTROL 
% Tf sat 
CSD PROX RT ICA (mm) -0.02 0.91 -0.09 0.66 25 CONTROL 
% Tf sat 
PROX ECA RT PSV (cm/s) -0.19 0.36 -0.28 0.17 25 CONTROL 
% Tf sat 
CSD PROX RT ECA (mm) -0.1 0.64 -0.04 0.84 25 CONTROL 
% Tf sat 
RT VA PSV (cm/s) -0.15 0.48 -0.11 0.61 25 CONTROL 
% Tf sat 
RT VA EDV (cm/s) -0.14 0.51 -0.08 0.71 25 CONTROL 
% Tf sat 
CSD PROX RT VA (mm) 0.31 0.14 0.23 0.27 25 CONTROL 
% Tf sat 
RT PSV ICA/CCA ratio 0.11 0.62 0.1 0.63 25 CONTROL 
% Tf sat 
RT EDV ICA/ECA ratio 0.31 0.13 0.25 0.23 25 CONTROL 
% Tf sat 
LT CCA IMT (mm) 0.13 0.53 0.07 0.75 25 CONTROL 
% Tf sat 
LT CCA PSV (cm/s) -0.15 0.47 -0.1 0.64 25 CONTROL 
% Tf sat 
LT CCA EDV (cm/s) -0.05 0.83 0.07 0.73 25 CONTROL 
% Tf sat 
CSD PROX LT CCA (mm) -0.05 0.81 -0.18 0.39 25 CONTROL 
% Tf sat 
CSD MID LT CCA (mm) 0.12 0.56 0.05 0.83 25 CONTROL 
% Tf sat 
CSD DIST LT CCA (mm) 0.11 0.59 0.03 0.88 25 CONTROL 
% Tf sat 
LT ICA PSV (cm/s) 0.04 0.85 0.12 0.56 25 CONTROL 
% Tf sat 
LT ICA EDV (cm/s) 0 0.98 -0.04 0.85 25 CONTROL 
% Tf sat 
CSD PROX LT ICA (mm) -0.01 0.95 0 1 25 CONTROL 
% Tf sat 
PROX LT ECA PSV (cm/s) 0.12 0.56 0.12 0.56 25 CONTROL 
% Tf sat 
CSD PROX LT ECA (mm) -0.2 0.33 -0.2 0.33 25 CONTROL 
% Tf sat 
LT VA PSV (cm/s) -0.11 0.6 -0.03 0.88 25 CONTROL 
% Tf sat 
LT VA EDV (cm/s) -0.18 0.39 -0.01 0.95 25 CONTROL 
% Tf sat 
CSD PROX LT VA (mm) 0.21 0.32 0.18 0.4 25 CONTROL 
% Tf sat 
LT PSV ICA/CCA ratio 0.25 0.23 0.24 0.25 25 CONTROL 
% Tf sat 
LT EDV ICA/ECA ratio 0.02 0.91 0.01 0.95 25 CONTROL 
% Tf sat 
PV PROX RT IJV (cm/s) -0.26 0.21 -0.11 0.61 25 CONTROL 
% Tf sat 
PV MID RT IJV (cm/s) 0.17 0.41 0.25 0.23 25 CONTROL 
% Tf sat 
PV DIST RT IJV (cm/s) 0.13 0.52 0.14 0.51 25 CONTROL 
% Tf sat 
CSA PROX RT IJV (mm2) 0.05 0.82 0.08 0.71 25 CONTROL 
% Tf sat 
PV PROX LT IJV (cm/s) -0.31 0.13 -0.09 0.67 25 CONTROL 
% Tf sat 
PV MID LT IJV (cm/s) -0.35 0.08 -0.27 0.2 25 CONTROL 
% Tf sat 
PV DIST LT IJV (cm/s) -0.5 0.01 -0.38 0.06 25 CONTROL 
% Tf sat 
CSA PROX LT IJV (mm2) -0.16 0.44 0 0.99 25 CONTROL 
 
 
 
 
 
% Tf sat, percentage transferrin saturation; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, 
peak systolic velocity; EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; 
ICA, internal carotid artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein. 
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4.4.4 Association between serum ferritin and the extracranial vascular ultrasound 
variables 
 
MS group: As seen in Table 4.14, a statistically significant negative association was found 
between ferritin and the PV of the proximal left IJV (Pearson p-value 0.02). No statistically 
significant association was found between ferritin and the remaining 39 extracranial vascular 
ultrasound variables in the MS group.  
 
Control group: In the control group, a significant positive correlation was found between 
ferritin and the IMT of the left CCA (Pearson p-value 0.01). No significant associations were 
demonstrated between ferritin and the remaining 39 extracranial vascular ultrasound variables 
(Table 4.15). 
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Table 4.14: Correlation between ferritin and the extracranial vascular ultrasound variables in the 
MS group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Ferritin RT CCA IMT (mm) 0.02 0.94 0.04 0.87 25 MS 
Ferritin RT CCA PSV (cm/s) -0.18 0.39 0.02 0.91 25 MS 
Ferritin RT CCA EDV (cm/s) 0.03 0.88 0.25 0.23 25 MS 
Ferritin CSD PROX RT CCA (mm) -0.15 0.48 -0.17 0.42 25 MS 
Ferritin CSD MID RT CCA (mm) 0.05 0.81 -0.06 0.78 25 MS 
Ferritin CSD DIST RT CCA (mm) 0.1 0.64 -0.04 0.84 25 MS 
Ferritin RT ICA PSV (cm/s) 0.09 0.68 0.23 0.28 25 MS 
Ferritin RT ICA EDV (cm/s) 0.18 0.4 0.32 0.12 25 MS 
Ferritin CSD PROX RT ICA (mm) 0.11 0.62 -0.03 0.89 25 MS 
Ferritin PROX ECA RT PSV (cm/s) -0.21 0.32 -0.02 0.93 25 MS 
Ferritin CSD PROX RT ECA (mm) 0.11 0.6 -0.02 0.92 25 MS 
Ferritin RT VA PSV (cm/s) 0.18 0.4 0.22 0.28 25 MS 
Ferritin RT VA EDV (cm/s) 0.14 0.51 0.12 0.56 25 MS 
Ferritin CSD PROX RT VA (mm) -0.32 0.12 -0.18 0.4 25 MS 
Ferritin RT PSV ICA/CCA ratio 0.27 0.18 0.29 0.16 25 MS 
Ferritin RT EDV ICA/ECA ratio 0.13 0.53 0.15 0.47 25 MS 
Ferritin LT CCA IMT (mm) 0.09 0.65 0.12 0.56 25 MS 
Ferritin LT CCA PSV (cm/s) 0.04 0.84 0.08 0.72 25 MS 
Ferritin LT CCA EDV (cm/s) 0.24 0.25 0.4 0.05 25 MS 
Ferritin CSD PROX LT CCA (mm) 0.02 0.91 0.01 0.96 25 MS 
Ferritin CSD MID LT CCA (mm) -0.18 0.4 -0.24 0.24 25 MS 
Ferritin CSD DIST LT CCA (mm) -0.18 0.39 -0.33 0.11 25 MS 
Ferritin LT ICA PSV (cm/s) 0.12 0.57 0.29 0.16 25 MS 
Ferritin LT ICA EDV (cm/s) 0.18 0.4 0.17 0.42 25 MS 
Ferritin CSD PROX LT ICA (mm) -0.21 0.32 -0.18 0.38 25 MS 
Ferritin PROX LT ECA PSV (cm/s) 0.14 0.51 0.2 0.34 25 MS 
Ferritin CSD PROX LT ECA (mm) -0.12 0.56 -0.08 0.69 25 MS 
Ferritin LT VA PSV (cm/s) 0.03 0.9 0.11 0.6 25 MS 
Ferritin LT VA EDV (cm/s) 0.15 0.47 0.15 0.47 25 MS 
Ferritin CSD PROX LT VA (mm) -0.25 0.23 -0.06 0.77 25 MS 
Ferritin LT PSV ICA/CCA ratio 0.16 0.45 0.11 0.61 25 MS 
Ferritin LT EDV ICA/ECA ratio -0.04 0.86 -0.17 0.42 25 MS 
Ferritin PV PROX RT IJV (cm/s) 0.07 0.74 0.18 0.4 25 MS 
Ferritin PV MID RT IJV (cm/s) -0.07 0.73 0.05 0.8 25 MS 
Ferritin PV DIST RT IJV (cm/s) 0 1 0.03 0.91 25 MS 
Ferritin CSA PROX RT IJV (mm2) 0.28 0.18 0.2 0.33 25 MS 
Ferritin PV PROX LT IJV (cm/s) -0.35 0.09 -0.46 0.02 25 MS 
Ferritin PV MID LT IJV (cm/s) -0.24 0.24 -0.08 0.69 25 MS 
Ferritin PV DIST LT IJV (cm/s) -0.12 0.58 -0.05 0.81 25 MS 
Ferritin CSA PROX LT IJV (mm2) -0.04 0.85 -0.01 0.94 25 MS 
 
 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic 
velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, 
external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein. 
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Table 4.15: Correlation between ferritin and the extracranial vascular ultrasound variables in 
the control group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Ferritin RT CCA IMT (mm) -0.04 0.85 0.02 0.93 25 CONTROL 
Ferritin RT CCA PSV (cm/s) -0.11 0.61 -0.17 0.42 25 CONTROL 
Ferritin RT CCA EDV (cm/s) -0.24 0.24 -0.33 0.11 25 CONTROL 
Ferritin CSD PROX RT CCA (mm) 0.02 0.91 0.21 0.31 25 CONTROL 
Ferritin CSD MID RT CCA (mm) -0.07 0.75 0.01 0.95 25 CONTROL 
Ferritin CSD DIST RT CCA (mm) 0.25 0.23 0.23 0.28 25 CONTROL 
Ferritin RT ICA PSV (cm/s) 0.25 0.23 0.14 0.52 25 CONTROL 
Ferritin RT ICA EDV (cm/s) 0.15 0.48 0.06 0.79 25 CONTROL 
Ferritin CSD PROX RT ICA (mm) 0.02 0.91 0.01 0.96 25 CONTROL 
Ferritin PROX ECA RT PSV (cm/s) 0.36 0.07 0.16 0.43 25 CONTROL 
Ferritin CSD PROX RT ECA (mm) -0.19 0.35 -0.14 0.51 25 CONTROL 
Ferritin RT VA PSV (cm/s) -0.13 0.52 -0.28 0.17 25 CONTROL 
Ferritin RT VA EDV (cm/s) 0.02 0.92 -0.16 0.44 25 CONTROL 
Ferritin CSD PROX RT VA (mm) 0.2 0.33 0.39 0.06 25 CONTROL 
Ferritin RT PSV ICA/CCA ratio 0.3 0.14 0.23 0.28 25 CONTROL 
Ferritin RT EDV ICA/ECA ratio 0.36 0.08 0.26 0.21 25 CONTROL 
Ferritin LT CCA IMT (mm) 0.48 0.01 0.24 0.24 25 CONTROL 
Ferritin LT CCA PSV (cm/s) 0.03 0.88 -0.01 0.98 25 CONTROL 
Ferritin LT CCA EDV (cm/s) -0.11 0.6 -0.06 0.77 25 CONTROL 
Ferritin CSD PROX LT CCA (mm) -0.11 0.61 -0.19 0.36 25 CONTROL 
Ferritin CSD MID LT CCA (mm) 0.15 0.47 0.07 0.72 25 CONTROL 
Ferritin CSD DIST LT CCA (mm) 0.29 0.16 0.16 0.45 25 CONTROL 
Ferritin LT ICA PSV (cm/s) 0.13 0.53 0.03 0.88 25 CONTROL 
Ferritin LT ICA EDV (cm/s) -0.12 0.56 -0.2 0.34 25 CONTROL 
Ferritin CSD PROX LT ICA (mm) 0.21 0.31 0.14 0.51 25 CONTROL 
Ferritin PROX LT ECA PSV (cm/s) 0.36 0.08 0.33 0.11 25 CONTROL 
Ferritin CSD PROX LT ECA (mm) -0.36 0.08 -0.33 0.11 25 CONTROL 
Ferritin LT VA PSV (cm/s) -0.19 0.36 -0.28 0.17 25 CONTROL 
Ferritin LT VA EDV (cm/s) -0.2 0.33 -0.31 0.13 25 CONTROL 
Ferritin CSD PROX LT VA (mm) 0.4 0.05 0.22 0.28 25 CONTROL 
Ferritin LT PSV ICA/CCA ratio 0.17 0.41 0.07 0.76 25 CONTROL 
Ferritin LT EDV ICA/ECA ratio -0.05 0.81 -0.18 0.4 25 CONTROL 
Ferritin PV PROX RT IJV (cm/s) -0.16 0.44 -0.12 0.56 25 CONTROL 
Ferritin PV MID RT IJV (cm/s) 0 0.98 0.09 0.67 25 CONTROL 
Ferritin PV DIST RT IJV (cm/s) 0.07 0.73 0.18 0.38 25 CONTROL 
Ferritin CSA PROX RT IJV (mm2) -0.01 0.95 -0.15 0.47 25 CONTROL 
Ferritin PV PROX LT IJV (cm/s) -0.3 0.14 -0.25 0.24 25 CONTROL 
Ferritin PV MID LT IJV (cm/s) -0.14 0.5 -0.06 0.77 25 CONTROL 
Ferritin PV DIST LT IJV (cm/s) -0.11 0.58 -0.15 0.48 25 CONTROL 
Ferritin CSA PROX LT IJV (mm2) -0.39 0.05 -0.37 0.07 25 CONTROL 
 
 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic 
velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, external 
carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein. 
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4.4.5 Association between haemoglobin and the extracranial vascular ultrasound 
variables 
 
MS group: No significant association (p>0.05) was observed between haemoglobin and most 
of the extracranial vascular ultrasound variables in the MS group. However, a significant 
negative correlation was observed between haemoglobin and the following extracranial 
vascular ultrasound variables (Table 4.16): 
 EDV of the right ICA; Pearson p-value 0.03 
 EDV of the right VA; Pearson p-value 0.01, Spearman p-value <0.01 
 PSV of the left VA; Pearson p-value 0.03, Spearman p-value 0.02 
 EDV of the left VA; Pearson p-value 0.02, Spearman p-value 0.03 
 PV of the proximal right IJV; Pearson p-value <0.01, Spearman p-value <0.01 
 PV of the mid right IJV; Pearson p-value <0.01, Spearman p-value 0.01 
 PV of the distal right IJV; Pearson p-value 0.02, Spearman p-value 0.04 
Control group: The association between haemoglobin and the extracranial vascular 
ultrasound variables in the control group is given in Table 4.17. A significant negative 
correlation was found between haemoglobin and the EDV of the right VA (Spearman p-value 
0.04) and EDV of the left ICA (Spearman p-value 0.02, Pearson p-value 0.01). No significant 
association (p>0.05) was found between haemoglobin and the remaining extracranial vascular 
ultrasound variables in this specific group of participants. 
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Table 4.16: Correlation between haemoglobin and the extracranial ultrasound variables in the 
MS group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
HB RT CCA IMT (mm) 0.19 0.37 0.2 0.33 25 MS 
HB RT CCA PSV (cm/s) -0.13 0.53 -0.04 0.87 25 MS 
HB RT CCA EDV (cm/s) -0.31 0.13 -0.27 0.19 25 MS 
HB CSD PROX RT CCA (mm) 0.14 0.5 0.15 0.48 25 MS 
HB CSD MID RT CCA (mm) 0.31 0.13 0.27 0.2 25 MS 
HB CSD DIST RT CCA (mm) 0.4 0.05 0.36 0.07 25 MS 
HB RT ICA PSV (cm/s) -0.19 0.36 -0.11 0.59 25 MS 
HB RT ICA EDV (cm/s) -0.42 0.03 -0.39 0.05 25 MS 
HB CSD PROX RT ICA (mm) 0.27 0.19 0.23 0.26 25 MS 
HB PROX ECA RT PSV (cm/s) 0.15 0.46 0.21 0.31 25 MS 
HB CSD PROX RT ECA (mm) 0.03 0.91 0.02 0.92 25 MS 
HB RT VA PSV (cm/s) -0.29 0.15 -0.33 0.11 25 MS 
HB RT VA EDV (cm/s) -0.49 0.01 -0.53 <0.01 25 MS 
HB CSD PROX RT VERT A (mm) -0.24 0.24 -0.23 0.27 25 MS 
HB RT PSV ICA/CCA ratio -0.12 0.56 -0.11 0.59 25 MS 
HB RT EDV ICA/ECA ratio -0.07 0.74 -0.18 0.38 25 MS 
HB LT CCA IMT (mm) 0.08 0.7 0.12 0.57 25 MS 
HB LT CCA PSV (cm/s) -0.02 0.91 0.13 0.54 25 MS 
HB LT CCA EDV (cm/s) -0.19 0.36 -0.16 0.45 25 MS 
HB CSD PROX LT CCA (mm) -0.08 0.72 -0.03 0.88 25 MS 
HB CSD MID LT CCA (mm) 0.09 0.66 0.2 0.33 25 MS 
HB CSD DIST LT CCA (mm) 0.08 0.7 0.11 0.6 25 MS 
HB LT ICA PSV (cm/s) -0.26 0.21 -0.24 0.25 25 MS 
HB LT ICA EDV (cm/s) -0.19 0.36 -0.09 0.66 25 MS 
HB CSD PROX LT ICA (mm) -0.02 0.92 0.05 0.81 25 MS 
HB PROX LT ECA PSV (cm/s) 0.06 0.76 0.11 0.59 25 MS 
HB CSD PROX LT ECA (mm) -0.06 0.77 -0.04 0.85 25 MS 
HB LT VA PSV (cm/s) -0.43 0.03 -0.47 0.02 25 MS 
HB LT VA EDV (cm/s) -0.47 0.02 -0.42 0.03 25 MS 
HB CSD PROX LT VERT A (mm) 0.12 0.56 0.08 0.7 25 MS 
HB LT PSV ICA/CCA ratio -0.18 0.38 -0.17 0.42 25 MS 
HB LT EDV ICA/ECA ratio -0.04 0.84 -0.16 0.44 25 MS 
HB PV PROX RT IJV (cm/s) -0.62 <0.01 -0.6 <0.01 25 MS 
HB PV MID RT IJV (cm/s) -0.58 <0.01 -0.47 0.02 25 MS 
HB PV DIST RT IJV (cm/s) -0.45 0.02 -0.41 0.04 25 MS 
HB CSA PROX RT IJV (mm2) -0.22 0.3 -0.25 0.24 25 MS 
HB PV PROX LT IJV (cm/s) 0.04 0.86 0.11 0.6 25 MS 
HB PV MID LT IJV (cm/s) -0.11 0.61 0.08 0.71 25 MS 
HB PV DIST LT IJV (cm/s) -0.14 0.52 -0.04 0.86 25 MS 
HB CSA PROX LT IJV (mm2) 0.06 0.77 -0.08 0.72 25 MS 
 
 
 
 
HB, haemoglobin; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, 
end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; 
ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein. 
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Table 4.17: Correlation between haemoglobin and the extracranial vascular ultrasound variables 
in the control group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
HB RT CCA IMT (mm) -0.15 0.48 -0.1 0.63 25 CONTROL 
HB RT CCA PSV (cm/s) 0.01 0.95 -0.03 0.9 25 CONTROL 
HB RT CCA EDV (cm/s) -0.34 0.09 -0.36 0.08 25 CONTROL 
HB CSD PROX RT CCA (mm) 0.07 0.73 0.01 0.95 25 CONTROL 
HB CSD MID RT CCA (mm) 0.07 0.75 -0.09 0.69 25 CONTROL 
HB CSD DIST RT CCA (mm) 0.04 0.83 -0.08 0.71 25 CONTROL 
HB RT ICA PSV (cm/s) -0.2 0.33 -0.23 0.28 25 CONTROL 
HB RT ICA EDV (cm/s) -0.12 0.58 -0.18 0.39 25 CONTROL 
HB CSD PROX RT ICA (mm) 0.25 0.23 0.16 0.44 25 CONTROL 
HB PROX ECA RT PSV (cm/s) 0.14 0.49 -0.01 0.95 25 CONTROL 
HB CSD PROX RT ECA (mm) -0.03 0.88 -0.09 0.67 25 CONTROL 
HB RT VA PSV (cm/s) -0.23 0.27 -0.23 0.26 25 CONTROL 
HB RT VA EDV (cm/s) -0.4 0.05 -0.42 0.04 25 CONTROL 
HB CSD PROX RT VA (mm) 0.17 0.42 0.29 0.15 25 CONTROL 
HB RT PSV ICA/CCA ratio -0.03 0.88 -0.03 0.87 25 CONTROL 
HB RT EDV ICA/ECA ratio 0.2 0.34 0.25 0.23 25 CONTROL 
HB LT CCA IMT (mm) 0.05 0.8 -0.1 0.62 25 CONTROL 
HB LT CCA PSV (cm/s) -0.07 0.76 -0.16 0.44 25 CONTROL 
HB LT CCA EDV (cm/s) 0.02 0.92 0.04 0.85 25 CONTROL 
HB CSD PROX LT CCA (mm) 0 0.99 -0.04 0.86 25 CONTROL 
HB CSD MID LT CCA (mm) 0.3 0.14 0.23 0.26 25 CONTROL 
HB CSD DIST LT CCA (mm) 0.35 0.09 0.27 0.19 25 CONTROL 
HB LT ICA PSV (cm/s) -0.14 0.51 -0.16 0.45 25 CONTROL 
HB LT ICA EDV (cm/s) -0.46 0.02 -0.49 0.01 25 CONTROL 
HB CSD PROX LT ICA (mm) 0.2 0.35 0.18 0.4 25 CONTROL 
HB PROX LT ECA PSV (cm/s) 0.35 0.09 0.28 0.17 25 CONTROL 
HB CSD PROX LT ECA (mm) 0.05 0.8 0.01 0.95 25 CONTROL 
HB LT VA PSV (cm/s) -0.31 0.14 -0.26 0.21 25 CONTROL 
HB LT VA EDV (cm/s) -0.39 0.05 -0.37 0.07 25 CONTROL 
HB CSD PROX LT VA (mm) 0.07 0.76 0 1 25 CONTROL 
HB LT PSV ICA/CCA ratio 0.17 0.41 0.12 0.58 25 CONTROL 
HB LT EDV ICA/ECA ratio -0.35 0.09 -0.34 0.1 25 CONTROL 
HB PV PROX RT IJV (cm/s) 0.1 0.65 0.13 0.54 25 CONTROL 
HB PV MID RT IJV (cm/s) 0.27 0.2 0.28 0.18 25 CONTROL 
HB PV DIST RT IJV (cm/s) -0.03 0.89 0.16 0.45 25 CONTROL 
HB CSA PROX RT IJV (mm2) 0.06 0.77 -0.02 0.93 25 CONTROL 
HB PV PROX LT IJV (cm/s) 0.13 0.52 0.18 0.39 25 CONTROL 
HB PV MID LT IJV (cm/s) 0.12 0.56 0.09 0.67 25 CONTROL 
HB PV DIST LT IJV (cm/s) -0.08 0.71 -0.02 0.93 25 CONTROL 
HB CSA PROX LT IJV (mm2) -0.26 0.2 -0.15 0.47 25 CONTROL 
 
. 
HB, haemoglobin; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, 
end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; 
ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein. 
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4.4.6 Association between serum vitamin B12 and the extracranial vascular ultrasound 
variables 
 
MS group: In the MS group, a statistically significant positive correlation was found between 
vitamin B12 and PSV of the right CCA (Spearman p-value <0.01) as well as the PSV of the left 
CCA (Spearman p-value <0.01). Similarly, a significant negative correlation was found 
between vitamin B12 and the EDV of the left VA (Pearson p-value 0.03) and PV of the proximal 
right IJV (Spearman p-value 0.02). No other significant associations were found between 
vitamin B12 and the remainder of the extracranial ultrasound variables (Table 4.18). 
 
Control group: The correlation between vitamin B12 and the extracranial vascular ultrasound 
variables in the control group are presented in Table 4.19. No significant associations were 
observed between vitamin B12 and ultrasound variables except for one significant positive 
association between vitamin B12 and the left PSV ICA/CCA ratio (Pearson p-value 0.02). 
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Table 4.18: Correlation between vitamin B12 and the extracranial vascular ultrasound variables 
in the MS group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Vit B12 RT CCA IMT (mm) -0.14 0.51 -0.05 0.82 25 MS 
Vit B12 RT CCA PSV (cm/s) 0.38 0.06 0.52 <0.01 25 MS 
Vit B12 RT CCA EDV (cm/s) -0.06 0.76 -0.02 0.93 25 MS 
Vit B12 CSD PROX RT CCA (mm) -0.08 0.69 0 0.99 25 MS 
Vit B12 CSD MID RT CCA (mm) -0.12 0.57 -0.06 0.76 25 MS 
Vit B12 CSD DIST RT CCA (mm) 0.1 0.64 0.19 0.37 25 MS 
Vit B12 RT ICA PSV (cm/s) 0.2 0.35 0.11 0.61 25 MS 
Vit B12 RT ICA EDV (cm/s) 0.18 0.38 0.16 0.46 25 MS 
Vit B12 CSD PROX RT ICA (mm) -0.14 0.52 -0.14 0.51 25 MS 
Vit B12 PROX ECA RT PSV (cm/s) 0.14 0.51 0.13 0.54 25 MS 
Vit B12 CSD PROX RT ECA (mm) 0.04 0.85 0.05 0.82 25 MS 
Vit B12 RT VA PSV (cm/s) 0.22 0.29 0.21 0.33 25 MS 
Vit B12 RT VA EDV (cm/s) -0.06 0.76 -0.1 0.64 25 MS 
Vit B12 CSD PROX RT VA (mm) -0.26 0.21 -0.25 0.24 25 MS 
Vit B12 RT PSV ICA/CCA ratio -0.12 0.57 -0.26 0.21 25 MS 
Vit B12 RT EDV ICA/ECA ratio 0.3 0.15 0.12 0.58 25 MS 
Vit B12 LT CCA IMT (mm) 0.13 0.54 0.19 0.37 25 MS 
Vit B12 LT CCA PSV (cm/s) 0.39 0.05 0.52 <0.01 25 MS 
Vit B12 LT CCA EDV (cm/s) 0.09 0.66 0.16 0.44 25 MS 
Vit B12 CSD PROX LT CCA (mm) 0.16 0.46 0.28 0.18 25 MS 
Vit B12 CSD MID LT CCA (mm) 0.08 0.72 0.17 0.43 25 MS 
Vit B12 CSD DIST LT CCA (mm) 0.02 0.93 0.06 0.78 25 MS 
Vit B12 LT ICA PSV (cm/s) 0.02 0.91 0.12 0.58 25 MS 
Vit B12 LT ICA EDV (cm/s) 0.2 0.35 0.1 0.62 25 MS 
Vit B12 CSD PROX LT ICA (mm) -0.12 0.57 -0.14 0.51 25 MS 
Vit B12 PROX LT ECA PSV (cm/s) 0.08 0.7 0.11 0.61 25 MS 
Vit B12 CSD PROX LT ECA (mm) 0.02 0.92 0.06 0.78 25 MS 
Vit B12 LT VA PSV (cm/s) -0.25 0.24 -0.17 0.41 25 MS 
Vit B12 LT VA EDV (cm/s) -0.44 0.03 -0.36 0.08 25 MS 
Vit B12 CSD PROX LT VA (mm) -0.18 0.38 -0.08 0.72 25 MS 
Vit B12 LT PSV ICA/CCA ratio -0.14 0.5 -0.2 0.33 25 MS 
Vit B12 LT EDV ICA/ECA ratio 0.13 0.53 -0.11 0.62 25 MS 
Vit B12 PV PROX RT IJV (cm/s) -0.38 0.06 -0.45 0.02 25 MS 
Vit B12 PV MID RT IJV (cm/s) -0.31 0.13 -0.24 0.24 25 MS 
Vit B12 PV DIST RT IJV (cm/s) -0.28 0.17 -0.28 0.17 25 MS 
Vit B12 CSA PROX RT IJV (mm2) 0.08 0.71 0.1 0.64 25 MS 
Vit B12 PV PROX LT IJV (cm/s) 0.01 0.95 -0.08 0.7 25 MS 
Vit B12 PV MID LT IJV (cm/s) -0.05 0.82 0.03 0.9 25 MS 
Vit B12 PV DIST LT IJV (cm/s) -0.29 0.16 -0.25 0.22 25 MS 
Vit B12 CSA PROX LT IJV (mm2) -0.01 0.97 -0.18 0.4 25 MS 
 
 
 
Vit B12, serum vitamin B12; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; 
EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid 
artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein. 
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Table 4.19: Correlation between serum vitamin B12 and the extracranial vascular ultrasound 
variables in the control group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Vit B12 RT CCA IMT (mm) -0.12 0.58 -0.17 0.43 25 CONTROL 
Vit B12 RT CCA PSV (cm/s) 0.04 0.85 0.11 0.61 25 CONTROL 
Vit B12 RT CCA EDV (cm/s) -0.19 0.37 -0.2 0.34 25 CONTROL 
Vit B12 CSD PROX RT CCA (mm) 0.05 0.81 0 1 25 CONTROL 
Vit B12 CSD MID RT CCA (mm) 0.02 0.92 0 0.99 25 CONTROL 
Vit B12 CSD DIST RT CCA (mm) -0.19 0.37 -0.24 0.26 25 CONTROL 
Vit B12 RT ICA PSV (cm/s) -0.2 0.34 -0.06 0.77 25 CONTROL 
Vit B12 RT ICA EDV (cm/s) -0.06 0.76 -0.07 0.76 25 CONTROL 
Vit B12 CSD PROX RT ICA (mm) -0.04 0.84 -0.06 0.76 25 CONTROL 
Vit B12 PROX ECA RT PSV (cm/s) -0.35 0.09 -0.37 0.07 25 CONTROL 
Vit B12 CSD PROX RT ECA (mm) -0.12 0.57 -0.15 0.48 25 CONTROL 
Vit B12 RT VA PSV (cm/s) -0.29 0.16 -0.19 0.37 25 CONTROL 
Vit B12 RT VA EDV (cm/s) -0.23 0.26 -0.23 0.27 25 CONTROL 
Vit B12 CSD PROX RT VA (mm) 0.14 0.52 0.03 0.9 25 CONTROL 
Vit B12 RT PSV ICA/CCA ratio -0.21 0.31 -0.2 0.33 25 CONTROL 
Vit B12 RT EDV ICA/ECA ratio 0.08 0.69 0.14 0.51 25 CONTROL 
Vit B12 LT CCA IMT (mm) -0.25 0.24 -0.19 0.35 25 CONTROL 
Vit B12 LT CCA PSV (cm/s) -0.03 0.9 -0.05 0.81 25 CONTROL 
Vit B12 LT CCA EDV (cm/s) -0.11 0.62 -0.16 0.46 25 CONTROL 
Vit B12 CSD PROX LT CCA (mm) -0.06 0.78 0 0.99 25 CONTROL 
Vit B12 CSD MID LT CCA (mm) -0.14 0.51 -0.01 0.97 25 CONTROL 
Vit B12 CSD DIST LT CCA (mm) 0.01 0.95 0.05 0.82 25 CONTROL 
Vit B12 LT ICA PSV (cm/s) -0.35 0.08 -0.12 0.56 25 CONTROL 
Vit B12 LT ICA EDV (cm/s) -0.29 0.15 -0.19 0.37 25 CONTROL 
Vit B12 CSD PROX LT ICA (mm) 0.11 0.6 0.09 0.69 25 CONTROL 
Vit B12 PROX LT ECA PSV (cm/s) 0 0.99 0.06 0.79 25 CONTROL 
Vit B12 CSD PROX LT ECA (mm) 0.01 0.98 0 0.99 25 CONTROL 
Vit B12 LT VA PSV (cm/s) -0.04 0.87 0.05 0.8 25 CONTROL 
Vit B12 LT VA EDV (cm/s) 0.04 0.85 0.08 0.72 25 CONTROL 
Vit B12 CSD PROX LT VA (mm) 0.2 0.34 0.18 0.38 25 CONTROL 
Vit B12 LT PSV ICA/CCA ratio 0.45 0.02 0.13 0.53 25 CONTROL 
Vit B12 LT EDV ICA/ECA ratio -0.18 0.38 -0.13 0.53 25 CONTROL 
Vit B12 PV PROX RT IJV (cm/s) 0.04 0.86 0.07 0.73 25 CONTROL 
Vit B12 PV MID RT IJV (cm/s) 0.28 0.17 0.25 0.23 25 CONTROL 
Vit B12 PV DIST RT IJV (cm/s) 0.07 0.74 0.15 0.46 25 CONTROL 
Vit B12 CSA PROX RT IJV (mm2) -0.24 0.25 -0.22 0.29 25 CONTROL 
Vit B12 PV PROX LT IJV (cm/s) 0.09 0.66 0.26 0.2 25 CONTROL 
Vit B12 PV MID LT IJV (cm/s) 0.05 0.8 0 0.98 25 CONTROL 
Vit B12 PV DIST LT IJV (cm/s) 0.21 0.32 0.17 0.41 25 CONTROL 
Vit B12 CSA PROX LT IJV (mm2) 0.03 0.89 -0.08 0.7 25 CONTROL 
 
 
 
 
Vit B12, serum vitamin B12; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; 
EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid 
artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein. 
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4.4.7 Association between serum folate (s-folate) and the extracranial vascular 
ultrasound variables 
MS group: As seen in the MS group in Table 4.20, a significant positive correlation was found 
between s-folate and the PSV of the right ICA (Pearson p-value 0.04), EDV of the right ICA 
(Pearson p-value 0.01, Spearman p-value 0.03) and the IMT of the left CCA (Spearman p-
value 0.02). Similarly, a significant negative correlation was found between s-folate of the CSD 
of the proximal left VA (Spearman p-value 0.04). No significant correlation was found between 
s-folate and the remaining ultrasound variables. 
 
Control group: In the control group (Table 4.21), a significant negative correlation was found 
between s-folate and the EDV of the right ICA (Spearman p-value 0.04) and the EDV of the 
right VA (Spearman p-value 0.03). 
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Table 4.20:  Correlation between serum folate (s-folate) and the extracranial vascular ultrasound 
variables in the MS group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
S-fol RT CCA IMT (mm) 0.15 0.48 0.15 0.48 25 MS 
S-fol RT CCA PSV (cm/s) 0.24 0.26 0.24 0.24 25 MS 
S-fol RT CCA EDV (cm/s) 0.13 0.52 0.09 0.65 25 MS 
S-fol CSD PROX RT CCA (mm) -0.14 0.5 -0.16 0.43 25 MS 
S-fol CSD MID RT CCA (mm) -0.21 0.32 -0.14 0.5 25 MS 
S-fol CSD DIST RT CCA (mm) -0.08 0.7 0.1 0.64 25 MS 
S-fol RT ICA PSV (cm/s) 0.41 0.04 0.38 0.06 25 MS 
S-fol RT ICA EDV (cm/s) 0.49 0.01 0.44 0.03 25 MS 
S-fol CSD PROX RT ICA (mm) -0.14 0.5 -0.1 0.64 25 MS 
S-fol PROX ECA RT PSV (cm/s) -0.05 0.81 0.05 0.82 25 MS 
S-fol CSD PROX RT ECA (mm) 0.29 0.16 0.28 0.18 25 MS 
S-fol RT VA PSV (cm/s) 0.33 0.1 0.27 0.2 25 MS 
S-fol RT VA EDV (cm/s) 0.24 0.25 0.14 0.5 25 MS 
S-fol CSD PROX RT VA (mm) 0.01 0.98 0.03 0.88 25 MS 
S-fol RT PSV ICA/CCA ratio 0.2 0.34 0.15 0.47 25 MS 
S-fol RT EDV ICA/ECA ratio 0.32 0.11 0.3 0.15 25 MS 
S-fol LT CCA IMT (mm) 0.36 0.08 0.47 0.02 25 MS 
S-fol LT CCA PSV (cm/s) 0.06 0.78 0.01 0.97 25 MS 
S-fol LT CCA EDV (cm/s) 0.11 0.6 0.12 0.56 25 MS 
S-fol CSD PROX LT CCA (mm) 0.15 0.48 0.22 0.3 25 MS 
S-fol CSD MID LT CCA (mm) -0.02 0.91 0.08 0.7 25 MS 
S-fol CSD DIST LT CCA (mm) -0.17 0.41 -0.09 0.66 25 MS 
S-fol LT ICA PSV (cm/s) 0.09 0.66 0.21 0.31 25 MS 
S-fol LT ICA EDV (cm/s) 0.32 0.12 0.32 0.12 25 MS 
S-fol CSD PROX LT ICA (mm) -0.11 0.62 -0.11 0.59 25 MS 
S-fol PROX LT ECA PSV (cm/s) 0.14 0.5 0.18 0.39 25 MS 
S-fol CSD PROX LT ECA (mm) 0.2 0.34 0.25 0.23 25 MS 
S-fol LT VA PSV (cm/s) 0.11 0.59 0.1 0.63 25 MS 
S-fol LT VA EDV (cm/s) -0.06 0.78 -0.08 0.7 25 MS 
S-fol CSD PROX LT VA (mm) -0.39 0.06 -0.4 0.04 25 MS 
S-fol LT PSV ICA/CCA ratio 0.23 0.26 0.2 0.34 25 MS 
S-fol LT EDV ICA/ECA ratio 0.31 0.14 0.21 0.32 25 MS 
S-fol PV PROX RT IJV (cm/s) 0.05 0.81 0.01 0.96 25 MS 
S-fol PV MID RT IJV (cm/s) 0.11 0.6 0.17 0.43 25 MS 
S-fol PV DIST RT IJV (cm/s) -0.04 0.84 0.04 0.84 25 MS 
S-fol CSA PROX RT IJV (mm2) 0.17 0.42 0.16 0.43 25 MS 
S-fol PV PROX LT IJV (cm/s) -0.25 0.22 -0.39 0.05 25 MS 
S-fol PV MID LT IJV (cm/s) -0.01 0.94 -0.02 0.93 25 MS 
S-fol PV DIST LT IJV (cm/s) -0.11 0.6 0 1 25 MS 
S-fol CSA PROX LT IJV (mm2) 0.01 0.97 -0.16 0.43 25 MS 
 
 
 
 
 
S-fol, serum folate; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; 
EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid 
artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.21: Correlation between serum folate (s-folate) and the extracranial vascular ultrasound 
variables in the control group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
S-fol RT CCA IMT (mm) -0.07 0.73 -0.04 0.84 24 CONTROL 
S-fol RT CCA PSV (cm/s) 0.09 0.67 0.01 0.95 24 CONTROL 
S-fol RT CCA EDV (cm/s) -0.09 0.67 -0.21 0.32 24 CONTROL 
S-fol CSD PROX RT CCA (mm) -0.05 0.83 -0.02 0.94 24 CONTROL 
S-fol CSD MID RT CCA (mm) -0.05 0.81 -0.04 0.86 24 CONTROL 
S-fol CSD DIST RT CCA (mm) 0.19 0.38 0.09 0.66 24 CONTROL 
S-fol RT ICA PSV (cm/s) -0.24 0.27 -0.27 0.21 24 CONTROL 
S-fol RT ICA EDV (cm/s) -0.25 0.24 -0.42 0.04 24 CONTROL 
S-fol CSD PROX RT ICA (mm) 0.26 0.21 0.15 0.47 24 CONTROL 
S-fol PROX ECA RT PSV (cm/s) -0.01 0.97 -0.12 0.59 24 CONTROL 
S-fol CSD PROX RT ECA (mm) 0.13 0.54 0.02 0.91 24 CONTROL 
S-fol RT VA PSV (cm/s) -0.03 0.9 -0.17 0.43 24 CONTROL 
S-fol RT VA EDV (cm/s) -0.25 0.24 -0.44 0.03 24 CONTROL 
S-fol CSD PROX RT VA (mm) 0.21 0.32 0.29 0.17 24 CONTROL 
S-fol RT PSV ICA/CCA ratio -0.24 0.26 -0.18 0.39 24 CONTROL 
S-fol RT EDV ICA/ECA ratio -0.2 0.35 -0.24 0.26 24 CONTROL 
S-fol LT CCA IMT (mm) 0.13 0.55 -0.09 0.68 24 CONTROL 
S-fol LT CCA PSV (cm/s) 0.06 0.79 0.07 0.73 24 CONTROL 
S-fol LT CCA EDV (cm/s) -0.03 0.88 0.04 0.86 24 CONTROL 
S-fol CSD PROX LT CCA (mm) 0.05 0.83 -0.04 0.84 24 CONTROL 
S-fol CSD MID LT CCA (mm) 0.28 0.19 0.29 0.16 24 CONTROL 
S-fol CSD DIST LT CCA (mm) 0.03 0.88 0.08 0.69 24 CONTROL 
S-fol LT ICA PSV (cm/s) 0.1 0.64 -0.02 0.93 24 CONTROL 
S-fol LT ICA EDV (cm/s) -0.16 0.45 -0.27 0.2 24 CONTROL 
S-fol CSD PROX LT ICA (mm) 0.09 0.66 0.12 0.57 24 CONTROL 
S-fol PROX LT ECA PSV (cm/s) 0.28 0.19 0.16 0.44 24 CONTROL 
S-fol CSD PROX LT ECA (mm) -0.3 0.15 -0.15 0.48 24 CONTROL 
S-fol LT VA PSV (cm/s) -0.09 0.69 -0.05 0.82 24 CONTROL 
S-fol LT VA EDV (cm/s) -0.21 0.32 -0.1 0.64 24 CONTROL 
S-fol CSD PROX LT VA (mm) 0.26 0.22 0.27 0.19 24 CONTROL 
S-fol LT PSV ICA/CCA ratio 0.02 0.92 -0.09 0.69 24 CONTROL 
S-fol LT EDV ICA/ECA ratio -0.16 0.44 -0.31 0.15 24 CONTROL 
S-fol PV PROX RT IJV (cm/s) -0.15 0.48 -0.12 0.58 24 CONTROL 
S-fol PV MID RT IJV (cm/s) 0.12 0.59 0.09 0.69 24 CONTROL 
S-fol PV DIST RT IJV (cm/s) -0.01 0.96 0.09 0.69 24 CONTROL 
S-fol CSA PROX RT IJV (mm2) 0.05 0.83 -0.04 0.84 24 CONTROL 
S-fol PV PROX LT IJV (cm/s) -0.13 0.54 -0.03 0.89 24 CONTROL 
S-fol PV MID LT IJV (cm/s) -0.22 0.31 -0.2 0.34 24 CONTROL 
S-fol PV DIST LT IJV (cm/s) 0.01 0.95 0.06 0.77 24 CONTROL 
S-fol CSA PROX LT IJV (mm2) 0.15 0.49 0.13 0.53 24 CONTROL 
 
 
 
S-fol, serum folate; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, 
end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; 
ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.4.8 Association between homocysteine and the extracranial vascular ultrasound 
variables  
 
MS group: Homocysteine results were available for 24 MS participants. Table 4.22 (MS group) 
indicates that a significant negative correlation was found between homocysteine and the PSV 
of the right CCA (Pearson p-value <0.01, Spearman p-value 0.03) as well as the PV of the mid 
left IJV (Spearman p-value 0.04). A significant positive association was found between 
homocysteine and CSD of the proximal right ECA. No other significant associations were found 
between homocysteine and the extracranial vascular ultrasound variables in the MS group. 
 
Control group: The correlations between homocysteine and the extracranial vascular 
ultrasound variables in the control group is tabulated in Table 4.23. A significant positive 
correlation was found between homocysteine and the following ultrasound variables: 
 Right EDV ICA/CCA ratio; Spearman p-value <0.01 
 Left CCA IMT; Spearman p-value 0.02 
 CSA proximal right IJV; Spearman p-value 0.03 
Similarly, a negative correlation was found between homocysteine and the PSV of the left CCA 
(Spearman p-value 0.04). 
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Table 4.22: Correlation between homocysteine and the extracranial ultrasound variables in the 
MS group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman  # 
cases group r p r p 
H-cyst RT CCA IMT (mm) 0.12 0.57 0.15 0.48 24 MS 
H-cyst RT CCA PSV (cm/s) -0.53 <0.01 -0.45 0.03 24 MS 
H-cyst RT CCA EDV (cm/s) -0.31 0.14 -0.30 0.15 24 MS 
H-cyst CSD PROX RT CCA (mm) 0.26 0.23 0.24 0.25 24 MS 
H-cyst CSD MID RT CCA (mm) 0.10 0.65 0.17 0.43 24 MS 
H-cyst CSD DIST RT CCA (mm) 0.16 0.46 0.18 0.40 24 MS 
H-cyst RT ICA PSV (cm/s) -0.11 0.60 -0.03 0.89 24 MS 
H-cyst RT ICA EDV (cm/s) -0.24 0.25 -0.22 0.31 24 MS 
H-cyst CSD PROX RT ICA (mm) 0.19 0.37 0.14 0.50 24 MS 
H-cyst PROX ECA RT PSV (cm/s) -0.11 0.60 -0.16 0.45 24 MS 
H-cyst CSD PROX RT ECA (mm) 0.38 0.06 0.48 0.02 24 MS 
H-cyst RT VA PSV (cm/s) -0.28 0.19 -0.25 0.23 24 MS 
H-cyst RT VA EDV (cm/s) -0.23 0.29 -0.25 0.23 24 MS 
H-cyst CSD PROX RT VA (mm) -0.04 0.85 -0.15 0.48 24 MS 
H-cyst RT PSV ICA/CCA ratio 0.34 0.10 0.34 0.11 24 MS 
H-cyst RT EDV ICA/ECA ratio -0.11 0.62 0.07 0.75 24 MS 
H-cyst LT CCA IMT (mm) 0.24 0.26 0.27 0.21 24 MS 
H-cyst LT CCA PSV (cm/s) -0.07 0.75 -0.13 0.55 24 MS 
H-cyst LT CCA EDV (cm/s) -0.21 0.31 -0.16 0.45 24 MS 
H-cyst CSD PROX LT CCA (mm) 0.03 0.90 0.18 0.40 24 MS 
H-cyst CSD MID LT CCA (mm) -0.01 0.97 -0.02 0.94 24 MS 
H-cyst CSD DIST LT CCA (mm) -0.08 0.70 -0.11 0.61 24 MS 
H-cyst LT ICA PSV (cm/s) -0.11 0.60 -0.19 0.39 24 MS 
H-cyst LT ICA EDV (cm/s) -0.16 0.45 -0.19 0.38 24 MS 
H-cyst CSD PROX LT ICA (mm) 0.25 0.25 0.19 0.37 24 MS 
H-cyst PROX LT ECA PSV (cm/s) -0.25 0.24 -0.23 0.29 24 MS 
H-cyst CSD PROX LT ECA (mm) 0.27 0.19 0.33 0.11 24 MS 
H-cyst LT VA PSV (cm/s) -0.24 0.26 -0.18 0.40 24 MS 
H-cyst LT VA EDV (cm/s) -0.22 0.30 -0.20 0.35 24 MS 
H-cyst CSD PROX LT VA (mm) 0.10 0.63 0.04 0.84 24 MS 
H-cyst LT PSV ICA/CCA ratio -0.08 0.71 -0.11 0.61 24 MS 
H-cyst LT EDV ICA/ECA ratio 0.03 0.88 0.03 0.88 24 MS 
H-cyst PV PROX RT IJV (cm/s) 0.16 0.46 0.27 0.20 24 MS 
H-cyst PV MID RT IJV (cm/s) -0.16 0.45 -0.11 0.62 24 MS 
H-cyst PV DIST RT IJV (cm/s) -0.09 0.66 -0.07 0.74 24 MS 
H-cyst CSA PROX RT IJV (mm2) 0.33 0.12 0.41 0.05 24 MS 
H-cyst PV PROX LT IJV (cm/s) -0.19 0.37 -0.21 0.33 24 MS 
H-cyst PV MID LT IJV (cm/s) -0.38 0.07 -0.42 0.04 24 MS 
H-cyst PV DIST LT IJV (cm/s) -0.17 0.42 -0.12 0.58 24 MS 
H-cyst CSA PROX LT IJV (mm2) 0.23 0.28 0.32 0.13 24 MS 
 
 
 
H-cyst, homocysteine; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; 
EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid 
artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.23: Correlation between homocysteine and the extracranial vascular ultrasound 
variables in the control group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
H-cyst RT CCA IMT (mm) 0.29 0.16 0.34 0.10 25 CONTROL 
H-cyst RT CCA PSV (cm/s) -0.17 0.42 -0.14 0.51 25 CONTROL 
H-cyst RT CCA EDV (cm/s) -0.12 0.58 -0.20 0.34 25 CONTROL 
H-cyst CSD PROX RT CCA (mm) -0.07 0.72 0.03 0.88 25 CONTROL 
H-cyst CSD MID RT CCA (mm) 0.25 0.23 0.27 0.20 25 CONTROL 
H-cyst CSD DIST RT CCA (mm) 0.22 0.29 0.27 0.18 25 CONTROL 
H-cyst RT ICA PSV (cm/s) 0.24 0.25 0.25 0.24 25 CONTROL 
H-cyst RT ICA EDV (cm/s) 0.30 0.14 0.29 0.16 25 CONTROL 
H-cyst CSD PROX RT ICA (mm) -0.07 0.75 -0.10 0.64 25 CONTROL 
H-cyst PROX ECA RT PSV (cm/s) 0.27 0.19 0.31 0.13 25 CONTROL 
H-cyst CSD PROX RT ECA (mm) 0.05 0.81 0.09 0.67 25 CONTROL 
H-cyst RT VA PSV (cm/s) 0.15 0.48 0.04 0.84 25 CONTROL 
H-cyst RT VA EDV (cm/s) 0.07 0.75 0.08 0.69 25 CONTROL 
H-cyst CSD PROX RT VA (mm) -0.17 0.42 -0.13 0.53 25 CONTROL 
H-cyst RT PSV ICA/CCA ratio 0.34 0.10 0.39 0.05 25 CONTROL 
H-cyst RT EDV ICA/CCA ratio 0.38 0.06 0.54 <0.01 25 CONTROL 
H-cyst LT CCA IMT (mm) 0.31 0.13 0.46 0.02 25 CONTROL 
H-cyst LT CCA PSV (cm/s) -0.37 0.07 -0.41 0.04 25 CONTROL 
H-cyst LT CCA EDV (cm/s) -0.11 0.60 -0.17 0.41 25 CONTROL 
H-cyst CSD PROX LT CCA (mm) -0.08 0.72 0.01 0.95 25 CONTROL 
H-cyst CSD MID LT CCA (mm) 0.02 0.92 0.04 0.85 25 CONTROL 
H-cyst CSD DIST LT CCA (mm) 0.30 0.14 0.26 0.20 25 CONTROL 
H-cyst LT ICA PSV (cm/s) 0.02 0.91 0.00 1.00 25 CONTROL 
H-cyst LT ICA EDV (cm/s) 0.19 0.37 0.12 0.56 25 CONTROL 
H-cyst CSD PROX LT ICA (mm) -0.14 0.52 -0.21 0.32 25 CONTROL 
H-cyst PROX LT ECA PSV (cm/s) 0.06 0.77 0.08 0.71 25 CONTROL 
H-cyst CSD PROX LT ECA (mm) 0.17 0.43 0.13 0.53 25 CONTROL 
H-cyst LT VA PSV (cm/s) -0.19 0.37 -0.25 0.22 25 CONTROL 
H-cyst LT VA EDV (cm/s) -0.17 0.41 -0.19 0.36 25 CONTROL 
H-cyst CSD PROX LT VA (mm) -0.08 0.71 0.05 0.83 25 CONTROL 
H-cyst LT PSV ICA/CCA ratio 0.11 0.60 0.33 0.11 25 CONTROL 
H-cyst LT EDV ICA/ECA ratio 0.22 0.29 0.37 0.07 25 CONTROL 
H-cyst PV PROX RT IJV (cm/s) -0.09 0.65 -0.03 0.91 25 CONTROL 
H-cyst PV MID RT IJV (cm/s) -0.06 0.79 0.08 0.71 25 CONTROL 
H-cyst PV DIST RT IJV (cm/s) 0.10 0.64 0.18 0.39 25 CONTROL 
H-cyst CSA PROX RT IJV (mm2) 0.37 0.07 0.44 0.03 25 CONTROL 
H-cyst PV PROX LT IJV (cm/s) -0.29 0.16 -0.30 0.15 25 CONTROL 
H-cyst PV MID LT IJV (cm/s) -0.07 0.72 -0.06 0.78 25 CONTROL 
H-cyst PV DIST LT IJV (cm/s) -0.12 0.58 -0.08 0.72 25 CONTROL 
H-cyst CSA PROX LT IJV (mm2) -0.08 0.70 -0.10 0.62 25 CONTROL 
 
 
H-cyst, homocysteine; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; 
EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid 
artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.4.9 Association between C-reactive protein (CRP) and the extracranial vascular 
ultrasound variables 
 
MS group: Association between CRP and the extracranial vascular ultrasound variables in the 
MS group are shown in Table 4.24. A significant positive correlation was found between CRP 
and the CSD of the distal left CCA (Spearman p-value 0.03); and significant negative 
correlation between CRP and the PSV of the mid left IJV (Spearman p-value 0.03). 
 
Control group: A significant positive correlation was found between CRP and the CSD of the 
distal left CCA (Spearman p-value 0.01) and negative correlation with the PV of the mid left 
IJV (Spearman p-value 0.03) (Table 4.25). 
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Table 4.24: Correlation between C-reactive protein and the extracranial vascular ultrasound 
variables in the MS group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
CRP RT CCA IMT (mm) -0.11 0.61 0 0.98 25 MS 
CRP RT CCA PSV (cm/s) -0.17 0.42 -0.21 0.31 25 MS 
CRP RT CCA EDV (cm/s) -0.14 0.5 -0.13 0.55 25 MS 
CRP CSD PROX RT CCA (mm) 0.03 0.9 -0.06 0.78 25 MS 
CRP CSD MID RT CCA (mm) 0.11 0.6 0.15 0.49 25 MS 
CRP CSD DIST RT CCA (mm) 0.24 0.24 0.32 0.12 25 MS 
CRP RT ICA PSV (cm/s) -0.2 0.33 0.04 0.86 25 MS 
CRP RT ICA EDV (cm/s) -0.2 0.35 -0.16 0.43 25 MS 
CRP CSD PROX RT ICA (mm) 0.04 0.86 -0.01 0.97 25 MS 
CRP PROX ECA RT PSV (cm/s) -0.19 0.36 -0.27 0.19 25 MS 
CRP CSD PROX RT ECA (mm) 0.18 0.4 0.22 0.28 25 MS 
CRP RT VA PSV (cm/s) 0.1 0.65 -0.21 0.31 25 MS 
CRP RT VA EDV (cm/s) 0.09 0.67 0.05 0.8 25 MS 
CRP CSD PROX RT VA (mm) 0.17 0.41 0.31 0.13 25 MS 
CRP RT PSV ICA/CCA ratio -0.03 0.87 0.03 0.88 25 MS 
CRP RT EDV ICA/ECA ratio -0.01 0.95 0.21 0.31 25 MS 
CRP LT CCA IMT (mm) 0.04 0.85 0.06 0.79 25 MS 
CRP LT CCA PSV (cm/s) -0.04 0.83 -0.15 0.47 25 MS 
CRP LT CCA EDV (cm/s) -0.19 0.37 -0.32 0.12 25 MS 
CRP CSD PROX LT CCA (mm) 0.1 0.65 0.04 0.84 25 MS 
CRP CSD MID LT CCA (mm) 0.23 0.27 0.3 0.15 25 MS 
CRP CSD DIST LT CCA (mm) 0.3 0.15 0.43 0.03 25 MS 
CRP LT ICA PSV (cm/s) -0.25 0.23 -0.3 0.15 25 MS 
CRP LT ICA EDV (cm/s) -0.28 0.17 -0.25 0.23 25 MS 
CRP CSD PROX LT ICA (mm) 0.18 0.39 -0.01 0.97 25 MS 
CRP PROX LT ECA PSV (cm/s) -0.31 0.13 -0.12 0.58 25 MS 
CRP CSD PROX LT ECA (mm) 0.28 0.18 0.22 0.28 25 MS 
CRP LT VA PSV (cm/s) -0.12 0.56 -0.29 0.16 25 MS 
CRP LT VA EDV (cm/s) -0.11 0.6 -0.2 0.33 25 MS 
CRP CSD PROX LT VA (mm) 0.19 0.37 -0.13 0.52 25 MS 
CRP LT PSV ICA/CCA ratio -0.28 0.18 -0.1 0.65 25 MS 
CRP LT EDV ICA/ECA ratio -0.21 0.31 -0.19 0.36 25 MS 
CRP PV PROX RT IJV (cm/s) -0.03 0.9 0.08 0.71 25 MS 
CRP PV MID RT IJV (cm/s) -0.3 0.15 -0.21 0.32 25 MS 
CRP PV DIST RT IJV (cm/s) -0.22 0.28 -0.32 0.12 25 MS 
CRP CSA PROX RT IJV (mm2) 0.12 0.56 -0.11 0.61 25 MS 
CRP PV PROX LT IJV (cm/s) -0.23 0.26 -0.24 0.25 25 MS 
CRP PV MID LT IJV (cm/s) -0.39 0.06 -0.45 0.03 25 MS 
CRP PV DIST LT IJV (cm/s) -0.27 0.19 -0.37 0.07 25 MS 
CRP CSA PROX LT IJV (mm2) -0.13 0.54 -0.01 0.95 25 MS 
 
 
 
 
 
CRP, c-reactive protein; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic 
velocity; EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, 
internal carotid artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.25: Correlation between C-reactive protein and the extracranial vascular ultrasound 
variables in the control group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
CRP RT CCA IMT (mm) -0.01 0.95 0.00 0.98 25 CONTROL 
CRP RT CCA PSV (cm/s) -0.17 0.43 -0.24 0.24 25 CONTROL 
CRP RT CCA EDV (cm/s) -0.21 0.31 -0.19 0.36 25 CONTROL 
CRP CSD PROX RT CCA (mm) 0.10 0.62 0.30 0.14 25 CONTROL 
CRP CSD MID RT CCA (mm) 0.07 0.74 0.23 0.27 25 CONTROL 
CRP CSD DIST RT CCA (mm) 0.10 0.62 0.32 0.12 25 CONTROL 
CRP RT ICA PSV (cm/s) 0.11 0.61 0.02 0.91 25 CONTROL 
CRP RT ICA EDV (cm/s) -0.08 0.69 0.00 0.98 25 CONTROL 
CRP CSD PROX RT ICA (mm) -0.12 0.55 -0.18 0.40 25 CONTROL 
CRP PROX ECA RT PSV (cm/s) 0.08 0.71 -0.10 0.65 25 CONTROL 
CRP CSD PROX RT ECA (mm) -0.19 0.37 -0.26 0.22 25 CONTROL 
CRP RT VA PSV (cm/s) -0.03 0.88 -0.06 0.77 25 CONTROL 
CRP RT VA EDV (cm/s) -0.05 0.81 -0.01 0.95 25 CONTROL 
CRP CSD PROX RT VA (mm) -0.04 0.84 -0.08 0.71 25 CONTROL 
CRP RT PSV ICA/CCA ratio 0.20 0.34 0.22 0.29 25 CONTROL 
CRP RT EDV ICA/ECA ratio 0.12 0.57 0.26 0.20 25 CONTROL 
CRP LT CCA IMT (mm) 0.10 0.64 0.04 0.86 25 CONTROL 
CRP LT CCA PSV (cm/s) -0.01 0.98 -0.16 0.43 25 CONTROL 
CRP LT CCA EDV (cm/s) -0.20 0.33 -0.23 0.28 25 CONTROL 
CRP CSD PROX LT CCA (mm) 0.24 0.24 0.48 0.01 25 CONTROL 
CRP CSD MID LT CCA (mm) 0.10 0.63 0.09 0.68 25 CONTROL 
CRP CSD DIST LT CCA (mm) 0.24 0.25 0.10 0.62 25 CONTROL 
CRP LT ICA PSV (cm/s) -0.18 0.38 -0.09 0.68 25 CONTROL 
CRP LT ICA EDV (cm/s) -0.35 0.09 -0.25 0.22 25 CONTROL 
CRP CSD PROX LT ICA (mm) -0.08 0.69 -0.08 0.71 25 CONTROL 
CRP PROX LT ECA PSV (cm/s) -0.13 0.54 -0.36 0.08 25 CONTROL 
CRP CSD PROX LT ECA (mm) 0.02 0.94 0.12 0.55 25 CONTROL 
CRP LT VA PSV (cm/s) 0.04 0.86 -0.20 0.35 25 CONTROL 
CRP LT VA EDV (cm/s) 0.11 0.60 0.03 0.88 25 CONTROL 
CRP CSD PROX LT VA (mm) -0.10 0.64 0.00 0.99 25 CONTROL 
CRP LT PSV ICA/CCA ratio -0.11 0.61 0.13 0.53 25 CONTROL 
CRP LT EDV ICA/ECA ratio -0.17 0.42 -0.14 0.51 25 CONTROL 
CRP PV PROX RT IJV (cm/s) -0.15 0.47 -0.04 0.83 25 CONTROL 
CRP PV MID RT IJV (cm/s) -0.53 <0.01 -0.52 <0.01 25 CONTROL 
CRP PV DIST RT IJV (cm/s) -0.17 0.42 -0.09 0.66 25 CONTROL 
CRP CSA PROX RT IJV (mm2) -0.11 0.59 0.11 0.59 25 CONTROL 
CRP PV PROX LT IJV (cm/s) 0.09 0.66 0.02 0.91 25 CONTROL 
CRP PV MID LT IJV (cm/s) -0.01 0.96 -0.02 0.92 25 CONTROL 
CRP PV DIST LT IJV (cm/s) 0.00 1.00 0.01 0.97 25 CONTROL 
CRP CSA PROX LT IJV (mm2) -0.05 0.83 0.06 0.77 25 CONTROL 
 
 
 
CRP, c-reactive protein; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; 
EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid 
artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.4.10. Association between serum 25-OH vitamin D and the extracranial vascular 
ultrasound variables 
 
MS group: As shown in Table 4.26, a significant positive correlation was found between serum 
vitamin D and the following ultrasound variables: 
 PSV of the right CCA; Pearson p-value 0.03, Spearman p-value 0.03 
 PSV of the left CCA; Spearman p-value 0.03 
 PSV of the left VA; Spearman p-value <0.01 
Similarly, a significant negative correlation was found between serum vitamin D and the CSA 
of the proximal left IJV (Spearman p-value 0.02). 
 
Control group:  Table 4.27 shows that a significant negative association was found between 
serum vitamin D and the following ultrasound variables in the control group: 
 EDV of the left ICA; Pearson p-value 0.04, Spearman p-value <0.01 
 CSD of the proximal left ICA; Pearson p-value 0.02 
 Left EDV ICA/CCA ratio; Spearman p-value 0.04 
In addition, a significant positive association was found between serum vitamin D and the CSD 
of the proximal left VA (Pearson p-value 0.02). 
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Table 4.26 Correlation between serum 25-OH vitamin D and the extracranial vascular ultrasound 
variables in the MS group 
Biochemical 
 marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
25 OH- Vit D 
RT CCA IMT (mm) 0.08 0.71 0.15 0.47 24 MS 
25 OH -Vit D 
RT CCA PSV (cm/s) 0.45 0.03 0.46 0.02 24 MS 
25 OH- Vit D 
RT CCA EDV (cm/s) 0.3 0.15 0.23 0.28 24 MS 
25 OH- Vit D 
CSD PROX RT CCA (mm) 0.02 0.94 0.04 0.87 24 MS 
25 OH- Vit D 
CSD MID RT CCA (mm) -0.23 0.27 -0.15 0.48 24 MS 
25 OH- Vit D 
CSD DIST RT CCA (mm) -0.09 0.69 0.02 0.94 24 MS 
25 OH- Vit D 
RT ICA PSV (cm/s) 0.34 0.11 0.31 0.14 24 MS 
25 OH- Vit D 
RT ICA EDV (cm/s) 0.46 0.02 0.33 0.11 24 MS 
25 OH- Vit D 
CSD PROX RT ICA (mm) -0.03 0.9 -0.24 0.26 24 MS 
25 OH- Vit D 
PROX ECA RT PSV (cm/s) -0.27 0.21 -0.08 0.69 24 MS 
25 OH- Vit D 
CSD PROX RT ECA (mm) 0.31 0.14 0.14 0.51 24 MS 
25 OH- Vit D 
RT VA PSV (cm/s) 0.18 0.4 0.09 0.68 24 MS 
25 OH- Vit D 
RT VA EDV (cm/s) 0.36 0.08 0.19 0.38 24 MS 
25 OH- Vit D 
CSD PROX RT VA (mm) 0.05 0.83 -0.05 0.82 24 MS 
25 OH- Vit D 
RT PSV ICA/CCA ratio 0.03 0.89 -0.14 0.53 24 MS 
25 OH- Vit D 
RT EDV ICA/ECA ratio 0.21 0.32 0.13 0.54 24 MS 
25 OH- Vit D 
LT CCA IMT (mm) -0.02 0.94 -0.06 0.79 24 MS 
25 OH- Vit D 
LT CCA PSV (cm/s) 0.24 0.26 0.45 0.03 24 MS 
25 OH- Vit D 
LT CCA EDV (cm/s) 0.23 0.27 0.35 0.09 24 MS 
25 OH- Vit D 
CSD PROX LT CCA (mm) 0.07 0.76 0.11 0.6 24 MS 
25 OH- Vit D 
CSD MID LT CCA (mm) 0.02 0.92 0.08 0.73 24 MS 
25 OH- Vit D 
CSD DIST LT CCA (mm) 0.19 0.38 0.18 0.4 24 MS 
25 OH- Vit D 
LT ICA PSV (cm/s) -0.17 0.42 -0.05 0.8 24 MS 
25 OH- Vit D 
LT ICA EDV (cm/s) 0.22 0.3 0.12 0.57 24 MS 
25 OH- Vit D 
CSD PROX LT ICA (mm) -0.14 0.51 -0.17 0.42 24 MS 
25 OH- Vit D 
PROX LT ECA PSV (cm/s) -0.1 0.64 -0.08 0.73 24 MS 
25 OH- Vit D 
CSD PROX LT ECA (mm) -0.06 0.78 -0.03 0.88 24 MS 
25 OH- Vit D 
LT VA PSV (cm/s) 0.39 0.06 0.52 <0.01 24 MS 
25 OH- Vit D 
LT VA EDV (cm/s) 0.36 0.09 0.37 0.08 24 MS 
25 OH- Vit D 
CSD PROX LT VA (mm) -0.31 0.14 -0.27 0.21 24 MS 
25 OH- Vit D 
LT PSV ICA/CCA ratio -0.17 0.43 -0.38 0.07 24 MS 
25 OH- Vit D 
LT EDV ICA/ECA ratio 0.03 0.9 0.07 0.75 24 MS 
25 OH- Vit D 
PV PROX RT IJV (cm/s) 0.17 0.42 -0.03 0.89 24 MS 
25 OH-Vit D 
PV MID RT IJV (cm/s) 0.18 0.4 0.26 0.22 24 MS 
25 OH- Vit D 
PV DIST RT IJV (cm/s) 0.29 0.18 0.22 0.31 24 MS 
25 OH- Vit D 
CSA PROX RT IJV (mm2) 0.13 0.53 0.08 0.71 24 MS 
25 OH- Vit D 
PV PROX LT IJV (cm/s) -0.04 0.84 0.14 0.52 24 MS 
25 OH- Vit D 
PV MID LT IJV (cm/s) -0.18 0.41 -0.02 0.93 24 MS 
25 OH- Vit D 
PV DIST LT IJV (cm/s) -0.25 0.23 -0.05 0.81 24 MS 
25 OH- Vit D CSA PROX LT IJV (mm2) -0.38 0.07 -0.48 0.02 24 MS 
 
 
 
 
 
25 OH-vit D, serum 25 hydroxyvtiamin D; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, 
peak systolic velocity; EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, 
distal; ICA, internal carotid artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal 
jugular vein 
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Table 4.27: Correlation between vitamin D and the extracranial vascular ultrasound variables in 
the control group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
25 OH-Vit D 
RT CCA IMT (mm) -0.08 0.72 0.13 0.53 25 CONTROL 
25 OH-Vit D 
RT CCA PSV (cm/s) -0.03 0.88 -0.03 0.90 25 CONTROL 
25 OH-Vit D 
RT CCA EDV (cm/s) -0.08 0.70 -0.17 0.41 25 CONTROL 
25 OH-Vit D 
CSD PROX RT CCA (mm) 0.10 0.62 -0.09 0.66 25 CONTROL 
25 OH-Vit D 
CSD MID RT CCA (mm) 0.01 0.95 -0.05 0.81 25 CONTROL 
25 OH-Vit D 
CSD DIST RT CCA (mm) -0.04 0.86 0.02 0.94 25 CONTROL 
25 OH-Vit D 
RT ICA PSV (cm/s) -0.12 0.56 -0.10 0.63 25 CONTROL 
25 OH-Vit D 
RT ICA EDV (cm/s) -0.09 0.66 -0.17 0.42 25 CONTROL 
25 OH-Vit D 
CSD PROX RT ICA (mm) -0.32 0.12 -0.17 0.41 25 CONTROL 
25 OH-Vit D 
PROX ECA RT PSV (cm/s) -0.21 0.31 0.04 0.87 25 CONTROL 
25 OH-Vit D 
CSD PROX RT ECA (mm) -0.12 0.55 -0.20 0.34 25 CONTROL 
25 OH-Vit D 
RT VA PSV (cm/s) -0.13 0.53 -0.05 0.83 25 CONTROL 
25 OH-Vit D 
RT VA EDV (cm/s) -0.33 0.11 -0.47 0.02 25 CONTROL 
25 OH-Vit D 
CSD PROX RT VA (mm) 0.22 0.28 0.33 0.11 25 CONTROL 
25 OH-Vit D 
RT PSV ICA/CCA ratio -0.10 0.64 0.05 0.83 25 CONTROL 
25 OH-Vit D 
RT EDV ICA/ECA ratio -0.05 0.79 0.09 0.67 25 CONTROL 
25 OH-Vit D 
LT CCA IMT (mm) -0.10 0.62 -0.05 0.80 25 CONTROL 
25 OH-Vit D 
LT CCA PSV (cm/s) 0.05 0.81 0.00 0.99 25 CONTROL 
25 OH-Vit D 
LT CCA EDV (cm/s) -0.05 0.83 -0.01 0.96 25 CONTROL 
25 OH-Vit D 
CSD PROX LT CCA (mm) -0.18 0.39 -0.28 0.18 25 CONTROL 
25 OH-Vit D 
CSD MID LT CCA (mm) -0.10 0.63 0.07 0.75 25 CONTROL 
25 OH-Vit D 
CSD DIST LT CCA (mm) -0.11 0.59 0.08 0.69 25 CONTROL 
25 OH-Vit D 
LT ICA PSV (cm/s) -0.29 0.16 -0.21 0.31 25 CONTROL 
25 OH-Vit D 
LT ICA EDV (cm/s) -0.41 0.04 -0.52 <0.01 25 CONTROL 
25 OH-Vit D 
CSD PROX LT ICA (mm) -0.46 0.02 -0.32 0.12 25 CONTROL 
25 OH-Vit D 
PROX LT ECA PSV (cm/s) -0.17 0.42 0.16 0.44 25 CONTROL 
25 OH-Vit D 
CSD PROX LT ECA (mm) -0.06 0.79 -0.14 0.50 25 CONTROL 
25 OH-Vit D 
LT VA PSV (cm/s) -0.16 0.44 -0.14 0.50 25 CONTROL 
25 OH-Vit D 
LT VA EDV (cm/s) -0.15 0.47 -0.24 0.25 25 CONTROL 
25 OH-Vit D 
CSD PROX LT VA (mm) 0.46 0.02 0.32 0.12 25 CONTROL 
25 OH-Vit D 
LT PSV ICA/CCA ratio 0.30 0.15 -0.04 0.86 25 CONTROL 
25 OH-Vit D 
LT EDV ICA/CCA ratio -0.36 0.07 -0.41 0.04 25 CONTROL 
25 OH-Vit D 
PV PROX RT IJV (cm/s) 0.15 0.48 0.04 0.85 25 CONTROL 
25 OH-Vit D 
PV MID RT IJV (cm/s) 0.21 0.31 0.16 0.45 25 CONTROL 
25 OH-Vit D 
PV DIST RT IJV (cm/s) -0.01 0.97 0.17 0.41 25 CONTROL 
25 OH-Vit D 
CSA PROX RT IJV (mm2) -0.20 0.35 -0.18 0.38 25 CONTROL 
25 OH-Vit D 
PV PROX LT IJV (cm/s) -0.02 0.94 -0.03 0.88 25 CONTROL 
25 OH-Vit D 
PV MID LT IJV (cm/s) 0.04 0.84 -0.04 0.85 25 CONTROL 
25 OH-Vit D 
PV DIST LT IJV (cm/s) 0.08 0.70 0.02 0.91 25 CONTROL 
25 OH-Vit D CSA PROX LT IJV (mm2) -0.16 0.46 -0.21 0.32 25 CONTROL 
 
 
25 OH-vit D, serum 25 hydroxyvtiamin D; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; 
PSV, peak systolic velocity; EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, 
proximal; DIST, distal; ICA, internal carotid artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional 
area; IJV, internal jugular vein 
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4.4.11 Association between total cholesterol and the extracranial vascular ultrasound 
variables  
MS group: A significant negative association was found between total cholesterol and the EDV 
of the left CCA (Pearson p-value 0.03, Spearman p-value 0.01) as well as the PSV of the left 
VA (Pearson p-value 0.03) (Table 4.28). 
 
Control group: A significant correlation was found between total cholesterol and the EDV of 
the left ICA (Pearson p-value 0.04) (Table 4.29). 
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Table 4.28. Correlation between total cholesterol and the extracranial vascular ultrasound 
variables in the MS group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Total cholesterol RT CCA IMT (mm) 0.1 0.63 0.09 0.67 25 MS 
Total cholesterol RT CCA PSV (cm/s) -0.08 0.71 -0.16 0.44 25 MS 
Total cholesterol RT CCA EDV (cm/s) -0.33 0.11 -0.29 0.16 25 MS 
Total cholesterol CSD PROX RT CCA (mm) 0.07 0.75 -0.03 0.87 25 MS 
Total cholesterol CSD MID RT CCA (mm) 0.17 0.41 0.16 0.45 25 MS 
Total cholesterol CSD DIST RT CCA (mm) 0.3 0.15 0.23 0.27 25 MS 
Total cholesterol RT ICA PSV (cm/s) -0.04 0.86 -0.18 0.38 25 MS 
Total cholesterol RT ICA EDV (cm/s) -0.13 0.54 -0.22 0.28 25 MS 
Total cholesterol CSD PROX RT ICA (mm) 0 0.99 0.01 0.97 25 MS 
Total cholesterol PROX ECA RT PSV (cm/s) 0.33 0.1 0.37 0.07 25 MS 
Total cholesterol CSD PROX RT ECA (mm) -0.02 0.91 -0.06 0.78 25 MS 
Total cholesterol RT VA PSV (cm/s) -0.37 0.07 -0.36 0.08 25 MS 
Total cholesterol RT VA EDV (cm/s) -0.3 0.15 -0.31 0.13 25 MS 
Total cholesterol CSD PROX RT VA (mm) 0.4 0.05 0.28 0.17 25 MS 
Total cholesterol RT PSV ICA/CCA ratio 0.05 0.82 -0.03 0.9 25 MS 
Total cholesterol RT EDV ICA/ECA ratio 0.3 0.15 0.05 0.8 25 MS 
Total cholesterol LT CCA IMT (mm) 0.22 0.28 0.33 0.1 25 MS 
Total cholesterol LT CCA PSV (cm/s) -0.32 0.11 -0.38 0.06 25 MS 
Total cholesterol LT CCA EDV (cm/s) -0.43 0.03 -0.5 0.01 25 MS 
Total cholesterol CSD PROX LT CCA (mm) 0.09 0.68 -0.12 0.58 25 MS 
Total cholesterol CSD MID LT CCA (mm) 0.17 0.41 0.04 0.85 25 MS 
Total cholesterol CSD DIST LT CCA (mm) 0.08 0.69 -0.01 0.95 25 MS 
Total cholesterol LT ICA PSV (cm/s) -0.31 0.13 -0.22 0.29 25 MS 
Total cholesterol LT ICA EDV (cm/s) -0.25 0.22 -0.3 0.15 25 MS 
Total cholesterol CSD PROX LT ICA (mm) -0.18 0.38 -0.18 0.4 25 MS 
Total cholesterol PROX LT ECA PSV (cm/s) 0.21 0.32 0.26 0.21 25 MS 
Total cholesterol CSD PROX LT ECA (mm) 0.22 0.3 0.09 0.69 25 MS 
Total cholesterol LT VA PSV (cm/s) -0.44 0.03 -0.39 0.05 25 MS 
Total cholesterol LT VA EDV (cm/s) -0.37 0.07 -0.33 0.1 25 MS 
Total cholesterol CSD PROX LT VA (mm) -0.03 0.89 0 0.99 25 MS 
Total cholesterol LT PSV ICA/CCA ratio 0.22 0.3 0.15 0.48 25 MS 
Total cholesterol LT EDV ICA/ECA ratio 0.16 0.44 -0.09 0.66 25 MS 
Total cholesterol PV PROX RT IJV (cm/s) -0.02 0.94 0.12 0.56 25 MS 
Total cholesterol PV MID RT IJV (cm/s) 0.02 0.94 0.06 0.76 25 MS 
Total cholesterol PV DIST RT IJV (cm/s) -0.16 0.46 -0.14 0.52 25 MS 
Total cholesterol CSA PROX RT IJV (mm2) -0.23 0.26 -0.35 0.08 25 MS 
Total cholesterol PV PROX LT IJV (cm/s) -0.35 0.09 -0.2 0.33 25 MS 
Total cholesterol PV MID LT IJV (cm/s) -0.01 0.97 0.11 0.6 25 MS 
Total cholesterol PV DIST LT IJV (cm/s) 0.05 0.83 0.08 0.69 25 MS 
Total cholesterol CSA PROX LT IJV (mm2) 0.21 0.32 0.22 0.3 25 MS 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic 
velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, external 
carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.29: Correlation between total cholesterol and the extracranial vascular ultrasound 
variables in the control group 
Biochemical 
marker 
 
Ultrasound variable 
Pearson Spearman # 
cases 
 
group r p r p 
Total cholesterol RT CCA IMT (mm) 0.37 0.07 0.24 0.24 25 CONTROL 
Total cholesterol RT CCA PSV (cm/s) -0.02 0.94 -0.08 0.69 25 CONTROL 
Total cholesterol RT CCA EDV (cm/s) -0.19 0.37 -0.32 0.12 25 CONTROL 
Total cholesterol CSD PROX RT CCA (mm) 0.15 0.47 0.14 0.51 25 CONTROL 
Total cholesterol CSD MID RT CCA (mm) 0.24 0.25 0.20 0.35 25 CONTROL 
Total cholesterol CSD DIST RT CCA (mm) 0.16 0.46 0.23 0.28 25 CONTROL 
Total cholesterol RT ICA PSV (cm/s) -0.33 0.10 -0.20 0.35 25 CONTROL 
Total cholesterol RT ICA EDV (cm/s) -0.35 0.08 -0.35 0.09 25 CONTROL 
Total cholesterol CSD PROX RT ICA (mm) -0.14 0.50 -0.10 0.64 25 CONTROL 
Total cholesterol PROX ECA RT PSV (cm/s) 0.08 0.70 0.05 0.81 25 CONTROL 
Total cholesterol CSD PROX RT ECA (mm) -0.07 0.75 -0.06 0.78 25 CONTROL 
Total cholesterol RT VA PSV (cm/s) -0.04 0.86 -0.17 0.40 25 CONTROL 
Total cholesterol RT VA EDV (cm/s) -0.12 0.56 -0.18 0.38 25 CONTROL 
Total cholesterol CSD PROX RT VA (mm) 0.17 0.41 0.07 0.76 25 CONTROL 
Total cholesterol RT PSV ICA/CCA ratio -0.20 0.33 -0.04 0.87 25 CONTROL 
Total cholesterol RT EDV ICA/ECA ratio -0.25 0.23 0.02 0.93 25 CONTROL 
Total cholesterol LT CCA IMT (mm) 0.23 0.26 0.08 0.72 25 CONTROL 
Total cholesterol LT CCA PSV (cm/s) 0.09 0.68 -0.11 0.60 25 CONTROL 
Total cholesterol LT CCA EDV (cm/s) 0.05 0.82 0.06 0.78 25 CONTROL 
Total cholesterol CSD PROX LT CCA (mm) 0.29 0.16 0.23 0.28 25 CONTROL 
Total cholesterol CSD MID LT CCA (mm) 0.28 0.18 0.27 0.18 25 CONTROL 
Total cholesterol CSD DIST LT CCA (mm) 0.02 0.91 0.14 0.50 25 CONTROL 
Total cholesterol LT ICA PSV (cm/s) -0.09 0.69 0.05 0.80 25 CONTROL 
Total cholesterol LT ICA EDV (cm/s) -0.42 0.04 -0.39 0.06 25 CONTROL 
Total cholesterol CSD PROX LT ICA (mm) 0.17 0.43 0.22 0.30 25 CONTROL 
Total cholesterol PROX LT ECA PSV (cm/s) 0.17 0.42 0.17 0.41 25 CONTROL 
Total cholesterol CSD PROX LT ECA (mm) -0.23 0.27 -0.18 0.39 25 CONTROL 
Total cholesterol LT VA PSV (cm/s) 0.15 0.48 0.04 0.83 25 CONTROL 
Total cholesterol LT VA EDV (cm/s) 0.00 0.98 0.04 0.85 25 CONTROL 
Total cholesterol CSD PROX LT VA (mm) 0.08 0.71 -0.03 0.90 25 CONTROL 
Total cholesterol LT PSV ICA/CCA ratio 0.06 0.79 0.20 0.34 25 CONTROL 
Total cholesterol LT EDV ICA/ECA ratio -0.39 0.06 -0.19 0.36 25 CONTROL 
Total cholesterol PV PROX RT IJV (cm/s) -0.34 0.10 -0.16 0.44 25 CONTROL 
Total cholesterol PV MID RT IJV (cm/s) 0.24 0.25 0.19 0.36 25 CONTROL 
Total cholesterol PV DIST RT IJV (cm/s) -0.01 0.97 -0.15 0.47 25 CONTROL 
Total cholesterol CSA PROX RT IJV (mm2) -0.11 0.59 -0.06 0.76 25 CONTROL 
Total cholesterol PV PROX LT IJV (cm/s) 0.04 0.84 0.09 0.68 25 CONTROL 
Total cholesterol PV MID LT IJV (cm/s) 0.04 0.85 -0.01 0.98 25 CONTROL 
Total cholesterol PV DIST LT IJV (cm/s) -0.16 0.45 -0.08 0.72 25 CONTROL 
Total cholesterol CSA PROX LT IJV (mm2) 0.03 0.87 0.14 0.51 25 CONTROL 
 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic velocity; 
PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, external carotid 
artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.4.12 Association between High-density lipoprotein (HDL) and the extracranial vascular 
ultrasound variables 
The correlations between HDL and the extracranial vascular ultrasound variables are shown 
in Tables 4.30 and 4.31. HDL results were available for 24 MS participants and 24 controls. 
 
MS group: The negative correlation between HDL and the CSD of the proximal right ECA 
(Pearson p-value 0.03, Spearman p-value <0.01) and the CSA of the proximal right IJV 
(Pearson p-value 0.04) was found to be statistically significant. A positive correlation was found 
between HDL and the PV of the proximal right IJV (Pearson p-value 0.02) (Table 4.30). 
 
Control group: No significant correlations (p-value >0.05) were found between HDL and the 
extracranial vascular ultrasound variables in this group of participants (Table 4.31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
79 
 
Table 4.30: Correlation between HDL and the extracranial vascular ultrasound variables in the 
MS group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
HDL RT CCA IMT (mm) -0.13 0.53 -0.14 0.51 24 MS 
HDL RT CCA PSV (cm/s) 0.25 0.23 0.19 0.38 24 MS 
HDL RT CCA EDV (cm/s) -0.11 0.62 -0.11 0.61 24 MS 
HDL CSD PROX RT CCA (mm) 0.13 0.54 0.07 0.76 24 MS 
HDL CSD MID RT CCA (mm) 0.02 0.93 0.04 0.86 24 MS 
HDL CSD DIST RT CCA (mm) -0.09 0.69 -0.14 0.52 24 MS 
HDL RT ICA PSV (cm/s) 0.02 0.92 -0.02 0.93 24 MS 
HDL RT ICA EDV (cm/s) 0.15 0.48 0.16 0.46 24 MS 
HDL CSD PROX RT ICA (mm) -0.26 0.23 -0.25 0.24 24 MS 
HDL PROX ECA RT PSV (cm/s) -0.06 0.79 0.02 0.93 24 MS 
HDL CSD PROX RT ECA (mm) -0.43 0.03 -0.57 <0.01 24 MS 
HDL RT VA PSV (cm/s) -0.03 0.88 -0.01 0.97 24 MS 
HDL RT VA EDV (cm/s) -0.03 0.87 0.06 0.77 24 MS 
HDL CSD PROX RT VA (mm) 0.14 0.53 0.07 0.76 24 MS 
HDL RT PSV ICA/CCA ratio -0.19 0.38 -0.17 0.43 24 MS 
HDL RT EDV ICA/ECA ratio 0.32 0.13 0.25 0.24 24 MS 
HDL LT CCA IMT (mm) -0.31 0.14 -0.41 0.05 24 MS 
HDL LT CCA PSV (cm/s) 0.24 0.26 0.25 0.25 24 MS 
HDL LT CCA EDV (cm/s) 0.06 0.78 0.1 0.64 24 MS 
HDL CSD PROX LT CCA (mm) -0.01 0.97 -0.11 0.61 24 MS 
HDL CSD MID LT CCA (mm) 0.05 0.8 0 1 24 MS 
HDL CSD DIST LT CCA (mm) 0.18 0.41 0.13 0.56 24 MS 
HDL LT ICA PSV (cm/s) 0.02 0.93 -0.05 0.83 24 MS 
HDL LT ICA EDV (cm/s) -0.08 0.71 -0.12 0.57 24 MS 
HDL CSD PROX LT ICA (mm) -0.02 0.94 -0.09 0.67 24 MS 
HDL PROX LT ECA PSV (cm/s) -0.06 0.78 -0.04 0.84 24 MS 
HDL CSD PROX LT ECA (mm) -0.33 0.12 -0.37 0.07 24 MS 
HDL LT VA PSV (cm/s) 0.11 0.59 0.16 0.46 24 MS 
HDL LT VA EDV (cm/s) 0.23 0.28 0.28 0.18 24 MS 
HDL CSD PROX LT VA (mm) 0.16 0.45 0.23 0.29 24 MS 
HDL LT PSV ICA/CCA ratio -0.19 0.38 -0.15 0.48 24 MS 
HDL LT EDV ICA/ECA ratio -0.18 0.39 -0.11 0.61 24 MS 
HDL PV PROX RT IJV (cm/s) 0.03 0.89 0.03 0.9 24 MS 
HDL PV MID RT IJV (cm/s) 0.19 0.39 0.19 0.37 24 MS 
HDL PV DIST RT IJV (cm/s) 0.27 0.19 0.22 0.29 24 MS 
HDL CSA PROX RT IJV (mm2) -0.42 0.04 -0.4 0.05 24 MS 
HDL PV PROX LT IJV (cm/s) 0.4 0.05 0.49 0.02 24 MS 
HDL PV MID LT IJV (cm/s) 0.22 0.29 0.32 0.12 24 MS 
HDL PV DIST LT IJV (cm/s) -0.02 0.94 0.08 0.7 24 MS 
HDL CSA PROX LT IJV (mm2) -0.26 0.22 -0.3 0.15 24 MS 
 
 
 
 
 
HDL, high-density lipoprotein; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic 
velocity; EDV, end-diastolic velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, 
external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.31: Correlation between HDL and the extracranial vascular ultrasound variables in the 
control group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
HDL RT CCA IMT (mm) 0.13 0.54 0.33 0.11 24 CONTROL 
HDL RT CCA PSV (cm/s) 0.24 0.26 0.31 0.14 24 CONTROL 
HDL RT CCA EDV (cm/s) 0.11 0.61 0.03 0.90 24 CONTROL 
HDL CSD PROX RT CCA (mm) 0.03 0.88 0.01 0.95 24 CONTROL 
HDL CSD MID RT CCA (mm) 0.00 0.99 0.12 0.59 24 CONTROL 
HDL CSD DIST RT CCA (mm) -0.08 0.71 -0.01 0.98 24 CONTROL 
HDL RT ICA PSV (cm/s) 0.04 0.84 0.05 0.81 24 CONTROL 
HDL RT ICA EDV (cm/s) 0.11 0.61 0.13 0.56 24 CONTROL 
HDL CSD PROX RT ICA (mm) -0.18 0.41 -0.11 0.62 24 CONTROL 
HDL PROX ECA RT PSV (cm/s) -0.26 0.23 -0.16 0.44 24 CONTROL 
HDL CSD PROX RT ECA (mm) 0.18 0.40 0.29 0.16 24 CONTROL 
HDL RT VA PSV (cm/s) -0.01 0.96 0.00 1.00 24 CONTROL 
HDL RT VA EDV (cm/s) -0.12 0.56 -0.11 0.60 24 CONTROL 
HDL CSD PROX RT VA (mm) 0.23 0.28 0.19 0.37 24 CONTROL 
HDL RT PSV ICA/CCA ratio -0.28 0.19 -0.26 0.22 24 CONTROL 
HDL RT EDV ICA/ECA ratio -0.02 0.92 0.09 0.66 24 CONTROL 
HDL LT CCA IMT (mm) -0.11 0.61 0.05 0.82 24 CONTROL 
HDL LT CCA PSV (cm/s) 0.08 0.71 0.03 0.87 24 CONTROL 
HDL LT CCA EDV (cm/s) -0.12 0.57 -0.10 0.65 24 CONTROL 
HDL CSD PROX LT CCA (mm) -0.11 0.60 -0.19 0.39 24 CONTROL 
HDL CSD MID LT CCA (mm) 0.01 0.96 0.08 0.70 24 CONTROL 
HDL CSD DIST LT CCA (mm) -0.12 0.56 0.00 0.99 24 CONTROL 
HDL LT ICA PSV (cm/s) 0.05 0.80 0.20 0.34 24 CONTROL 
HDL LT ICA EDV (cm/s) -0.11 0.62 -0.08 0.73 24 CONTROL 
HDL CSD PROX LT ICA (mm) -0.37 0.07 -0.31 0.14 24 CONTROL 
HDL PROX LT ECA PSV (cm/s) -0.10 0.66 0.13 0.55 24 CONTROL 
HDL CSD PROX LT ECA (mm) -0.18 0.40 -0.27 0.21 24 CONTROL 
HDL LT VA PSV (cm/s) 0.11 0.62 0.12 0.57 24 CONTROL 
HDL LT VA EDV (cm/s) 0.05 0.83 0.02 0.92 24 CONTROL 
HDL CSD PROX LT VA (mm) 0.20 0.36 -0.03 0.89 24 CONTROL 
HDL LT PSV ICA/CCA ratio -0.03 0.90 0.10 0.66 24 CONTROL 
HDL LT EDV ICA/ECA ratio -0.02 0.94 0.13 0.55 24 CONTROL 
HDL PV PROX RT IJV (cm/s) 0.05 0.80 0.00 0.99 24 CONTROL 
HDL PV MID RT IJV (cm/s) 0.29 0.16 0.33 0.12 24 CONTROL 
HDL PV DIST RT IJV (cm/s) 0.26 0.21 0.21 0.33 24 CONTROL 
HDL CSA PROX RT IJV (mm2) -0.25 0.24 -0.24 0.25 24 CONTROL 
HDL PV PROX LT IJV (cm/s) -0.12 0.58 -0.04 0.84 24 CONTROL 
HDL PV MID LT IJV (cm/s) -0.11 0.60 -0.15 0.49 24 CONTROL 
HDL PV DIST LT IJV (cm/s) -0.06 0.79 -0.11 0.61 24 CONTROL 
HDL CSA PROX LT IJV (mm2) 0.01 0.98 0.13 0.55 24 CONTROL 
 
 
 
HDL, high-density lipoprotein; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic 
velocity; EDV, end-diastolic velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; 
ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.4.13 Association between Low-density lipoprotein and the extracranial vascular 
ultrasound variables 
 
Low-density lipoprotein (LDL) results were available for 23 MS participants and 23 controls. 
 
MS group: There were no significant correlations (p-value >0.05) between LDL and the 
extracranial vascular ultrasound variables in the MS group of participants (Table 4.32). 
 
Control group:  In this group, only the CSD of the proximal left CCA had a significant negative 
correlation (Spearman p-value 0.04) with LDL (Table 4.33). 
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Table 4.32: Correlation between LDL and the extracranial vascular ultrasound variables in the 
MS group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
LDL RT CCA IMT (mm) -0.13 0.54 0 1 23 MS 
LDL RT CCA PSV (cm/s) 0.06 0.8 -0.01 0.96 23 MS 
LDL RT CCA EDV (cm/s) 0.12 0.6 0.12 0.57 23 MS 
LDL CSD PROX RT CCA (mm) -0.27 0.21 -0.31 0.15 23 MS 
LDL CSD MID RT CCA (mm) -0.37 0.08 -0.24 0.27 23 MS 
LDL CSD DIST RT CCA (mm) -0.14 0.54 0.01 0.98 23 MS 
LDL RT ICA PSV (cm/s) -0.02 0.91 -0.02 0.92 23 MS 
LDL RT ICA EDV (cm/s) 0.1 0.65 0.13 0.54 23 MS 
LDL CSD PROX RT ICA (mm) 0 0.99 0.03 0.89 23 MS 
LDL PROX ECA RT PSV (cm/s) 0.38 0.07 0.39 0.07 23 MS 
LDL CSD PROX RT ECA (mm) 0.17 0.43 0.28 0.2 23 MS 
LDL RT VA PSV (cm/s) -0.24 0.27 -0.27 0.21 23 MS 
LDL RT VA EDV (cm/s) -0.1 0.66 -0.08 0.73 23 MS 
LDL CSD PROX RT VA (mm) 0.23 0.28 0.23 0.3 23 MS 
LDL RT PSV ICA/CCA ratio -0.09 0.69 0.01 0.97 23 MS 
LDL RT EDV ICA/ECA ratio 0 1 -0.13 0.54 23 MS 
LDL LT CCA IMT (mm) 0.01 0.97 0.36 0.09 23 MS 
LDL LT CCA PSV (cm/s) -0.13 0.57 -0.18 0.41 23 MS 
LDL LT CCA EDV (cm/s) 0.01 0.98 -0.02 0.92 23 MS 
LDL CSD PROX LT CCA (mm) -0.3 0.16 -0.36 0.09 23 MS 
LDL CSD MID LT CCA (mm) -0.14 0.51 -0.16 0.46 23 MS 
LDL CSD DIST LT CCA (mm) -0.15 0.49 -0.25 0.24 23 MS 
LDL LT ICA PSV (cm/s) -0.34 0.12 -0.22 0.32 23 MS 
LDL LT ICA EDV (cm/s) 0.17 0.43 0.22 0.31 23 MS 
LDL CSD PROX LT ICA (mm) -0.19 0.39 -0.14 0.53 23 MS 
LDL PROX LT ECA PSV (cm/s) 0.11 0.63 0.11 0.61 23 MS 
LDL CSD PROX LT ECA (mm) 0.23 0.29 0.27 0.22 23 MS 
LDL LT VA PSV (cm/s) -0.2 0.37 -0.14 0.51 23 MS 
LDL LT V A EDV (cm/s) -0.17 0.43 -0.1 0.65 23 MS 
LDL CSD PROX LT VA (mm) -0.15 0.49 -0.19 0.39 23 MS 
LDL LT PSV ICA/CCA ratio 0 1 0.03 0.88 23 MS 
LDL LT EDV ICA/ECA ratio 0.3 0.17 0.21 0.33 23 MS 
LDL PV PROX RT IJV (cm/s) -0.08 0.73 0.07 0.75 23 MS 
LDL PV MID RT IJV (cm/s) -0.02 0.93 0 0.98 23 MS 
LDL PV DIST RT IJV (cm/s) -0.19 0.39 -0.07 0.74 23 MS 
LDL CSA PROX RT IJV (mm2) 0.07 0.74 0.05 0.81 23 MS 
LDL PV PROX LT IJV (cm/s) -0.26 0.24 -0.18 0.41 23 MS 
LDL PV MID LT IJV (cm/s) 0.14 0.53 0.17 0.43 23 MS 
LDL PV DIST LT IJV (cm/s) -0.25 0.25 -0.07 0.74 23 MS 
LDL CSA PROX LT IJV (mm2) 0.22 0.32 0.01 0.98 23 MS 
 
 
LDL, low-density lipoprotein; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic 
velocity; EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, 
internal carotid artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.33: Correlation between LDL and the extracranial vascular ultrasound variables in the 
control group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
LDL RT CCA IMT (mm) 0.29 0.17 0.18 0.41 23 CONTROL 
LDL RT CCA PSV (cm/s) -0.07 0.75 -0.07 0.76 23 CONTROL 
LDL RT CCA EDV (cm/s) -0.23 0.29 -0.27 0.21 23 CONTROL 
LDL CSD PROX RT CCA (mm) 0.14 0.53 0.22 0.32 23 CONTROL 
LDL CSD MID RT CCA (mm) 0.26 0.23 0.30 0.17 23 CONTROL 
LDL CSD DIST RT CCA (mm) 0.17 0.43 0.23 0.29 23 CONTROL 
LDL RT ICA PSV (cm/s) -0.21 0.33 -0.13 0.54 23 CONTROL 
LDL RT ICA EDV (cm/s) -0.35 0.11 -0.37 0.09 23 CONTROL 
LDL CSD PROX RT ICA (mm) 0.01 0.95 0.00 0.98 23 CONTROL 
LDL PROX ECA RT PSV (cm/s) 0.20 0.35 0.17 0.44 23 CONTROL 
LDL CSD PROX RT ECA (mm) -0.07 0.75 -0.10 0.64 23 CONTROL 
LDL RT VA PSV (cm/s) -0.01 0.97 -0.11 0.63 23 CONTROL 
LDL RT VA EDV (cm/s) -0.05 0.83 -0.14 0.51 23 CONTROL 
LDL CSD PROX RT VA (mm) -0.06 0.80 -0.23 0.30 23 CONTROL 
LDL RT PSV ICA/CCA ratio -0.01 0.95 0.03 0.90 23 CONTROL 
LDL RT EDV ICA/ECA ratio -0.16 0.45 -0.05 0.81 23 CONTROL 
LDL LT CCA IMT (mm) 0.25 0.24 0.10 0.66 23 CONTROL 
LDL LT CCA PSV (cm/s) 0.07 0.74 0.02 0.92 23 CONTROL 
LDL LT CCA EDV (cm/s) 0.11 0.60 0.21 0.35 23 CONTROL 
LDL CSD PROX LT CCA (mm) 0.36 0.09 0.43 0.04 23 CONTROL 
LDL CSD MID LT CCA (mm) 0.35 0.11 0.39 0.07 23 CONTROL 
LDL CSD DIST LT CCA (mm) 0.14 0.51 0.26 0.23 23 CONTROL 
LDL LT ICA PSV (cm/s) -0.01 0.98 0.01 0.95 23 CONTROL 
LDL LT ICA EDV (cm/s) -0.30 0.16 -0.38 0.07 23 CONTROL 
LDL CSD PROX LT ICA (mm) 0.36 0.09 0.31 0.15 23 CONTROL 
LDL PROX LT ECA PSV (cm/s) 0.25 0.25 0.24 0.27 23 CONTROL 
LDL CSD PROX LT ECA (mm) -0.07 0.75 -0.04 0.87 23 CONTROL 
LDL LT VA PSV (cm/s) 0.15 0.48 0.11 0.61 23 CONTROL 
LDL LT VA EDV (cm/s) 0.04 0.85 0.14 0.53 23 CONTROL 
LDL CSD PROX LT VA (mm) -0.09 0.70 -0.05 0.83 23 CONTROL 
LDL LT PSV ICA/CCA ratio -0.06 0.80 -0.02 0.93 23 CONTROL 
LDL LT EDV ICA/ECA ratio -0.31 0.14 -0.31 0.14 23 CONTROL 
LDL PV PROX RT IJV (cm/s) -0.32 0.13 -0.22 0.31 23 CONTROL 
LDL PV MID RT IJV (cm/s) 0.12 0.60 0.02 0.92 23 CONTROL 
LDL PV DIST RT IJV (cm/s) -0.05 0.83 -0.19 0.39 23 CONTROL 
LDL CSA PROX RT IJV (mm2) 0.08 0.71 0.14 0.53 23 CONTROL 
LDL PV PROX LT IJV (cm/s) 0.16 0.45 0.20 0.36 23 CONTROL 
LDL PV MID LT IJV (cm/s) 0.08 0.73 0.08 0.73 23 CONTROL 
LDL PV DIST LT IJV (cm/s) -0.14 0.51 -0.05 0.82 23 CONTROL 
LDL CSA PROX LT IJV (mm2) 0.09 0.69 0.21 0.34 23 CONTROL 
 
 
 
 
LDL, low-density lipoprotein; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; 
EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid 
artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.4.14 Association between triglycerides and the extracranial vascular ultrasound 
variables 
 
Triglycerides results were available for 24 MS participants and 23 participants free from MS 
(control group). 
 
MS group: Triglycerides had a significant negative correlation with PV of the proximal left IJV 
(Spearman p-value 0.02) (Table 4.34). 
 
Control group: A significant negative correlation was found between triglycerides and the 
following extracranial vascular ultrasound variables: 
 PSV of the right ICA; Pearson p-value <0.01, Spearman p-value 0.02 
 PSV of the left ICA; Pearson p-value 0.04, Spearman p-value 0.04 
Similarly, a significant positive correlation was found between triglycerides and the CSD of the 
proximal right VA (Pearson p-value 0.03, Spearman p-value <0.01) (Table 4.35). 
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Table 4.34: Correlation between triglycerides and the extracranial vascular ultrasound variables 
in the MS group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Trigs RT CCA IMT (mm) -0.17 0.41 -0.07 0.75 24 MS 
Trigs RT CCA PSV (cm/s) 0.02 0.92 -0.17 0.44 24 MS 
Trigs RT CCA EDV (cm/s) 0.07 0.73 0.07 0.76 24 MS 
Trigs CSD PROX RT CCA (mm) -0.08 0.70 -0.24 0.26 24 MS 
Trigs CSD MID RT CCA (mm) 0.00 0.99 -0.05 0.80 24 MS 
Trigs CSD DIST RT CCA (mm) 0.04 0.86 -0.06 0.77 24 MS 
Trigs RT ICA PSV (cm/s) -0.09 0.66 -0.16 0.45 24 MS 
Trigs RT ICA EDV (cm/s) -0.10 0.63 -0.10 0.65 24 MS 
Trigs CSD PROX RT ICA (mm) -0.07 0.75 -0.02 0.92 24 MS 
Trigs PROX ECA RT PSV (cm/s) 0.09 0.69 -0.15 0.47 24 MS 
Trigs CSD PROX RT ECA (mm) -0.01 0.96 -0.03 0.88 24 MS 
Trigs RT VA PSV (cm/s) 0.17 0.43 0.08 0.73 24 MS 
Trigs RT VA EDV (cm/s) 0.10 0.65 0.15 0.48 24 MS 
Trigs CSD PROX RT VA (mm) 0.20 0.35 0.29 0.18 24 MS 
Trigs RT PSV ICA/CCA ratio -0.07 0.73 0.08 0.70 24 MS 
Trigs RT EDV ICA/ECA ratio -0.14 0.53 -0.03 0.89 24 MS 
Trigs LT CCA IMT (mm) 0.12 0.58 0.11 0.61 24 MS 
Trigs LT CCA PSV (cm/s) -0.20 0.36 -0.36 0.08 24 MS 
Trigs LT CCA EDV (cm/s) -0.23 0.28 -0.29 0.17 24 MS 
Trigs CSD PROX LT CCA (mm) 0.19 0.36 -0.06 0.76 24 MS 
Trigs CSD MID LT CCA (mm) 0.06 0.78 -0.14 0.52 24 MS 
Trigs CSD DIST LT CCA (mm) -0.09 0.66 -0.16 0.45 24 MS 
Trigs LT ICA PSV (cm/s) 0.15 0.49 0.16 0.44 24 MS 
Trigs LT ICA EDV (cm/s) -0.05 0.82 -0.13 0.53 24 MS 
Trigs CSD PROX LT ICA (mm) -0.15 0.50 -0.08 0.72 24 MS 
Trigs PROX LT ECA PSV (cm/s) 0.12 0.58 0.16 0.47 24 MS 
Trigs CSD PROX LT ECA (mm) 0.17 0.44 0.05 0.81 24 MS 
Trigs LT VA PSV (cm/s) -0.20 0.34 -0.22 0.30 24 MS 
Trigs LT VA EDV (cm/s) -0.22 0.31 -0.24 0.25 24 MS 
Trigs CSD PROX LT VA (mm) 0.10 0.64 -0.04 0.86 24 MS 
Trigs LT PSV ICA/CCA ratio 0.32 0.12 0.34 0.11 24 MS 
Trigs LT EDV ICA/ECA ratio 0.23 0.28 -0.10 0.65 24 MS 
Trigs PV PROX RT IJV (cm/s) 0.07 0.73 0.11 0.62 24 MS 
Trigs PV MID RT IJV (cm/s) -0.02 0.91 -0.18 0.40 24 MS 
Trigs PV DIST RT IJV (cm/s) -0.23 0.28 -0.28 0.19 24 MS 
Trigs CSA PROX RT IJV (mm2) 0.20 0.34 0.03 0.88 24 MS 
Trigs PV PROX LT IJV (cm/s) -0.35 0.09 -0.49 0.02 24 MS 
Trigs PV MID LT IJV (cm/s) -0.09 0.68 -0.15 0.48 24 MS 
Trigs PV DIST LT IJV (cm/s) -0.14 0.53 -0.23 0.28 24 MS 
Trigs CSA PROX LT IJV (mm2) 0.15 0.47 0.35 0.09 24 MS 
 
 
 
 
Trigs, triglycerides; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; 
EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid 
artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.35: Correlation between triglycerides and the extracranial vascular ultrasound variables 
in the control group 
Biochemical 
marker Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Trigs RT CCA IMT (mm) 0.09 0.69 -0.01 0.97 23 CONTROL 
Trigs RT CCA PSV (cm/s) -0.36 0.09 -0.22 0.31 23 CONTROL 
Trigs RT CCA EDV (cm/s) -0.21 0.34 -0.27 0.22 23 CONTROL 
Trigs CSD PROX RT CCA (mm) 0.23 0.28 0.07 0.76 23 CONTROL 
Trigs CSD MID RT CCA (mm) 0.06 0.78 -0.04 0.84 23 CONTROL 
Trigs CSD DIST RT CCA (mm) 0.21 0.34 0.18 0.42 23 CONTROL 
Trigs RT ICA PSV (cm/s) -0.56 <0.01 -0.48 0.02 23 CONTROL 
Trigs RT ICA EDV (cm/s) -0.38 0.07 -0.38 0.07 23 CONTROL 
Trigs CSD PROX RT ICA (mm) -0.16 0.47 -0.10 0.66 23 CONTROL 
Trigs PROX ECA RT PSV (cm/s) -0.06 0.80 0.16 0.47 23 CONTROL 
Trigs CSD PROX RT ECA (mm) 0.05 0.80 0.02 0.92 23 CONTROL 
Trigs RT VA PSV (cm/s) -0.02 0.93 0.15 0.48 23 CONTROL 
Trigs RT VA EDV (cm/s) 0.02 0.91 0.09 0.68 23 CONTROL 
Trigs CSD PROX RT VA (mm) 0.45 0.03 0.55 <0.01 23 CONTROL 
Trigs RT PSV ICA/CCA ratio -0.09 0.67 -0.12 0.58 23 CONTROL 
Trigs RT EDV ICA/ECA ratio -0.22 0.31 -0.06 0.78 23 CONTROL 
Trigs LT CCA IMT (mm) 0.19 0.38 0.12 0.60 23 CONTROL 
Trigs LT CCA PSV (cm/s) -0.20 0.35 -0.18 0.40 23 CONTROL 
Trigs LT CCA EDV (cm/s) -0.32 0.14 -0.37 0.08 23 CONTROL 
Trigs CSD PROX LT CCA (mm) 0.20 0.35 0.06 0.80 23 CONTROL 
Trigs CSD MID LT CCA (mm) 0.01 0.98 0.02 0.94 23 CONTROL 
Trigs CSD DIST LT CCA (mm) 0.00 1.00 0.04 0.84 23 CONTROL 
Trigs LT ICA PSV (cm/s) -0.44 0.04 -0.44 0.04 23 CONTROL 
Trigs LT ICA EDV (cm/s) -0.39 0.07 -0.36 0.09 23 CONTROL 
Trigs CSD PROX LT ICA (mm) 0.15 0.50 0.20 0.36 23 CONTROL 
Trigs PROX LT ECA PSV (cm/s) -0.36 0.09 -0.14 0.51 23 CONTROL 
Trigs CSD PROX LT ECA (mm) 0.03 0.88 -0.10 0.67 23 CONTROL 
Trigs LT VA PSV (cm/s) -0.01 0.97 -0.02 0.93 23 CONTROL 
Trigs LT VA EDV (cm/s) -0.09 0.69 -0.16 0.47 23 CONTROL 
Trigs CSD PROX LT VA (mm) 0.08 0.72 0.13 0.56 23 CONTROL 
Trigs LT PSV ICA/CCA ratio -0.11 0.61 -0.10 0.65 23 CONTROL 
Trigs LT EDV ICA/ECA ratio -0.15 0.48 -0.10 0.65 23 CONTROL 
Trigs PV PROX RT IJV (cm/s) 0.01 0.95 -0.15 0.51 23 CONTROL 
Trigs PV MID RT IJV (cm/s) -0.19 0.40 -0.11 0.61 23 CONTROL 
Trigs PV DIST RT IJV (cm/s) -0.41 0.05 -0.36 0.09 23 CONTROL 
Trigs CSA PROX RT IJV (mm2) 0.08 0.73 -0.03 0.89 23 CONTROL 
Trigs PV PROX LT IJV (cm/s) -0.12 0.60 -0.18 0.42 23 CONTROL 
Trigs PV MID LT IJV (cm/s) 0.02 0.94 0.03 0.89 23 CONTROL 
Trigs PV DIST LT IJV (cm/s) 0.09 0.70 0.13 0.55 23 CONTROL 
Trigs CSA PROX LT IJV (mm2) -0.04 0.85 -0.18 0.40 23 CONTROL 
 
 
 
Trigs, triglycerides; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, 
end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; 
ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.5 ASSOCIATION BETWEEN LIFESTYLE FACTORS AND THE GREY-SCALE, COLOUR 
AND SPECTRAL DOPPLER ANALYSIS OF THE CAs AND IJVs IN PARTICIPANTS WITH 
MS AND PARTICIPANTS FREE FROM MS (CONTROL GROUP). 
 
The lifestyle parameters of the participants were retrieved from the medical and lifestyle 
questionnaire which was completed on entry to the study (Appendix D). The saturated fat, 
folate and fruit/vegetable/fibre intake scores, retrieved from the questionnaire, were based on 
the types of food the participants ate and the frequency of intake per week. 
 
4.5.1 Association between saturated fat and the extracranial vascular ultrasound 
variables 
 
MS group – A significant positive association was found between saturated fat and the right 
CCA IMT (Pearson p-value 0.04, Spearman p-vale <0.01) and negative correlation with the 
CSD of the proximal left VA (Pearson p-value 0.01, Spearman p-value <0.01) (Table 4.36). 
 
Control group – Table 4.37 shows the significant positive correlations found between 
saturated fat and the following ultrasound variables: 
 RT CCA EDV ; Spearman p-value 0.03 
 LT CCA EDV; Spearman p-value 0.03 
 PV PROX LT IJV; Pearson p-value <0.01, Spearman p-value 0.01  
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Table 4.36: Correlation between saturated fat and the extracranial vascular ultrasound variables 
in the MS group 
Lifestyle 
parameter Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Saturated Fat RT CCA IMT (mm) 0.43 0.04 0.53 <0.01 24 MS 
Saturated Fat RT CCA PSV (cm/s) -0.34 0.11 -0.33 0.11 24 MS 
Saturated Fat RT CCA EDV (cm/s) -0.19 0.36 -0.21 0.32 24 MS 
Saturated Fat CSD PROX RT CCA (mm) -0.16 0.46 -0.21 0.34 24 MS 
Saturated Fat CSD MID RT CCA (mm) 0.25 0.23 0.14 0.5 24 MS 
Saturated Fat CSD DIST RT CCA (mm) 0.28 0.19 0.19 0.38 24 MS 
Saturated Fat RT ICA PSV (cm/s) -0.02 0.94 0.13 0.56 24 MS 
Saturated Fat RT ICA EDV (cm/s) -0.06 0.78 -0.14 0.52 24 MS 
Saturated Fat CSD PROX RT ICA (mm) 0.19 0.38 0.2 0.35 24 MS 
Saturated Fat PROX ECA RT PSV (cm/s) -0.07 0.73 -0.23 0.28 24 MS 
Saturated Fat CSD PROX RT ECA (mm) 0.23 0.28 0.23 0.28 24 MS 
Saturated Fat RT VA PSV (cm/s) -0.05 0.83 -0.06 0.78 24 MS 
Saturated Fat RT VA EDV (cm/s) 0.17 0.42 0.12 0.58 24 MS 
Saturated Fat CSD PROX RT VA (mm) 0.23 0.27 0.27 0.2 24 MS 
Saturated Fat RT PSV ICA/CCA ratio 0.27 0.2 0.34 0.11 24 MS 
Saturated Fat RT EDV ICA/ECA ratio 0.16 0.46 0.21 0.34 24 MS 
Saturated Fat LT CCA IMT (mm) 0.19 0.38 0.35 0.1 24 MS 
Saturated Fat LT CCA PSV (cm/s) -0.18 0.41 -0.2 0.34 24 MS 
Saturated Fat LT CCA EDV (cm/s) -0.16 0.47 -0.22 0.3 24 MS 
Saturated Fat CSD PROX LT CCA (mm) -0.24 0.26 -0.18 0.39 24 MS 
Saturated Fat CSD MID LT CCA (mm) -0.12 0.58 -0.1 0.64 24 MS 
Saturated Fat CSD DIST LT CCA (mm) -0.03 0.91 0.04 0.86 24 MS 
Saturated Fat LT ICA PSV (cm/s) -0.16 0.46 -0.09 0.67 24 MS 
Saturated Fat LT ICA EDV (cm/s) -0.17 0.42 -0.14 0.52 24 MS 
Saturated Fat CSD PROX LT ICA (mm) 0.03 0.88 0.1 0.63 24 MS 
Saturated Fat PROX LT ECA PSV (cm/s) 0.2 0.34 0.05 0.8 24 MS 
Saturated Fat CSD PROX LT ECA (mm) 0.06 0.79 0.01 0.97 24 MS 
Saturated Fat LT VA PSV (cm/s) -0.12 0.58 -0.15 0.48 24 MS 
Saturated Fat LT VA EDV (cm/s) -0.14 0.51 -0.17 0.41 24 MS 
Saturated Fat CSD PROX LT VA (mm) -0.5 0.01 -0.61 <0.01 24 MS 
Saturated Fat LT PSV ICA/CCA ratio -0.05 0.81 0.15 0.48 24 MS 
Saturated Fat LT EDV ICA/ECA ratio -0.19 0.38 0.07 0.73 24 MS 
Saturated Fat PV PROX RT IJV (cm/s) 0.11 0.62 -0.01 0.97 24 MS 
Saturated Fat PV MID RT IJV (cm/s) -0.25 0.24 -0.28 0.18 24 MS 
Saturated Fat PV DIST RT IJV (cm/s) -0.12 0.59 -0.04 0.86 24 MS 
Saturated Fat CSA PROX RT IJV (mm2) -0.03 0.9 -0.01 0.96 24 MS 
Saturated Fat PV PROX LT IJV (cm/s) -0.26 0.21 -0.2 0.35 24 MS 
Saturated Fat PV MID LT IJV (cm/s) -0.34 0.1 -0.33 0.11 24 MS 
Saturated Fat PV DIST LT IJV (cm/s) 0.11 0.62 0.09 0.69 24 MS 
Saturated Fat CSA PROX LT IJV (mm2) 0.09 0.69 0.1 0.63 24 MS 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic velocity; 
PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, external carotid 
artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.37: Correlation between saturated fat and the extracranial vascular ultrasound variables 
in the control group 
Lifestyle 
parameter Ultrasound variables 
Pearson Spearman # 
cases group r p r p 
Saturated Fat RT CCA IMT (mm) -0.08 0.69 -0.05 0.82 25 CONTROL 
Saturated Fat RT CCA PSV (cm/s) 0.14 0.5 0.17 0.43 25 CONTROL 
Saturated Fat RT CCA EDV (cm/s) 0.39 0.05 0.44 0.03 25 CONTROL 
Saturated Fat CSD PROX RT CCA (mm) -0.16 0.44 -0.2 0.35 25 CONTROL 
Saturated Fat CSD MID RT CCA (mm) -0.16 0.44 -0.21 0.31 25 CONTROL 
Saturated Fat CSD DIST RT CCA (mm) -0.31 0.13 -0.32 0.11 25 CONTROL 
Saturated Fat RT ICA PSV (cm/s) 0.22 0.29 0.12 0.56 25 CONTROL 
Saturated Fat RT ICA EDV (cm/s) 0.01 0.98 0.13 0.54 25 CONTROL 
Saturated Fat CSD PROX RT ICA (mm) 0.07 0.76 0.09 0.67 25 CONTROL 
Saturated Fat PROX ECA RT PSV (cm/s) -0.04 0.85 -0.06 0.79 25 CONTROL 
Saturated Fat CSD PROX RT ECA (mm) 0.01 0.97 0.02 0.92 25 CONTROL 
Saturated Fat RT VA PSV (cm/s) -0.18 0.39 -0.2 0.34 25 CONTROL 
Saturated Fat RT VA EDV (cm/s) -0.22 0.29 -0.28 0.18 25 CONTROL 
Saturated Fat CSD PROX RT VA (mm) -0.27 0.19 -0.45 0.02 25 CONTROL 
Saturated Fat RT PSV ICA/CCA ratio 0.07 0.73 0.02 0.93 25 CONTROL 
Saturated Fat RT EDV ICA/ECA ratio -0.29 0.16 -0.19 0.36 25 CONTROL 
Saturated Fat LT CCA IMT (mm) -0.28 0.18 -0.3 0.15 25 CONTROL 
Saturated Fat LT CCA PSV (cm/s) 0.15 0.47 0.17 0.43 25 CONTROL 
Saturated Fat LT CCA EDV (cm/s) 0.34 0.1 0.43 0.03 25 CONTROL 
Saturated Fat CSD PROX LT CCA (mm) 0.08 0.69 0.17 0.41 25 CONTROL 
Saturated Fat CSD MID LT CCA (mm) -0.01 0.97 0.02 0.92 25 CONTROL 
Saturated Fat CSD DIST LT CCA (mm) -0.1 0.63 0 0.99 25 CONTROL 
Saturated Fat LT ICA PSV (cm/s) 0.04 0.87 0.04 0.83 25 CONTROL 
Saturated Fat LT ICA EDV (cm/s) -0.07 0.75 0.05 0.83 25 CONTROL 
Saturated Fat CSD PROX LT ICA (mm) 0.06 0.79 -0.02 0.91 25 CONTROL 
Saturated Fat PROX LT ECA PSV (cm/s) 0.14 0.51 0.13 0.52 25 CONTROL 
Saturated Fat CSD PROX LT ECA (mm) 0.28 0.17 0.29 0.15 25 CONTROL 
Saturated Fat LT VA PSV (cm/s) 0.01 0.96 0.01 0.94 25 CONTROL 
Saturated Fat LT VA EDV (cm/s) 0.03 0.89 0.06 0.77 25 CONTROL 
Saturated Fat CSD PROX LT VA (mm) -0.15 0.48 -0.19 0.37 25 CONTROL 
Saturated Fat LT PSV ICA/CCA ratio -0.18 0.39 -0.14 0.49 25 CONTROL 
Saturated Fat LT EDV ICA/ECA ratio -0.24 0.24 -0.13 0.55 25 CONTROL 
Saturated Fat PV PROX RT IJV (cm/s) 0.33 0.11 0.31 0.14 25 CONTROL 
Saturated Fat PV MID RT IJV (cm/s) 0.14 0.5 0.16 0.44 25 CONTROL 
Saturated Fat PV DIST RT IJV (cm/s) 0.09 0.67 0.09 0.66 25 CONTROL 
Saturated Fat CSA PROX RT IJV (mm2) -0.06 0.79 -0.05 0.83 25 CONTROL 
Saturated Fat PV PROX LT IJV (cm/s) 0.62 <0.01 0.48 0.01 25 CONTROL 
Saturated Fat PV MID LT IJV (cm/s) 0.35 0.08 0.28 0.17 25 CONTROL 
Saturated Fat PV DIST LT IJV (cm/s) 0.1 0.63 0.05 0.83 25 CONTROL 
Saturated Fat CSA PROX LT IJV (mm2) 0.18 0.39 0.31 0.13 25 CONTROL 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic velocity; 
PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, external carotid 
artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.5.2 Association between consumption of chicken with skin and the extracranial 
vascular ultrasound variables 
 
MS group – As seen in Table 4.38, a significant negative correlation was found between 
consumption of chicken with skin and the CSD of the proximal right CCA (Pearson p-value 
0.04). 
 
Control group – A significant positive correlation as found between consumption of chicken 
with skin and the following ultrasound variables (Table 4.39): 
 Left CCA EDV; Pearson p-value 0.04 
 PV of the proximal right IJV; Pearson p-value 0.02, Spearman p-value 0.03 
 PV of the proximal left IJV; Pearson p-value 0.03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
91 
 
Table 4.38: Correlation between chicken with skin consumption and the extracranial vascular 
ultrasound variables in the MS group 
Lifestyle 
parameter Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Chicken with skin RT CCA IMT (mm) -0.24 0.27 -0.12 0.57 23 MS 
Chicken with skin RT CCA PSV (cm/s) 0.08 0.72 0.02 0.93 23 MS 
Chicken with skin RT CCA EDV (cm/s) 0.39 0.06 0.24 0.27 23 MS 
Chicken with skin CSD PROX RT CCA (mm) -0.42 0.04 -0.31 0.15 23 MS 
Chicken with skin CSD MID RT CCA (mm) -0.34 0.11 -0.38 0.08 23 MS 
Chicken with skin CSD DIST RT CCA (mm) -0.34 0.11 -0.25 0.25 23 MS 
Chicken with skin RT ICA PSV (cm/s) -0.2 0.36 -0.19 0.38 23 MS 
Chicken with skin RT ICA EDV (cm/s) 0.12 0.58 0.07 0.74 23 MS 
Chicken with skin CSD PROX RT ICA (mm) -0.01 0.97 -0.02 0.92 23 MS 
Chicken with skin PROX ECA RT PSV (cm/s) 0.04 0.84 -0.14 0.52 23 MS 
Chicken with skin CSD PROX RT ECA (mm) -0.02 0.94 0.2 0.37 23 MS 
Chicken with skin RT VA PSV (cm/s) -0.05 0.84 -0.12 0.57 23 MS 
Chicken with skin RT VA EDV (cm/s) 0.25 0.25 0.24 0.26 23 MS 
Chicken with skin CSD PROX RT VA (mm) 0.18 0.4 0.19 0.4 23 MS 
Chicken with skin RT PSV ICA/CCA ratio -0.21 0.33 -0.17 0.45 23 MS 
Chicken with skin RT EDV ICA/ECA ratio -0.2 0.35 -0.12 0.58 23 MS 
Chicken with skin LT CCA IMT (mm) -0.33 0.12 -0.28 0.19 23 MS 
Chicken with skin LT CCA PSV (cm/s) 0.1 0.64 0.04 0.86 23 MS 
Chicken with skin LT CCA EDV (cm/s) 0.36 0.09 0.29 0.17 23 MS 
Chicken with skin CSD PROX LT CCA (mm) -0.37 0.08 -0.3 0.16 23 MS 
Chicken with skin CSD MID LT CCA (mm) -0.42 0.05 -0.4 0.06 23 MS 
Chicken with skin CSD DIST LT CCA (mm) -0.21 0.33 -0.11 0.61 23 MS 
Chicken with skin LT ICA PSV (cm/s) -0.05 0.82 -0.15 0.49 23 MS 
Chicken with skin LT ICA EDV (cm/s) 0.03 0.9 -0.12 0.59 23 MS 
Chicken with skin CSD PROX LT ICA (mm) -0.09 0.68 -0.02 0.92 23 MS 
Chicken with skin PROX LT ECA PSV (cm/s) 0.19 0.39 0.01 0.95 23 MS 
Chicken with skin CSD PROX LT ECA (mm) -0.17 0.43 -0.14 0.53 23 MS 
Chicken with skin LT VA PSV (cm/s) 0.19 0.4 0.15 0.5 23 MS 
Chicken with skin LT VA EDV (cm/s) 0.29 0.19 0.17 0.42 23 MS 
Chicken with skin CSD PROX LT VA (mm) -0.15 0.51 -0.16 0.46 23 MS 
Chicken with skin LT PSV ICA/CCA ratio -0.15 0.49 -0.25 0.25 23 MS 
Chicken with skin LT EDV ICA/ECA ratio -0.28 0.19 -0.2 0.36 23 MS 
Chicken with skin PV PROX RT IJV (cm/s) -0.02 0.94 -0.12 0.57 23 MS 
Chicken with skin PV MID RT IJV (cm/s) 0.06 0.8 -0.14 0.53 23 MS 
Chicken with skin PV DIST RT IJV (cm/s) -0.09 0.69 -0.1 0.64 23 MS 
Chicken with skin CSA PROX RT IJV (mm2) 0.32 0.14 0.37 0.08 23 MS 
Chicken with skin PV PROX LT IJV (cm/s) -0.29 0.17 -0.27 0.21 23 MS 
Chicken with skin PV MID LT IJV (cm/s) 0.1 0.64 -0.12 0.6 23 MS 
Chicken with skin PV DIST LT IJV (cm/s) 0.12 0.58 -0.13 0.55 23 MS 
Chicken with skin CSA PROX LT IJV (mm2) 0.18 0.41 0.18 0.41 23 MS 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic velocity; 
PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, external carotid 
artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.39: Correlation between chicken with skin consumption and the extracranial vascular 
ultrasound variables in the control group 
Lifestyle 
parameter Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Chicken with skin RT CCA IMT (mm) -0.28 0.17 -0.27 0.2 25 CONTROL 
Chicken with skin RT CCA PSV (cm/s) 0.17 0.4 0.08 0.71 25 CONTROL 
Chicken with skin RT CCA EDV (cm/s) 0.17 0.43 0.2 0.34 25 CONTROL 
Chicken with skin CSD PROX RT CCA (mm) -0.16 0.45 -0.15 0.47 25 CONTROL 
Chicken with skin CSD MID RT CCA (mm) -0.2 0.34 -0.24 0.24 25 CONTROL 
Chicken with skin CSD DIST RT CCA (mm) -0.25 0.24 -0.23 0.27 25 CONTROL 
Chicken with skin RT ICA PSV (cm/s) 0.39 0.05 0.32 0.12 25 CONTROL 
Chicken with skin RT ICA EDV (cm/s) 0.27 0.2 0.26 0.2 25 CONTROL 
Chicken with skin CSD PROX RT ICA (mm) -0.17 0.41 -0.11 0.6 25 CONTROL 
Chicken with skin PROX ECA RT PSV (cm/s) 0.27 0.19 0.27 0.18 25 CONTROL 
Chicken with skin CSD PROX RT ECA (mm) -0.06 0.77 -0.07 0.74 25 CONTROL 
Chicken with skin RT VA PSV (cm/s) 0.02 0.92 -0.05 0.83 25 CONTROL 
Chicken with skin RT VA EDV (cm/s) 0.06 0.77 0.06 0.78 25 CONTROL 
Chicken with skin CSD PROX RT VA (mm) -0.25 0.23 -0.18 0.4 25 CONTROL 
Chicken with skin RT PSV ICA/CCA ratio 0.16 0.45 0.14 0.51 25 CONTROL 
Chicken with skin RT EDV ICA/ECA ratio 0.18 0.4 0.13 0.55 25 CONTROL 
Chicken with skin LT CCA IMT (mm) -0.22 0.29 -0.2 0.34 25 CONTROL 
Chicken with skin LT CCA PSV (cm/s) 0.16 0.46 0.17 0.43 25 CONTROL 
Chicken with skin LT CCA EDV (cm/s) 0.42 0.04 0.35 0.08 25 CONTROL 
Chicken with skin CSD PROX LT CCA (mm) -0.28 0.18 -0.19 0.36 25 CONTROL 
Chicken with skin CSD MID LT CCA (mm) -0.27 0.19 -0.28 0.17 25 CONTROL 
Chicken with skin CSD DIST LT CCA (mm) 0.01 0.97 -0.02 0.92 25 CONTROL 
Chicken with skin LT ICA PSV (cm/s) 0.05 0.81 -0.09 0.67 25 CONTROL 
Chicken with skin LT ICA EDV (cm/s) 0.09 0.69 0.02 0.93 25 CONTROL 
Chicken with skin CSD PROX LT ICA (mm) -0.12 0.58 -0.05 0.82 25 CONTROL 
Chicken with skin PROX LT ECA PSV (cm/s) 0.03 0.9 0.08 0.7 25 CONTROL 
Chicken with skin CSD PROX LT ECA (mm) 0.4 0.05 0.45 0.03 25 CONTROL 
Chicken with skin LT VA PSV (cm/s) -0.14 0.5 -0.16 0.44 25 CONTROL 
Chicken with skin LT VA EDV (cm/s) -0.07 0.75 -0.07 0.75 25 CONTROL 
Chicken with skin CSD PROX LT VA (mm) 0.01 0.97 0.05 0.8 25 CONTROL 
Chicken with skin LT PSV ICA/CCA ratio -0.06 0.76 -0.13 0.54 25 CONTROL 
Chicken with skin LT EDV ICA/ECA ratio -0.15 0.46 -0.26 0.2 25 CONTROL 
Chicken with skin PV PROX RT IJV (cm/s) 0.47 0.02 0.43 0.03 25 CONTROL 
Chicken with skin PV MID RT IJV (cm/s) 0.13 0.52 0.14 0.5 25 CONTROL 
Chicken with skin PV DIST RT IJV (cm/s) -0.02 0.93 0.13 0.53 25 CONTROL 
Chicken with skin CSA PROX RT IJV (mm2) 0.23 0.28 0.16 0.45 25 CONTROL 
Chicken with skin PV PROX LT IJV (cm/s) 0.44 0.03 0.37 0.07 25 CONTROL 
Chicken with skin PV MID LT IJV (cm/s) 0.23 0.28 0.33 0.11 25 CONTROL 
Chicken with skin PV DIST LT IJV (cm/s) 0.24 0.25 0.23 0.27 25 CONTROL 
Chicken with skin CSA PROX LT IJV (mm2) 0.07 0.73 -0.01 0.96 25 CONTROL 
 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic 
velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, external 
carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.5.3 Association between fruit/veg/fibre intake and the extracranial vascular ultrasound 
variables 
 
MS group – No significant correlations were found in this group of participants (Table 4.40). 
 
Control group – A significant negative correlation was found between fruit/veg/fibre intake 
and the following ultrasound variables (Table 4.14): 
 PV of the proximal right IJV; Pearson p-value 0.02, Spearman p-value <0.01 
 PV of the proximal left IJV; Pearson p-value 0.02, Spearman p-value 0.04 
 PV of the mid left IJV; Pearson p-value <0.01, Spearman p-value 0.01 
 PV of the distal left IJV; Pearson p-value 0.02, Spearman p-value 0.02 
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Table 4.40: Correlation between fruit/veg/fibre intake and the extracranial vascular ultrasound 
variables in the MS group 
Lifestyle 
parameter Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Fruit/Veg/Fibre RT CCA IMT (mm) -0.04 0.87 -0.07 0.75 24 MS 
Fruit/Veg/Fibre RT CCA PSV (cm/s) -0.13 0.55 -0.04 0.87 24 MS 
Fruit/Veg/Fibre RT CCA EDV (cm/s) -0.32 0.12 -0.33 0.12 24 MS 
Fruit/Veg/Fibre CSD PROX RT CCA (mm) 0.24 0.26 0.16 0.45 24 MS 
Fruit/Veg/Fibre CSD MID RT CCA (mm) 0.23 0.29 0.22 0.29 24 MS 
Fruit/Veg/Fibre CSD DIST RT CCA (mm) 0.23 0.28 0.25 0.25 24 MS 
Fruit/Veg/Fibre RT ICA PSV (cm/s) -0.08 0.7 -0.11 0.62 24 MS 
Fruit/Veg/Fibre RT ICA EDV (cm/s) -0.22 0.3 -0.18 0.41 24 MS 
Fruit/Veg/Fibre CSD PROX RT ICA (mm) 0.08 0.7 0.06 0.79 24 MS 
Fruit/Veg/Fibre PROX ECA RT PSV (cm/s) 0.25 0.24 0.23 0.28 24 MS 
Fruit/Veg/Fibre CSD PROX RT ECA (mm) -0.19 0.38 -0.14 0.52 24 MS 
Fruit/Veg/Fibre RT VA PSV (cm/s) -0.04 0.87 0.06 0.76 24 MS 
Fruit/Veg/Fibre RT VA EDV (cm/s) -0.29 0.17 -0.29 0.17 24 MS 
Fruit/Veg/Fibre CSD PROX RT VA (mm) 0.1 0.63 0.02 0.93 24 MS 
Fruit/Veg/Fibre RT PSV ICA/CCA ratio 0.07 0.74 0.05 0.81 24 MS 
Fruit/Veg/Fibre RT EDV ICA/ECA ratio 0.03 0.87 0.1 0.64 24 MS 
Fruit/Veg/Fibre LT CCA IMT (mm) 0.28 0.19 0.24 0.25 24 MS 
Fruit/Veg/Fibre LT CCA PSV (cm/s) -0.06 0.8 -0.05 0.82 24 MS 
Fruit/Veg/Fibre LT CCA EDV (cm/s) -0.15 0.47 -0.11 0.61 24 MS 
Fruit/Veg/Fibre CSD PROX LT CCA (mm) 0.39 0.06 0.4 0.05 24 MS 
Fruit/Veg/Fibre CSD MID LT CCA (mm) 0.26 0.22 0.2 0.36 24 MS 
Fruit/Veg/Fibre CSD DIST LT CCA (mm) -0.02 0.91 -0.07 0.74 24 MS 
Fruit/Veg/Fibre LT ICA PSV (cm/s) 0.11 0.62 0.19 0.38 24 MS 
Fruit/Veg/Fibre LT ICA EDV (cm/s) -0.15 0.49 -0.05 0.8 24 MS 
Fruit/Veg/Fibre CSD PROX LT ICA (mm) 0.05 0.83 -0.1 0.64 24 MS 
Fruit/Veg/Fibre PROX LT ECA PSV (cm/s) -0.03 0.91 0.1 0.63 24 MS 
Fruit/Veg/Fibre CSD PROX LT ECA (mm) 0.11 0.62 0.14 0.53 24 MS 
Fruit/Veg/Fibre LT VA PSV (cm/s) -0.25 0.24 -0.18 0.39 24 MS 
Fruit/Veg/Fibre LT VA EDV (cm/s) -0.11 0.59 -0.12 0.58 24 MS 
Fruit/Veg/Fibre CSD PROX LT VA (mm) 0.28 0.19 0.19 0.38 24 MS 
Fruit/Veg/Fibre LT PSV ICA/CCA ratio 0.21 0.31 0.2 0.34 24 MS 
Fruit/Veg/Fibre LT EDV ICA/ECA ratio 0.03 0.88 -0.07 0.76 24 MS 
Fruit/Veg/Fibre PV PROX RT IJV (cm/s) 0.03 0.89 0.02 0.91 24 MS 
Fruit/Veg/Fibre PV MID RT IJV (cm/s) 0.29 0.18 0.25 0.24 24 MS 
Fruit/Veg/Fibre PV DIST RT IJV (cm/s) 0.35 0.1 0.26 0.22 24 MS 
Fruit/Veg/Fibre CSA PROX RT IJV (mm2) -0.01 0.97 -0.07 0.74 24 MS 
Fruit/Veg/Fibre PV PROX LT IJV (cm/s) -0.2 0.35 -0.29 0.17 24 MS 
Fruit/Veg/Fibre PV MID LT IJV (cm/s) -0.01 0.96 -0.02 0.91 24 MS 
Fruit/Veg/Fibre PV DIST LT IJV (cm/s) 0.04 0.85 0.01 0.97 24 MS 
Fruit/Veg/Fibre CSA PROX LT IJV (mm2) 0.12 0.58 0.16 0.46 24 MS 
 
 
 
 
Veg, vegetables; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, 
end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; 
ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.41: Correlation between weekly fruit/vegetable/fibre intake and the extracranial vascular 
ultrasound variables in the control group 
Lifestyle 
parameter Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Fruit/Veg/Fibre RT CCA IMT (mm) 0.35 0.08 0.34 0.1 25 CONTROL 
Fruit/Veg/Fibre RT CCA PSV (cm/s) -0.26 0.21 -0.15 0.46 25 CONTROL 
Fruit/Veg/Fibre RT CCA EDV (cm/s) -0.21 0.31 -0.25 0.22 25 CONTROL 
Fruit/Veg/Fibre CSD PROX RT CCA (mm) -0.12 0.56 -0.04 0.85 25 CONTROL 
Fruit/Veg/Fibre CSD MID RT CCA (mm) -0.03 0.87 0.14 0.51 25 CONTROL 
Fruit/Veg/Fibre CSD DIST RT CCA (mm) -0.03 0.87 0.09 0.65 25 CONTROL 
Fruit/Veg/Fibre RT ICA PSV (cm/s) -0.2 0.34 -0.11 0.6 25 CONTROL 
Fruit/Veg/Fibre RT ICA EDV (cm/s) -0.09 0.67 -0.02 0.91 25 CONTROL 
Fruit/Veg/Fibre CSD PROX RT ICA (mm) 0.21 0.31 0.26 0.21 25 CONTROL 
Fruit/Veg/Fibre PROX ECA RT PSV (cm/s) 0.08 0.7 0.14 0.51 25 CONTROL 
Fruit/Veg/Fibre CSD PROX RT ECA (mm) -0.18 0.38 -0.2 0.33 25 CONTROL 
Fruit/Veg/Fibre RT VA PSV (cm/s) -0.17 0.41 -0.18 0.4 25 CONTROL 
Fruit/Veg/Fibre RT VA EDV (cm/s) -0.23 0.28 -0.18 0.39 25 CONTROL 
Fruit/Veg/Fibre CSD PROX RT VA (mm) -0.05 0.8 -0.02 0.93 25 CONTROL 
Fruit/Veg/Fibre RT PSV ICA/CCA ratio 0.01 0.95 -0.02 0.94 25 CONTROL 
Fruit/Veg/Fibre RT EDV ICA/ECA ratio 0.09 0.68 0.08 0.72 25 CONTROL 
Fruit/Veg/Fibre LT CCA IMT (mm) 0.18 0.38 0.27 0.19 25 CONTROL 
Fruit/Veg/Fibre LT CCA PSV (cm/s) 0.05 0.8 0.04 0.86 25 CONTROL 
Fruit/Veg/Fibre LT CCA EDV (cm/s) -0.08 0.72 -0.05 0.83 25 CONTROL 
Fruit/Veg/Fibre CSD PROX LT CCA (mm) -0.08 0.71 -0.1 0.65 25 CONTROL 
Fruit/Veg/Fibre CSD MID LT CCA (mm) 0.15 0.49 0.15 0.49 25 CONTROL 
Fruit/Veg/Fibre CSD DIST LT CCA (mm) 0.24 0.24 0.21 0.32 25 CONTROL 
Fruit/Veg/Fibre LT ICA PSV (cm/s) -0.3 0.15 -0.17 0.41 25 CONTROL 
Fruit/Veg/Fibre LT ICA EDV (cm/s) -0.08 0.69 0.03 0.89 25 CONTROL 
Fruit/Veg/Fibre CSD PROX LT ICA (mm) 0.23 0.27 0.26 0.22 25 CONTROL 
Fruit/Veg/Fibre PROX LT ECA PSV (cm/s) 0.06 0.77 0.14 0.51 25 CONTROL 
Fruit/Veg/Fibre CSD PROX LT ECA (mm) -0.12 0.58 -0.06 0.77 25 CONTROL 
Fruit/Veg/Fibre LT VA PSV (cm/s) 0.26 0.2 0.23 0.27 25 CONTROL 
Fruit/Veg/Fibre LT VA EDV (cm/s) 0.19 0.36 0.25 0.23 25 CONTROL 
Fruit/Veg/Fibre CSD PROX LT VA (mm) 0 0.99 0 0.99 25 CONTROL 
Fruit/Veg/Fibre LT PSV ICA/CCA ratio -0.17 0.42 -0.19 0.36 25 CONTROL 
Fruit/Veg/Fibre LT EDV ICA/ECA ratio -0.04 0.85 -0.15 0.47 25 CONTROL 
Fruit/Veg/Fibre PV PROX RT IJV (cm/s) -0.45 0.02 -0.57 <0.01 25 CONTROL 
Fruit/Veg/Fibre PV MID RT IJV (cm/s) -0.23 0.27 -0.2 0.33 25 CONTROL 
Fruit/Veg/Fibre PV DIST RT IJV (cm/s) -0.03 0.89 -0.14 0.5 25 CONTROL 
Fruit/Veg/Fibre CSA PROX RT IJV (mm2) -0.18 0.4 -0.12 0.57 25 CONTROL 
Fruit/Veg/Fibre PV PROX LT IJV (cm/s) -0.45 0.02 -0.42 0.04 25 CONTROL 
Fruit/Veg/Fibre PV MID LT IJV (cm/s) -0.51 <0.01 -0.5 0.01 25 CONTROL 
Fruit/Veg/Fibre PV DIST LT IJV (cm/s) -0.46 0.02 -0.47 0.02 25 CONTROL 
Fruit/Veg/Fibre CSA PROX LT IJV (mm2) -0.34 0.09 -0.21 0.32 25 CONTROL 
 
 
 
 
 
Veg, vegetables; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, 
end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; 
ECA, external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.5.4 Association between folate and the extracranial vascular ultrasound variables 
 
MS group – In this group of participants, a significant positive correlation was found between 
folate and the CSA of the proximal left IJV (Pearson p-value 0.01). Similarly, a significant 
negative correlation was found between folate and the EDV of the left VA (Spearman p-value 
0.02) (Table 4.42). 
 
Control group – A significant positive correlation was found between the PSV of the left VA 
(Pearson p-value 0.03, Spearman p-value 0.02). Folate was also negatively correlated with 
the PSV of the right ICA (Pearson p-value 0.03, Spearman p-value 0.02) (Table 4.43).  
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Table 4.42: Correlation between folate and the extracranial vascular ultrasound variables in the 
MS group 
Lifestyle 
parameter Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Folate RT CCA IMT (mm) -0.02 0.93 -0.01 0.96 24 MS 
Folate RT CCA PSV (cm/s) -0.24 0.26 -0.11 0.61 24 MS 
Folate RT CCA EDV (cm/s) -0.31 0.14 -0.43 0.04 24 MS 
Folate CSD PROX RT CCA (mm) -0.04 0.84 -0.07 0.74 24 MS 
Folate CSD MID RT CCA (mm) -0.07 0.75 -0.05 0.8 24 MS 
Folate CSD DIST RT CCA (mm) 0 0.99 0.08 0.71 24 MS 
Folate RT ICA PSV (cm/s) -0.14 0.52 -0.2 0.36 24 MS 
Folate RT ICA EDV (cm/s) -0.14 0.52 -0.16 0.44 24 MS 
Folate CSD PROX RT ICA (mm) -0.01 0.95 -0.08 0.71 24 MS 
Folate PROX ECA RT PSV (cm/s) 0.17 0.42 0.26 0.22 24 MS 
Folate CSD PROX RT ECA (mm) 0.14 0.53 0.02 0.93 24 MS 
Folate RT VA PSV (cm/s) -0.14 0.52 -0.11 0.6 24 MS 
Folate RT VA EDV (cm/s) -0.24 0.25 -0.18 0.4 24 MS 
Folate CSD PROX RT VA (mm) 0.14 0.52 0.23 0.29 24 MS 
Folate RT PSV ICA/CCA ratio -0.03 0.87 -0.07 0.75 24 MS 
Folate RT EDV ICA/ECA ratio 0.11 0.6 0.07 0.73 24 MS 
Folate LT CCA IMT (mm) 0.16 0.46 0.25 0.25 24 MS 
Folate LT CCA PSV (cm/s) -0.07 0.75 0.03 0.89 24 MS 
Folate LT CCA EDV (cm/s) -0.12 0.57 -0.25 0.25 24 MS 
Folate CSD PROX LT CCA (mm) -0.11 0.62 -0.17 0.43 24 MS 
Folate CSD MID LT CCA (mm) -0.14 0.5 -0.06 0.77 24 MS 
Folate CSD DIST LT CCA (mm) -0.22 0.3 -0.2 0.35 24 MS 
Folate LT ICA PSV (cm/s) -0.02 0.94 -0.09 0.68 24 MS 
Folate LT ICA EDV (cm/s) -0.06 0.78 -0.06 0.78 24 MS 
Folate CSD PROX LT ICA (mm) 0.18 0.4 0.13 0.54 24 MS 
Folate PROX LT ECA PSV (cm/s) 0.03 0.89 0.12 0.57 24 MS 
Folate CSD PROX LT ECA (mm) 0.23 0.28 0.32 0.13 24 MS 
Folate LT VA PSV (cm/s) -0.31 0.13 -0.33 0.12 24 MS 
Folate LT VA EDV (cm/s) -0.39 0.06 -0.48 0.02 24 MS 
Folate CSD PROX LT VA (mm) 0.05 0.83 0 1 24 MS 
Folate LT PSV ICA/CCA ratio -0.03 0.91 0.01 0.96 24 MS 
Folate LT EDV ICA/ECA ratio 0.02 0.91 -0.06 0.79 24 MS 
Folate PV PROX RT IJV (cm/s) -0.31 0.14 -0.19 0.38 24 MS 
Folate PV MID RT IJV (cm/s) -0.19 0.37 -0.17 0.44 24 MS 
Folate PV DIST RT IJV (cm/s) -0.14 0.51 -0.28 0.19 24 MS 
Folate CSA PROX RT IJV (mm2) 0.06 0.79 -0.08 0.7 24 MS 
Folate PV PROX LT IJV (cm/s) -0.19 0.38 -0.08 0.72 24 MS 
Folate PV MID LT IJV (cm/s) 0.06 0.77 0.09 0.67 24 MS 
Folate PV DIST LT IJV (cm/s) 0.05 0.8 0.14 0.5 24 MS 
Folate CSA PROX LT IJV (mm2) 0.5 0.01 0.12 0.57 24 MS 
 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic 
velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, 
external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.43: Correlation between folate and the extracranial vascular ultrasound variables in the 
control group 
Lifestyle 
parameter Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Folate RT CCA IMT (mm) 0.29 0.17 0.23 0.27 25 CONTROL 
Folate RT CCA PSV (cm/s) -0.03 0.89 0.01 0.98 25 CONTROL 
Folate RT CCA EDV (cm/s) -0.05 0.81 -0.05 0.82 25 CONTROL 
Folate CSD PROX RT CCA (mm) 0.08 0.69 0.11 0.59 25 CONTROL 
Folate CSD MID RT CCA (mm) 0.11 0.59 0.19 0.37 25 CONTROL 
Folate CSD DIST RT CCA (mm) -0.08 0.72 -0.06 0.76 25 CONTROL 
Folate RT ICA PSV (cm/s) -0.45 0.02 -0.38 0.06 25 CONTROL 
Folate RT ICA EDV (cm/s) -0.21 0.31 -0.23 0.28 25 CONTROL 
Folate CSD PROX RT ICA (mm) 0.11 0.6 0.13 0.55 25 CONTROL 
Folate PROX ECA RT PSV (cm/s) -0.22 0.29 -0.25 0.22 25 CONTROL 
Folate CSD PROX RT ECA (mm) 0.13 0.52 0.17 0.41 25 CONTROL 
Folate RT VA PSV (cm/s) -0.02 0.92 -0.12 0.56 25 CONTROL 
Folate RT VA EDV (cm/s) 0.02 0.93 -0.07 0.72 25 CONTROL 
Folate CSD PROX RT VA (mm) 0.13 0.54 0.11 0.59 25 CONTROL 
Folate RT PSV ICA/CCA ratio -0.32 0.12 -0.35 0.09 25 CONTROL 
Folate RT EDV ICA/ECA ratio -0.19 0.37 -0.28 0.17 25 CONTROL 
Folate LT CCA IMT (mm) -0.11 0.6 0 1 25 CONTROL 
Folate LT CCA PSV (cm/s) 0.22 0.28 0.11 0.59 25 CONTROL 
Folate LT CCA EDV (cm/s) -0.01 0.94 -0.07 0.74 25 CONTROL 
Folate CSD PROX LT CCA (mm) -0.05 0.8 -0.11 0.59 25 CONTROL 
Folate CSD MID LT CCA (mm) 0.05 0.81 0.04 0.86 25 CONTROL 
Folate CSD DIST LT CCA (mm) -0.21 0.32 -0.13 0.53 25 CONTROL 
Folate LT ICA PSV (cm/s) -0.24 0.24 -0.27 0.19 25 CONTROL 
Folate LT ICA EDV (cm/s) -0.14 0.5 0 1 25 CONTROL 
Folate CSD PROX LT ICA (mm) 0.2 0.33 0.14 0.49 25 CONTROL 
Folate PROX LT ECA PSV (cm/s) -0.1 0.62 -0.14 0.52 25 CONTROL 
Folate CSD PROX LT ECA (mm) -0.12 0.58 0.02 0.92 25 CONTROL 
Folate LT VA PSV (cm/s) 0.43 0.03 0.45 0.02 25 CONTROL 
Folate LT VA EDV (cm/s) 0.27 0.2 0.3 0.15 25 CONTROL 
Folate CSD PROX LT VA (mm) 0.1 0.64 0.18 0.4 25 CONTROL 
Folate LT PSV ICA/CCA ratio -0.2 0.34 -0.29 0.17 25 CONTROL 
Folate LT EDV ICA/ECA ratio -0.09 0.66 -0.02 0.92 25 CONTROL 
Folate PV PROX RT IJV (cm/s) -0.18 0.39 -0.24 0.26 25 CONTROL 
Folate PV MID RT IJV (cm/s) 0.33 0.1 0.28 0.18 25 CONTROL 
Folate PV DIST RT IJV (cm/s) 0.08 0.7 -0.07 0.75 25 CONTROL 
Folate CSA PROX RT IJV (mm2) -0.17 0.41 -0.19 0.35 25 CONTROL 
Folate PV PROX LT IJV (cm/s) -0.22 0.3 -0.06 0.76 25 CONTROL 
Folate PV MID LT IJV (cm/s) -0.18 0.38 -0.21 0.31 25 CONTROL 
Folate PV DIST LT IJV (cm/s) -0.24 0.25 -0.28 0.18 25 CONTROL 
Folate CSA PROX LT IJV (mm2) -0.03 0.87 0.04 0.84 25 CONTROL 
 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic 
velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, 
external carotid artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.5.5 Association between physical activity and the extracranial vascular ultrasound 
variables 
 
MS group – A significant positive correlation was found between physical activity and the 
following ultrasound variables (Table 4.44): 
 PSV of the right CCA; Pearson p-value 0.03, Spearman p-value 0.02 
 EDV of the right CCA; Pearson p-value 0.01, Spearman p-value <0.01 
 EDV of the right VA; Pearson p-value 0.03 
 PSV of the left ICA; Pearson p-value 0.02, Spearman p-value 0.03 
 EDV of the left ICA; Pearson p-value, Spearman p-value 0.04 
 
Control group – No significant correlations were found (Table 4.45). 
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Table 4.44: Correlation between physical activity and the extracranial vascular ultrasound 
variables in the MS group 
Lifestyle 
parameter Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Physical activity RT CCA IMT (mm) -0.23 0.28 -0.18 0.41 24 MS 
Physical activity RT CCA PSV (cm/s) 0.45 0.03 0.46 0.02 24 MS 
Physical activity RT CCA EDV (cm/s) 0.51 0.01 0.54 <0.01 24 MS 
Physical activity CSD PROX RT CCA (mm) -0.14 0.51 -0.08 0.71 24 MS 
Physical activity CSD MID RT CCA (mm) -0.29 0.17 -0.29 0.17 24 MS 
Physical activity CSD DIST RT CCA (mm) -0.39 0.06 -0.33 0.11 24 MS 
Physical activity RT ICA PSV (cm/s) 0.16 0.46 0.03 0.89 24 MS 
Physical activity RT ICA EDV (cm/s) 0.38 0.07 0.35 0.1 24 MS 
Physical activity CSD PROX RT ICA (mm) -0.04 0.85 -0.07 0.73 24 MS 
Physical activity PROX ECA RT PSV (cm/s) 0.11 0.6 0.18 0.41 24 MS 
Physical activity CSD PROX RT ECA (mm) -0.27 0.2 -0.31 0.15 24 MS 
Physical activity RT VA PSV (cm/s) 0.37 0.08 0.38 0.07 24 MS 
Physical activity RT VA EDV (cm/s) 0.44 0.03 0.41 0.05 24 MS 
Physical activity CSD PROX RT VA (mm) 0.24 0.26 0.18 0.39 24 MS 
Physical activity RT PSV ICA/CCA ratio -0.19 0.37 -0.16 0.45 24 MS 
Physical activity RT EDV ICA/ECA ratio -0.03 0.91 0.02 0.94 24 MS 
Physical activity LT CCA IMT (mm) -0.31 0.14 -0.28 0.18 24 MS 
Physical activity LT CCA PSV (cm/s) 0.1 0.66 0.06 0.78 24 MS 
Physical activity LT CCA EDV (cm/s) 0.35 0.09 0.37 0.08 24 MS 
Physical activity CSD PROX LT CCA (mm) -0.04 0.85 -0.09 0.69 24 MS 
Physical activity CSD MID LT CCA (mm) -0.2 0.34 -0.21 0.32 24 MS 
Physical activity CSD DIST LT CCA (mm) -0.2 0.35 -0.18 0.4 24 MS 
Physical activity LT ICA PSV (cm/s) 0.46 0.02 0.44 0.03 24 MS 
Physical activity LT ICA EDV (cm/s) 0.5 0.01 0.43 0.04 24 MS 
Physical activity CSD PROX LT ICA (mm) -0.19 0.37 -0.32 0.13 24 MS 
Physical activity PROX LT ECA PSV (cm/s) 0.18 0.41 0.25 0.24 24 MS 
Physical activity CSD PROX LT ECA (mm) -0.1 0.66 -0.19 0.37 24 MS 
Physical activity LT VA PSV (cm/s) 0.33 0.11 0.34 0.1 24 MS 
Physical activity LT VA EDV (cm/s) 0.33 0.12 0.28 0.19 24 MS 
Physical activity CSD PROX LT VA (mm) -0.24 0.25 -0.19 0.37 24 MS 
Physical activity LT PSV ICA/CCA ratio 0.34 0.1 0.34 0.1 24 MS 
Physical activity LT EDV ICA/ECA ratio 0.31 0.14 0.32 0.13 24 MS 
Physical activity PV PROX RT IJV (cm/s) 0.21 0.32 0.16 0.46 24 MS 
Physical activity PV MID RT IJV (cm/s) 0.33 0.12 0.3 0.16 24 MS 
Physical activity PV DIST RT IJV (cm/s) 0.39 0.06 0.38 0.07 24 MS 
Physical activity CSA PROX RT IJV (mm2) 0.25 0.23 0.16 0.45 24 MS 
Physical activity PV PROX LT IJV (cm/s) 0.04 0.85 0.11 0.62 24 MS 
Physical activity PV MID LT IJV (cm/s) 0.24 0.27 0.21 0.32 24 MS 
Physical activity PV DIST LT IJV (cm/s) 0.07 0.75 0.07 0.76 24 MS 
Physical activity CSA PROX LT IJV (mm2) -0.2 0.34 -0.05 0.82 24 MS 
 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic velocity; 
PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, external carotid 
artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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Table 4.45: Correlation between physical activity and the extracranial vascular ultrasound 
variables in the control group 
Lifestyle 
parameter Ultrasound variable 
Pearson Spearman # 
cases group r p r p 
Physical activity RT CCA IMT (mm) -0.19 0.37 -0.08 0.69 25 CONTROL 
Physical activity RT CCA PSV (cm/s) 0.21 0.31 0.23 0.27 25 CONTROL 
Physical activity RT CCA EDV (cm/s) 0.28 0.18 0.26 0.21 25 CONTROL 
Physical activity CSD PROX RT CCA (mm) -0.22 0.3 -0.23 0.27 25 CONTROL 
Physical activity CSD MID RT CCA (mm) -0.14 0.49 -0.12 0.57 25 CONTROL 
Physical activity CSD DIST RT CCA (mm) 0.01 0.96 -0.04 0.84 25 CONTROL 
Physical activity RT ICA PSV (cm/s) -0.09 0.66 -0.05 0.8 25 CONTROL 
Physical activity RT ICA EDV (cm/s) 0.13 0.53 0.08 0.72 25 CONTROL 
Physical activity CSD PROX RT ICA (mm) -0.09 0.67 -0.11 0.59 25 CONTROL 
Physical activity PROX ECA RT PSV (cm/s) 0.13 0.53 0.17 0.43 25 CONTROL 
Physical activity CSD PROX RT ECA (mm) 0.2 0.35 0.2 0.35 25 CONTROL 
Physical activity RT VA PSV (cm/s) 0.18 0.38 0.21 0.3 25 CONTROL 
Physical activity RT VA EDV (cm/s) 0.28 0.18 0.29 0.16 25 CONTROL 
Physical activity CSD PROX RT VA (mm) 0.07 0.74 0.06 0.77 25 CONTROL 
Physical activity RT PSV ICA/CCA ratio -0.3 0.14 -0.29 0.17 25 CONTROL 
Physical activity RT EDV ICA/ECA ratio -0.16 0.46 -0.12 0.58 25 CONTROL 
Physical activity LT CCA IMT (mm) -0.12 0.56 -0.08 0.7 25 CONTROL 
Physical activity LT CCA PSV (cm/s) 0.04 0.84 0.02 0.94 25 CONTROL 
Physical activity LT CCA EDV (cm/s) 0.02 0.91 0.04 0.85 25 CONTROL 
Physical activity CSD PROX LT CCA (mm) -0.27 0.19 -0.26 0.22 25 CONTROL 
Physical activity CSD MID LT CCA (mm) -0.19 0.36 -0.25 0.24 25 CONTROL 
Physical activity CSD DIST LT CCA (mm) -0.03 0.9 -0.03 0.9 25 CONTROL 
Physical activity LT ICA PSV (cm/s) -0.07 0.75 0.02 0.92 25 CONTROL 
Physical activity LT ICA EDV (cm/s) -0.01 0.96 0.12 0.56 25 CONTROL 
Physical activity CSD PROX LT ICA (mm) 0 0.98 0.01 0.97 25 CONTROL 
Physical activity PROX LT ECA PSV (cm/s) 0.01 0.96 0.07 0.73 25 CONTROL 
Physical activity CSD PROX LT ECA (mm) -0.29 0.16 -0.31 0.13 25 CONTROL 
Physical activity LT VA PSV (cm/s) 0.12 0.58 0.12 0.56 25 CONTROL 
Physical activity LT VA EDV (cm/s) 0.09 0.67 0.06 0.77 25 CONTROL 
Physical activity CSD PROX LT VA (mm) 0.19 0.36 0.26 0.21 25 CONTROL 
Physical activity LT PSV ICA/CCA ratio -0.09 0.68 -0.07 0.74 25 CONTROL 
Physical activity LT EDV ICA/ECA ratio -0.1 0.63 -0.02 0.92 25 CONTROL 
Physical activity PV PROX RT IJV (cm/s) 0.09 0.66 0.08 0.72 25 CONTROL 
Physical activity PV MID RT IJV (cm/s) 0.25 0.23 0.2 0.33 25 CONTROL 
Physical activity PV DIST RT IJV (cm/s) 0.16 0.43 0.08 0.7 25 CONTROL 
Physical activity CSA PROX RT IJV (mm2) -0.3 0.14 -0.29 0.16 25 CONTROL 
Physical activity PV PROX LT IJV (cm/s) -0.28 0.18 -0.11 0.61 25 CONTROL 
Physical activity PV MID LT IJV (cm/s) 0.22 0.28 0.19 0.36 25 CONTROL 
Physical activity PV DIST LT IJV (cm/s) 0.26 0.2 0.24 0.25 25 CONTROL 
Physical activity CSA PROX LT IJV (mm2) -0.13 0.54 -0.05 0.83 25 CONTROL 
 
 
 
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic velocity; 
PV, peak velocity; CSD, cross-sectional diameter; PROX, proximal; DIST, distal; ICA, internal carotid artery; ECA, external carotid 
artery; VA, vertebral artery; CSA, cross-sectional area; IJV, internal jugular vein 
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4.5.6 Association between passive smoking and the extracranial vascular ultrasound 
variables  
 
MS group:The smoking status results were available for 24 MS participants. 
 
In total, 10 out of 24 (42%)  MS participants were passive smokers and 14 (58%) non-smokers. 
In this analysis,  a significant difference (Mann-Whitney U test p-value 0.03)  in the EDV  of the 
rigth ICA was found between passive smokers (31.20 ± 9.21)  and non-smokers (36.35 ± 9.26) 
(Figure 4.3).  Additionally,passive smokers displayed a significnatly larger CSA of the proximal 
left IJV (138 ± 74.17)  in comparison to non-smokers (72.14 ± 22.4) (Mann-Whitney U test p-
value <0.01)  (Figure 4.4). 
 
 Mann-Whitney U p=0.03
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Figure 4.11: Significant difference in the EDV of the RT ICA in passive smokers and non-smokers 
in the MS group 
RT, right, ICA, internal carotid artery; EDV, end-diastolic velocity; Passive smoking (no): mean EDV of the RT ICA = 36.35 ± 
9.26; Passive smoking (yes): mean EDV of the RT ICA= 31.20 ± 9.21 
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Figure 4.4: Significant difference in the CSA of the proximal left IJV in passive smokers and 
non-smokers in the MS group 
 
 
Control group: The smoking status results were available for 25 controls. 
 
Ten (10) out of the 25 (40%) controls were passive smokers and 15 (60%) non-smokers. 
A significant difference (Mann-Whitney U test p-value 0.02) was found between the PSV of the 
left ICA in passive smokers and non-smokers. The peak systolic blood flow velocity in the left 
ICA was lower in passive smokers (85.49, 76.82-94.16) in comparison to non-smokers (96.12, 
89.04-103.20) (Figure 4.5). 
Similarly, the cross-sectional area of the proximal left IJV in passive smokers (185, 124.34-
245.66) were significantly larger (Pearson p-value 0.04) in comparison to non-smokers 
(101.73, 52.21-151.26) (Figure 4.6). 
CSA, cross-sectional area; PROX, proximal; LT, left; IJV, internal jugular vein; Passive smoking (no), mean CSA of the PROX 
LT IJV =72.14 ± 22.4; Passive smoking (yes), mean CSA of the PROX LT IJV=138 ± 74.17. 
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Figure 4.5: Significant difference between the PSV of left ICA in passive smokers and non-
smokers in the control group 
 
 
LT, left; ICA, internal carotid artery; PSV, peak systolic velocity; Passive smoking (no), mean CSA of the PROX LT ICA = 101.73 
(52.21-151.26); Passive smoking (yes), mean CSA of the PROX LT ICA = 185 (124.34-245.66) 
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Current effect: F(1, 23)=4.8384, p=0.04
Vertical bars denote 0.95 confidence intervals
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Figure 4.6: Significant difference in the CSA of the proximal left IJV in passive smokers and 
non-smokers in the control  group 
 
 
4.5.7 Association between alcohol intake and the extracranial vascular ultrasound 
variables 
 
Alcohol intake was categorised into scores 0, 1, 2 and 3 (0=abstain, 1= 1-2 units /week, 2= 3-
13 units/week and 3= 14-21 units/week). 
 
MS group: The alcohol intake status was available for 24 MS participants. A significant 
difference (Kruskal-Wallis test p-value 0.02) in the PSV of the RT CCA was found between MS 
person consuming alcohol and those abstaining. The peak systolic blood flow velocity was 
higher in MS persons with an alcohol intake score of 1 (n=12; 97.41 ± 15.19) and 2 (n=6; 
104.30 ± 13.80) in comparison to those with a score of 0 (n=6; 83.38 ± 9.55) (Figure 4.7). 
 
CSA, cross-sectional area; PROX, proximal; LT, left; IJV, internal jugular vein; Passive smoking (no): mean CSA PROX LT 
IJV = 101.73 (2.21-151.26); Passive smoking (yes): mean CSA PROX LT IJV = 185, (124.34-245.66) 
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Current effect: F(2, 21)=3.6935, p=0.04 Kruskal-Wallis p=0.02
Vertical bars denote 0.95 confidence intervals
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Figure 4.7: Significant difference in the PSV of the RT CCA in MS persons consuming alcohol in 
comparison to MS persons abstaining from alcohol 
 
 
RT, right; CCA, common carotid artery; PSV, peak systolic velocity; 0=abstain; 1= 1-2 units /week; 2= 3-13 units/week; 3= 14-21 
units/week; score 0=83.38 ± 9.55; score 1=97.41 ± 15.19; score 2=104.30 ± 13.80 
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Current effect: F(2, 21)=5.1448, p=0.02 Kruskal-Wallis p=0.02
Vertical bars denote 0.95 confidence intervals
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Figure 4.8: Significant difference in the RT CCA EDV in MS persons who consumed alcohol in 
comparison to MS persons abstaining 
 
 
The end-diastolic blood flow velocity in the right CCA and right VA was found to be significantly 
higher (Kruskal-Wallis test p-value 0.02) in MS persons who consumed alcohol in comparison 
to those who abstained. 
The mean end-diastolic blood flow velocity in the right CCA in MS persons with score 1 = 29.67 
± 4.63, score 2 = 32.30 ± 7.11 and score 0= 22.68 ± 5.20 (Figure 4.8). 
Figure 4.9 shows that the end-diastolic blood flow velocity was significantly higher (Kruskal-
Wallis p-value 0.02) in MS persons consuming alcohol than MS person abstaining from 
alcohol. The mean end-diastolic velocity of the RT VA in persons with score 0 = 11.7± 1.99; 
score 1= 20.36 ± 6.44 and score 2= 18.53 ± 5.24. 
 
 
 
RT, right; CCA, common carotid artery EDV, end-diastolic velocity; sore 0=22.68 ± 5.20; score 1=29.67 ± 4.63; score 2=32.30 ± 
7.11 
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Current effect: F(2, 21)=5.2255, p=0.01 Kruskal-Wallis p=0.02
Vertical bars denote 0.95 confidence intervals
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Figure 4.9: Significant difference in the EDV of the RT VERT artery in MS persons consuming 
alcohol compared to MS persons abstaining 
 
 
 
Control group:  The alcohol intake results were available for 23 controls where 12 controls 
had a score of 0 and 11 controls had a score of 1. The cross-sectional diameter of the proximal 
right VA in controls was significantly higher (Mann-Whitney U test p-value 0.02) in controls with 
a score of 1 (3.81 ± 0.53) compared to controls with a score of 0 (3.30 ±0.41) (Figure 4.10). 
Additionally, the end-diastolic velocity of LT ICA was significantly higher (Mann-Whitney U test 
p-value 0.01) in controls with a score of 0 (38.76 ± 7.59) in comparison to controls with a score 
of 1 (30.69 ± 6.82) (Figure 4.11). 
 
 
score 0 = 11.7± 1.99; score 1= 20.36 ± 6.44 and score 2= 18.53 ± 5.24. 
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Current effect: F(1, 21)=6.7104, p=0.02 Mann-Whitney U p=0.02
Vertical bars denote 0.95 confidence intervals
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Figure 4.10: Significant difference in the CSD of the proximal RT VA in controls consuming 
alcohol compared to controls abstaining 
 
 
 
CSD, cross-sectional diameter; PROX, proximal; RT, right; VA, vertebral artery; score 0=3.30 ±0.41; score 1=3.81 ± 
0.53 
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Current effect: F(1, 21)=7.1388, p=0.01 Mann-Whitney U p=0.01
Vertical bars denote 0.95 confidence intervals
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Figure 4.11: Significant difference in the EDV of the LT ICA in controls consuming alcohol and 
controls abstaining 
 
 
 
4.6 ASSOCIATION BETWEEN DISABILITY AND THE GREY-SCALE, COLOUR AND 
SPECTRAL DOPPLER ANALYSIS OF THE CAs AND IJVs IN THE ACTIVE MS COHORT 
Expanded disability status scale (EDSS) scores were available for 23 MS participants. Table 
4.46 summarises the correlations between EDSS and the extracranial vascular ultrasound 
variables.   
 
Significant positive correlations were found between EDSS and the following ultrasound 
variables: 
 
 RT CCA IMT (mm); Pearson p-value <0.01 (Figure 4.12) 
 
LT, left; ICA, internal carotid artery; EDV, end-diastolic velocity; score 0=38.76 ± 7.59; score 1=30.69 ± 6.82. 
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  EDSS:RT CCA IMT (mm):   r = 0.5419, p = 0.0076
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Figure 4.12: Significant positive association between disability and the RT CCA IMT  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RT, right; CCA, common carotid artery; IMT, intima media thickness; EDSS, expanded disability status scale 
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 CSD MID RT CCA (mm); Pearson p-value <0.01, Spearman p-value 0.01 (Figure 
4.13) 
  EDSS:CSD MID RT CCA (mm):   r = 0.7084, p = 0.0002
 Spearman r = 0.55 p=0.01
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Figure 4.13: Significant positive association between disability and the CSD of the mid RT CCA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CSD, cross-sectional diameter; CCA; RT, right; CCA, common carotid artery 
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 CSD DIST RT CCA (mm); Pearson p-value <0.01, Spearman p-value 0.01 (Figure 
4.14) 
  EDSS:CSD DIST RT CCA (mm):   r = 0.6461, p = 0.0009
 Spearman r = 0.50 p=0.01
0 1 2 3 4 5 6 7 8 9
EDSS
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
C
S
D
 D
IS
T
 R
T
 C
C
A
 (
m
m
)
 
Figure 4.14: Significant positive association between the CSD of the distal RT CCA and disability 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CSD, cross-sectional diameter; DIST, distal; RT, right; CCA, common carotid artery 
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 LT CCA IMT (mm); Pearson p-value 0.04 (Figure 4.15). 
  EDSS:LT CCA IMT (mm):   r = 0.4236, p = 0.0440
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Figure 4.15: Significant positive association between disability and the left CCA IMT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LT, left; CCA, common carotid artery; IMT, intima media thickness; EDSS, expanded disability status scale 
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 CSD MID LT CCA (mm); Pearson p-value <0.01, Spearman p-value 0.01 (Figure 
4.16). 
  EDSS:CSD MID LT CCA (mm):   r = 0.5530, p = 0.0062
 Spearman r = 0.54 p=0.01
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Figure 4.16: Significant positive association between disability and the CSD of the MID LT CCA 
 
 
Similarly, significant negative associations were found between EDSS and the following 
ultrasound variables: 
 RT CCA PSV (cm/s); Pearson p-value 0.02, Spearman p-value 0.01 (Figure 4.17) 
 RT CCA EDV (cm/s); Pearson p-value 0.02 (Figure 4.18) 
 RT ICA EDV (cm/s); Pearson p-value 0.04 (Figure 4.19) 
 RT VERT A PSV (cm/s); Pearson p-value 0.04 (Figure 4.20) 
 LT CCA EDV (cm/s); Pearson p-value 0.01 (Figure 4.21) 
 LT ICA EDV (cm/s); Pearson p-value 0.01 (Figure 4.22) 
 
 
 
 
 
CSD, cross-sectional diameter; LT, left; CCA, common carotid artery; EDSS, expanded disability status scale 
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  EDSS:RT CCA PSV (cm/s):   r = -0.4752, p = 0.0219
 Spearman r = -0.52 p=0.01
0 1 2 3 4 5 6 7 8 9
EDSS
60
70
80
90
100
110
120
130
R
T
 C
C
A
 P
S
V
 (
c
m
/s
)
 
Figure 4.17: Significant negative association between disability and the PSV of the RT CCA 
 
RT, right; CCA, common carotid artery; PSV, peak systolic velocity; EDSS, expanded disability status scale 
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  EDSS:RT CCA EDV (cm/s):   r = -0.4976, p = 0.0157
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 Figure 4.18: Significant negative association between disability and the EDV of the RT CCA 
 
 
 
RT, right; CCA, common carotid artery; EDV, end-diastolic; EDSS, expanded disability status scale 
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  EDSS:RT ICA EDV (cm/s):   r = -0.4307, p = 0.0402
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Figure 4.19: Significant negative association between disability and the EDV of the RT ICA 
 
 
RT, right; ICA, internal carotid artery; EDV, end-diastolic velocity; EDSS, expanded disability status scale 
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  EDSS:RT VERT A PSV (cm/s):   r = -0.4323, p = 0.0394
 Spearman r = -0.31 p=0.15
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Figure 4.20: Significant negative association between disability and the PSV of the right vertebral 
artery 
 
 
RT, right; VA, vertebral artery; PSV, peak systolic velocity; EDSS, expanded disability status scale 
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  EDSS:LT CCA EDV (cm/s):   r = -0.5117, p = 0.0126
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Figure 4.21: significant negative association between disability and the EDV of the left CCA 
LT, left; CCA, common carotid artery; EDV, end-diastolic velocity; EDSS, expanded disability status 
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  EDSS:LT ICA EDV (cm/s):   r = -0.5057, p = 0.0138
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Figure 4.22: Significant negative association between disability and the EDV of the LT ICA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LT, left; ICA, internal carotid artery; EDV, end-diastolic velocity; EDSS, expanded disability status scale. 
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Table 4.46: Correlation between disability and the extracranial vascular ultrasound                       
variables in the MS group 
Disability 
parameter Ultrasound variable 
Pearson Spearman # 
cases r p r p 
EDSS RT CCA IMT (mm) 0.54 <0.01 0.39 0.07 23 
EDSS RT CCA PSV (cm/s) -0.48 0.02 -0.52 0.01 23 
EDSS RT CCA EDV (cm/s) -0.5 0.02 -0.36 0.09 23 
EDSS CSD PROX RT CCA (mm) 0.3 0.16 0.08 0.72 23 
EDSS CSD MID RT CCA (mm) 0.71 <0.01 0.55 <0.01 23 
EDSS CSD DIST RT CCA (mm) 0.65 <0.01 0.5 0.01 23 
EDSS RT ICA PSV (cm/s) -0.14 0.53 0.07 0.73 23 
EDSS RT ICA EDV (cm/s) -0.43 0.04 -0.3 0.17 23 
EDSS CSD PROX RT ICA (mm) 0.25 0.25 0.27 0.22 23 
EDSS PROX ECA RT PSV (cm/s) 0.14 0.51 0.11 0.63 23 
EDSS CSD PROX RT ECA (mm) -0.01 0.95 0.16 0.48 23 
EDSS RT VA PSV (cm/s) -0.43 0.04 -0.31 0.15 23 
EDSS RT VA EDV (cm/s) -0.4 0.06 -0.35 0.1 23 
EDSS CSD PROX RT VA (mm) -0.02 0.93 -0.1 0.65 23 
EDSS RT PSV ICA/CCA ratio 0.23 0.28 0.36 0.09 23 
EDSS RT EDV ICA/ECA ratio 0.04 0.84 0.06 0.79 23 
EDSS LT CCA IMT (mm) 0.42 0.04 0.4 0.06 23 
EDSS LT CCA PSV (cm/s) -0.37 0.08 -0.32 0.14 23 
EDSS LT CCA EDV (cm/s) -0.51 0.01 -0.32 0.14 23 
EDSS CSD PROX LT CCA (mm) 0.31 0.14 0.2 0.35 23 
EDSS CSD MID LT CCA (mm) 0.55 <0.01 0.54 <0.01 23 
EDSS CSD DIST LT CCA (mm) 0.34 0.11 0.29 0.19 23 
EDSS LT ICA PSV (cm/s) -0.26 0.22 -0.38 0.07 23 
EDSS LT ICA EDV (cm/s) -0.51 0.01 -0.26 0.23 23 
EDSS CSD PROX LT ICA (mm) 0.11 0.62 0.25 0.25 23 
EDSS PROX LT ECA PSV (cm/s) 0.21 0.34 -0.02 0.92 23 
EDSS CSD PROX LT ECA (mm) 0.21 0.33 0.22 0.32 23 
EDSS LT VA PSV (cm/s) -0.25 0.25 -0.21 0.34 23 
EDSS LT VA EDV (cm/s) -0.24 0.27 -0.1 0.65 23 
EDSS CSD PROX LT VA (mm) -0.06 0.8 -0.13 0.56 23 
EDSS LT PSV ICA/CCA ratio -0.02 0.94 -0.05 0.82 23 
EDSS LT EDV ICA/ECA ratio -0.22 0.32 -0.12 0.57 23 
EDSS PV PROX RT IJV (cm/s) 0.09 0.69 0.18 0.4 23 
EDSS PV MID RT IJV (cm/s) -0.12 0.6 -0.04 0.87 23 
EDSS PV DIST RT IJV (cm/s) 0.01 0.95 0.13 0.56 23 
EDSS CSA PROX RT IJV (mm2) -0.36 0.09 -0.24 0.28 23 
EDSS PV PROX LT IJV (cm/s) 0.03 0.89 0.04 0.87 23 
EDSS PV MID LT IJV (cm/s) -0.26 0.23 -0.2 0.36 23 
EDSS PV DIST LT IJV (cm/s) 0.28 0.2 0.09 0.67 23 
EDSS CSA PROX LT IJV (mm2) -0.05 0.81 -0.12 0.6 23 
 
 
EDSS, expanded disability status scale; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; 
PSV, peak systolic velocity; EDV, end-diastolic velocity; PV, peak velocity; CSD, cross-sectional diameter; PROX, 
proximal; DIST, distal; ICA, internal carotid artery; ECA, external carotid artery; VA, vertebral artery; CSA, cross-
sectional area; IJV, internal jugular vein 
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4.7 MATCH-MERGED DATA 
The current case-control study data (Study B) and data of a previous study entitled: Ultrasound 
investigation of risk factors for extracranial vascular pathology in patients with multiple 
sclerosis (Study A), were matched and merged. The matching genetic, lifestyle, biochemical 
and ultrasound variables including disability status of the cohort of 23 MS participants for study 
A (excluding males) and 25 MS participants on study B, were merged and analysed. The 
merging of the study data created a larger cohort of MS participants (n=48) which improved 
the statistical power and correlations between the multiple variables. 
 
4.7.1 ASSOCIATION BETWEEN BIOCHEMICAL PARAMETERS AND THE 
EXTRACRANIAL VASCULAR ULTRASOUND VARIABLES IN THE MERGED MS GROUP 
 
Biochemical parameters were not available for all 48 MS participants in the merged group. 
                      
Table 4.47 shows the statistically significant correlations found between the following match-
merged biochemical parameters and the extracranial ultrasound variables: 
 Iron - positively correlated with the 
o EDV of the right ICA (Pearson p-value 0.01),  
o RT PSV ICA/CCA ratio (Pearson p-value 0.01, Spearman p-value 0.01)  
o RT EDV ICA/CCA ratio (Pearson p-value <0.01, Spearman p-value 0.04) 
 
 Transferrin – positively correlated with the 
o RT CCA PSV (Spearman p-value <0.01) 
o RT PSV ICA/CCA ratio (Spearman p-value <0.01)  
o LT CCA PSV (Pearson p-value 0.03) 
 
 % saturated transferrin – positively correlated with the  
o RT CCA PSV (Spearman p-value 0.04) 
o RT ICA EDV (Pearson p-value <0.01) 
o RT PSV ICA/CCA ratio (Pearson p-value <0.01, Spearman p-value <0.01) 
o RT EDV ICA/CCA ratio (Pearson p-value <0.01, Spearman p-value <0.01) 
 
 Ferritin – positively correlated with the LT ICA PSV (Spearman p-value 0.04) 
 
 25 OH-Vitamin D – positively correlated with the  
o PSV of the LT CCA  (Spearman p-value 0.02) 
o EDV of the RT ICA  (Pearson p-value 0.04) 
o PSV of the RT CCA  (Pearson p-value 0.02, Spearman p-value <0.01) 
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o PSV of the LT VA (Pearson p-value 0.02, Spearman p-value <0.01) 
 Homocysteine – positively correlated with the 
o RT PSV ICA/CCA ratio (Pearson p-value 0.03, Spearman p-value 0.02) 
o PSV of the RT CCA (Pearson p-value <0.01, Spearman p-value <0.01) 
 
 Serum folate – positively correlated with the PSV of the right VA (Pearson p-value 0.02, 
Spearman p-value 0.03) 
 
 Vitamin B12 – negatively correlated with the PSV of the left VA (Pearson p-value <0.01) 
 
 Total cholesterol – negatively correlated with the  
o PSV of the LT CCA (Spearman p-value 0.03) 
o EDV of the LT CCA (Pearson p-value 0.02, Spearman p-value <0.01) 
o PSV of the LT VA (Pearson p-value <0.01, Spearman p-value <0.01) 
 
  HDL – negatively correlated with left CCA IMT (Spearman p-value 0.03) 
 
 Triglycerides – negatively correlated with the PSV of the left CCA (Spearman p-value 
0.04) 
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Table 4.47: Significant correlations between the biochemical parameters and the extracranial 
vascular ultrasound variables in the match-merged MS group (Study A and B) 
Biochemical 
maker 
Ultrasound 
variable 
Pearson Spearman # 
cases 
Merged  
group r p r p 
S-iron  RT ICA EDV (cm/s) 0.41 0.01 0.27 0.1 38 MS 
S-iron  RT PSV ICA/CCA ratio 0.39 0.01 0.41 0.01 38 MS 
S-iron  RT EDV ICA/ECA ratio 0.46 <0.01 0.33 0.04 38 MS 
S-transf  RT CCA PSV (cm/s) 0.2 0.24 0.43 <0.01 38 MS 
S-transf  RT PSV ICA/CCA ratio 0.04 0.81 -0.44 <0.01 38 MS 
S-transf  LT CCA PSV (cm/s) 0.35 0.03 0.25 0.12 38 MS 
% Tf sat RT CCA PSV (cm/s) -0.32 0.05 -0.33 0.04 38 MS 
 
% Tf sat RT ICA EDV (cm/s) 0.42 <0.01 0.32 0.05 38 MS 
% Tf sat RT PSV ICA/CCA ratio 0.53 <0.01 0.56 <0.01 38 MS 
% Tf sat RT EDV ICA/CCA ratio 0.48 <0.01 0.43 <0.01 38 MS 
Ferritin LT ICA PSV (cm/s) 0.17 0.31 0.34 0.04 38 MS 
25 OH-Vit D LT CCA PSV (cm/s) 0.24 0.18 0.39 0.02 34 MS 
25 OH-Vit D RT ICA EDV (cm/s) 0.36 0.04 0.3 0.09 34 MS 
25 OH-Vit D RT CCA PSV (cm/s) 0.4 0.02 0.44 <0.01 34 MS 
25 OH-Vit D LT VA PSV (cm/s) 0.4 0.02 0.47 <0.01 34 MS 
H-cyst RT PSV ICA/CCA ratio 0.36 0.03 0.38 0.02 38 MS 
H-cyst RT CCA PSV (cm/s) -0.49 <0.01 -0.45 <0.01 38 MS 
S-fol RT VA PSV (cm/s) 0.38 0.02 0.36 0.03 38 MS 
Vit B12 LT VA PSV (cm/s) -0.41 <0.01 -0.22 0.19 38 MS 
Total cholesterol LT CCA PSV (cm/s) -0.26 0.11 -0.34 0.03 39 MS 
Total cholesterol LT CCA EDV (cm/s) -0.37 0.02 -0.42 <0.01 39 MS 
Total cholesterol LT VA PSV (cm/s) -0.44 <0.01 -0.47 <0.01 39 MS 
HDL LT CCA IMT (mm) -0.31 0.12 -0.43 0.03 26 MS 
Trigs LT CCA PSV (cm/s) -0.32 0.11 -0.41 0.04 26 MS 
 
 
 
 
 
 
 
4.7.2 ASSOCIATION BETWEEN LIFESTYLE FACTORS AND THE EXTRACRANIAL 
VASCULAR ULTRASOUND VARIABLES IN THE MERGED MS GROUP 
 
4.7.2.1 Saturated fat, chicken with skin and physical activity 
Statistically significant correlations (p-value <0.05) are summarised in Table 4.48. Physical 
activity is found to be strongly correlated with multiple carotid artery ultrasound variables. A 
statistically negative association exists between physical activity and the IMT of the left CCA 
(Pearson p-value 0.03, Spearman p-value 0.04) as well as a significant positive correlation 
with the carotid artery blood flow velocities. Similarly, a significant positive correlation is found 
between saturated fat and the IMT of the right CCA; and consumption of chicken with carotid 
artery blood flow velocity (Table 4.48). 
S-iron, serum iron; S-transf, serum transferrin; % Tf sat, percentage transferrin saturation; 25-OH VIt D, serum 25-hydroxyvitamin 
D ; H-cyst, homocysteine; S-fol, serum  folate; HDL, high-density lipoprotein; Trigs, triglycerides; RT, right; LT, left; CCA, common 
carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic velocity; PROX, proximal;; ICA, internal 
carotid artery; ECA, external carotid artery; VA, vertebral artery  
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Table 4.48: Correlation between the lifestyle parameters and the extracranial vascular ultrasound 
variables in the merged MS group 
Lifestyle 
parameter Ultrasound variable 
Pearson Spearman # 
cases 
Merged 
group r p r p 
Saturated Fat RT CCA IMT (mm) 0.3 0.08 0.37 0.03 36 MS 
Chicken with 
skin PROX LT ECA PSV (cm/s) 0.38 0.02 0.24 0.16 35 MS 
Chicken with 
skin RT CCA EDV (cm/s) 0.39 0.02 0.37 0.03 35 MS 
Physical activity RT VA PSV (cm/s) 0.4 0.01 0.42 <0.01 37 MS 
Physical activity LT CCA IMT (mm) -0.35 0.03 -0.34 0.04 37 MS 
Physical activity LT ICA PSV (cm/s) 0.41 0.01 0.4 0.01 37 MS 
Physical activity LT ICA EDV (cm/s) 0.43 <0.01 0.38 0.02 37 MS 
Physical activity LT VA PSV (cm/s) 0.37 0.02 0.42 0.01 37 MS 
Physical activity LT PSV ICA/CCA ratio 0.37 0.02 0.39 0.02 37 MS 
Physical activity LT EDV ICA/ECA ratio 0.34 0.04 0.34 0.04 37 MS 
 
                  
                                                                                                                                                                 
 
4.7.2.2 Passive smoking 
The passive smoking status results were available for 25 MS participants in the merged group. 
No significant associations were found between passive smoking and the extracranial 
ultrasound variables. 
 
4.7.2.3 Alcohol intake 
Further analysis examined the association between alcohol intake and the extracranial 
vascular ultrasound variables.  Alcohol intake was categorised into scores 0, 1, 2 and 3 
(0=abstain, 1= 1-2 units /week, 2= 3-13 units/week and 3= 14-21 units/week). 
Figure 4.23 indicates that the IMT of the left CCA was significantly thinner (Kruskal-Wallis p-
value 0.02) in MS participants with an alcohol intake score of 1 (n=17; 0.55 ± 0.07) and 2 (n=8, 
0.56 ± 0.19) in comparison to those MS participants who abstained from alcohol (score 0) 
(n=12; 0.67 ± 0.18).  
 
 
RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; PSV, peak systolic velocity; EDV, end-diastolic 
velocity; PROX, proximal; ICA, internal carotid artery; ECA, external carotid artery; VA, vertebral artery  
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Current effect: F(2, 34)=3.9319, p=0.03 Kruskal-Wallis p=0.02
Vertical bars denote 0.95 confidence intervals
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Figure 4.23: Significant difference in IMT of the left CCA between MS persons consuming alcohol 
and those abstaining from alcohol 
 
 
 
A significant difference (Kruskal-Wallis p-value 0.02) was also found between the left EDV 
ICA/CCA ratio in MS participants with an alcohol intake score of 1 and 2 and MS participants 
who abstained (score 0).  The LT EDV ICA/CCA ratio was higher in MS participants with a 
score of 1 (n=17, 1.45 ± 0.34) and score of 2 (n=8, 1.31 ± 0.31) in comparison to those who 
had a score of 0 (n=12, 1.11 ± 0.25) (Figure 4.24). 
LT, left; CCA, common carotid artery; IMT, intima media thickness; 0=abstain; 1= 1-2 units /week; 2= 3-13 units/week; 3= 
14-21 units/week; 
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Alcohol Intake; LS Means
Current effect: F(2, 34)=4.4265, p=0.02 Kruskal-Wallis p=0.02
Vertical bars denote 0.95 confidence intervals
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Figure 4.24: Significant difference in the LT EDV ICA/CCA ratio between MS persons consuming 
alcohol and MS persons abstaining from alcohol. 
 
 
4.7.3 ASSOCIATION BETWEEN DISABILITY AND THE EXTRACRANIAL VASCULAR 
ULTRASOUND VARIABLES IN THE MERGED MS GROUP 
 
The disability status was available for 36 MS participants in the merged group. 
As seen in Table 4.49 and the scatter plot graphs (Figure 4.25 - 4.28) the EDDS had a 
significant positive association with IMT of the right CCA (Pearson p-value <0.01, Spearman 
p-value 0.03). 
Similarly, a significant negative association was found between EDSS and the following 
ultrasound variables: 
 EDV of the RT CCA (Pearson p-value 0.04) (Figure 4.25) 
 PSV of the right VA (Pearson p-value 0.02, Spearman p-value 0.03) (Figure 4.26) 
 EDV of the LT CCA (Pearson p-value 0.02) (Figure 4.27) 
 EDV of the LT ICA (Pearson p-value 0.01) (Figure 4.28) 
 
 
LT, left; EDV, end-diastolic velocity; ICA, internal carotid artery; CCA, common carotid artery.; 0= abstain from alcohol; 1 = 1-
2 units/week; 2 = 3-13 units/week. 
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Table 4.49. Significant correlation between disability and the extracranial vascular ultrasound 
variables in the merged MS group 
Disability 
parameter Ultrasound variable 
Pearson Spearman # 
cases 
Merged 
group r p r p 
EDSS RT CCA IMT (mm) 0.48 <0.01 0.37 0.03 36 
 
MS 
EDSS RT CCA EDV (cm/s) -0.35 0.04 -0.26 0.13 36 
 
MS 
EDSS RT VA PSV (cm/s) -0.4 0.02 -0.37 0.03 36 
 
MS 
EDSS LT CCA EDV (cm/s) -0.37 0.02 -0.23 0.17 36 
 
MS 
EDSS LT ICA EDV (cm/s) -0.41 0.01 -0.22 0.19 36 
 
MS 
 
 
 
 
 
  EDSS:RT CCA EDV (cm/s):   r = -0.3471, p = 0.0381
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Figure 4.25: Significant association between disability and the EDV of the right CCA in the 
merged MS group 
EDSS, expanded disability status scale; RT, right; LT, left; CCA, common carotid artery; IMT, intima media thickness; EDV, 
end-diastolic velocity; VA, vertebral artery; PSV, peak systolic velocity 
RT, right; CCA, common carotid artery; EDV, end-diastolic velocity; EDSS, expanded disability status scale 
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  EDSS:RT VERT A PSV (cm/s):   r = -0.3956, p = 0.0169
 Spearman r = -0.37 p=0.03
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Figure 4.26: Significant negative association between disability and the PSV of the right VA 
 
RT, right; VA, vertebral artery; PSV, peak systolic velocity; EDSS, expanded disability status scale 
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  EDSS:LT CCA EDV (cm/s):   r = -0.3744, p = 0.0245
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Figure 4.27: Significant negative association between disability and the EDV of the left CCA 
 
LT, left; CCA, common carotid artery; EDV, end-diastolic velocity; EDSS, expanded disability status scale 
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  EDSS:LT ICA EDV (cm/s):   r = -0.4130, p = 0.0123
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Figure 4.28: Significant negative association between disability and the EDV of the left ICA 
 
 
 
CONCLUSION 
The study data provided a magnitude of significant and non-significant results which will be 
discussed and described in chapter 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
LT, left; ICA, internal carotid artery; EDV, end-diastolic velocity; EDSS, expanded disability status scale 
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CHAPTER 5  
DISCUSSION 
 
INTRODUCTION 
Multiple sclerosis is described as a complex chronic inflammatory disease involving vascular, 
genetic, lifestyle and biochemical factors. This study demonstrated multiple significant 
associations between lifestyle, biochemical and disability parameters which unfold new 
hypotheses regarding the pathophysiological processes associated with MS. The discussion 
includes the associations in the match-merged cohort of MS participants (from Study A and 
Study B) and healthy controls. Study A is a previous ethically approved study titled: Ultrasound 
evaluation of the extracranial cerebrospinal venous system and carotid arteries in patients with 
multiple sclerosis; and study B is the current study titled: Ultrasound investigation of risk factors 
for extracranial vascular pathology in patients with multiple sclerosis (MS). 
 
5.1. Vascular ultrasound parameters in the cohort of MS participants and controls 
The internal jugular veins (IJVs) are the main venous drainage pathway for blood leaving the 
brain where venous outflow is more prominent in the supine position (Al-Omari & Rousan, 
2010). According to Bos et al. (2016) and Czyzewska et al. (2015) the cross-sectional area 
(CSA) of the right IJV is larger than the left IJV in healthy persons. Stenosis of the IJV, defined 
as a reduction in the CSA of the IJV, is on one of the multiple CCSVI criteria in MS patients 
(Zamboni et al., 2009a,  Zamboni et al., 2009b; Doepp et al., 2010). However this hypothesis 
of CCSVI and its association with MS has been disproved by Wattjes et al. (2011) and Gandhi 
et al. (2019) who state that CCSVI does not play a causative role in MS. In this study, one out 
of the 25 MS participants displayed a stenosis of the distal segment of the left IJV, however 
there was no evidence of significant venous reflux, valvular incompetence or septae. The 
patient therefore did not fulfil the criteria for CCSVI as this was an isolated finding. Pelizzari et 
al. (2018) conducted a 5 year longitudinal study aimed to investigate the evolution of the CSA 
of the major neck vessels in patients with MS and in healthy controls. Their findings indicated 
a significant consistent reduction of the IJV CSA with time, which may suggest that an 
association exists between IJV CSA and the disease course of MS. However, in this cross-
sectional study there was no significant reduction in the IJV CSA in MS participants (n=25) 
compared to healthy controls (n=25).  
According to Sethi et al. (2017), patients with MS exhibit reduced venous flow in the IJVs in 
comparison to healthy controls. On the contrary, in this study, peak velocity of the mid right IJV 
in the MS participants was significantly higher in comparison to the healthy controls (p=0.02, 
Figure 4.1, Table 4.4). There was no evidence of stenosis (reduced CSA) of the mid right IJV 
in the MS group which could cause the increased peak velocity. 
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5.2 Genetics and vascular ultrasound parameters 
 
In this study, a significant association was found between the cross-sectional diameter (CSD) 
of the external carotid artery and genetic parameter (HLA DRB1*1501 allele) (p=0.03, Table 
4.5). Although HLA DRB1*1501 has the strongest association with MS risk (Didonna & 
Oksenberg, 2015), no previous studies have been conducted to determine an association 
between genetics and carotid artery disease in MS. Therefore, this finding is novel and further 
research needs to be conducted to determine the effects of genetics on the extracranial 
vasculature in MS. 
 
5.3 Biochemistry and vascular ultrasound parameters 
Serum ferritin is described as a major iron storage protein and increased levels of ferritin are 
attributed to inflammation, infection and malignancy (Wang et al., 2010;  Knovich et al., 2009).  
Kell and  Pretorius (2014) confirm that serum ferritin is an inflammatory biomarker, which leaks 
from damaged cells and correlates with numerous inflammatory and degenerative diseases. 
Ma et al. (2015) conducted a study on serum ferritin levels and its association with carotid 
atherosclerosis in Chinese postmenopausal women and found that serum ferritin was 
independently associated with carotid atherosclerosis. The cIMT and prevalence of carotid 
plaque lesions were significantly increased in persons with increased levels of serum ferritin. 
These findings are further corroborated by Prats-Puig et al. (2016) who conducted a study to  
determine the association between circulating ferritin levels and carotid intima-media thickness 
(cIMT) in a cohort of healthy children and found a significant positive association between 
children’s serum ferritin levels and cIMT (r=0.123; P=0.001). This current study demonstrated 
a significant positive association between cIMT and ferritin (Pearson p-value 0.01; Table 4.15) 
in the control group, which is keeping with findings of previous studies of similar context. 
 
Folate is vital for neural tube development  during infancy and is involved in maintaining the 
normal function of the nervous system in all ages as it plays an important role in the conversion 
of homocysteine to methionine (Horvat et al., 2016, Reynolds, 2006). Homocysteine, proven 
to correlate with the severity of coronary artery disease (CAD) (Shenoy et al., 2014), is an 
independent risk factor for atherosclerosis which is the most common pathological process 
that leads to cardiovascular diseases (Ganguly & Alam, 2015). Carotid intima-media thickness, 
measured by high resolution ultrasound, is accepted as the non-invasive marker for subclinical 
atherosclerosis (Basu et al., 2014). Increased levels of folate can reduce homocysteine levels 
to the normal range (Liebman & Weitz, 2014) which in turn can reduce the risk of 
cardiovascular disease. In addition, Durga et al. (2005) postulate that low concentrations of 
folate, which play a pathogenic role in atherosclerosis, are significantly associated with cIMT.  
However, this study found a significant positive association (Spearman p-value 0.02) between 
serum folate and cIMT in the cohort of MS participants; contradicting the results of previous 
135 
 
studies which demonstrated that serum folate is negatively associated with cIMT. This leads 
to question (I) why the finding is contradictory and (II) is this finding only specific to MS. 
 
High-density lipoprotein (HDL), known  to facilitate cholesterol uptake, plays an 
atheroprotective role by inducing the regression of atherosclerotic cardiovascular disease 
(Klancic et al., 2016;  Fisher et al., 2012).  The mechanism by which HDL is antiatherogenic is 
through reverse cholesterol transport. Through this pathway excess cholesterol is transferred 
from peripheral tissues, including arterial wall macrophages, to the liver for excretion (Rader, 
2006; Tall, 2008). According to Stein (2004), risk factors for coronary artery disease (CAD) are 
the same as for cerebrovascular disease.  In the current study, HDL had a significant negative 
association (Spearman p-value 0.03) with cIMT in MS participants. As per Tettey and 
colleagues (2014), low high-density lipoprotein cholesterol (HDL-c) levels are associated with 
increased cIMT, whereas higher levels are associated with lower acute inflammatory activity 
and lower disability in MS. A study by Liuba et al. (2003), which investigated  whether acute 
infections in children could alter the carotid wall morphology and the lipid profile, demonstrated 
that acute infections in children appear to be complemented by enhanced oxidative 
modification of low-density lipoprotein (LDL) and a decrease in HDL-c. Carotid artery intima-
media thickening may result from these lipid changes. Similarly, Tiozzo et al. (2016), postulate 
that HDL2, a subfraction of HDL, is inversely associated with cIMT and may have a protective 
biological role against atherosclerosis. The findings of this study suggest that MS patients may 
be at increased risk of developing CVD.  
 
In this study, significant associations were also found between the right and left carotid artery 
peak and end-diastolic blood flow velocities and biochemical parameters. Total cholesterol 
was negatively associated with end-diastolic velocities of the left CCA and ICA in the MS group 
and the peak systolic velocity of the left vertebral artery in the control group. An increase in 
cholesterol signifies a reduction in blood flow in diastole within the vessels. Farhoudi et al. 
(2011) report that a higher cholesterol level (LDL,180 mg/dL), decreases mean blood flow 
velocity of the internal carotid artery. A reduction in blood flow velocity results in low shear 
stress which induces a reduction in the vessel diameter and intimal hyperplasia (Papaioanno 
& Stefanadis, 2005). Lowering total cholesterol levels will therefore improve blood flow in MS 
and prevent intimal hyperplasia associated with early atherosclerosis.  
 
Alíefendíoğlu and colleagues (2007) conducted a study to determine the effects on iron 
deficiency anaemia on cerebral blood flow in infants aged 6-36 months. Their findings showed 
a significant increase in cerebral blood flow velocities in children with low haemoglobin values. 
This may be due to increased cardiac output and decreased vascular resistance caused by 
anaemia. In this study, haemoglobin levels were negatively associated with the carotid artery 
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blood flow velocities in the MS cohort of participants (Table 4.16), where extracranial arterial 
blood flow was increased in MS participants with low haemoglobin values. This finding confirms 
the study findings of Alíefendíoğlu and colleagues (2007).  
 
 Iron deficiency and increased homocysteine levels in MS is associated with vascular damage 
(Van Rensburg et al., 2006). Serum iron levels in the MS group were positively associated with 
blood flow velocities in the right ICA and right ICA/ECA ratios, negatively associated with the 
peak systolic velocity of the right ECA and negatively associated with the peak systolic velocity 
of the right ECA in controls. The lack of literature on the association between blood flow 
velocities in the extracranial vascular systems and biochemical parameters in MS suggests 
that the significant associations found between carotid artery blood flow velocities and 
biochemical parameters in this study are novel and further prospective studies need to be 
undertaken to verify or contradict the current findings.  
 
In this study, a significant association was also found between the cross-sectional diameter 
(CSD) of the carotid arteries and biochemical parameters (s-iron, s-transferrin, LDL, 
triglycerides, %Tf saturation, s-folate, homocysteine, CRP, 25 OH-Vit D and HDL). There’s no 
evidence in literature which reports studies conducted on the assessment of the 
sonographically measured cross-sectional diameters of the carotid arteries in MS and its 
association with biochemical parameters. 
 
Furthermore, this study also indicated a significant association between the CSA of the IJVs 
and biochemical parameters [%Tf saturation (negative association); homocysteine (positive 
association); 25-OH Vitamin D (negative association); HDL (negative association)]. 
The IJVs are the dominant drainage pathway for the cerebrovenous system in the supine 
position. Arterial inflow from the  carotid arteries into the brain must equal venous outflow from 
the cranium (Mancini et al., 2014). In this study, significant associations were found between 
the peak velocities of the IJVs and biochemical parameters (s-iron, s-transferrin, %Tf 
saturation, ferritin, haemoglobin, vitamin B12, homocysteine, CRP, 25 OH-Vit D, HDL and 
triglycerides). The reason for the significance of these associations remains unanswered as 
literature on IJV blood flow velocity in MS and biochemistry has not been reported.  
 
There are numerous questions that emanate from these new findings, thus the clinical 
relevance of the findings of IJV CSA and its significant association with biochemical 
parameters in MS in this current study need to be investigated further. 
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5.4 Lifestyle factors and vascular ultrasound parameters 
There is evidence that intake of saturated fatty acids is associated with increased risk of 
coronary artery disease (Hu et al., 2001 Hooper et al., 2001). A significant positive association 
between cIMT and saturated fat (Spearman p-value <0.01) was found in the MS cohort of 
participants in the study conducted. 
Reducing dietary intake of saturated fat is recommended for reducing CVD risk based on the 
hypothesis that saturated fat is positively associated with low-density lipoprotein cholesterol 
(LDL-c) which plays a role in the development of atherosclerosis and coronary heart disease 
(Liu et al., 2017; Sacks et al., 2017). Greater consumption of dietary pulses and lower saturated 
fat is significantly associated with lower cIMT and cholesterol, thus reducing the risk of CVD 
(Chiavaroli et al., 2017). Similarly, Petersen et al. (2014) conducted a study to review the 
correlation and association between dietary components and cIMT. They found that saturated 
fat is positively associated with cIMT and a Mediterranean style dietary pattern (high in fruits, 
wholegrains, fibre, olive oil and low in saturated fat) may reduce carotid atherosclerosis 
development and progression. 
This current study also demonstrated a significant association between the CSD of the carotid 
arteries and lifestyle parameters (alcohol intake, consumption of chicken with skin and 
saturated fat). Lee et al. (2009) have shown that alcohol intake was significantly positively 
associated with the common carotid artery diameter in men and women. Significant 
associations were found between the right and left carotid artery peak and end-diastolic blood 
flow velocities and lifestyle parameters (intake of saturated fat, consumption of chicken with 
skin, fruit/vegetable/fibre intake, dietary folate, physical activity, passive smoking and alcohol 
intake). During physical exercise, cerebral blood flow increases, resulting in an increase in the 
blood flow velocity in the CCA, ICA and ECA (Sato et al., 2011). Similarly, in this study, a 
significant positive association was found between physical activity and peak and end-diastolic 
velocities in the right and left carotid arteries in MS participants. Hagg et al. (2005),  Fragoso  
(2014)  and Marck et al. (2016) postulate that physical exercise improves cardiac and vascular 
function by reducing cIMT and lowering the risk of CVD in MS. Participation in physical activity 
by MS patients may improve vascular function,  slow down disability progression and  improve 
quality of life in MS. 
 
Passive smoking increases the risk of cardiovascular disease by approximately 30% and the 
effects thereof are nearly as damaging as those from chronic active smoking (Barnoya & 
Glantz, 2005). This current study excluded smokers, however still demonstrated a significant 
negative association between passive smoking and blood flow velocity in the internal carotid 
arteries in the MS and control groups. The blood flow velocity in the major neck arteries was 
significantly reduced in passive smokers in comparison to non-smokers. Kim and Gornik 
(2014) postulate that smoking increases blood viscosity in a dose-dependent manner. This 
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means that an increase in blood viscosity causes a reduction in flow rate due an in increase in 
friction between the blood and vessel wall. This could explain the study finding of reduced 
blood flow in the internal carotid arteries in passive smokers. Cessation of passive smoking 
will therefore not only reduce blood viscosity and improve blood flow, but reduce the risk of 
CVD in MS. Regarding passive smoking and its positive association with IJV CSA in MS 
persons and healthy controls, it can be questioned whether the increase in IJV CSA can be 
due to an increase in the IJV pressure.  
 
A significant difference was found in carotid artery blood flow velocities between MS persons 
and healthy controls who drank alcohol and those who abstained from alcohol intake (MS 
persons; Kruskal-Wallis p-value 0.02 and controls; Mann-Whitney U test p-value 0.01). The 
blood flow velocities (cm/s) in the right CCA, right VA and left ICA were significantly higher in 
persons drinking alcohol (1-13 units/week) in comparison to those abstaining. According to 
Schminke et al., (2005) alcohol intake shows a protective effect against atherosclerosis. 
Gundersen et al., (2013) postulate that the vasoactive properties of social alcohol intake are 
dose dependent, suggesting that low doses of alcohol intake increases cerebral blood flow, 
which is congruent with the current study findings. Furthermore, long-term alcohol 
consumption results in cerebral hypoperfusion (Gundersen et al., 2013). 
 
It can thus be concluded that modification of lifestyle and dietary habits, involving increased 
consumption of polyunsaturated fats and reduced consumption of saturated fats, may reduce 
the risk of CVD in persons with MS. 
 
 
5.5 Disability and vascular ultrasound parameters 
 
Multiple sclerosis (MS) is the most common cause of neurological disability in young adults 
(Kingwell et al., 2013; Marck et al., 2017). The primary purpose of early treatment in MS is to 
reduce neurological disability and slow down disease progression (Jokubaitis et al., 2015). 
The disability status of MS persons is assessed using the Expanded Disability Status Scale 
(EDSS) (Kurtzke, 1983). This scale quantifies disability in MS patients according to their signs 
and symptoms observed during a neurological assessment (Madras, 2014). 
The associations between MS disability and carotid artery atherosclerosis is currently under-
investigated, therefore literature on associations between cIMT and EDSS remains limited. 
Talaat and colleagues (2015) investigated possible carotid artery changes and arterial stiffness 
in MS patients where the EDSS, pulse wave velocity, ankle brachial index and cIMT were 
measured in all participants. The study included 33 patients with MS and 22 healthy controls. 
Their findings showed that there were no significant correlations between cIMT and EDSS in 
MS patients. On the contrary, Nelson et al. (2014) investigated the prevalence of vascular 
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dysfunction and the effects of biochemical and lifestyle factors on carotid arteries and internal 
jugular veins (IJVs) in patients diagnosed with multiple sclerosis (MS); and found that EDSS 
was significantly associated with cIMT (p<0.0001). This is congruent with the findings of this 
current study which demonstrates that EDSS is significantly positively associated with cIMT in 
persons with MS (Pearson p-value <0.01). This present study also showed that the disability 
status of MS participants was significantly negatively associated with the blood flow velocities 
in the right and left CCA, ICA and right VA. The peak and end-diastolic blood flow velocities 
were lower in MS persons with a greater disability. This association suggests that due to 
greater disability, physical activity is limited, resulting in altered peripheral circulation and 
cerebral hypoperfusion.  
 
Although more research is needed to determine associations between MS disability and 
carotid artery disease, it can be deduced that cIMT is significantly associated with MS disability. 
Reducing risk factors associated with carotid intima media thickening may reduce the risk of 
CVD and slow down disability progression in MS patients. 
 
CONCLUSION 
This cross-sectional observational case-control study has demonstrated, with vascular 
ultrasound, a plethora of significant positive and negative associations between extracranial 
vascular ultrasound variables and genetic, lifestyle, biochemical and vascular factors as well 
as MS disability. Some of these significant findings were determined in previous MS studies of 
similar context, however there are several novel findings which unfolded in this study. The new 
MS findings include significant associations between: 1) the carotid vessel diameters and 
biochemical and lifestyle parameters as well as the presence of the HLA DRB1*1501 allele; 2) 
IJV CSA in MS and biochemical and lifestyle parameters, specifically passive smoking; 3) MS 
disability and carotid artery blood flow velocities; and 4) carotid artery blood flow parameters 
and biochemical markers. 
 
These encouraging findings indicate that the pathophysiological processes associated with MS 
and disability progression is complex and integrated, where vascular factors play an integral 
part in the disease process. Further studies are therefore needed to establish the clinical 
relevance of these new findings and determine treatment measures to reduce MS disability 
and improve quality of life.  
 
 
 
 
 
140 
 
REFERENCES 
 
Abbasi, M. 2016. Potential Environmental Risk Factor of MS. SM journals. 
https://smjournals.com/ebooks/multiple-sclerosis/chapters/MS-16-06.pdf: 1–9. 
 
Akbari-Sedigh, A., Asghari, G., Yuzbashian, E., Dehghan, P., Imani, H. & Mirmiran, P. 2019. 
Association of dietary pattern with carotid intima media thickness among children with 
overweight or obesity. Diabetology & Metabolic Syndrome, 11(1): 1–9. 
https://doi.org/10.1186/s13098-019-0472-4. 
 
Alcina, A., de Abad-Grau, M.M., Fedetz, M., Izquierdo, G., Lucas, M., Fernández, Ó., Ndagire, 
D., Catalá-Rabasa, A., Ruiz, A., Gayán, J., Delgado, C., Arnal, C. & Matesanz, F. 2012. 
Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene 
in different human populations. PLoS ONE, 7(1): 1–9. 
 
Alíefendíoğlu, D., Yilmaz, S., Misirlioğlu, E.D., Saygi, S., Ozdogan, S., & Koçak, U. (2007). Do 
cerebral blood flow velocities change in iron deficiency anemia? Journal of pediatric 
hematology/oncology, 29 11, 747-51. 
 
Al-Omari, M.H. & Rousan, L.A. 2010. Internal jugular vein morphology and hemodynamics in 
patients with multiple sclerosis. Int Angiol, 29(April): 115–20. 
 
Ascherio, A. & Munger, K.L. 2007. Environmental risk factors for multiple sclerosis. Part I: The 
role of infection. Annals of Neurology, 61(4): 288–299. 
 
Axtell, R.C., Raman, C. & Steinman, L. 2011. Interferon-β exacerbates Th17-mediated 
inflammatory disease. Trends in Immunology. 32(6):272-7. June 
 
Baker, E.J., Yusof, M.H., Yaqoob, P., Miles, E.A. & Calder, P.C. 2018. Omega-3 fatty acids 
and leukocyte-endothelium adhesion: Novel anti-atherosclerotic actions. Molecular Aspects 
of Medicine, 64(August): 169–181. https://doi.org/10.1016/j.mam.2018.08.002 
 
Bakshi, R., Neema, M., Tauhid, S., Healy, B.C., Glanz, B.I., Kim, G., Miller, J., Berkowitz, J.L., 
Bove, R., Houtchens, M.K., Severson, C., Stankiewicz, J.M., Stazzone, L., Chitnis, T., 
Guttmann, C.R.G., Weiner, H.L. & Ceccarelli, A. 2014. An expanded composite scale of MRI-
defined disease severity in multiple sclerosis: MRDSS2. NeuroReport, 25(14): 1156–1161. 
 
 
141 
 
 
Barkhof, F., Filippi, M., Miller, D.H., Scheltens, P., Campi, A., Polman, C.H., Comi, G., Adèr, 
H.J., Losseff, N. & Valk, J. 1997. Comparison of MRI criteria at first presentation to predict 
conversion to clinically definite multiple sclerosis. Brain, 120(11): 2059–2069. 
 
Barnoya, J. & Glantz, S.A. 2005. Cardiovascular effects of secondhand smoke: Nearly as 
large as smoking. Circulation, 111(20): 2684–2698. 
 
Barreto, A.D., Brod, S.A., Bui, T.T., Jemelka, J.R., Kramer, L.A., Ton, K., Cohen, A.M., Lindsey, 
J.W., Nelson, F., Narayana, P.A. & Wolinsky, J.S. 2013. Chronic cerebrospinal venous 
insufficiency: Case-control neurosonography results. Annals of Neurology, 73(6): 721–728. 
 
Bartzokis, G. 2011. Alzheimer’s disease as hemoestatic responses to age-related myelin 
breakdown. Neurobiol aging, 32(8): 1341–1371. 
 
Basu, A., Jenkins, A.J., Stoner, J.A., Thorpe, S.R., Klein, R.L., Lopes-Virella, M.F., Garvey, 
W., Lyons, T.J. & Group, T.D.R. 2014. Plasma Homocysteine and Carotid Intima-Media 
Thickness in Type 1 Diabetes: A Prospective Study. Atherosclerosi, 236(1): 188–195. 
 
Beggs, C.B. 2013. Venous hemodynamics in neurological disorders: an analytical review with 
hydrodynamic analysis. BMC medicine, 11(1). 
 
Berezowska, M., Coe, S. & Dawes, H. 2019. Effectiveness of vitamin D supplementation in the 
management of multiple sclerosis: A systematic review. International Journal of Molecular 
Sciences, 20(6). 
 
Blake, G.J., Ridker, P.M., 2001. Novel clinical markers of vascular wall inflammation. Circ. Res. 
89 (9), 763–771 
 
Bogie, J.F.J., Stinissen, P. & Hendriks, J.J.A. 2014. Macrophage subsets and microglia in 
multiple sclerosis. Acta Neuropathologica, 128(2): 191–213. 
 
Bos, M.J., Loon, R.F.H.J. Van, Mbbs, L.H., Bappsc, M.P.M., Qld, M. & Zundert, A.A.J. Van. 
2016. Comparison of the diameter , cross-sectional area , and position of the left and right 
internal jugular vein and carotid artery in adults. Journal of Clinical Anesthesia, 32: 65–69. 
http://dx.doi.org/10.1016/j.jclinane.2015.12.034. 
 
Bosevski M. 2011. Carotid IMT in type 2 diabetic patients: a survey on factors of influence. 
142 
 
Prilozi,32(2):289-97. 
 
 
Burke, A.P., Kolodgie, F.D., Zieske, A., Fowler, D.R., Weber, D.K., Varghese, P.J., Farb, A. & 
Virmani, R. 2004. Morphologic findings of coronary atherosclerotic plaques in diabetics: A 
postmortem study. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(7): 1266–1271. 
 
Calder, P.C., 2012. The role of marine omega-3 (n-3) fatty acids in inflammatory pro- cesses, 
atherosclerosis and plaque stability. Mol. Nutr. Food Res. 56 (7), 1073–1080. 
 
Carroll, B.A. 2005. The Extracranial Cerebral Vessels. In Rumack, C., Wilson, S., Charboneau, 
J. & Johnson, J. (eds). Diagnostic Ultrasound. 3rd ed. St. Louis, Missouri: Elsevier Mosby: 943-
991. 
 
Chang, C.T., Yang, C.Y., Tsai, F.J., Lin, S.Y. & Chen, C.J. 2015. Mass spectrometry-based 
proteomic study makes high-density lipoprotein a biomarker for atherosclerotic vascular 
disease. BioMed Research International, 2015. 
 
Chen, X.U.E., Pyzik, R., Yong, A. & Striker, G.E. 2013. NIH Public Access. J Am Diet Assoc., 
110(6): 911–16. 
 
Chiavaroli, L., Mirrahimi, A., Ireland, C., Mitchell, S., Sahye-Pudaruth, S., Coveney, J., 
Olowoyeye, O., Patel, D., De Souza, R.J., Augustin, L.S.A., Bashyam, B., Pichika, S.C., 
Blanco Mejia, S., Nishi, S.K., Leiter, L.A., Josse, R.G., McKeown-Eyssen, G.E., Moody, A.R., 
Kendall, C.W.C., Sievenpiper, J.L. & Jenkins, D.J.A. 2017. Cross-sectional associations 
between dietary intake and carotid intima media thickness in type 2 diabetes: Baseline data 
from a randomised trial. BMJ Open, 7(3). 
 
Ciciarello, F., Mandolesi, S., Galeandro, A., Marceca, A., Rossi, M., Fedele, F., Gesualdo, 
M., Cortese, F., Zito, A., Federico, F., Livrea, P., Trojano, M., Scicchitano, P. & Ciccone, M. 
2014. Age-related Vascular Differences among Patients Suffering from Multiple Sclerosis. 
Current Neurovascular Research, 11(1): 23–30.  
 
Comi, G., Battaglia, M.A., Bertolotto, A., Del Sette, M., Ghezzi, A., Malferrari, G., Salvetti, M., 
Sormani, M.P., Tesio, L., Stolz, E. & Mancardi, G. 2013. Italian multicentre observational study 
of the prevalence of CCSVI in multiple sclerosis (CoSMo study): Rationale, design, and 
methodology. Neurological Sciences, 34(8): 1297–1307. 
 
143 
 
Correale, J. & Gaitán, M.I. 2015. Multiple sclerosis and environmental factors: The role of 
vitamin D, parasites, and Epstein-Barr virus infection. Acta Neurologica Scandinavica, 
132(S199). 
 
Culpepper, W. J. & Wallin, M. T. 2015. Comorbidity increases the risk of hospitalizations in 
MS: prevention opportunities. Neurology; 84(4):335–6. PMID: 25540316 
 
Czyzewska, D., Ustymowicz, A. & Kosel, J. 2015. Internal jugular veins must be measured 
before catheterization. Journal of Clinical Anesthesia, 27(2): 129–131. 
http://dx.doi.org/10.1016/j.jclinane.2014.09.010. 
 
D’haeseleer, M., Cambron, M., Vanopdenbosch, L. & De Keyser, J. 2011. Vascular aspects 
of multiple sclerosis. The Lancet. Neurology, 10(7): 657–66. 
http://www.sciencedirect.com/science/article/pii/S1474442211701053 12 May 2016. 
 
Dähnert, W. 2007. Radiology Review Manual. 6th ed. USA: Lippincott Williams & Wilkins. 
 
Davis, W., Van Rensburg, S.J., Cronje, F.J., Whati, L., Fisher, L.R., Van Der Merwe, L., Geiger, 
D., Hassan, M.S., Matsha, T., Erasmus, R.T. & Kotze, M.J. 2014. The fat mass and obesity-
associated FTO rs9939609 polymorphism is associated with elevated homocysteine levels in 
patients with multiple sclerosis screened for vascular risk factors. Metabolic Brain Disease, 
29(2): 409–419. 
 
Dawson, V.L., Dawson, T.M., Bartley, D.A., Uhl, G.R. & Snyder, S.H. 1993. Mechanisms of 
Nitric Oxide-mediated Neurotoxicity in Primary Brain Cultures. The Journal of Neuroscience, 
13(6): 2651–2661. 
 
Dean, G. 1967. Annual Incidence, Prevalence, and Mortality of Multiple Sclerosis in White 
South-African-born and in White Immigrants to South Africa. British Medical Journal, 2: 724-
730 
 
Dessein,  P. H., Woodiwiss, A. J., Norton, G. R. & Solomon, A. 2013. Rheumatoid arthritis is 
associated with reduced adiposity but not with unfavorable major cardiovascular risk factor 
profiles and enhanced carotid atherosclerosis in black Africans from a developing population: 
a cross-sectional study. Arthritis Res Ther,15(4):R96. doi:10.1186/ar4276 
 
Didonna, A. & Oksenberg, J.R. 2015. Genetic determinants of risk and progression in multiple 
sclerosis. Clinica Chimica Acta, 20(449): 16–22. 
144 
 
 
Dinarello, C.A. 2000. Proinflammatory Cytokines. Chest, 118: 503-508. 
 
Doepp, F., Paul, F., Valdueza, J.M., Schmierer, K. & Schreiber, S.J. 2010. No cerebrocervical 
venous congestion in patients with multiple sclerosis. Annals of Neurology, 68(2): 173–183. 
 
Doshi, A. & Chataway, J. 2017. Multiple sclerosis, a treatable disease. Clinical Medicine, 
Journal of the Royal College of Physicians of London, 17(6): 530–536. 
 
Duan, S., Lv, Z., Fan, X., Wang, L., Han, F., Wang, H. & Bi, S. 2014. Vitamin D status and the 
risk of multiple sclerosis: A systematic review and meta-analysis. Neuroscience Letters, 570. 
 
Dulamea, A.O. 2017. Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination 
and Neurodegeneration in Multiple Sclerosis. Advances in Experimental Medicine and Biology, 
958:91-127. 
 
Ďurfinová, M., Procházková, Petrleničová, D., Bystrická, Z., Orešanská, K., Kuračka & Líška, 
B. 2018. Cholesterol level correlate with disability score in patients with relapsing-remitting 
form of multiple sclerosis. Neuroscience Letters, 687(October): 304–307. 
 
Durga, J., Bots, M.L., Schouten, E.G., Kok, F.J. & Verhoef, P. 2005. Low concentrations of 
folate, not hyperhomocysteinemia, are associated with carotid intima-media thickness. 
Atherosclerosis, 179(2): 285–292. 
 
Ebers, G., Sadovnick, A.D., & Risch, N.J. 1995. A genetic basis for familial aggregation in 
multiple sclerosis. Nature, 377:150-151. 
 
Farhoudi, M., Mehrvar, K., Aslanabadi, N., Ghabili, K., Rasi Baghmishe, N. & Ilkhchoei, F. 
2011. Doppler study of cerebral arteries in hypercholesterolemia. Vascular Health and Risk 
Management, 7(1): 203–207. 
 
Farina, M., Novelli, E. & Pagani, R. 2013. Cross-sectional area variations of internal jugular 
veins during supine head rotation in multiple sclerosis patients with chronic cerebrospinal 
venous insufficiency: A prospective diagnostic controlled study with duplex ultrasound 
investigation. BMC Neurology, 13(1): 1.  
 
Feinstein, A., Freeman, J. & Lo, A.C. 2015. Treatment of progressive multiple sclerosis: what 
works, what does not, and what is needed. The Lancet Neurology, 14(2): 194–207. 
145 
 
 
Field, J., Browning, S. R., Johnson, L. J., Danoy, P., Varney, M. D., Tait, B. D., Gandhi, K. S., 
Charlesworth, J. C., Heard, R. N., Australia and New Zealand Multiple Sclerosis Genetics 
Consortium, Stewart, G. J., Kilpatrick, T. J., Foote, S. J., Bahlo, M., Butzkueven, H., Wiley, 
J., Booth, D. R., Taylor, B.V., Brown, M. A., Rubio, J. P., Stankovich, J. 2010. A 
polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis. 
PLoS One 5, e13454 
 
Fisher, E.A., Feig, J.E., Hewing, B., Hazen, S.L. & Smith, J.D. 2012. High-density lipoprotein 
function, dysfunction, and reverse cholesterol transport. Arteriosclerosis, Thrombosis, and 
Vascular Biology, 32(12): 2813–2820. 
 
Fitzgerald, K.C., Munger, K.L., Köchert, K., Arnason, B.G.W., Comi, G., Cook, S., Goodin, 
D.S., Filippi, M., Hartung, H.P., Jeffery, D.R., O’Connor, P., Suarez, G., Sandbrink, R., Kappos, 
L., Pohl, C. & Ascherio, A. 2015. Association of Vitamin D levels with multiple sclerosis activity 
and progression in patients receiving interferon Beta-1b. JAMA Neurology, 72(12): 1458–1465. 
 
Fowlkes, J.B. & Holland, C.K. 1998. Biological effects and safety in Rumack, C., Wilson, S., 
Charboneau, J. & Johnson, J. Diagnostic Ultrasound. 2nd Edition, USA, Elsevier, Mosby 
 
Fragoso, Y.D. 2014. Modifiable environmental factors in multiple sclerosis. Arq Neuropsiquiatr, 
72(11):889-894 
 
Funfschilling, U., Supplie, L.M., Mahad, D., Boretius, S., Aiman, S., Edgar, J., Brinkmann, B.G., 
Kassmann, C.M., Tzvetanova, I.D., Sereda, W., Moraes, C.T., Frahm, J., Goebbels, S. & Nave, 
K. 2013. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature, 
485(7399): 517–521. 
 
Gandhi, S., Marr, K., Mancini, M., Caprio, M.G., Jakimovski, D., Chandra, A., Hagemeier, J., 
Hojnacki, D., Kolb, C., Weinstock-Guttman, B. & Zivadinov, R. 2019. No association between 
variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients 
over 5 years. BMC Neurology, 19(1): 1–9. 
 
Ganguly, P. & Alam, S.F. 2015. Role of homocysteine in the development of cardiovascular 
disease. Nutrition Journal, 14(6): 1–10. 
 
Garg, N. & Smith, T.W. 2015. An update on immunopathogenesis , diagnosis , and treatment 
of multiple sclerosis. Brain and Behavior, 362: 1–13. 
146 
 
 
Ghasemi, N., Razavi, S. & Nikzad, E. 2017. Multiple Sclerosis : Pathogenesis , Symptoms , 
Diagnoses and Cell-Based Therapy. Cell Journal, 19(1): 1–10. 
 
Giampaolo, D.L., Bhigjee, A., Retief, C., Isaacs, M., Britz, M., Opperman, D., Govender, R., 
Rensburg, M. Van, Hospital, R. & Africa, S. 2013. Guideline for the diagnosis and management 
of multiple sclerosis : A Southern African perspective. South African Journal of Psychiatry, 
103(9): 670–691. 
 
Glass, C.K., Witztum, J.L., 2001. Atherosclerosis. the road ahead. Cell 104 (4), 503–516 
 
Goldin, A., Beckman, J.A., Schmidt, A.M. & Creager, M.A. 2006. Advanced glycation end 
products: Sparking the development of diabetic vascular injury. Circulation, 114(6): 597–605. 
 
Goodin, D.S. 2015. The pathogenesis of multiple sclerosis. Clinical and Experimental 
Neuroimmunology, 6: 2–22. 
 
Gotthardt, M., Trommsdorff, M., Nevitt, M. F., Shelton, J, Richardson, J. A., Stockinger, W., 
Nimpf, J. &  Herz, J. 2000. Interactions of the low density lipoprotein receptor gene family with 
cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular 
communication and signal transduction. J Biol Chem, 275(33):25616-24 
 
Grebe, M. T., Luu, B., Sedding, D., Heidt, M. C., Kemkes-Matthes, B., Schaefer, C. A., 
Tillmanns, H. H. & Gündüz, D. 2010. Fibrinogen Promotes Early Atherosclerotic Changes of 
the Carotid Artery in Young, Healthy Adults. Journal of Atherosclerosis and Thrombosis, 
17(10): 1003-1008. 
 
Gulani, V., Calamante, F., Shellock, F., Kanal, E., Reeder, S. & The International Society for 
Magnetic Resonance in Medicine. 2017. Gadolinium deposition in the brain: summary of 
evidence and recommendations. Lancet Neurology, 16: 564-70. 
 
 
Gundersen, H., van Wageningen, H. & Grüner, R. 2013. Alcohol-induced changes in cerebral 
blood flow and cerebral blood volume in social drinkers. Alcohol and Alcoholism, 48(2): 160–
165. 
 
147 
 
Guo, H., Chi, J., Xing, Y. & Wang, P. 2009. Influence of folic acid on plasma homocysteine 
levels & arterial endothelial function in patients with unstable angina. Indian Journal of Medical 
Research, 129:279-284, March. 
 
Hadgkiss, E.J., Jelinek, G. a, Weiland, T.J., Pereira, N.G., Marck, C.H. & van der Meer, D.M. 
2014. The association of diet with quality of life, disability, and relapse rate in an international 
sample of people with multiple sclerosis. Nutritional neuroscience, 0(0): 1–12. 
http://www.ncbi.nlm.nih.gov/pubmed/24628020. 
Hafler, D.A., 1999. The distinctive blurs between an autoimmune versus microbial hypothesis 
in multiple sclerosis. The Journal of Clinical Investigation, 104(5):527-529. 
Hägg, U., Wandt, B., Bergstrom, G., Volkmann, R. & Gan, L.M. 2005. Physical exercsie 
capaciy is associated with coronoary and peripheral vascular function in healthy young adults. 
Am J Physiol Heart Circ Physiol.  Oct; 289 (4):H1627-34 
 
Haider, L. 2015. Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis 
of Multiple Sclerosis. Oxidative Medicine and Cellular Longevity, 2015(iii). 
 
Hankey, G. J. & Eikelboom, J. W. 1999. Homocysteine and vascular disease. Lancet; 354:407–
13. 
 
Hallenbeck, J.M., Hansson, G.K., Becker, K.J., 2005. Immunology of ischemic vascular 
disease: plaque to attack. Trends Immunol. 26 (10), 550–556 
 
Hansson, G.K., 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. 
Med. 352 (16), 1685–1695 
 
Harandi, A., Harandi, A., Pakdaman, H. & Sahraian, M. 2014. Vitamin D and Multiple Sclerosis. 
Iranian Journal of Neurology, 13(1): 1–6. 
 
Hedstrom, A.K., Bomfim, I.L., Barcellos, L.F., Briggs, F., Schaefer, C., Kockum, I., Olsson, T. 
& Alfredsson, L. 2014a. Interaction between passive smoking and two HLA genes with regard 
to multiple sclerosis risk. International Journal of Epidemiology, 43(6): 1791–1798. 
 
Hedström, A.K., Bomfim, I.L., Barcellos, L., Gianfrancesco, M., Schaefer, C., Kockum, I., 
Olsson, T. & Alfredsson, L. 2014b. Interaction between adolescent obesity and HLA risk genes 
in the etiology of multiple sclerosis. Neurology, 82(10): 865–872. 
148 
 
 
Hooper, L., Summerbell, C.D., Higgins, J.P.T., Thompson, R.L., Capps, N.E., Smith, G.D., 
Riemersma, R.A. & Ebrahim, S. 2001. Dietary fat intake and prevention of cardiovascular 
disease: Systematic review. British Medical Journal, 322(7289): 757–763. 
 
Horvat, P., Gardiner, J., Kubinova, R., Pajak, A., Tamosiunas, A., Schöttker, B., Pikhart, H., 
Peasey, A., Jansen, E. & Bobak, M. 2016. Serum folate, vitamin B-12 and cognitive function 
in middle and older age: The HAPIEE study. Experimental Gerontology, 76: 33–38. 
http://dx.doi.org/10.1016/j.exger.2016.01.011. 
 
Hu, F.B., Manson, J.E. & Willett, W.C. 2001. Types of dietary fat and risk of coronary heart 
disease: a critical review. Journal of the American College of Nutrition, 20(1):5-19.  
 
Huang, W.J., Chen, W.W. & Zhang, X. 2017. Multiple sclerosis: Pathology, diagnosis and 
treatments (review). Experimental and Therapeutic Medicine, 13(6): 3163–3166. 
 
Hunt, K. J., Baker, N., Cleary, P., Backlund, J. Y., Lyons, T., Jenkins, A., Virella, G., Lopes-
Virella, M. F. & the DCCT/EDIC Research Group. 2013.  Oxidized LDL and AGE-LDL in 
circulating immune complexes strongly predict progression of carotid artery IMT in type 1 
diabetes. Atherosclerosis, 231(2):315-22 
 
Issazadeh-Navikas, S., Teimer, R. & Bockermann, R. 2012. Influence of Dietary Components 
on Regulatory T Cells. Molecular Medicine, 18(1): 95–110. 
 
Jelinek, G.A., Hadgkiss, E.J., Weiland, T.J., Pereira, N.G., Marck, C.H. & Van Der Meer, D.M. 
2013. Association of fish consumption and omega 3 supplementation with quality of life, 
disability and disease activity in an international cohort of people with multiple sclerosis. 
International Journal of Neuroscience, 123(11): 792–801. 
 
Jokubaitis, V.G., Spelman, T., Kalincik, T., Izquierdo, G., Grand’Maison, F., Duquette, P., 
Girard, M., Lugaresi, A., Grammond, P., Hupperts, R., Cabrera-Gomez, J., Oreja-Guevara, 
C., Boz, C., Giuliani, G., Fernández-Bolaños, R., Iuliano, G., Lechner-Scott, J., Verheul, F., 
van Pesch, V., Petkovska-Boskova, T., Fiol, M., Moore, F., Cristiano, E., Alroughani, R., 
Bergamaschi, R., Barnett, M., Slee, M., Vella, N., Herbert, J., Shaw, C., Saladino, M.L., 
Amato, M.P., Liew, D., Paolicelli, D., Butzkueven, H. & Trojano, M. 2015. Predictors of 
disability worsening in clinically isolated syndrome. Annals of Clinical and Translational 
Neurology: n/a-n/a. http://doi.wiley.com/10.1002/acn3.187. 
 
149 
 
 
Kamenskiy, A. V., Pipinos, I.I., Carson, J.S., Mactaggart, J.N. & Baxter, B.T. 2015. Age and 
disease-related geometric and structural remodeling of the carotid artery. Journal of Vascular 
Surgery, 62(6): 1521–1528. http://dx.doi.org/10.1016/j.jvs.2014.10.041. 
 
Kappus, R.M., Fahs, C.A., Smith, D., Horn, G.P., Agiovlasitis, S., Rossow, L., Jae, S.Y., 
Heffernan, K.S. & Fernhall, B. 2014. Obesity and overweight associated with increased 
carotid diameter and decreased arterial function in young otherwise healthy men. American 
Journal of Hypertension, 27(4): 628–634. 
 
Kavak, K.S., Teter, B.E., Hagemeier, J., Zakalik, K. & Weinstock-Guttman, B. 2015. Higher 
weight in adolescence and young adulthood is associated with an earlier age at multiple 
sclerosis onset. Multiple sclerosis (Houndmills, Basingstoke, England), 21(7). 
 
Kell, D.B. & Pretorius, E. 2014. Serum ferritin is an important inflammatory disease marker, 
as it is mainly a leakage product from damaged cells. Metallomics, 6(4): 748–773. 
 
Kidd, P. 2001. Multiple Sclerosis, An Autoimmune Inflammatory Disease: Prospects for its 
Integratiev Management. Alternative Medicine Review, 6(6): 26. 
 
Kim, E.S. and Gornik, H.L. 2014. Atherosclerotic Risk Factors: Smoking. In Cronenwett, J.L. 
& Johnston, K.W. (eds). Rutherfrod’s Vascular Surgery .8th ed. Philadelphia: Elsevier: 416-428 
 
Kim, W. & Lee, H. 2013. Advances in nutritional research on regulatory T-cells. Nutrients, 
5(11): 4305–4315. 
 
Kingwell, E., Marriott, J.J., Jetté, N., Pringsheim, T., Makhani, N., Morrow, S.A., Fisk, J.D., 
Evans, C., Béland, S.G., Kulaga, S., Dykeman, J., Wolfson, C., Koch, M.W. & Marrie, R.A. 
2013. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC 
neurology, 13. 
 
Klancic, T., Woodward, L., Hofmann, S.M. & Fisher, E.A. 2016. High density lipoprotein and 
metabolic disease: Potential benefits of restoring its functional properties. Molecular 
Metabolism, 5(5): 321–327. http://dx.doi.org/10.1016/j.molmet.2016.03.001. 
 
Knovich, M.A., Storey, J.A., Coffman, L.G., Torti, S. V. & Torti, F.M. 2009. Ferritin for the 
clinician. Blood Reviews, 23(3): 95–104. http://dx.doi.org/10.1016/j.blre.2008.08.001. 
 
150 
 
Koriem, K.M.M. 2016. Multiple sclerosis: New insights and trends. Asian Pacific Journal of 
Tropical Biomedicine, 6(5): 429–440. 
http://www.sciencedirect.com/science/article/pii/S2221169116302453 11 May 2016. 
 
Kremkau, F.W. 2006. Diagnostic Ultrasound, Principles and Instruments 7th ed. St. Louis, 
Missouri: W.B Saunders Company. 
 
Krsmanović, Ž., Živković, M., Lepić, T., Stanković, A., Raičević, R. & Dinčić, E. 2013. Small 
internal jugular veins with restricted outflow are associated with severe multiple sclerosis: A 
sonographer-blinded, case-control ultrasound study. BMC Neurology, 13: 1–9. 
 
Küçükali, C., Kürtüncü, M., Çoban, A., Çebi, M. & Tüzün, E. 2015. Epigenetics of Multiple 
Sclerosis : An Updated Review. Neuromolecular medicine, 17(2): 83–96. 
 
Kurtzke, J.F. 1983. Rating neurologic impairment in multiple sclerosis: an expanded disability 
status scale (EDSS). Neurology, 33(11): 1444–1452. 
 
Lee, C.J. & Park, S. 2014. The role of carotid ultrasound for cardiovascular risk stratification 
beyond traditional risk factors. Yonsei Medical Journal, 55(3): 551–557. 
 
Lee, Y.H., Shin, M.H., Kweon, S.S., Choi, S.W., Kim, H.Y., Ryu, S.Y., Kim, B.H., Rhee, J.A. 
& Choi, J.S. 2009. Alcohol consumption and carotid artery structure in Korean adults aged 50 
years and older. BMC public health, 9: 358. 
 
Leone, M.A., Raymkulova, O., Lucenti, A., Stecco, A., Bolamperti, L., Coppo, L., Liboni, W., 
Rivadossi, G., Zaccala, G., Maggio, M., Melis, F., Giaccone, C., Carriero, A. & Lochner, P. 
2013. A reliability study of colour-Doppler sonography for the diagnosis of chronic 
cerebrospinal venous insufficiency shows low inter-rater agreement. BMJ Open, 3(11): 1–7. 
 
Leray, E., Moreau, T., Fromont, A. & Edan, G. 2016. Epidemiology of multiple sclerosis. Revue 
Neurologique, 172(1): 3–13. http://dx.doi.org/10.1016/j.neurol.2015.10.006. 
 
Levy, B.I. & Tedgui, A. 1999. Biology of the arterial wall. Boston: Kluwer Academic Publishers 
 
Liebman, H.A and Weitz, I.C. 2014. Hypercoagulable states. In Cronenwett, J.L. & Johnston, 
K.W. (eds). Rutherfrod’s Vascular Surgery .8th ed. Philadelphia: Elsevier:599-611. 
 
Liu, A.G., Ford, N.A., Hu, F.B., Zelman, K.M., Mozaffarian, D. & Kris-Etherton, P.M. 2017. A 
151 
 
healthy approach to dietary fats: Understanding the science and taking action to reduce 
consumer confusion. Nutrition Journal, 16(1): 1–15. 
 
 
Liuba, P., Persson, J., Luoma, J., Ylä-Herttuala, S. & Pesonen, E. 2003. Acute infections in 
children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, 
and are followed by thickening of carotid intima-media. European Heart Journal, 24(6): 515–
521. 
 
Lopes-Virella, M. F., Hunt, K. J., Baker, N. L., Lachin, J., Nathan, D. M., Virella, G. &  the 
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications Research Group. 2011. Levels of oxidized LDL and advanced glycation end 
products-modified LDL in circulating immune complexes are strongly associated with 
increased levels of carotid intima-media thickness and its progression in type 1 diabetes. 
Diabetes, 60(2):582-9. 
 
Lövblad, K.O., Anzalone, N., Dörfler, A., Essig, M., Hurwitz, B., Kappos, L., Lee, S.K. & 
Filippi, M. 2010. MR imaging in multiple sclerosis: Review and recommendations for current 
practice. American Journal of Neuroradiology, 31: 983–989. 
 
Loy, B. D., Taylor, R. L., Fling, B. W., & Horak, F.B. 2017. Relationship between perceived 
fatigue and performance fatigability in people with multiple sclerosis: A systematic review and 
meta-analysis. Journal of Psychosomatic Research, 100: 1–7. 
Lublin, F.D. and Reingold, S.C. 1996. Defining the clinical course of multiple sclerosis: results 
of an   international survey. Neurology, 46(4):907–11. 
Ma, H., Lin, H., Hu, Y., Li, X., He, W., Jin, X., Gao, J., Zhao, N., Song, B., Pan, B. & Gao, X. 
2015. Serum ferritin levels are associated with carotid atherosclerosis in Chinese 
postmenopausal women: The Shanghai Changfeng Study. British Journal of Nutrition, 
114(7): 1064–1071. 
 
Madras, D. 2014. Multiple Sclerosis. In Kauffman, T., Barr, J. O., Scott, R. and Moran, M.L. 
(eds). A comprehensive guide to Geriatric Rehabilitation. 3rd ed. USA: Elsevier Ltd: 203-20 
 
Maillard-Lefebvre, H., Boulanger, E., Daroux, M., Gaxatte, C., Hudson, B.I. & Lambert, M. 
2009. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and 
prognosis of chronic inflammatory diseases. Rheumatology (Oxford, England), 48(10): 1190–
152 
 
1196. 
 
Mancini, M., Lanzillo, R., Liuzzi, R., Di Donato, O., Ragucci, M., Monti, S., Salvatore, E., Morra, 
V.B. & Salvatore, M. 2014. Internal jugular vein blood flow in multiple sclerosis patients and 
matched controls. PLoS ONE, 9(3): 1–7. 
 
Marck, C.H., Neate, S.L., Taylor, K.L., Weiland, T.J. & Jelinek, G.A. 2016. Prevalence of 
Comorbidities, Overweight and Obesity in an International Sample of People with Multiple 
Sclerosis and Associations with Modifiable Lifestyle Factors. PloS one, 11(2): e0148573. 
http://dx.doi.org/10.1371/journal.pone.0148573 16 May 2016. 
 
Marck, C.H., de Livera, A.M., Weiland, T.J., Jelinek, P.L., Neate, S.L., Brown, C.R., Taylor, 
K.L., Khan, F. & Jelinek, G.A. 2017. Pain in people with multiple sclerosis: Associations with 
modifiable lifestyle factors, fatigue, depression, anxiety, and mental health quality of life. 
Frontiers in Neurology, 8(SEP): 1–7. 
 
Marshall, G. & Jonker, L. 2011. An introduction to inferential statistics: A review and practical 
guide. Radiography, 17: e1-e6. 
 
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H. P., Lublin, F. D., 
McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., Sandberg-Wollheim, M., Sibley, 
W., Thompson, A., van den Noort, S., Weinshenker, B. Y. & Wolinsky, J. S. 2001. 
Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International 
Panel on the Diagnosis of Multiple Sclerosis: Annals of Neurology, 50:121-127 
 
Merlino G, Fratticci L, Lenchig C, Valente M, Cargnelutti D, Picello M, Sarafini, A, Doslo, P & 
Gigli, G.L. 2009.  Prevalence of 'poor sleep' among patients with multiple sclerosis: an 
independent predictor of mental and physical status. Sleep Med; 10(1):26–34. doi: 
10.1016/j.sleep.2007.11.004 PMID: 18207453 
 
Merrill, J. E, Ignarro, L.J., Sherman, M.P., Melinek, J, Lane, T.E. 1993. Microglial cell 
cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol, 151(4): 2132-
2141. 
 
Mike, A., Glanz, B.I., Hildenbrand, P., Meier, D., Bolden, K., Liguori, M., Dell’Oglio, E., Healy, 
B.C., Bakshi, R. & Guttmann, C.R.G. 2011. Identification and clinical impact of multiple 
sclerosis cortical lesions as assessed by routine 3T MR imaging. American Journal of 
Neuroradiology, 32(3): 515–521. 
153 
 
Millefiorini, E., Gasperini, C., Pozzilli, C., D’Andrea, F., Bastianello, S., Trojano, M., Morino, S., 
Morra, V.B., Bozzao, A., Calo’, A., Bernini, M.L., Gambi, D., and Prencipe, M. 1997. 
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 
24-month clinical and MRI outcome. Journal of Neurology, 244(3):153-9. 
 
Mitrovic, B., Ignarro, J., Vinters, H., Akers, M., Schmid, I., Uittenbogaart, C. & Merrill, J. 1995. 
Nitric Oxide Induces Necrotic But Not Apoptotic Cell Death in Oligodendroctes. Neuroscience, 
65(2): 531–539. 
 
Modi, G., Mochan, A., du Toit, M. & Stander, I. 2008. Multiple Sclerosis in South Africa. South 
African Medical Journal, 98:391-393. 
 
Mokry, L.E., Ross, S., Ahmad, O.S., Forgetta, V., Smith, G.D., Leong, A., Greenwood, 
C.M.T., Thanassoulis, G. & Richards, J.B. 2015. Vitamin D and Risk of Multiple Sclerosis: A 
Mendelian Randomization Study. PLoS Medicine, 12(8): 1–20. 
http://dx.doi.org/10.1371/journal.pmed.1001866. 
 
Monti, L., Menci, E., Ulivelli, M., Cerase, A., Bartalini, S., Piu, P., Marotti, N., Leonini, S., 
Galluzzi, P., Romano, D.G., Casasco, A.E. & Venturi, C. 2011. Quantitative Colour Doppler 
Sonography evaluation of cerebral venous outflow: A comparative study between patients with 
multiple sclerosis and controls. PLoS ONE, 6(9): 1–7. 
 
Mora, J.R., Iwata, M. & Andrian, U.H. Von. 2008. Vitamin effects on the immune system. 
Nature Review Immunology, 8(9): 685–698.  
 
Motl, R.W, Fernhall, B, McAuley, E, Cutter, G. 2011. Physical activity and self-reported 
cardiovascular comorbidities in persons with multiple sclerosis: evidence from a cross-
sectional analysis. Neuroepidemiology.; 36(3):183–91. doi: 10.1159/000327749 PMID: 
21597305 
 
Müller-Scholden, L., Kirchhof, J., Morbach, C., Breunig, M., Meijer, R., Rücker, V., Tiffe, T., 
Yurdadogan, T., Wagner, M., Gelbrich, G., Bots, M.L., Störk, S. & Heuschmann, P.U. 2019. 
Segment-specific association of carotid-intima-media thickness with cardiovascular risk 
factors - Findings from the STAAB cohort study. BMC Cardiovascular Disorders, 19(1): 1–7. 
 
Multiple Sclerosis Association of America (MSAA). 2019. Types of MS. 
https://mymsaa.org/ms-information/overview/types/. [30 August 2019] 
154 
 
 
Multiple Sclerosis International Federation. 2013. Atlas of MS 2013: Mapping Multiple 
Sclerosis Around the World. https://www.msif.org/wp-content/uploads/2014/09/Atlas-of-
MS.pdf [15 July 2019]. 
 
Muñoz-Culla, M., Irizar, H. & Otaegui, D. 2013. The genetics of multiple sclerosis: review of 
current and emerging candidates. The application of clinical genetics, 6: 63–73.  
 
Myers, K. & Clough, A. 2004. Making Sense of Vascular Ultrasound: A hands-on guide. 
London: Arnold. 
 
National MS Society. 2010. What is Multiple Sclerosis? 
http://www.nationalmssociety.org/about-multiple-svlerosis/what-we-know-about-ms/what-is-
ms/index.aspx [10 April 2010] 
 
National MS Society. 2016. Definition of MS. http://www.nationalmssociety.org/What-is-
MS/Definition-of-MS [13 May 2016]. 
 
National MS Society. 2017a. Types of MS.  https://www.nationalmssociety.org/What-is-
MS/Types-of-MS. [30 August 2019] 
 
National MS Society. 2017b. Diagnosing MS. https://www.nationalmssociety.org/Symptoms-
Diagnosis/Diagnosing-MS. [30 August 2019] 
 
Nelson, M.C., Isaacs, F., Hassan, S., Kidd, M., Cronje, F.J. & Van Rensburg, S.J. 2014. 
Prevalence of abnormal bloodflow patterns and effects of biochemistry and lifestyle factors on 
the major neck vessels in patients with Multiple Sclerosis in the Western Cape , South Africa. 
Medical Tehcnology SA, 28(1): 43–50. 
 
Nicolaides, A.N., Morovic, S., Menegatti, E., Viselner, G. & Zamboni, P. 2011. Screening for 
chronic cerebrospinal venous insufficiency (CCSVI) using ultrasound--recommendations for a 
protocol. International angiology : a journal of the International Union of Angiology, 30(6): 571–
597. 
 
North American Symptomatic Carotid Endarterectomy Trial (NASCET) Collaborators: 
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid 
stenosis. 1991. New England Journal of Medicine. 325:445-453. 
 
155 
 
Okuda, D.T., Srinivasan, R., Oksenberg, J.R., Goodin, D.S., Baranzini, S.E., Beheshtian, A., 
Waubant, E., Zamvil, S.S., Leppert, D., Qualley, P., Lincoln, R., Gomez, R., Caillier, S., 
George, M., Wang, J., Nelson, S.J., Cree, B.A.C., Hauser, S.L. & Pelletier, D. 2009. Genotype-
phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 
1HMR spectroscopy and MRI measures. Brain, 132(1): 250–259. 
 
Owens, C.D. 2014. Atherosclerosis. In Cronenwett, J.L. & Johnston, K.W. (eds). Rutherfrod’s 
Vascular Surgery .8th ed. Philadelphia: Elsevier: 66-77. 
 
 
Paim, L. R.,  Schreiber, R.,  Matos-Souza, J. R, Silva, A. A.,  Campos, L. F., Azevedo,  E. R., 
Alonso, K., de Rossi, G., Etchebehere, M.,  Gorla, J., Cliquet, A Jr, Nadruz, W Jr. 2013. 
Oxidized low-density lipoprotein, matrix-metalloproteinase-8 and carotid atherosclerosis in 
spinal cord injured subjects. Atherosclerosis, 231(2):341-345 
 
Palavra, F., Marado, D., Mascarenhas-Melo, F., Sereno, J., Teixeira-Lemos, E., Nunes, C.C., 
Gonçalves, G., Teixeira, F. & Reis, F. 2013. New markers of early cardiovascular risk in 
multiple sclerosis patients: Oxidized-LDL correlates with clinical staging. Disease Markers, 
34(5): 341–348. 
 
Palumbo, S. 2017. Pathogenesis and Progression of Multiple Sclerosis: The Role of 
Arachdonic Acid-Mediated Neuroinflammation. In Zagon, I. S & McLaughlin, P. J. (eds). 
Multiple Sclerosis: Perspectives in Treatment and Pathogenesis. Australia: Codon Publishers. 
 
Papaioannou, T & Stefanadis, C. 2005. Vascular Wall Shear Stress: Basic Principles and 
Methods. Hellenic Journal of Cardiology: 46. 9-15. 
 
Paz Soldan, M.M. & Rodriguez, M. 2002. Heterogeneity of Pathogenesis in Multiple Sclerosis: 
Implications for Promotion of Remyelination. The Journal of Infectious Diseases, 186(s2): 
S248–S253. 
 
Pelizzari, L., Jakimovski, D., Laganà, M.M., Bergsland, N., Hagemeier, J., Baselli, G., 
Weinstock-Guttman, B. & Zivadinov, R. 2018. Five-year longitudinal study of neck vessel 
cross-sectional area in multiple sclerosis. American Journal of Neuroradiology, 39(9): 1703–
1709. 
 
Penson, P.E., Long, D.L., Howard, G., Toth, P.P., Muntner, P., Howard, V.J., Safford, M.M., 
Jones, S.R., Martin, S.S., Mazidi, M., Catapano, A.L. & Banach, M. 2018. Associations 
156 
 
between very low concentrations of low density lipoprotein cholesterol , high sensitivity C-
reactive protein , and health outcomes in the Reasons for Geographical and Racial Differences 
in Stroke ( REGARDS ) study. European Heart Journal, 39: 3641–3653. 
 
Petersen, K.S., Clifton, P.M. & Keogh, J.B. 2014. The association between carotid intima 
media thickness and individual dietary components and patterns. Nutrition, Metabolism and 
Cardiovascular Diseases, 24(5): 495–502. http://dx.doi.org/10.1016/j.numecd.2013.10.024. 
 
Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., Cohen, J.A., Filippi, M., Fujihara, K., 
Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F.D., Montalban, X., O’Connor, P., 
Sandberg-Wollheim, M., Thompson, A.J., Waubant, E., Weinshenker, B. & Wolinsky, J.S. 
2011. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals 
of Neurology, 69(2): 292–302. 
 
Prats-Puig, A., Moreno, M., Carreras-Badosa, G., Bassols, J., Ricart, W., López-Bermejo, A. 
& Fernández-Real, J.M. 2016. Serum Ferritin Relates to Carotid Intima-Media Thickness in 
Offspring of Fathers with Higher Serum Ferritin Levels. Arteriosclerosis, Thrombosis, and 
Vascular Biology, 36(1): 174–180. 
 
Qu, B. & Qu, T. 2015. Causes of changes in carotid intima-media thickness: a literature 
review. Cardiovascular ultrasound, 13(1): 46. 
 
Rader, D. 2006. Molecular regulation of HDL metabolism and function: implications for novel 
therapies. J Clin Invest, 116: 3090–3100. 
 
Ramagopalan, S.V., Deluca, G.C., Morrison, K.M., Herrera, B. M., Dyment, D. A., Lincoln, M. 
R., Orton, S. M., Chao, M. J., Degenhardt, A., Pugliatti, M., Sadovnick, A. D., Sotgiu, S. & 
Ebers, G. C. 2008. Analysis of 45 candidate genes for disease modifying activity in multiple 
sclerosis. Journal of Neurology, 255:1215-1219 
 
Ramasamy, R., Yan, S.F. & Schmidt, A.M. 2012. Advanced glycation endproducts: From 
precursors to RAGE: Round and round we go. Amino Acids, 42(4): 1151–1161. 
 
Rasman, A. 2015. Chronic cerebrospinal venous insufficiency. Vascular Specialist 
International, 31(3): 106–107.  
 
Reinhart, W. H. 2003. Fibrinogen - marker or mediator of vascular disease. Vascular Medicine, 
8: 211-216. 
157 
 
 
Robinson, A. B., Tangpricha, V., Yow, E., Gurion, R., Schanberg, L. E., McComsey, G. A. for 
the APPLE investigators. 2014.  Vitamin D status is a determinant of atorvastatin effect on 
carotid intima medial thickening progression rate in children with lupus: An Atherosclerosis 
Prevention in Pediatric Lupus Erythematosus (APPLE) substudy. Lupus Science and 
Medicine, 1: e000037. doi:10.1136/lupus-2014-000037.  
 
Ross, A.C., Manson, J.A.E., Abrams, S.A., Aloia, J.F., Brannon, P.M., Clinton, S.K., Durazo-
Arvizu, R.A., Gallagher, J.C., Gallo, R.L., Jones, G., Kovacs, C.S., Mayne, S.T., Rosen, C.J. 
& Shapses, S.A. 2011. The 2011 report on dietary reference intakes for calcium and vitamin D 
from the Institute of Medicine: What clinicians need to know. Journal of Clinical Endocrinology 
and Metabolism, 96(1): 53–58. 
 
Ross, R., 1999. Atherosclerosis–an inflammatory disease. New England Journal of Medicine, 
340 (2), 115–126. 
 
Rovaris, M., Confavreux, C., Furlan, R., Kappos, L., Comi, G. & Filippi, M. 2006. Secondary 
progressive multiple sclerosis: Current knowledge and future challenges. Lancet Neurology, 
5(4): 343–354. 
 
Runia, T.F., Hop, W.C., de Rijke, Y.B., Buljevac, D. & Hintzen, R.Q. 2012. Lower serum vitamin 
D levels are associated with a higher relapse risk in multiple sclerosis. Neurology, 79, 261–
266 
 
Sacks, F.M., Lichtenstein, A.H., Wu, J.H.Y., Appel, L.J., Creager, M.A., Kris-Etherton, P.M., 
Miller, M., Rimm, E.B., Rudel, L.L., Robinson, J.G., Stone, N.J. & Van Horn, L. V. 2017. 
Dietary fats and cardiovascular disease: A presidential advisory from the American Heart 
Association. Circulation, 136(3): e1–e23. 
 
Sadovnick, A., Dircks, A. & Ebers, G. 1999. Genetic counselling in multiple sclerosis : risks to 
sibs and children of affected individuals. Clinical Genetics, 56: 118–122. 
 
Sadovnick, A.D., Ebers, G.C., Dyment, D.A. & Risch, N.J. 1996. Evidence for genetic basis of 
multiple sclerosis. Lancet, 347(9017): 1728–1730. 
 
Sand, I.K. 2015. Classification, diagnosis, and differential diagnosis of multiple sclerosis. 
Current Opinion in Neurology, 28(3): 193–205. 
 
158 
 
Sato, K., Ogoh, S., Hirasawa, A., Oue, A. & Sadamoto, T. 2011. The distribution of blood 
flow in the carotid and vertebral arteries during dynamic exercise in humans. Journal of 
Physiology, 589(11): 2847–2856. 
 
Schminke, U., Luedemann, J., Berger, K., Alte, D., Mitusch, R., Wood, W.G., Jaschinski, A., 
Barnow, S., John, U. & Kessler, C. 2005. Association between alcohol consumption and 
subclinical carotid atherosclerosis: The Study of Health in Pomerania. Stroke, 36(8): 1746–
1752. 
 
Schreiber, S.J., Lűrtzing, F., Gőtze, R., Doepp, F., Klingebiel, R. & Valdueza, J.M. 2003. 
Extrajugular pathways of human cerebral venous blood drainage assessed by duplex 
ultrasound. Journal of Applied Physiology, 94:1802-1805, January 10. 
 
Sethi, S.K., Daugherty, A.M., Gadda, G., Utriainen, D.T., Jiang, J., Raz, N. & Haacke, E.M. 
2017. Jugular anomalies in multiple sclerosis are associated with increased collateral venous 
flow. American Journal of Neuroradiology, 38(8): 1617–1622. 
 
Shenoy, V., Mehendale, V., Prabhu, K., Shetty, R. & Rao, P. 2014. Correlation of serum 
homocysteine levels with the severity of coronary artery disease. Indian Journal of Clinical 
Biochemistry, 29(3): 339–344. 
 
Simka, M., Kostecki, J. Zaniewski, M. & Hartel, M. 2010. Extracranial Doppler sonographic 
criteria of chronic cerebrospinal venous insufficiency in the patients with multiple sclerosis. 
International Angiology, 29(2):109-114, April. 
 
Sintzel, M.B., Rametta, M. & Reder, A.T. 2018. Vitamin D and Multiple Sclerosis: A 
Comprehensive Review. Neurology and Therapy, 7(1): 59–85. https://doi.org/10.1007/s40120-
017-0086-4. 
 
Somogyi, E., Balogh, I., Rubányi, G., Sótonyi, P. & Szegedi, L. 1981. New findings concerning 
the pathogenesis of acute carbon monoxide (CO) poisoning. American Journal of Forensic 
Medicine and Pathology, 2(1): 31-39 
 
Stadelmann, C., Wegner, C. & Brück, W. 2011. Inflammation, demyelination, and degeneration 
- Recent insights from MS pathology. Biochimica et Biophysica Acta - Molecular Basis of 
Disease, 1812(2): 275–282. http://dx.doi.org/10.1016/j.bbadis.2010.07.007. 
 
Stein, J.H. 2004. Carotid intima-media thickness and vascular age: You are only as old as your 
159 
 
arteries look. Journal of the American Society of Echocardiography, 17(6): 686–689. 
 
Stockinger, W., Brandes, C., Fasching, D., Hermann, M., Gotthardt, M.,  Herz, J.,  Schneider,  
W. J. &  Nimpf, J.  2000. The reelin receptor ApoER2 recruits JNK-interacting proteins-1 and -
2.  Journal of Biological Chemistry; 275(33):25625-32. 
 
Stone, P.A. and Hass, S.M. 2014. Vascular Laboratory: Arterial Duplex Scanning. In 
Cronenwett, J.L. & Johnston, K.W. (eds). Rutherford’s Vascular Surgery .8th ed. Philadelphia: 
Elsevier. 230-256. 
 
 
Sumpio, B. and Chin, J. 2014. Vessel Wall Biology. In Cronenwett, J.L. & Johnston, K.W. (eds). 
Rutherford’s Vascular Surgery .8th ed. Philadelphia: Elsevier. 
 
Sundström, P., Wåhlin, A., Ambarki, K., Birgander, R., Eklund, A. & Malm, J. 2010. Venous 
and cerebrospinal Fluid Flow in Multiple Sclerosis: A Case-Control Study. Annals of Neurology, 
68:255-259. 
 
Talaat, F.M., Nassef, S.A., El-Fayomy, N.M., Abdelalim, A.M., EL-Mazny, A.N. & Fawzy, 
M.W. 2015. Arterial compliance and carotid artery changes in multiple sclerosis. Life Science 
Journal, 12(9): 96–100. 
 
Tall, A. 2008. Cholesterol efflux pathways and other potential mechanisms involved in the 
atheroprotective effect of high density lipoproteins. J Intern Med, 263: 256–273. 
 
Taylor, K.L., Hadgkiss, E.J., Jelinek, G.A., Weiland, T.J., Pereira, N.G., Marck, C.H. & van der 
Meer, D.M. 2014. Lifestyle factors, demographics and medications associated with depression 
risk in an international sample of people with multiple sclerosis. BMC Psychiatry, 14: 327.  
 
Tettey, P., Simpson, S., Taylor, B. V & van der Mei, I.A.F. 2014. Vascular comorbidities in the 
onset and progression of multiple sclerosis. Journal of the neurological sciences, 347(1–2): 
23–33. http://www.sciencedirect.com/science/article/pii/S0022510X1400673X 3 March 2016. 
 
Thom, S.R., Bhopale, V.M., Fisher, D., Zhang, J. & Gimotty, P. 2004. Delayed neuropathology 
after carbon monoxide poisoning is immune-mediated. Proceedings of the National Academy 
of Sciences, 101(37): 13660–13665. 
 
 
160 
 
Thompson, A.J., Banwell, B.L., Barkhof, F., Carroll, W.M., Coetzee, T., Comi, G., Correale, J., 
Fazekas, F., Filippi, M., Freedman, M.S., Fujihara, K., Galetta, S.L., Hartung, H.P., Kappos, 
L., Lublin, F.D., Marrie, R.A., Miller, A.E., Miller, D.H., Montalban, X., Mowry, E.M., Sorensen, 
P.S., Tintoré, M., Traboulsee, A.L., Trojano, M., Uitdehaag, B.M.J., Vukusic, S., Waubant, E., 
Weinshenker, B.G., Reingold, S.C. & Cohen, J.A. 2017. Diagnosis of multiple sclerosis: 2017 
revisions of the McDonald criteria. Lancet Neurology, 4422(17): 30470–30472. 
 
Thompson, A.J., Baranzini, S.E., Geurts, J., Hemmer, B. & Ciccarelli, O. 2018. Multiple 
sclerosis. Lancet, 391: 1622–1636. http://dx.doi.org/10.1016/S0140-6736(18)30481-1. 
 
Tintoré, M.,  Rovisa, A.,  Rio, J., Nos, C., Grivé, E., Sastre-Garriga, J.,  Pericot, I., Sánchez, 
E., Comabella,  M. & Montalban X. 2003.  New diagnostic criteria for Multiple sclerosis: 
Application in first demyelinating episode. Neurology, 60(1):27-30.  
 
Tiozzo, E., Gardener, H., Hudson, B.I., Dong, C., Della-Morte, D., Crisby, M., Goldberg, R.B., 
Elkind, M.S.V., Cheung, Y.K., Wright, C.B., Sacco, R.L., Desvarieux, M. & Rundek, T. 2016. 
Subfractions of High-Density Lipoprotein-Cholesterol and Carotid Intima-Media Thickness: 
The Northern Manhattan Study. Stroke, 47(6): 1508–1513. 
 
Van den Berg, B. M., Vink, H., Spaan, J.A.E. 2003. The endothelial glycocalyx protects against 
myocardial edema. Circulation Research, 92(6):592–594. 
 
Van der Vuurst de Vries, R.M., Mescheriakova, J.Y., Runia, T.F., Siepman, T.A.M., Wokke, 
B.H.A., Samijn, J.P.A. & Hintzen, R.Q. 2018. Smoking at time of CIS increases the risk of 
clinically definite multiple sclerosis. Journal of Neurology, 265(5): 1010–1015. 
https://doi.org/10.1007/s00415-018-8780-4. 
 
Van Horssen, J., Witte, M.E., Schreibelt, G. & de Vries, H.E. 2011. Radical changes in 
multiple sclerosis pathogenesis. Biochimica et Biophysica Acta - Molecular Basis of Disease, 
1812(2): 141–150. http://dx.doi.org/10.1016/j.bbadis.2010.06.011. 
 
Van Rensburg, S.J., Kotze, M.J., Hon, D., Haug, P., Kuyler, J., Hendricks, M., Botha, J., 
Potocnik, F.C. V, Matsha, T. & Erasmus, R.T. 2006. Iron and the folate-vitamin B12-
methylation pathway in multiple sclerosis. Metabolic Brain Disease, 21(2–3): 121–137. 
 
Wacker, M. & Holick, M.F. 2013. A global perspective for health. Dermato-Endocrinology, 
5:1(March): 51–108. 
 
161 
 
Wang, W., Knovich, M.A., Coffman, L.G., Torti, F.M. & Torti, S. V. 2010. Serum Ferritin: Past, 
Present and Future. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1800(8): 
760–769. 
 
Wattjes, M.P., Oosten, B.W. Van, Graaf, W.L. De, Seewann, A., Berg, V. Den, Uitdehaag, 
B.M.J., Polman, C.H., Bot, J.C.J. & Barkhof, F. 2011. No association of abnormal cranial 
venous drainage with multiple sclerosis : a magnetic resonance venography and flow-
quantification study. Journal of Neurology, Neurosurgery and Psychiatry, 82: 429–435. 
 
Wingerchuk, D.M. & Carter, J.L. 2014. Multiple sclerosis: Current and emerging disease-
modifying therapies and treatment strategies. Mayo Clinic Proceedings, 89(2). 
 
Woo, K.S., Chook, P., Chan, L.L.T., Cheung, A.S.P., Fung, W.H., Qiao, M.u., Lolin, Y.I., 
Thomas, G.N., Sanderson, J.E., Metreweli, C. & Celermajer, D. S. 2002. Long-term 
improvement in homocysteine levels and arterial endothelial function after 1-year folic acid 
supplementation. The American Journal of Medicine, 112(7):535-539, May. 
 
World Medical Association Declaration of Helsinki, 2013.  
https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-
research-involving-human-subjects/ [08 August 2019]. 
 
Yadav, V., Marracci, G., Kim, E., Spain, R., Cameron, M., Overs, S., Riddehough, A., Li, 
D.K.B., McDougall, J., Lovera, J., Murchison, C. & Bourdette, D. 2016. Low-fat, plant-based 
diet in multiple sclerosis: A randomized controlled trial. Multiple Sclerosis and Related 
Disorders, 9. 
 
Yaldizli, Ö., Sethi, V., Pardini, M., Tur, C., Mok, K.Y., Muhlert, N., Liu, Z., Samson, R.S., 
Wheeler-Kingshott, C.A.M., Yousry, T.A., Houlden, H., Hardy, J., Miller, D.H. & Chard, D.T. 
2016. HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter 
pathology in multiple sclerosis. Multiple Sclerosis and Related Disorders, 7: 47–52. 
http://www.sciencedirect.com/science/article/pii/S2211034816300232 11 May 2016. 
 
Zamboni, P. 2006. The big idea Iron-dependent inflammation in venous disease and proposed 
parallels in multiple sclerosis. Journal of the Royal Society of Medicine, 99:589-593, 
November. 
  
Zamboni, P., Galeotti, R., Menegatti, E., Malagoni, A.M., Tacconi, G., Dall’ara, S., Bartolomei, 
I. & Salvi, F. 2009a. Chronic cerebrospinal venous insufficiency in patients with multiple 
162 
 
sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 80(4): 392–399. 
 
Zamboni, P, Menegatti, E., Galeotti, R., Malagoni, A.M., Tacconi, G., Dall’Ara, S., Bartolomei, 
I. & Salvi, F. 2009b. The value of cerebral Doppler venous haemodynamics in the assessment 
of multiple sclerosis. Journal of the Neurological Sciences, 282(1–2): 21–27. 
http://dx.doi.org/10.1016/j.jns.2008.11.027. 
 
Zamboni, P., Menegatti, E., Conforti, P., Shepherd, S., Tessari, M. & Beggs, C. 2012. 
Assessment of cerebral venous return by a novel plethysmography method. Journal of 
Vascular Surgery, 56(3): 677-685.e1. http://dx.doi.org/10.1016/j.jvs.2012.01.074. 
 
Zavoreo, I., Bašić-Kes, V., Zadro-Matovina, L., Lisak, M., Ćorić, L., Cvjetičanin, T., Ciliga, D. 
& Bobić, T.T. 2013. Cerebral venous circulatory system evaluation by ultrasonography. Acta 
Clinica Croatica, 52(2): 203–211.  
 
Zivadinov, R., Dolic, K., Marr, K., Karmon, Y., Benedict, R.H.B., Weinstock-Guttman, B., 
Ramanathan, M. & Siddiqui, A.H. 2011. Chronic cerebrospinal venous insufficiency in multiple 
sclerosis: Diagnostic, pathogenetic, clinical and treatment perspectives. Expert Review of 
Neurotherapeutics, 11(9): 1277–1294. 
 
Zivadinov, R., Karmon, Y., Dolic, K., Hagemeier, J., Marr, K., Valnarov, V., Kennedy, C.L., 
Hojnacki, D., Carl, E.M., Hopkins, L.N., Levy, E.I., Weinstock-Guttman, B. & Siddiqui, A.H. 
2013. Multimodal noninvasive and invasive imaging of extracranial venous abnormalities 
indicative of CCSVI: Results of the PREMiSe pilot study. BMC Neurology, 13:151  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
163 
 
Appendix A : CAROTID DUPLEX REPORT     
PATIENT NAME:        DATE: 
                   AGE:                                               CONTROL/MS: 
RIGHT LEFT 
 COMMON CAROTID intima media thickness (mm)  
 peak systolic velocity (cm/s)  
 peak diastolic velocity (cm/s)  
 CSD proximal COMMON CAROTID (mm)  
 CSD mid COMMON CAROTID  
 CSD distal COMMON CAROTID  
 INTERNAL CAROTID peak systolic velocity  
 Peak diastolic velocity  
 CSD proximal INTERNAL CAROTID  
 Proximal EXTERNAL CAROTID peak systolic velocity  
 CSD proximal EXTERNAL CAROTID (mm)  
 VERTEBRAL ARTERY peak systolic velocity  
 Peak diastolic velocity  
 CSD proximal VERTEBRAL ARTERY  
 Peak systolic ICA/CCA ratio  
 Peak diastolic ICA/CCA ratio  
 INTERNAL CAROTID %age stenosis  
 EXTERNAL CAROTID %age stenosis  
COMMENT: 
 
(Adapted from the E22 vascular laboratory, Groote Schuur Hospital, Carotid Artery Duplex template) 
 
 
 
 
 
 
 
 
 
PLAQUE: 
Calcified 
Mixed 
Fibrous 
Soft 
Ulcerated 
Sub-plaque 
haemorrhage 
PLAQUE: 
Calcified 
Mixed 
Fibrous 
Soft 
Ulcerated 
Sub-plaque 
haemorrhage 
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Appendix B. DOPPLER SPECTRAL ANALYSIS 
 
Diameter stenosis Peak Systolic velocity ICA/CCA Systolic 
ratio 
ICA EDV 
0-49% < 125cm/s <2 <40cm/s 
50-69% 125-210cm/s 2-3 40-70cm/s 
70-79% >210cm/s >3 70-100cm/s 
80-99% >280cm/s >3.7 >100cm/s 
Occlusion No flow detectable   
*Near occlusion velocities may be low  
 
(Adapted from the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Collaborators: 
Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis, 
1991, ICA=internal carotid artery, ECA=external carotid artery, EDV=end-diastolic velocity). 
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Appendix C: INTERNAL JUGULAR VEIN (IJV) DUPLEX 
 
PATIENT NAME:         DATE: 
AGE:          CONTROL / MS 
 
RIGHT  LEFT 
Velocity (cm/s) = PATENT Proximal IJV Velocity (cm/s)= 
Velocity (cm/s)= Mid IJV Velocity (cm/s)= 
Velocity (cm/s)= Distal IJV Velocity (cm/s)= 
 CSA proximal IJV (mm2)  
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Appendix D: BRAINBIOCHEM QUESTIONNAIRE  
 
DATE:  PATIENT CODE: 
FOLLOW-UP: BRAINBIOCHEM CONSENT CODE: 
VISIT: FOLLOW-UP CONSENT FOR STORING DNA:  
First Name  
Middle Name  
Surname  
Title  
Address  
Date Of Birth   
Age (Yrs)  
Marital status  
Number of children  
Highest level of education  
Profession  
Employment (Full time/Part time)  
Country of Residence  
Race  
Gender   
Home / Work Phone Number   
Email address  
Cell Phone Number  
Health Practitioners  
Referred by:  
 
MEDICAL HISTORY  
 
Do you have a medical diagnosis or condition? 
Please specify:  
Or  control subject for  research  
 
 
How old are you now?  
How old were you when the diagnosis was first made? 
(years of age) 
 
How old were you when you noted the first symptoms?  
 
 
Which symptoms are associated with your illness or condition?  
 
Please Specify:  
 
 
 
 
 
In your opinion, what event(s) preceded the diagnosis that may have caused the condition? 
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Did you make a change in diet/lifestyle before diagnosis/relapse (e.g. did you start taking coconut oil)? 
 
 
 
 
 
In your opinion, are you resistant to common infections such as colds and flu?  
Do you tend to push yourself harder than other people do?  
Are you a risk-taker?  
Would you neglect your own health to improve the health of other people?  
 
Height (in metres)  
Weight (in kilogrammes)  
Calculated BMI:   
 
Blood pressure: 
Systolic  
Diastolic  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following questions are meant to find out what dietary and lifestyle habits may have had an effect 
on your health 
(1) at the time of diagnosis 
(2) at follow-up, after you have implicated any lifestyle changes 
 
DIET QUESTIONNAIRE 
How many times a week have you consumed the following foods over the previous 3 months? E.g. 2x 
 
Beef hamburgers / minced meat  
Red meat (e.g. beef, lamb, mutton)  
Fried chicken / cooked chicken with skin  
Hot dogs / processed meat / Meat pies  
Salad dressings (excludes 'Lite' versions)  
Butter and margarine (excludes 'Flora olive' / proactive versions)  
Eggs (excludes cooking and baking)  
Full cream milk and full cream dairy products  
Fried hot potato chips, potato crisps, corn chips, buttered popcorn  
Biscuits, cake, cookies, pastries, muffins  
SATURATED AND TRANS-FAT SCORE (Office Use)   
 
Fibre intake through Bread: White/Whole Wheat/ Brown/Rye/Other  
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Fibre intake through Cereals: Cooked Oats  
Fibre intake through Cereals: Sorghum  
Fibre intake through Cereals: High fibre instant cereal  
Fibre intake through legumes (beans, peas, lentils)   
Potatoes (with the skin on) - no creamy sauces or butter added  
Five portions fruits and/or vegetables (whole, salad)  
FRUIT / VEG / FIBRE SCORE (Office use)  
 
Broccoli, cauliflower, mushrooms  
Avocado, spinach  
Citrus – oranges, grapefruit  
Turnips / artichokes  
Organ meats (e.g. liver, kidney, giblets)  
FOLATE SCORE (Office use)  
 
MEDITERRANEAN DIET 
Fish and seafood  
Olives and olive oil on salads  
Nuts and seeds (flaxseeds, rapeseed, pumpkin, walnuts)   
Plant-based meals: fruits, vegetables, beans, nuts, legumes, seeds  
Herbs and spices instead of salt  
Red wine 1 glass/day or less (OPTIONAL)  
MEDITERRANEAN DIET SCORE (Office use)  
 
IMPROVING EYESIGHT 
Red/orange/yellow peppers  
Kale, spinach, pumpkin, carrots, berries, mangoes, grapes, kiwi fruit  
LUTEIN / ZEAZANTHIN (MACULA/RETINA) SCORE (Office use)  
 
 
 
Coffee, Green Tea, Rooibos Tea  
Sweets or Chocolates  
Carbonated Drinks  
"Light" or "Diet" Carbonated Drinks?  
If you take Probiotics, how often?  
Please also provide the purpose that it is being used for: 
Please also provide the strain: 
What oil do you use for cooking? 
Food allergy/intolerance 
 
FOODS THAT PROMOTE GLYCATION  
 
Beef or beef sausage fried over the fire, or stir-fried  
Crumbed fried chicken  
Chicken with skin roasted or fried  
Bacon fried until brown  
AGEs SCORE (Office use)  
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PHYSICAL ACTIVITY 
Which best describes your physical activity status? (Includes walking, swimming, cycling, attending 
exercise classes, each lasting more than 30 minutes) 
 
Recreational sport occasionally or complete lack of exercise  
Recreational sport 1 time a week  
Exercise 2 - 3 times a week  
Exercise 4 or more times a week  
 
DAYTIME ACTIVITY 
Which best describes your day-time or occupational activity? 
 
Sedentary (desk, work, driving, etc.)  
Moderate (house work, gardening, walk often)  
Intense physical labour (building and construction work, etc.)  
 
ALCOHOL CONSUMPTION 
How many units of alcohol do you consume on average per week? One unit alcohol equals 250 ml 
beer or lager, 1 glass (125 ml) of wine, 1 pub measure of spirits. 
 
Abstain  
1 - 2 units occasionally only  
3 - 13 units  
14 - 21 units  
22 units or more  
 
BLOOD LOSS 
Blood Donor? 
No  
Current   
Previous  
 
 
 
IRON INTAKE   
 
 
 
VITAMIN B12 INJECTIONS 
No     No   
Current     Current   
Previous     Previous   
 
VEGETARIAN/VEGAN 
No  
Current   
Previous  
 
HRT AND CONTRACEPTIVES 
FEMALES -  
                
Are you pregnant      
Taking Hormone replacement therapy (HRT)  
Taking oral contraceptive pill (OCP)  
!!! NB:  If relevant, please provide the name of the medication  
 
SMOKING OR DRUG EXPOSURE 
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This section captures your exposure to smoke or recreational drugs prior to diagnosis.  
The information is completely confidential.  
 
Have you ever smoked tobacco (cigarettes, cigars or pipe?)  
 
NO, never smoked  
YES, previously  
CURRENT SMOKER  
 
Have you been exposed to significant PASSIVE SMOKING prior to diagnosis or relapse? 
 
NO, never been exposed to tobacco smoke  
YES, previously  
YES, at the time of diagnosis  
Did your father/mother/other family member smoke when you were young?  
 
IF YES 
Please provide the following information:  
If you have ever smoked, what would the total number of years be that you did 
smoke if you added them up?  
 
If you did not smoke, how long were you exposed to passive smoking before 
diagnosis/relapse? 
 
What was your highest number of cigarettes per day?   
What was your average number of cigarettes per day?  
If you stopped smoking, when was the last time you smoked?   
If you smoked within the past 30 days, how many cigarettes did you smoke 
every day on average?  
 
 
 
Have you ever taken recreational drugs (cannabis etc.)?_____________________________ 
(Please specify) _______________________________________________________________ 
SLEEP 
Do you sleep at least 7 hours per night? 
 
IF NO 
 
How many hours do you sleep at night on average?  
How many times do you wake up during the night on average?  
Do you turn on the light when you wake up?  
How long does it take you to fall asleep again on average?  
How many hours do you sleep during the day?  
Is your room dark at night?  
Is your bed comfortable?  
 
Do you have conditions that prevent you from sleeping peacefully? Please specify 
  
  
 
Do you have pain? Please specify what type of pain, how long you have had the pain and what you 
are doing to alleviate it 
 
Type?  
How long?  
Alleviation?  
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More information:  
           Age at 
Do you have problems with cognition?        Onset       Medication           Side effects 
Memory    
Depression / Anxiety LOW MOOD    
Other neurological or psychiatric diagnosis?     
 
MEDICAL HISTORY CONTINUED 
The questions that follow assess the way your body responds to nutrition and injuries.  
This first section relates to the way your body absorbs, uses or loses iron.  
                     Age at 
            Onset       Medication           Side effects 
Anaemia    
Heamochromatosis (iron overload)    
Thalassaemia    
Restless Legs Syndrome    
Affected by Blood loss during Child Birth    
Trauma with blood loss (shock)    
Major Surgery CAESAREAN    
Blood Donation    
Heavy Menstruation    
Porphyria-like symptoms    
Unexplained episodes of SEVERE abdominal 
pain  
   
Sun induced rashes    
Miscarriages (accidental loss of pregnancy)    
Abortions (medical facilitated loss of pregnancy)    
This section relates to the way your body absorbs, uses or loses energy and 
nutrients.  
        
 
 
                            Age at 
             Onset       Medication           Side effects 
Obesity/Overweight    
Metabolic syndrome/Insulin resistance    
Low body weight    
Anorexia (weight loss)    
Recurrent fatigue    
Chronic Fatigue Syndrome/ Yuppie Flu (ME)    
Fibromyalgia    
Low Blood Sugar    
Low Blood Pressure    
Recurrent diarrhoea    
Irritable bowel disease/Crohn's disease/Ulcerative 
colitis 
   
Coeliac disease    
 
This section relates to the way your body responds to infections and allergens.  
            Age at 
             Onset       Medication           Side effects 
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Recurrent sinusitis    
Asthma    
Hay fever    
Recurrent  cystitis (bladder infection)    
Inflamed gums (gingivitis or periodontitis)/  
Teeth with root canals 
   
Serious prolonged infection  
(e.g. hospitalisation when you were young) 
   
Epstein Barr Virus/ Coxackie virus    
Candida    
Other Chronic Infections (please specify):    
 
Symptoms of Cardiovascular Disease                                                  
            Age at 
             Onset       Medication           Side effects 
  
Hypothyroidism    
Heart Attack / CVD    
Heart Failure    
Hypertension    
High cholesterol    
Stroke    
Thrombosis    
Varicose veins    
Metabolic Syndrome / Diabetes    
 
 
 
 
The following section relates to the possible influence of occupational, surgical, accidental, or 
deliberate exposures to any of the following on your health.  
Please choose "YES" if any of the following conditions or events have ever applied  
 
 
 
 
Heavy / occupational exposure to solvents, glues or volatile substances (like 
benzene, toluene, contact adhesives, paints, welding fumes, etc.) 
 
Significant exposure to toxins / poisons such as spraying fruit trees or insects  
Occupational exposure to anaesthesia gases (anaesthetist, dental hygienist, 
theatre sister) 
 
Exposure to general anaesthesia (including dental procedures) before 
diagnosis/relapse 
 
Exposure to nitrous oxide (Entonox/laughing gas) during labour  
If you have ever had general anaesthesia, how many times?   
Did you have dental fillings removed before diagnosis/relapse?  
 
MEDICATION  
 
What prescription medication were you on when you were diagnosed/relapsed? (e.g. malaria 
prophylaxis) 
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What NON-PRESCRIPTION medication were you on when you were diagnosed/relapsed? (e.g. 
Panado) 
 
 
 
 
What NUTRITIONAL SUPPLEMENTS (i.e., NOT INCLUDING NATURAL REMEDIES OR HERBS) - 
were you taking when you were diagnosed/relapsed? (i.e. off the shelf vitamins and minerals)  
 
 
 
 
 
 
Were you taking any HOMEOPATHIC MEDICINE? (i.e. remedies prescribed by a neuropath, 
homeopath, acupuncturist, chelation therapist, etc. based on your own research)?  
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FAMILY MEDICAL HISTORY 
In this page you are asked to enter any of the following illnesses or conditions in your family. Please 
provide the most accurate information that you can 
Please select which, if any, of the following apply to THE CLIENT's genetic ancestry. This information 
is not essential, but will facilitate accurate interpretation of the test results:  
 
African - South of the Equator   
African - North of the Equator   
European - Scottish   
European - Scandinavian   
European - Other   
Asian   
Indian   
South American   
Arabic   
Other (Please Specify)  
 
FAMILY SUBSTANCE ABUSE 
Certain familial problems with alcohol and drug use or senility are relevant in evaluating risks for the 
CLIENT. Please provide the following information for this purpose if you experienced any of the 
following in your family home:  
 
 Affected Family Member 
Substance Abuse or Dependence: Alcoholism  
Substance Abuse or Dependence: Drug abuse  
 
MEDICAL CONDITIONS - Family History 
Are any of your family members (e.g. grandparents, parents, siblings, uncles, aunts, nephews, or 
cousins) affected by any of the following conditions? 
 
 Affected Family Member (s) Age at onset 
Multiple sclerosis   
Anaemia   
Alzheimer’s disease/dementia   
Hemochromatosis   
Restless Legs syndrome   
Porphyria   
Hypothyroidism   
Heart Attack / CVD   
Heart Failure   
Hypertension   
High cholesterol   
Stroke   
Varicose veins   
Recurrent pregnancy loss   
Thrombosis   
Obesity   
Metabolic Syndrome   
Diabetes Type 1   
Diabetes (adult onset/Type II)   
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Crohn's Disease/Ulcerative colitis/IBD   
Coeliac Disease   
Recurrent Sinusitis   
Recurrent cystitis (bladder infection)   
Asthma   
Hay Fever   
Parkinson's Disease   
Migraine   
Recurrent Headaches   
Epilepsy   
Bipolar   
Stress/Depression/Anxiety   
Schizophrenia   
Lupus (SLE)/Rheumatoid arthritis   
Thyroid disease   
Cancer   
Other Diseases not included on this list   
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Appendix G: INFORMED CONSENT (English and Afrikaans) 
 
CEREBROSPINAL VENOUS AND CAROTID ARTERY ULTRASOUND STUDY 
INFORMED CONSENT / 
INGELIGTE TOESTEMMING VIR SEREBROSPINAAL VENEUSE EN KAROTIS ARTERIE 
ULTRAKLANK STUDIE 
 
INVESTIGATORS STATEMENT/ VERKLARENDE ONDERSOEK:  
We are asking you to be part of this research study. The purpose of this consent form is to give you the 
information you will need to help you decide whether or not to join this study. Please read it carefully. 
You may ask questions about the purpose of the research, what you need to do, the possible risks and 
benefits, your rights as a volunteer and anything else about the research. Please ask if you do not 
understand any part of this form. When your questions have been answered you can decide if you want 
to join this study. This process is called ‘informed consent’.  
Ons vra dat U deel sal wees van hierdie navorsingstudie. Die doel van hierdie toestemmingsvorm is om 
inligting deur te gee wat help met die besluit om deel van die studie te wees of nie. Lees asseblief 
deeglik. Voel gerus on vrae to vra oor die doel van die navorsing, wat U as ‘n pasient moet doen, die 
risiko’s en voordele, U regte as ‘n vrywilliger en enige iets met betrekking tot die navorsing.  
Vra asseblief vrae as daar dele van die vorm is wat U nie verstaan nie. Na beantwoording van vrae kan 
u besluit of U wel aan die studie wil deelneem. Die proses staan bekend as ingeligte toestemming.  
 
VOLUNTARY PARTICIPATION / VRYWILLIGE DEELNAME:  
You have the right to withdraw from this study at any time. There will be no penalty or loss of benefits 
to which you are entitled.  
U het die reg om enige tyd van die studie te onttrek. Daar sal geen verlies of penalisering van voordele 
wees nie.  
 
BACKGROUND / AGTERGROND:  
Previous research has shown that some of MS patients have narrowing of the neck veins (demonstrated 
with ultrasound) which cause reflux (backflow) of blood to the brain. Scientists’ suggest that the 
narrowed veins in the neck are strongly associated with MS and could possibly be the cause of MS.  
An ultrasound machine uses sound waves to image parts of the body including blood vessels. This study 
will use such a machine to look at the veins and arteries in your neck for narrowing and clot formation 
as well as plaque formation in the arteries of the neck.  
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Vorige navorsing het bewys dat pasiente met veelvuldige skleroise vernouing van die nek venes het en 
terugvloei van die bloed na die brein veroorsaak. Wetenskaplike vermoed dat die vernoude venes in die 
nek kan geassosieer word met VS.  
‘n Ultraklankmasjien gebruik klankgolwe om dele van die liggaam te visualiseer insluitend bloedvate.  
Hierdie studie gaan gebruik maak van so ‘n masjien om te kyk na die vene en arteries in die nek vir 
vernouing, terugvloei, klont- en plaakformasie.  
 
THE PURPOSE OF THE STUDY / DIE DOEL VAN DIE STUDIE:  
The purpose of this study is to use Ultrasound to investigate the presence of abnormal blood flow in the 
veins and arteries of the neck. Furthermore, if any abnormal flow is detected then you will be referred 
to the appropriate medical practitioner for further management.  
Die doel van hierdie studie is om ultraklank te gebruik om die teenwoordigheid van abnormal bloedvloei 
in die vene en arteries in die nek te ondersoek. Indien daar enige abnormale vloei opgespoor word sal 
U verwys word na die mees gepasde medies praktisyn vir verder behandeling.  
 
ULTRASOUND EXAMINATION / ULTRAKLANK ONDERSOEK:  
This study will require the patients to undergo one ultrasound examination of the arteries and veins of 
the neck. This test takes about 30-40 minutes to carry out. It is a painless examination and requires the 
patients to lie on their back while a small instrument called a probe is moved across the skin. A water 
based gel is first applied to the skin so the probe has good contact and can move smoothly. This 
examination is not painful. Some patients find this test relaxing.  
 
Hierdie studie vereis dat pasiente ‘n verdure ultraklank ondersoek van die arteries en venes van die nek 
sal ondergaan, hierdie ondersoek duur ongeveer 30-40 minute. Dit is ‘n pynlose ondersoek en daar sal 
van U verwag word om op die rug te le of regop te sit terwyl  ‘n klein instrument oor die vel sal aangewend 
word, sodat die instrument in goeie kontak met die vel sal wees en maklik sal beweeg. Sommige 
pasiente ervaar hierdie studie as ontspannend.  
 
RISK AND BENEFITS / RISIKO’S EN VOORDELE:  
There are no known risks to an ultrasound examination. The most important benefit for this group of 
patients is that abnormal blood flow (if present) will be identified on ultrasound. If abnormal blood flow 
is identified, then appropriate steps can be taken to manage the patient as necessary.  
 
Daar is geen gevare aan ‘n ultraklank ondersoek verbande nie. Die mees belangrike voordeel vir hierdie 
groep pasiente is dat indien teenwoordig, abnormale bloedvloei geindentifiseer word, sal die nodige 
stappe in die behandeling van die pasient toegepas word.  
 
OTHER INFORMATION / ANDER INLIGTING  
Joining this study is voluntary. You can stop at any time. If you choose to join the study or not it will not 
affect your health care. Information about you is confidential. We will code the study records. The link 
between your name and code will be kept separate in a secure location. Only the study investigators 
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will have access to that information. The link between your name and the code will be kept for 10 years 
then destroyed. Results of the study will be published where participants will be informed of the outcome.  
 
Deelname aan hierdie studie is vrywillig. U kan enige tyd onttrek. Indien U kies om aan hierdie studie 
deel te neem sal dit nie U gesondheid affekteer nie. U informasie is vertroulik. Ons sal U studie rekords 
kodeer. Die skakel tussen U naam en kode sal op ‘n aparte en veilige bestemming gehou word. Slegs 
die persone wat vol mag het, sal toegang he tot die informasie. Die skakel tussen U naam en kode sal 
vir 10 jaar gehou word en dan vernietig word. Uitslae van hierdie studie sal gepubliseer word waar 
narvorsings onderwerpe ingelig sal word oor die resultate.  
 
SUBJECT’S STATEMENT / ONDERWERP VERKLARING:  
I understand what the procedure will be for this Ultrasound scan. I voluntarily agree to take part in this 
study. I have read and/or someone has read the information pertaining to the study to me. The 
information is in a language with which I am fluent and comfortable. I was given an opportunity to ask 
questions and all my questions have been answered to my satisfaction. I understand that taking part in 
this study is voluntary. I may choose to leave the study at any time.  
 
Die studie was aan my verduidelik. Ek bied aan om deel te neem aan hierdie navorsing. Ek het ‘n kans 
gehad om vrae to vra en my vrae was beantwoord. Ek verstaan dat ek kan enige tyd van die studie kan 
onttrek.  
 
Please complete the table indicating your voluntary participation in the study / Voltooi asseblief die 
tabel om U vrywillige deelname aan te dui. 
SIGNED AT / GETEKEN TE   
DATE / DATUM   
NAME OF WITNESS / NAAM VAN GETUIE   
SIGNATURE OF WITNESS / 
HANDTEKENING VAN GETUIE  
 
NAME OF PARTICIPANT / NAAM VAN 
NAVORSINGS ONDERWERP  
 
SIGNATURE OF PARTICIPANT / 
HANDTEKENING VAN NAVORSINGS 
ONDERWERP  
 
 
Contact details of researchers:  
Merlisa Kemp  
kempme@cput.ac.za  
office: 021 959 6538  
 
Prof. Susan J Van Rensburg  
sjvr@sun.ac.za  
office: 021 938 4611 
 
 
 
